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ABSTRACT 
MSCs (N=9) were isolated from the bone marrow of patients who had received hip 
replacement therapy. MSC-serum free conditioned media (MSC-CM) were collected 
at different time points during MSC passage and analysed for protein content using 
enzyme linked immunosorbent assay (ELISA). The effect of MSC-CM was tested on 
migration and proliferation of human skin cells (HaCat cell line, primary fibroblast and 
primary keratinocytes) (N=4) using a 2D scratch assay and tetrazolium salt proliferation 
assay respectively. For primary keratinocyte experiments, MSC-CM were collected in 
keratinocyte growth media containing low calcium levels (0.04 mM/L) (LC-CM). The 
effect of LC-CM was tested on migration and proliferation of primary keratinocytes 
during different testing conditions; normoxia (N=4), hypoxia (N=4), blocking of stromal 
derived factor-1α (SDF-1α) (N=4) and inhibition of proliferation (N=4). MSCs were 
tested for their ability to differentiate into epidermal like cells (ELCs) using both 2D and 
3D cultures. A human 3D skin model was developed for wound healing and micro RNA 
profiling studies. All MSCs met the criteria stipulated by the International Society for 
Cellular Therapy (ISCT). MSC-CM contained growth factors e.g. keratinocyte growth 
factor (KGF), hepatocyte growth factor (HGF), platelet derived growth factor-AB 
(PDGF-AB), transforming growth factor-β1 (TGF-β), macrophage stimulating protein-
1 (MSP-1) and SDF-1α and RT qPCR analysis demonstrated receptors of these growth 
factors e.g. FGFR2, c-MET, PDGFRA, TGFβ-R1, RON and CXCR4 respectively on 
both scratched and non-scratched primary keratinocytes. The main findings from this 
study showed that MSCs could differentiate into ELCs and MSC-CM were shown to 
have a positive effect on migration and proliferation of skin cells in 2D and 3D culture. 
MSC secretions collected at early time points were more effective on cell migration 
than those collected at later time points during MSC expansion. 2D and 3D studies 
also showed that cell migration was the first and the major mechanism evoked by MSC-
CM followed by proliferation and differentiation. Additionally, the 3D skin model 
developed in this study could be used as a skin replica for wound healing studies at 
the cellular and molecular level including the use of microRNA profiling. These 
microRNAs were regulated at different time points during the wound repair suggesting 
their participation in the different phases of the healing process. In conclusion, MSCs 
play a multifunctional role in the cellular and molecular mechanisms of the healing 
process and enhance the healing process via two mechanisms; cell mediated repair 
by differentiation into ELCs and secretory mediated repair by cytokines. 
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CHAPTER ONE: LITERATURE REVIEW AND AIMS OF THE STUDY 
 INTRODUCTION 
Chronic wounds significantly affect millions of people and impair their quality of life and 
represent the most challenging disease in modern pathological medicine requiring modern 
effective therapies (Morimoto et al., 2015; Tenci et al., 2016). In the UK, in 2003, 
approximately 200,000 patients experience a chronic wound of varying types, ranging 
from ulcerations, scars, trauma and burns. Unfortunately, patient morbidity and in some 
cases mortality may result from such injuries for which chronic ulceration is a major factor 
(Franks and Morgan, 2003; White, 2009). Consequently, both society and the health 
sector are affected by the burden of chronic wounds. One of which is the reduced 
contribution to society by individuals suffering from chronic wounds due to their inability to 
work (White, 2009). In the context of healthcare treatment and hospitalization, chronic 
wounds are very costly in both treatment time and nurse time (Posnett and Franks, 2008). 
In 2005 and 2006, the nursing care of patients with a chronic wound cost the NHS 
approximately £2.3bn–£3.1bn a year, £6.08 million in England alone (Drew et al., 2007). 
In 2012 and 2013, the annual cost of management of chronic wounds increased from £4.5 
to 5.1 billion (Guest et al., 2015) indicating that wound management is a growing costly 
problem. Furthermore, infection is inevitable, which not only negatively affects wound 
healing but is also life threatening (Butcher, 2013), requiring further hospitalisation and 
increased healthcare expenditure (Cook and Ousey, 2011). 
Moreover, despite great progress in wound treatment, including the implementation of 
growth factors and biologically engineered skin equivalents, present treatment options for 
burns and non-healing chronic wounds are limited and not always effective (Hocking, 
2012). Engineered skin models are limited by their construction from substances that are 
difficult to degrade, and do not always result in complete integration into normal uninjured 
skin. Furthermore, complete renewal of this model requires the alteration of immune 
responses to reduce fibrotic reactions in order to diminish scar production (Metcalfe and 
Ferguson, 2007). Therefore, there is an urgent need for new therapies for wounds with 
delayed healing (Hocking, 2012). Specific extra cellular matrix (ECM) proteins equivalent 
to the skin, specific growth factors, mesenchymal stem cells (MSCs), fibroblasts or viable 
epithelial cells may however impact on the wound healing process and their addition to 
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potential wound healing treatments may improve the efficacy of current therapeutic 
strategies (Maxson et al., 2012). MSCs are generally defined as self-renewable, multi-
potent progenitor adult stem cells. In vivo, they have the ability to differentiate widely into 
many mesenchymal lineages such as cartilage, bone, muscle and adipose tissues (Kadir 
et al., 2012). Furthermore, MSCs have the ability to migrate from bone marrow to an 
injured site and differentiate into functional skin cells (Badiavas et al., 2003; Sasaki et al., 
2008). In vitro, MSC’s can be defined as fibroblast-like cells capable of self-renewal with 
the ability to adhere to plastic and subsequently differentiate into adipose, bone, cartilage 
tissue (Dominici et al., 2006) as well as a multi-layered epidermis-like structures (Ma et 
al., 2009).  
The availability of MSCs in human skin (Hoogduijn and Dor, 2013) and their vital function 
in wound healing, suggests in particular the exogenous application of such cells may 
represent a promising solution for treatment of non-healing wounds (Paquet-Fifield et al., 
2009). 
MSCs are potentially recognized as a promising strategy not only to treat non healing 
wounds but also to accelerate wound closure, prevent infection and restrain wounds from 
reaching a chronic state. Given the ability of MSCs to differentiate into skin like cells in 
vitro this project will explore the potential molecular, cellular and extracellular mechanisms 
of MSCs in wound healing and their potential therapeutic application for the treatment of 
cutaneous wounds. 
 MESENCHYMAL STEM CELLS (MSCS): HISTORIC VIEW AND DEFINITION  
In 1968, Alexander Friedenstein and colleagues were the first to discover that, besides 
haematopoietic stem cells (HSC), bone marrow harbours adherent fibroblast-like cells 
referred to as colony-forming unit-fibroblasts (CFU-f). In 1994, Caplan and collaborators 
termed these cells mesenchymal stem cells (MSCs) (Caplan, 1994). In 1999, these cells 
were described by Pittenger and co-workers as multipotent stem cells capable of 
differentiating into other cells from mesenchymal tissues (Pittenger et al., 1999). They 
have also been termed marrow stromal cells, or fibroblastoid colony-forming units (FCFU) 
(Gregory et al., 2005). MSCs first defined by Song et al. in 2007 as a type of stem cell 
population capable of self-renewing and differentiating into different cell types with 
pluripotent potential (Song et al., 2007). They were defined as a heterogeneous 
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population of non-haematopoietic stem cells with the potential capacity to differentiate into 
various somatic lineages and tissues of both mesenchymal and non-mesenchymal origin 
(Rastegar et al., 2010). They were also termed mesenchymal stem cells, multipotent 
mesenchymal stromal cells or stromal progenitor cells (Hocking and Gibran, 2010) and 
characterised by their ability to differentiate into bone (Rastegar et al., 2010; Wang et al., 
2012a) with clonogenic properties in vitro (Semedo et al., 2009). Interestingly, they can 
be isolated from a variety of  tissue sources from the adult human body (Hass et al., 2011). 
 MAIN SOURCES OF MESENCHYMAL STEM CELLS 
Diverse tissues of the adult organism harbour MSCs capable of generating and renewing 
cell types specific for these tissues (Tuan et al., 2003). Primarily, bone marrow, adipose 
tissue, peripheral blood, umbilical cord and cord blood and placenta are primary sources 
of MSCs. They are also found in other tissues and organs such as liver, synovial fluid, 
muscle and dental pulp (Tuan et al., 2003; Yoshimura et al., 2007; Huang and Burd, 2012; 
Yalvac et al., 2013). Moreover, dermis, pericytes, synovial membrane and trabecular bone 
are identified as tissues harbouring MSCs (Tuan et al., 2003). 
1.3.1 BONE MARROW 
Stromal cells, haematopoietic stem cells and endothelial cells are the main three cell types 
contained in the bone marrow. Bone marrow stroma is considered to be the common 
harbor of multi-potent cells; thereby, key in maintaining the microenvironment of the bone 
marrow (Tuan et al., 2003; Barry and Murphy, 2004; Gimble et al., 2008; Hua et al., 2009). 
MSCs constitute approximately 0.01–0.001% of cell populations in the bone marrow 
(Rastegar et al., 2010; Akiyama et al., 2012). Although a small ratio is represented by this 
subtype of the cells, they are capable of proliferating and differentiating into osteoblastic, 
adipogenic, chondrogenic and neurogenic lineages (Akiyama et al., 2012). Tuan and 
colleagues thought that these heterogeneous cells possessed the ability to circulate and 
gain access to different tissues and participate in maintaining and repairing these tissues 
(Tuan et al., 2003). BM-MSCs are characterised by expressing cluster of differentiation 
(CD) markers such as CD73 (SH3), CD90 (Thy1), and CD105 (endoglin “SH2”) (Griffiths 
et al., 2005; Tondreau et al., 2005; Gang et al., 2007; Greco et al., 2007; Hass et al., 2011; 
Akiyama et al., 2012; Jin et al., 2013a). Moreover, other reports have showed that BM-
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MSCs can express more CD markers such as CD13, STRO-1, Octamer-4 (Oct4), and 
stage-specific embryonic antigen-4 (SSEA4) (Gang et al., 2007; Greco et al., 2007; 
Akiyama et al., 2012), STRO-1 (Gang et al., 2007; Greco et al., 2007; Hass et al., 2011; 
Akiyama et al., 2012) CD44, CD166 (Gang et al., 2007; Greco et al., 2007; Hass et al., 
2011; Akiyama et al., 2012; Jin et al., 2013a) and human leukocyte antigen (HLA)-ABC 
(Jin et al., 2013a). 
On the other hand, BM-MSCs lack the expression of monocytes/macrophage CD markers 
(CD14), lymphocyte marker (CD11a), endothelial cell marker (CD31) (Deans and 
Moseley, 2000), the primitive haematopoietic stem cell (HSCs) marker (CD34) and a 
marker of all haematopoietic cells (CD45) (Griffiths et al., 2005; Gang et al., 2007; Greco 
et al., 2007; Kolf et al., 2007; Hass et al., 2011; Akiyama et al., 2012; Jin et al., 2013a). 
Furthermore, BM-MSCs do not express other markers for example, CD11b (an immune 
cell marker ”myeloid”) (Kolf et al., 2007; Jin et al., 2013a), glycophorin-A (an erythroid 
lineage marker), CD14 (a myeloid biomarker), CD79a, and HLA-DR. Isolation of MCSs 
from bone marrow is characterised by two main advantages; (1) a large number of cells 
can be collected and (2) a low number of T-cells, while there are two disadvantages; (1) 
it requires a painful procedure with (2) risk of infection (Hass et al., 2011).  
1.3.2 UMBILICAL CORD BLOOD AND PLACENTA 
Umbilical cord blood (UCB) is a typical source of MSCs because their isolation is free from 
ethical concerns, and is carried out in a non-invasive manner (Jin et al., 2013a). 
Depending on the morphological phenotypes, two subsets of MSC populations can be 
recognized in umbilical cord blood; the first group is spindle-shaped fibroblasts which can 
express CD90 with more capacity for adipogenesis compared with other types of cells 
which are flattened fibroblasts and negative for CD90 showing less capacity for 
adipogenesis (Arufe et al., 2011). However, all UCB-MSCs share the same typical MSC 
criteria; for example, they are capable of self-renewing, differentiating into diverse cell 
linages such as bone, cartilage and adipose tissue in vitro and expressing cell surface 
markers with high levels of CD73, CD90 and CD105 while they are negative for CD14, 
CD34 and CD45 (Dominici et al., 2006; Hass et al., 2011; Jin et al., 2013a). On the other 
hand, Jin and colleagues state that UCB-MSCs can express CD29, CD44, CD166 and 
human leukocyte antigen (HLA) while lack the expression of CD11b, CD14, CD79a, and 
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HLA-DR (Jin et al., 2013a). Placental tissue is also considered as a great source of MSCs 
which could be utilised for translational research and regenerative medicine (Kadam et 
al., 2010). Placenta-derived mesenchymal stem cells (PL-MSCs) characterised by their 
plasticity, ease of isolation, high yields and in vitro rapid expansion, retain both 
morphological and functional features (Hass et al., 2011). These cells could be induced 
to give different cell linages such as neural-like cells, cartilage, hepatocyte and vascular 
endothelial cells (Matikainen and Laine, 2005; Kadam et al., 2010; Portmann-Lanz et al., 
2010).  
In general, neonatal tissues, as an MSC source, have significant benefits due to their 
availability and also potentially additional differentiation capacities when compared with 
MSCs obtained from adult tissues (Hass et al., 2011). For example, high yields of MSCs 
could be obtained from UCB, with immunosuppressive functions making them an 
attractive candidate for use in allogenic transplantation (Jin et al., 2013a). 
1.3.3 ADIPOSE TISSUE 
In comparison to other sources, adipose tissue is considered an ubiquitously available 
source, yielding high levels of MSCs, essential for tissue engineering and cell based 
therapies (Barry and Murphy, 2004; Gimble et al., 2008).  In addition, one gram of stromal 
vascular fraction (SVF) obtained from adipose tissue contains approximately five hundred 
times more MSCs than BM-MSCs (Strem et al., 2005; Astori et al., 2007; Varma et al., 
2007). Functionally, adipose tissue derived MSCs (AT-MSCs) and BM-MSCs are similar 
yet, some differences occur (Estes et al., 2006; da Silva Meirelles et al., 2009). At the 
level of CD marker expression, adipose tissue MSCs (AT-MSCs) are positive for CD73 
(SH3), CD90 and CD105 (SH2) while they are negative for CD19 (a lymphoid biomarker), 
CD34 and CD45 (Zuk et al., 2002; Schaffler and Buchler, 2007; Hass et al., 2011; Jin et 
al., 2013a). Other studies show that AT-MSCs possess the ability to express other CD 
markers such as CD9, CD13, CD54, CD106, CD146, HLA I, STRO-1 (Zuk et al., 2002; 
Schaffler and Buchler, 2007; Hass et al., 2011), CD29, CD44, CD166 (Hass et al., 2011; 
Jin et al., 2013a) and HLA ABC (Jin et al., 2013a). On the other hand, AT-MSCs lack 
expression of specific CD markers such as CD19, CD34, and CD45 (Zuk et al., 2002; 
Schaffler and Buchler, 2007; Hass et al., 2011; Jin et al., 2013a). Additionally, AT-MSCs 
express other markers for example, CD11b, CD14, CD 45, CD79α (a lymphoid 
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biomarker), HLA-DR (Hass et al., 2011; Jin et al., 2013a), CD31, CD133 and CD144 (Hass 
et al., 2011). Adipose tissues are characterised by ease of access, non-invasive cell 
harvesting technique and high collection yields of MSCs (Baer and Geiger, 2012). 
Additionally, AT-MSCs are functionally similar to BM-MSC with mild differences such as 
AT-MSCs have higher proliferative potential while BM-MSCs have greater capacity to 
commit osteogenic and chondrogenic differentiation (Li et al., 2015a).  
1.3.4 PERIPHERAL BLOOD 
Peripheral blood of normal individuals harbor MSCs (PB-MSCs) that share features and 
capacities of differentiation similar to these of BM-MSCs where they can differentiate into 
osteoblastic, chondrogenic, and adipogenic lineages. These cells therefore could serve 
as good candidates for repairing damaged cartilage. PB-MSCs are also capable of self-
renewing and rapid proliferation in vitro (Zvaifler et al., 2000). The surface of PB-MSCs 
are characterised by their ability to express CD44, CD54, CD105 (SH2) and CD166 (Cao 
and Dong, 2005; Tondreau et al., 2005; Kuhbier et al., 2010; Hass et al., 2011). While 
they lack the expression of CD14, CD34, CD45 and CD31 (Cao and Dong, 2005; 
Tondreau et al., 2005; Kuhbier et al., 2010; Hass et al., 2011). However, not all MSCs 
devoid of CD34 (Chong et al., 2012). Kassis and colleagues have isolated PB-MSC and 
described them as positive for CD90 and CD105 (SH2) and negative for CD45 and CD34 
(Kassis et al., 2006). Trivanović and others found that PB-MSCs were negative for CD11a, 
CD33, CD45 and Glycophorin-CD235a (Trivanovic et al., 2013). The main advantages of 
collecting PB-MSCs is the ease of isolation with multiple collections possible, while the 
drawback of this source is that the amount of isolated cells is limited and the donor 
requires treatment with granulocyte colony-stimulating factor (G-CSF) to mobilise the cells 
from the bone marrow (Kassis et al., 2006). 
1.3.5 OTHER SOURCES 
Although the bone marrow is the original source of MSCs, other sources have been 
described since 1999 (Gabbay et al., 2006) and many tissues have been successfully 
used to harvest MSCs (Rastegar et al., 2010). Almost, all adult tissues contain MSCs but 
in low numbers such as periosteum, trabecular bone, synovium, skeletal muscle, 
deciduous teeth (Barry and Murphy, 2004), liver (Kassis et al., 2006), spleen, cartilage, 
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tendon (Gimble et al., 2008), dermis (Hua et al., 2009), brain, periosteum and hair follicles 
(Zuk et al., 2001; Amoh et al., 2005a; Rastegar et al., 2010). MSCs are also found in 
kidney (Bussolati et al., 2005), dental pulp (Gabbay et al., 2006), amniotic fluid (Perin 
(Perin et al., 2008), limbus (Polisetty et al., 2008), amniotic membrane (Diaz-Prado et al., 
2010) and adenoid tissues (Lee et al., 2013). Also, Semedo and colleagues have reported 
that multipotent MSCs are found in almost every single tissue in the body and they could 
be isolated from these tissues and expanded in vitro keeping their ability of self-renew and 
differentiate into different linages of mesodermal origin (Semedo et al., 2009). 
Furthermore, postnatal tissues and organs have been described as sources for MSCs; for 
example, articular cartilage, trabecular bone, deciduous teeth, muscle, adipose, 
periosteum, pericytes, synovial fluid (SF), synovial membrane, dermis and infrapatellar fat 
pad (Bianco et al., 2008). Moreover, fetal organs for instance, lung (Hua et al., 2009), 
pancreas, first-trimester blood (Kassis et al., 2006), kidney, liver, bone marrow and the 
circulating blood preterm foetuses harbour MSCs (Miao et al., 2006). 
Although MSCs can be isolated from different tissues, they share the major criteria 
defining MSCs with minor differences related to their differentiation capacity and cell 
surface expression profile (Wagner et al., 2005; Rastegar et al., 2010). These differences 
were challenging to the scientists characterising MSCs (Dominici et al., 2006). 
1.4 IDENTIFYING CHARACTERISTICS OF MESENCHYMAL STEM CELLS 
The International Society for Cellular Therapy (ISCT) has suggested minimal criteria 
defining human MSCs in an attempt to resolve this challenge (Hocking and Gibran, 2010). 
Three minimal criteria have been agreed to become consensus characteristics shared by 
human MSCs and many scientists (Oswald et al., 2004; Dominici et al., 2006; Hocking 
and Gibran, 2010; Blaber et al., 2012; Wang et al., 2012a) have referred to them in their 
research (Figure 1.1). These criteria are: 
1. The isolated MSCs should possess plastic adherence ability. 
2. More than 95 % of the isolated MSCs must express CD73 (SH3), CD90 and CD105 
(HS2) and more than 98 % of the isolated MSCs do not express CD14, D19, CD34, CD45, 
CD11b, CD79a and HLA-DR surface molecules. 
3. The isolated MSCs have the capacity to differentiate into osteoblastic, chondrogenic, 
and adipogenic lineages under in vitro standard differentiation conditions. 
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Figure 1.1 Identifying characteristics of MSCs using the ISCT criteria. 
MSCs are fibroblast like cells able to re-new themselves in vitro. They are positive for stem cell markers 
such as CD73, CD90 and CD105, while negative for markers of haematopoietic stem cell such as CD14, 
CD19, CD34, CD45 and HLA-DR. They also differentiate into three lineages; adipocyte, chondroblast 
and osteoblast.   
1.4.1 MORPHOLOGY 
Morphologically, MSCs are characterised by a small longitudinal, thin body provided with 
long and thin appendages. Like other human cells, MSCs contain a round large nucleus 
with an obvious nucleolus surrounded by fine chromatin particles. Additionally, 
polyribosomes, mitochondria, rough endoplasmic reticulum and Golgi apparatus are 
present. Their extracellular matrix is filled with a few reticular fibrils while free of the other 
types of collagen fibrils (Brighton and Hunt, 1991). MSCs have also been described as 
spindle-shaped fibroblastic cells or polygonal with long processes and one nucleus and 
have the ability to form colonies after 7-10 days of in vivo plating (Xu et al., 2004; Zhu et 
al., 2006). 
1.4.2 IN VITRO CHARACTERISTICS 
MSCs look like spindle-shaped fibroblastic cells and start to form colonies, while after the 
second passage, they either keep the spindle-shaped cells or develop polygonal long 
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processes (Xu et al., 2004; Zhu et al., 2006). Digirolamo and colleagues reported that 
MSCs expand heterogeneously in vitro, even when using different samples from the same 
patient (Digirolamo et al., 1999). MSCs can also be propagated keeping their 
differentiation potential into osteocytic, adipocytic and chondrocytic linages in vitro 
(Maxson et al., 2012). In an attempt to investigate the in vivo characteristics of MSCs, 
most scientists cultured MSCs in vitro. However, the markers expressed under these 
conditions are determined by the culture conditions instead of the original characteristics 
of MSCs in situ. Therefore, it is difficult to characterise, track and detect the phenotype of 
MSCs in vivo; consequently, there are no agreed phenotypic characteristics to identify 
MSCs in vivo (Si et al., 2011). Many researchers have shown that tissues play a role in 
determining the specific biomarkers of MSCs in vivo. For example, MSCs in bone marrow 
are enriched with Stage-Specific Embryonic Antigen-1 (SSEA-1) and SSEA-4 or enriched 
with CD133 from peripheral and umbilical cord blood (Tondreau et al., 2005; Gang et al., 
2007; Si et al., 2011). 
1.4.3 PHENOTYPIC MARKERS OF MESENCHYMAL STEM CELLS 
Considerable studies have been conducted aiming to identify certain MSC markers for 
detection, isolation, characterisation and evaluation of human MSCs populations. 
Amongst these efforts is the rise of monoclonal antibodies as reagents for detecting and 
isolation of human MSCs. An example of these antibodies is Stro-1 a monoclonal antibody 
which can react with non-haematopoietic progenitor stromal cells derived from human 
bone marrow (Simmons and Torok-Storb, 1991). Also, the differentiation potential of 
MSCs is consistent with Stro-1 since MSCs positive for this marker become osteocyte, 
adipocyte, chondrocyte, smooth muscle cells and HSC-supporting fibroblasts (Kolf et al., 
2007). However, Gronthos and colleagues suggested Stro-1 is an unlikely generic MSCs 
biomarker for two main reasons: first; it is not secreted by MSCs exclusively, second; it is 
gradually lost during MSC in vitro expansion (Gronthos et al., 2003). Therefore, Stro-1 
expression as an MSC identification marker should be in conjunction with other markers 
such as vascular cell adhesion molecule-1 (VCAM-1) which is involved in MSC 
chemotaxis, adhesion, and signal transduction (Carter and Wicks, 2001) and CD106 
which could be an indicator for increasing frequency of CFU-F (Gronthos et al., 2003). 
Another example of reagents for MSC detection are the SH-2n SH3 and SH4 antibodies 
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which do not react with haematopoietic cells (Haynesworth et al., 1992; Kolf et al., 2007). 
A further example is the SB-10 antibody which reacts specifically with CD166 (activated 
leukocyte-cell adhesion molecule, ALCAM). In addition, SB-10 can react with an antigen 
expressed on undifferentiated MSC cells and once these undifferentiated MSCs initiate 
osteogenesis, this antigen disappears and is replaced by alkaline phosphatase (Bruder et 
al., 1998). For more details about MSC positive markers, see (Table 1.1). 
1.4.3.1 POSITIVE MARKERS 
The International Society for Cellular Therapy (ISCT) has minimised the criteria for 
defining human MSCs to be positive for CD73 (SH3/4), CD90 and CD105 (SH2) (Oswald 
et al., 2004; Dominici et al., 2006; Gimble et al., 2008; Hocking and Gibran, 2010; Blaber 
et al., 2012; Wang et al., 2012a). However, other CD marker profile have been expressed 
by MSCs such as CD106, CD120a, CD124  (Baron and Storb, 2012), CD29 (b1-integrin), 
CD13, CD44, CD71 (Oswald et al., 2004; Honczarenko et al., 2006; Wu et al., 2007; 
Motaln et al., 2010; Parekkadan and Milwid, 2010; Baron and Storb, 2012), CD166 
(ALCAM) (Motaln et al., 2010; Parekkadan and Milwid, 2010; Baron and Storb, 2012), 
CD146, CD58, CD54 (intercellular adhesion molecule-1 [ICAM]-1), CD49e (a5-integrin) 
and CD10 (Motaln et al., 2010; Parekkadan and Milwid, 2010) and CD271 (Quirici et al., 
2002; Motaln et al., 2010; Parekkadan and Milwid, 2010). Also, MSCs strongly express 
typical surface antigens such as stem cells antigen-1 (Sca-1) (Wu et al., 2007), HLA class 
I (HLA-I) and they can be induced by IFN-γ to express HLA-II (Baron and Storb, 2012). 
Additionally, they can express combination of chemokine receptors for example, CXCR 1, 
2, 3, 4 and 5, CCR 1, 4, 7, 9 and 10 and CX3CR1 (Patel et al., 2013). It is therefore difficult 
to identify human MSCs with the use of specific markers. 
1.4.3.2 NEGATIVE MARKERS 
As per the ISCT, the minimal criteria for defining h-MSCs pertaining the negative markers 
are CD14, D19, CD34, CD45, CD11b, CD79 alpha and HLA-DR (Oswald et al., 2004; 
Dominici et al., 2006; Gimble et al., 2008; Hocking and Gibran, 2010; Blaber et al., 2012; 
Wang et al., 2012a). Yet, there is an agreement that h-MSCs do not express CD3 (Oswald 
et al., 2004; Wu et al., 2007), CD14, CD34, CD45 (Baron and Storb, 2012), CD31, an 
endothelial and haematopoietic cells marker and CD117, a haematopoietic 
stem/progenitor cell biomarker (Kolf et al., 2007; Motaln et al., 2010; Parekkadan and 
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Milwid, 2010; Torsvik et al., 2010), CD15, CD33 (Oswald et al., 2004; Motaln et al., 2010; 
Parekkadan and Milwid, 2010), CD38 (Oswald et al., 2004), CD40 (Rastegar et al., 2010), 
CD80, CD86 (Motaln et al., 2010; Parekkadan and Milwid, 2010; Rastegar et al., 2010). 
Moreover, h-MSCs do not express CD106 (vascular cell adhesion molecule [VCAM]-1), 
CD62E, CD62L, CD62P, CD50, CD49b, CD49d, CD49f, CD25, CD16, CD11a, CD8, 
glycophorin A and cadherin V (Motaln et al., 2010; Parekkadan and Milwid, 2010). 
Accordingly, the criteria mentioned by Rastegar and colleagues that MSCs negative for 
CD40, CD80, CD86 and MHC II make these cells attractive candidate for treating human 
diseases especially allogenic stem cell transplantation without immunosuppression 
(Rastegar et al., 2010). 
1.4.3.3 CONTROVERSIAL MARKERS  
Human MSCs populations express considerable variability in their cell surface markers. 
There is therefore no unique surface antigen specific to MSCs (Quirici et al., 2002; 
Hocking and Gibran, 2010). Mabuchi and others (Mabuchi et al., 2013) reported that most 
CD markers expressed by h-MSCs such as CD49a, CD73, CD105, CD106, CD271, MSC 
antigen-1, Stro-1, and SSEA-4 are not specific for MSCs; rather, they are widely 
expressed in stromal cells. CD106 is also considered as a positive marker for h-MSCs 
while other researchers have shown that h-MSC do not express CD106 (Motaln et al., 
2010; Parekkadan and Milwid, 2010; Baron and Storb, 2012). Additionally, other CD 
markers such as CD271/NGFR (Quirici et al., 2002), CD10, CD13, CD29, CD44, 
CD90/Thy-1, CD105, foetal liver kinase 1 (Flk-1) /CD309 and Sca-1 (Honczarenko et al., 
2006) are often expressed on the MSC cell surface, but they lack specificity or consistent 
expression. Researchers have therefore reported an enormous variation in positive 
markers and each group of co-workers have used different subsets of markers. The lack 
of specific markers for h-MSCs represents the challenge of MSC identification (Kolf et al., 
2007) and attempts to investigate the true identity and function of these cells is still 
problematic (Mabuchi et al., 2013). 
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Positive Markers References Negative Markers References 
CD73 
CD90 
CD105 
(Oswald et al., 2004; 
Dominici et al., 2006; 
Gimble et al., 2008; 
Hocking and Gibran, 2010; 
Blaber et al., 2012; 
Wang et al., 2012) 
CD14 
CD34 
CD45 
 
(Oswald et al., 2004; 
Dominici et al., 2006; 
Gimble et al., 2008; 
Hocking and Gibran, 2010; 
Baron and Storb, 2012; 
Blaber et al., 2012; 
Wang et al., 2012) 
CD13 
 
(Oswald et al., 2004; 
Honczarenko et al., 2006; 
Wu et al., 2007; 
Motaln et al., 2010; 
Parekkadan and Milwid, 2010) 
D19 
CD11b 
CD79a 
HLA-DR 
(Oswald et al., 2004; 
Dominici et al., 2006; 
Gimble et al., 2008; 
Hocking and Gibran, 2010; 
Blaber et al., 2012; 
Wang et al., 2012) 
CD29 
CD44 
CD71 
(Oswald et al., 2004; 
Honczarenko et al., 2006; 
Wu et al., 2007; 
Motaln et al., 2010; 
Parekkadan and Milwid, 2010; 
Baron and Storb, 2012) 
CD31 
CD117 
(Kolf et al., 2007; 
Motaln et a l., 2010; 
Parekkadan and Milwid, 2010) 
CD38 (Oswald et al., 2004) 
CD40 (Rastegar et al., 2010) 
CD106 
CD120a 
CD124 
HLA-I 
HLA-II 
(Baron and Storb, 2012) 
CD15 
CD33 
(Oswald et a l., 2004; 
Motaln et al., 2010; 
Parekkadan and Milwid, 2010; 
CD3 
Oswald et al., 2004; 
Wu et al., 2007) 
CD106 
CD62E 
CD62L 
CD62P 
CD50 
CD49b 
CD49d 
CD49f 
CD25 
CD16 
CD11a 
CD8 
glycophorin A 
cadherin V 
(Motaln et al., 2010; 
Parekkadan and Milwid, 2010) 
CD166 
(Motaln et al., 2010; 
Parekkadan and Milwid, 2010; 
Baron and Storb, 2012) 
CD146 
CD58 
CD54 
CD49e 
CD10 
(Motaln et al., 2010; 
Parekkadan and Milwid, 2010) 
CD271 
(Quirici et al., 2002; 
Motaln et al., 2010; 
Parekkadan and Milwid,2010) 
Sca-1 (Wu et al., 2007) 
Chemokine Receptors 
CXCR1, CXCR2, 
CXCR3, CXCR4, 
CXCR5, CCR1, 
CCR4, CCR7, 
CCR9, CCR10, 
CX3CR1 
(Patel et al., 2013) CD80 
CD86 
(Motaln et al., 2010; 
Parekkadan and Milwid, 2010; 
Rastegar et al., 2010) 
Table 1.1 Positive and negative markers of MSCs. 
MSCs are able to express a wide range of cluster of differentiation (CD) markers and many chemokine 
receptors. These markers enable MSCs to bind to a variety of growth factors, cytokine and chemokines 
and their activating ligands thereby MSCs participate in a wide range of cellular activities and treating 
many pathological conditions. On the other hand, MSCs determined as negative haematopoietic stem 
cell markers. 
In addition to the phenotypic characterisation of MSCs, they could be characterised 
according to their differentiation potential. 
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1.5 DIFFERENTIATION POTENTIAL OF MESENCHYMAL STEM CELLS 
It has been well documented that MSCs possess the ability to remain undifferentiated for 
long periods keeping, concurrently, their differentiation potency along unipotent (one 
lineage), multipotent (multiple lineages) or pluripotent (all three germ lineages) (Young, 
2004; Hua et al., 2009; Rastegar et al., 2010) have described MSCs as progenitor cells 
with multipotency with the ability to differentiate into several types of cells. Other 
researchers have suggested that MSCs can differentiate into keratinocytes in epidermis, 
pericytes and endothelial cells in vivo (Li et al., 2006; Hocking and Gibran, 2010). They 
can also differentiate into a multi-layered epidermis-like structure (Ma et al., 2009) and 
skin cells (Hua et al., 2009). Additionally, MSCs in the skin adjacent to the wound, can 
differentiate into sebocytes of the sebaceous glands. Moreover, it has been reported that 
MSCs are capable of differentiating into tri-mesenchymal lineages, osteocyte, adipocytes 
and chondrocytes, under both in vivo conditions and in vitro culture (Deans and Moseley, 
2000; Oswald et al., 2004; Dan et al., 2006; Dominici et al., 2006; Rea et al., 2009; Wang 
et al., 2012a). Furthermore, BM-MSCs can differentiate into fibroblasts, and keratinocytes 
(Rea et al., 2009), tendonogenic lineages (Majumdar et al., 2000), cartilage, bone, 
muscle, adipose tissues (Kadir et al., 2012), cardiomyogenic and neuronal lineages 
(Jackson et al., 2007; Rastegar et al., 2010). Figure 1.2 illustrates the differentiation 
potential of MSCs. 
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Figure 1.2 Differentiation Potential of MSCs. 
MSCs are pluripotent stem cells and have the ability to differentiate into different cell types of all the 
germ layers, i.e., it is well documented that MSCs possess mesodermal commitment and differentiate 
into bone, cartilage and fat cells. * The ability of MSCs to possess endodermal commitment, such as 
cardiosmyocyte, lung cells, gut cells and muscle cells and ectodermal cells including neurons, 
sebocytes, epithelial cells and keratinocyte like cells is still controversial and more studies are required 
to confirm these claims.  
In addition to their differentiation potential, MSCs are a promising target for cellular therapy 
because they secrete a wide range of biomolecules. 
1.6 BIOLOGICALLY ACTIVE SUBSTANCES SECRETED BY MESENCHYMAL STEM CELLS 
The potential of MSCs in regenerative medicine and wound healing has been illustrated 
by their secretion of biomolecules including growth factors, cytokines and chemokines 
(Chen and Tuan, 2008; Gnecchi et al., 2008; Tamama and Kerpedjieva, 2012). Some 36 
cytokines have been reported to be released by MSCs which act in concert to promote 
the wound healing process (Hwang et al., 2009). 
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1.6.1 GROWTH FACTORS 
Human MSCs secrete a wide range of growth factors that play a significant role in the 
wound healing process. These are; angiopoietins (ANGPT), connective tissue growth 
factors (CTGFs), epidermal growth factor (EGF), fibroblast growth factors (FGFs), insulin-
like growth factors (IGF), keratinocyte growth factor (KGF), nerve growth factor (NGF), 
platelet derived growth factor (PDGF), transforming growth factor (TGF), vascular 
endothelial growth factor (VEGF) and scatter factors (SF) which are a family of growth 
factors also known as plasminogen-related growth factors (PRGFs), which include two 
members: hepatocyte growth factor (HGF) also referred to as plasminogen-related growth 
factor-1 (PRGF-1) and macrophage-stimulating protein (MSP) which is also known as 
scatter factor-2 (SF-2) or hepatocyte growth factor like protein (HGFL) (Table 1.2). 
Growth Factors Function(s) Reference 
ANGPT 
ANGPT-1 is responsible for the stabilization of blood 
vessels and promotes wound closure  
(Barrientos et al., 2008b) 
(Chen et al., 2008) 
ANGPT-2 causes vessel destabilization and remodelling  (Werner and Grose, 2003) 
CTGFs 
Stimulation of chemotaxis, proliferation of fibroblasts, and 
the induction of extracellular matrix proteins including 
fibronectin and collagen type I  
(Werner and Grose, 2003) 
Promote endothelial angiogenesis, survival, migration , 
proliferation, and adhesion.  
(Shimo et al., 1999) 
EGF 
Reepithelialisation of skin wounds (Alfaro et al., 2013) 
Promotion of wound closure (Werner and Grose, 2003) 
FGFs 
Exert a cytoprotective function in would repair , supporting 
cell survival under stress conditions  
(Wang et al., 2012a) 
Promotes mitogenic activity for keratinocytes and fibroblasts 
at the wound site. FGF1 and FGF2 stimulate angiogenesis. 
basic fibroblast growth factor (bFGF) enhances the 
proliferation of endothelial cells and smooth muscle cells.  
IGF 
In association with heparin-binding epidermal growth factor 
(HB-EGF), IGF enhances the proliferation of keratinocyte in 
vitro. Mitogenesis and survival of many cells is stimulated 
by IGF-I and IGF-II promoting wound closure.  
(Werner and Grose, 2003) 
KGF 
Promotes wound closure in two ways;  van de Kamp et al., 2013 
(1) it serves as a transporter for alveolar epithelial f luid  
(Werner and Grose, 2003) 
(2) Play a role in tissue remodeling.  
NGF 
Involved in fibroblast migration, increasing expression of 
actin by smooth muscle and collagen gel contraction by 
these cells 
(Wang et al., 2012a) 
Performs two functions in wound healing; (1) stimulation of 
keratinocyte proliferation and inhibiting apoptosis in vitro, 
(2) supporting the proliferation of human dermal 
microvascular endothelial cells and their adherence 
molecule expression.  
(Maxson et al., 2012) 
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PDGF 
Stimulates DNA synthesis, attracting fibroblasts to wound 
sites, enhancing their production of  collagenase, collagen 
and glycosaminoglycan 
(Micera et al., 2001) 
The first chemotactic growth factor participating in migration 
of fibroblasts, monocytes, and neutrophils into t he skin 
wound, subsequently stimulating the production of 
extracellular matrix and the induction of a myofibroblast 
phenotype. 
(Werner and Grose, 2003) 
HGF 
or 
PRGF-1 
It inhibits fibrosis and promotes re -epithelialisation 
(Maxson et al., 2012) 
Enhances keratinocytes to migrate, proliferate and produce 
matrix metalloproteinase and stimulates new blood vessel 
formation 
MSP 
Accelerates cell migration and proliferation with regulation 
of proliferation and differentiation of keratinocytes and 
macrophages. plays an integral role in inflammation, 
proliferation and the remodelling phases of the healing 
process 
(Werner and Grose, 2003) 
TGF 
Enhances proliferation of epithelial cells, expression of 
antimicrobial peptides and release of chemotactic cytokines  
(Alfaro et al., 2013) 
TGF-β1 activates keratinocytes and macrophages, while 
suppressing T-lymphocytes (Werner and Grose, 2003) 
TGF-β3 stimulates remodelling  
Activins which are members of TGF-β family act as 
enhancers for granulation tissue fibroblasts and the 
induction of extracellular matrix deposition 
(Wang et al., 2012a) 
Activin B supports wound repair and regeneration of hair 
follicles; promoting wound closure 
(Maxson et al., 2012) 
VEGF 
Regulates angiogenesis (Zhang et al., 2013) 
VEGF-α promotes wound closure  
Werner and Grose, 2003 
(Caplan, 2009) 
Promotes proliferation of endothelial cells  
(Barrientos et al., 2008b) 
(Chen et al., 2008) 
(Maxson et al., 2012) 
Table 1.2 Growth factors secreted by MSCs and their roles in wound healing. 
MSCs secrete a wide spectrum of growth factors. These biological substances participate in wound 
healing from early stages starting with haemostasis and coagulation and ending with remodelling. 
These growth factors promote angiogenesis, accelerate proliferation and also migration of endothelial 
cells. In addition, they are involved in the contraction phase, ending at the last stages of remodelling, 
leading to wound healing in the absence of scar formation. 
1.6.2 CYTOKINES  
Cytokines are small proteins secreted by many cell types which affect the activity of other 
cells including immune cells; they include interleukins, lymphokines and other signalling 
biomolecules including, prostaglandin E2 (PGE2) (Jackson et al., 2012a), cathelicidin 
antimicrobial peptide, 18 kDa (CAP-18) (Krasnodembskaya et al., 2010), granulocyte-
macrophage colony-stimulating factor (GM-CSF) (Hocking, 2012), interferons and tumour 
necrosis factor (TNF) (Werner and Grose, 2003). Here, they are categorised into groups 
depending on their role in the wound healing process (Table 1.3). 
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Cytokine 
Pro-inflammatory Cytokines 
Reference 
Function(s) 
IL-1α Stimulate proliferation of fibroblast and keratinocyte  
Enhance synthesis and breakdown of extracellular matrix proteins  
Control fibroblast chemotaxis 
Regulate immune response 
(Grellner, 2002); 
Werner and Grose, 
2003) 
IL-1β 
IL-6 
TNF-β 
Cytokine 
Anti-inflammatory cytokines 
Reference 
Function(s) 
PGE2 Possess multiple fibro-regulatory activit ies on the wound 
(Jackson et al., 
2012a) 
IL-1 Anti-inflammatory (Ortiz et al., 2007) 
IL-4 Anti-inflammatory 
(Blaber et al., 2012) 
(Maxson et al., 2012) 
IL-13 Anti-inflammatory (Blaber et al., 2012) 
CPA-18 
Anti-microbial peptide 
Reduces inflammation 
(Krasnodembskaya  et 
al., 2010) 
Cytokine 
Proliferative cytokines 
Reference 
Function(s) 
IL-10 
limitation and termination of inflammatory responses  
(Werner and Grose, 
2003; 
(Nemeth et al., 2009) 
(Maxson et al., 2012) 
regulates differentiation and/or growth of keratinocytes and endothelial 
and various immune cells  
(Moore et al., 2001) 
It regulates infiltration of macrophages neutrophils into the wound site  
Promotes expression of pro-inflammatory cytokines 
Reduces matrix deposition 
Inhibits scar formation 
(Werner and Grose, 
2003) 
IL-6 
Regulates cellular responses (Hocking, 2012) 
Promotes epithelial cell migration 
(Tamama and 
Kerpedjieva, 2012)  
Angiogenesis formation 
(Hocking, 2012) 
(Tamama and 
Kerpedjieva, 2012) 
GM-CSF 
Possess mitogenic activity for keratinocytes 
Stimulation of proliferation and migration of endothelial cells  
(Werner and Grose, 
2003) 
Regulates angiogenesis formation, cellular responses, and tissue 
remodelling 
(Hocking, 2012) 
Table 1.3 Cytokines secreted by MSCs and their roles in wound healing. 
MSCs secrete a wide range of cytokines. These secretions initiate and terminate the inflammatory 
phase and accelerate proliferation and also migration of endothelial cells. In addition, they are involved 
in the contraction phase, ending at the last stages of remodelling, leading to wound healing in the 
absence of scar formation. 
1.6.3 CHEMOKINES 
Chemokines are a large family of small cytokines (8–10 kDa) (Rees et al., 2015) 
responsible for stimulating chemotaxis and extravasation of leukocytes; hence referred to 
as so, they are called chemotactic cytokines (Werner and Grose, 2003). They could also 
be classified based on their functions; for example, inflammatory, homeostatic, or even 
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both (Rees et al., 2015). Chemokine receptors are G-protein coupled receptors (GPCRs) 
spanning the lipid bilayer of the cell membrane of the target cell and possess both 
extracellular and intracellular domains (Mellado et al., 2001). Upon binding to their 
receptors, chemokines exert their effect on the target cell, they stimulate a cytoplasmic 
signaling cascade and initiate several physiological processes such as migration, 
degranulation, and trafficking of leukocyte, myofibroblast recruitment, cell differentiation 
and angiogenesis (Rees et al., 2015). Human MSCs release several chemokines that 
participate in wound healing, such as IL-8 and its receptor (CXCL8), macrophage 
chemoattractant protein-1 (MCP-1) ant its receptor (CCL2), macrophage inflammatory 
protein-1 alpha and beta (MIP-1α and MIP-1β) and stromal-derived factor 1 (SDF-1) 
(Table 1.4). 
 Chemokine Function Reference 
1 IL-8 
Increase proliferation of keratinocyte  
Act as chemoattractant for neutrophils  
(Rennekampff et al., 2000) 
Enhances migration of epithelial cells  
(Yew et al., 2011; Tamama and 
Kerpedjieva, 2012) 
2 MCP-1 
Involved in macrophage infiltration   
Act as inflammation regulatory (Werner and Grose, 2003) 
3 
MIP-1α and 
MIP-1β 
Promote wound closure 
(Barrientos et al., 2008b; Chen 
et al., 2008) 
Increases macrophage trafficking  (Blaber et al., 2012) 
4 SDF-1 
Regulates skin homeostasis and tissue 
remodelling 
(Werner and Grose, 2003) 
Promotes wound closure 
(Barrientos et al., 2008b; Chen 
et al., 2008) 
Induces cell migration (Patel et al., 2013) 
Table 1.4 Chemokines secreted by MSCs and their roles in wound healing. 
MSCs secrete chemokines. These biological substances participate in wound healing from early stages 
starting with haemostasis and coagulation and ending with remodelling. They also participate in the 
inflammatory phase and accelerate proliferation and also migration of endothelial cells. In addition, they 
are involved in the contraction phase, ending at the last stages of remodelling, leading to wound healing 
in the absence of scar formation. 
1.6.4 EXOSOMES (MSC-EXOSOME) 
Exosomes are tiny vesicles (30 or 40-100 nm in diameter) present in blood and urine and 
perhaps all other biological fluids that can be collected from in vitro cell culture (Booth et 
al., 2006; Lai et al., 2015; Zhang et al., 2015b). They are Originated from the endosomal 
compartment and released from the  plasma membrane into the extracellular environment 
to participate in coagulation, intracellular signalling communication and cytoplasmic 
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cleaning (Booth et al., 2006; Muralidharan-Chari et al., 2010; Lai et al., 2015; Zhang et al., 
2015a). Like other exosomes, the main physiological role of MSC derived exosomes is 
communication through maintaining a dynamic and homeostatic niche for MSCs to 
communicate with multiple cell types and evoke cellular responses (Lai et al., 2015). 
Collectively, these criteria make MSCs  good candidates for a variety of clinical 
applications (Hocking, 2012) as discussed in the next section.     
1.7 CLINICAL APPLICATION OF MESENCHYMAL STEM CELLS 
As previously stated MSCs possess stem cell-like features including differentiation 
potential with multipotency and self-renewal capacities (Hass et al., 2011; Hocking, 2012). 
Also, they activate a protective mechanism and stimulate endogenous regeneration 
(Caplan and Dennis, 2006). They can be found in nearly all body tissues (Amoh et al., 
2005b; Rastegar et al., 2010; Hass et al., 2011). Furthermore, they are characterised by 
their homing ability and a wide range of secreting profiles of bioactive molecules important 
for wound healing, tissue regeneration and certain cancers (Hass et al., 2011). Moreover, 
the easy procedure of harvesting MSCs and their great plasticity are important 
characteristics for allogeneic and autologous cell mediated therapies (Song et al., 2007). 
Finally and fortunately, MSCs have been considered as safe, with respect to therapeutics 
since no critical adverse side effects of MSCs have been detected during therapy (Patel 
et al., 2013). Collectively, these characteristics and functions underlie the importance of 
MSCs in clinical application making them good candidates for regenerative medicine and 
tissue engineering (Hocking, 2012; Tamama and Kerpedjieva, 2012). MSCs are also 
characterised by proliferation and senescence which are very important concepts for 
researchers looking for new therapeutic strategies (Jin et al., 2013a). The most popular 
application of MSCs in regenerative medicine is utilising them in wound healing and skin 
regeneration (Yeum et al., 2013). However, MSCs have more clinical applications 
including ameliorating tissue damage in nearly all the major organs of the body such as 
skin regeneration, cardiac therapy, hepatic cirrhosis (Lau et al., 2009; Hocking and 
Gibran, 2010; Si et al., 2011), brain, lung, kidney and eye (Lau et al., 2009; Hocking and 
Gibran, 2010). Additional applications of MSCs are pancreatic regeneration, neurological 
defects, limb ischemia, graft-versus-host disease (GvHD), rheumatoid arthritis, 
osteoarthritis (OA) and other bone and cartilage disorders (Si et al., 2011). 
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1.7.1 MESENCHYMAL STEM CELLS IN SKIN REGENERATION 
Wounding in higher organisms will evoke two types of biological responses; tissue 
regeneration and wound repair. MSCs leave their niche to the affected tissues and 
participate mainly in both responses (Fu and Li, 2009). Recently, skin regeneration 
especially cutaneous regeneration via MSC engraftment to heal wounds has significantly 
progressed because they can accelerate wound closure as well as re-epithelialization and 
angiogenesis. Notably, BM-MSCs transplanted into the injury site express keratinocyte 
specific protein (KSP) and form glandular structures (Wu et al., 2007). One successful 
therapy was the induction of BM-MSCs, expressing the phenotypic characteristics of 
sweat gland cells (SGCs) in vitro and transplanting these cells into fresh wounds of deep 
burns. In five patients recovery of functional sweat glands with perspiration function 
occurred within 2–12 months follow up after the procedure, indicating that SGCs derived 
from MSCs were involved in the recovery of functional sweat glands (Sheng et al., 2009). 
Another study focusing on chronic diabetic foot ulcers showed that injection of a biograft, 
consisting of a combination of MSCs and autologous skin fibroblasts, increased both the 
thickness and the vascularity of the dermis and reduced wound size when applied directly 
to the wound site (Vojtassak et al., 2006; Fu and Li, 2009). Another study has investigated 
the differentiation potential of MSCs in skin regeneration and showed that MSCs acquire 
phenotypic characteristics of epidermal cells or vascular endothelial cells after in vitro 
culture in media supplemented with EGF or VEGF, respectively (Fu and Li, 2009). Finally, 
MSCs undergo transdifferentiation into keratinocytes enabling them to interact with 
original epidermal cells suggesting that MSCs can participate directly in tissue 
regeneration of both dermal and epidermal cells (Jackson et al., 2012a). These 
characteristics, collectively, reveal the plasticity of MSCs making them a promising cellular 
source to regenerate skin; consequently, their potential use as a therapeutic technology 
for wound healing (Sheng et al., 2009). However, more information is required about the 
use of MSCs before applying them as a therapeutic option, such as the MSC niche and 
factors required for MSC differentiation. In addition, the use of MSCs in the clinic is still 
challenging since it requires proof of concept MSC-therapy multi-centre large scale clinical 
trials (Si et al., 2011). 
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1.7.2 UTILISATION AND MODE OF ACTION OF MESENCHYMAL STEM CELLS IN WOUND HEALING 
MSCs are the pivotal player for coordinating the repair process by differentiation and 
secreting biologically active substances thereby recruiting other host cells. They are 
therefore involved in all phases of the healing process (Maxson et al., 2012; Zahorec et 
al., 2015). For instance, MSCs modulate the immune response (Yagi et al., 2010; Blaber 
et al., 2012) by enhancing the synthesis of anti-inflammatory cytokines including IL-10 and 
IL-4. They are also supress the production of pro-inflammatory cytokines such as tumor 
necrosis factor-alpha (TNF-α) and interferon-gamma (IFN-γ) (Aggarwal and Pittenger, 
2005). Additionally, MSCs can evoke several mechanisms (see 1.8.1) which result in 
escaping the immune surveillance during immunosuppressive therapies (Sasaki et al., 
2008). Moreover, MSCs produce bioactive substances to act as inhibitors for fibrosis and 
apoptosis and to act as inducers for angiogenesis, mitosis and / or differentiation of 
progenitor cells, activating target cells or neighbouring cells to release biologically active 
substances (Caplan and Dennis, 2006). All in all, MSCs impact the whole phases of 
wound healing; inflammation, proliferation and tissue remodelling (Hocking and Gibran, 
2010) including the cutaneous wound healing process (Rea et al., 2009). Many recent 
studies suggest that MSCs are the main candidates for cell mediated therapies and tissue 
regeneration (Sasaki et al., 2008) not only for their differentiation ability but also for their 
ability to produce active biomolecules (Caplan and Dennis, 2006). Therefore, 
differentiation and paracrine signalling have both been implicated as mechanisms by 
which MSCs recruit other host cells  in all steps of the healing process to improve tissue 
repair (Hocking and Gibran, 2010). To better understand the role of MSCs in wound 
healing, their participation in repair can be divided into two major mechanisms; (1) cell 
mediated repair and (2) secretory mediated repair as illustrated in (Figure 1.3). 
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Figure 1.3 Potential applications of MSCs in wound healing. 
MSC therapy contributes to skin wound healing via two mechanisms: (1) Differentiation into skin‐like 
cells (SLCs), thereby compensating for the loss of cells due to damaged tissue. (2) Promote proliferation 
and migration of skin cells into the injury site by secreting soluble factors and macrovesicles. MSC 
secretions represented by MSC‐CM and MSC‐EXOSOME can be either injected onto the wounded 
skin area or applied on the skin wound using biofilm dressings. 
1.7.2.1 CELL MEDIATED REPAIR 
In vitro studies have shown that MSCs possess phenotypic properties resembling native 
dermal fibroblasts or myoblasts (Yamaguchi et al., 2005). Furthermore, BM-MSCs may 
accelerate wound closure by differentiating into epidermal keratinocytes and other skin 
cells (Alfaro et al., 2008; Hocking and Gibran, 2010). Recent studies have shown that 
MSCs undergo transdifferentiation into keratinocytes, epidermal cells and microvascular 
endothelial cells when cultured under defined culture conditions (Jackson et al., 2012a) 
and express keratinocyte specific protein keratin (KSP) (Chen et al., 2009; Chen et al., 
2015). MSCs therefore could be utilised for wound healing by transplanting  aggregated 
MSCs into the injured tissue to increase collagen deposition and improve epithelisation 
(An et al., 2015). They can also differentiate into other skin cells such as endothelial cells, 
keratin-14-positive cells and pericytes (Sasaki et al., 2008), and when localised to blood 
vessels and dermis, sebaceous glands and hair follicles (Hocking and Gibran, 2010). 
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1.7.2.2 SECRETORY MEDIATED REPAIR: ROLE OF MSC-CM  
Paracrine signalling of BM-MSC is the major mechanism by which these cells contribute 
to wound repair, where their secretory products impact on inflammation, fibrotic 
proliferation and angiogenesis (Gnecchi et al., 2008). Many studies have reported that 
MSC-conditioned medium (MSC-CM) significantly promotes wound healing by affecting 
the pivotal steps of the repair process. The components of MSC-CM have accelerated 
epithelialization, and via chemotaxis recruited endothelial cells and macrophages to the 
injured site in vivo (Chen et al., 2008). The MSC-CM recruits both epidermal keratinocytes 
and dermal fibroblasts to the wound site in vitro (Chen and Tuan, 2008; Hocking and 
Gibran, 2010). As well as its activity as a chemo-attractant, MSC paracrine secretions 
serve as regulators of cell migration in response to wounding leading to faster wound 
closure by regulating dermal fibroblast migration (Smith et al., 2010). MSC secretory 
mitogens stimulate the proliferation of keratinocytes, dermal fibroblasts and endothelial 
cells (Kim et al., 2007). MSC-CM contains all the effector biomolecules for tissue 
regeneration and wound healing by promoting migration, proliferation and differentiation 
of human skin cells such as fibroblasts and keratinocytes. Collectively, these data suggest 
that MSC-CM may represent a novel therapeutic strategy for wound therapy (Tamama 
and Kerpedjieva, 2012). Figure 1.4 summarises the participation of MSC secretions in 
wound healing. 
1.7.2.3 SECRETORY MEDIATED REPAIR: ROLE OF MSC-EXOSOMES 
It has been reported that MSC-EXOSOMES repair renal injury indicating that MSC-
EXOSOMES are a potential mechanism which could be harnessed for wound healing (Li 
et al., 2013; Zhang et al., 2015a; Zhang et al., 2015b). With respect to wound healing, 
MSC-EXOSOMES play an important role in collagen synthesis, the acceleration of cell 
migration and proliferation and in the formation of new and mature blood vessels (Zhang 
et al., 2015b). Exosome healing action could be attributed to its ability to transfer RNA, 
microRNA and proteins into the injured tissues, participating in skin repair by promoting 
re-epithelialization and cell proliferation as well as activation of β-catenin, which plays a 
pivotal role in skin development and wound healing (Li et al., 2013). Additionally, MSC-
EXOSOMS have been shown to accelerate wound repair by mediating signalling 
cascades of some genes such as alpha serine/threonine kinase (Akt), extracellular signal-
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regulated kinase (ERK), and signal transducer and activator of transcription 3 (STAT3) as 
well as by enhancing the expression of important growth factors i.e., HGF, IGF-1, NGF 
and SDF-1 which collectively accelerate migration and proliferation of fibroblasts in normal 
and diabetic wounds (Shabbir et al., 2015). Moreover, MSC-EXOSOME reduces the 
levels of pro-apoptotic Bax gene, therefore inhibiting apoptosis of skin cells such 
keratinocytes and fibroblasts (Rani and Ritter, 2015; Zhang et al., 2015a). Collectively, 
these data suggest the MSC-EXOSOMES play a significant role in wound healing. 
The application of MSC-CM or MSC-EXOSOMES onto chronic wounds either by direct 
injection or by designing biological dressings enriched with MSC-CM or MSC-
EXOSOMES, collected from autologous MSCs, may therefore provide a valuable 
therapeutic strategy. 
 
Figure 1.4 Participation of MSC secretions in wound healing phases and events. 
MSCs secrete a wide spectrum of growth factors, cytokines and chemokines. These biological 
substances participate in wound healing from early stages, starting with haemostasis and coagulation 
and ending with remodelling. These secretions initiate and terminate the inflammatory phase and 
promote angiogenesis, accelerate proliferation and also migration of endothelial cells. In addition, they 
are involved in the contraction phase, ending at the last stages of remodelling, leading to wound healing 
in the absence of scar formation. 
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1.8 BENEFITS OF THE USE OF MESENCHYMAL STEM CELLS IN TREATING WOUNDS 
1.8.1 IMMUNOMODULATORY FEATURES OF MSCS  
In 2000, Liechty et al. were the first to recognise that MSCs possess unique immunologic 
features allowing them to persist in a xenogeneic environments and modulate the immune 
response (Liechty et al., 2000). They have the potential to reduce inflammation and 
enhance wound repair (Nuschke, 2014). The exact mechanism by which MSCs modulate 
the immune system is not fully understood. The potential mechanism includes cell to cell 
direct contact, secretion of immune suppressive factors and interaction with other immune 
cells such as T-lymphocytes, B- lymphocytes, dendritic cells (DC) and natural killer (NK) 
cells (Popp et al., 2008). In 2013 Patel and colleagues reported that MSCs suppress both 
the activation and proliferation of lymphocytes, in response to allogeneic antigens, as well 
as enhancing the development of CD8+ regulatory-T cells (T-reg) in suppressing an 
allogeneic lymphocyte response (Patel et al., 2013). Additional immune suppressive 
activities of MSC include inhibition of differentiation of peripheral blood monocyte 
progenitor cells and CD34+ haemopoietic progenitor cells (HPC) into antigen presenting 
cells (APCs) (Djouad et al., 2007). MSCs also inhibit the proliferation of NK cells mediated 
by IL-2 or IL-15 (Sotiropoulou et al., 2006). MSCs have been shown to exert other 
immunomodulatory activities including altering the proliferation and activation of B-cells, 
IgG production, antibody secretion, chemoattractant behaviour, and reducing the 
expression of CD40, and CD86 and major histocompatibility complex class II (MHC-II) 
(Petrie Aronin and Tuan, 2010). 
The ability of MSCs to modulate T-cell proliferation (Chamberlain et al., 2007) and 
suppress the proliferation of B-cells (Corcione et al., 2006) and NK cells (Sotiropoulou et 
al., 2006) is well documented. By attenuating the function of these cells, MSCs reduce the 
pro-fibrotic process (Redd et al., 2004). Importantly, by the secretion of prostaglandin 
E2   (PEG2) (Foraker et al., 2011) and IL-10 (Nemeth et al., 2009; Maxson et al., 2012). 
MSCs also regulate macrophage and lymphocyte function (Jackson et al., 2012a). For 
instance, PGE2 attenuate mitogenesis and proliferation of T-cells in the wound (Djouad 
et al., 2007) acting as co-operator in regulating the transition from Th1 cells into Th2 
cells (Zanone et al., 2010). On the other hand, IL-10 prevents the deposition of excessive 
collagen and inhibits the invasion of neutrophils into the wound and their release of 
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reactive oxygen species (ROS), which collectively participate in the prevention of scar 
tissue formation (Jackson et al., 2012a). 
1.8.2 MIGRATION AND ENGRAFTMENT CAPACITY  
Various studies have reported the capability of MSCs to selectively migrate to and engraft 
into the wound site and exert local functional effects on inflammatory reactions regardless 
of tissue type (Jackson et al., 2012a; Wang et al., 2012a). In this context, murine studies 
have shown that MSCs can home to the lung, adopting phenotypic characteristics of 
epithelium like cells and reducing inflammation in response to injury (Ortiz et al., 2003). 
Another study in mdx mice, a strain of mice arising from a spontaneous mutation (mdx) in 
inbred C57BL mice, showed that MSCs may migrate to muscle tissues (Liu et al., 2007).  
MSC migration has been shown to be regulated by a multitude of signals (Spaeth et al., 
2008) ranging from growth factors such as platelet derived growth factor (PDGF) insulin 
like growth factor-1 (IGF-1) and cytokines such as SDF-1, chemokines such as CCL5  and 
C-C motif chemokine receptors including; CCR2, CCR3 and CCR4 (Yagi et al., 2010; 
Wang et al., 2012a). 
1.8.3 WOUND CLOSURE ACCELERATION 
MSCs play a role not only in wound healing but also in accelerating the healing process 
by increasing the tensile strength of the healing wound (the ability of the healing wound 
to resist the tension) (Ireton et al., 2013) and by reducing scaring (Hocking and Gibran, 
2010). The effects of MSCs during wound healing include acceleration of epithelialization, 
an increase in angiogenesis and the formation of granulation tissue (Maxson et al., 2012). 
These activities are attributed to the ability of MSCs to produce biologically active 
substances capable of accelerating the regeneration process (Mishra and Banerjee, 
2012) including interlukin-8 (IL-8) and C-X-C motif ligand 1 (CXCL1), responsible for 
stimulating the migration of epithelial cells and accelerating wound closure (Yew et al., 
2011). 
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1.8.4 ANTIMICROBIAL ACTIVITY 
Secretions of MSCs (MSC-CM) is capable of inhibiting bacterial growth. MSCs produce 
and release substantial amounts of the anti-bacterial substance known as human 
cathelicidin peptide-18 (hCAP-18) produced by the gene LL-37, characterised by itsability 
to retard in vitro growth of P. aeruginosa and E. coli (Krasnodembskaya et al., 2010), thus, 
avoiding wound contamination and infectious complications which exacerbate the healing 
process (Guo and DiPietro, 2010). 
1.8.5 PREVENT CHRONIC CONDITION 
Besides having immunomodulatory activities, the effective biomolecules secreted by 
MSCs can prevent wounds from reaching a chronic state by their angiogenic and anti-
apoptotic characteristics (Blaber et al., 2012). For instance, transplantation of human 
MSCs intramyocardially, have the ability to improve cardiac function via enhancing 
myogenesis and angiogenesis in the ischemic myocardium (Liu et al., 2008). MSCs also, 
enable a wound to progress to healing beyond the inflammation stage and not regress 
into a chronic state (Maxson et al., 2012). 
1.8.6 ATTENUATION OF SCAR FORMATION 
The tissues in the scar have many disadvantages, including their undesirable visual 
appearance and lack of structures that are present in the native skin such as hair follicles, 
sebaceous glands and sensory nerve receptors (Jackson et al., 2012a). In addition, scar 
tissue weakens the skin making it more susceptible to re-injury (Buchanan et al., 2009). 
MSCs have been shown to overcome these disadvantages via attenuating scar formation 
(Jackson et al., 2012b).  
1.8.7 NEUTRALIZING THE REACTIVE OXYGEN SPECIES (ROS) 
Although IL-10 participates in preventing the invasion of neutrophils into the site of tissue 
injury and the enhancement of collagen deposition, the penetrations of some populations 
results in the release of reactive oxygen species (ROS), which are oxygen molecules 
with unpaired electrons making them extremely reactive. These include superoxide, 
hydrogen peroxide and alkyl peroxides (Poli, 2000). 
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Many tissues are susceptible to attack by ROS contributing to dangerous diseases 
including heart disease and cancer. Also, prolonged persistence of ROS induces 
fibrogenesis and the accumulation of fibrotic tissues (Jackson et al., 2012a). To counter 
such effects, MSCs significantly up-regulate the expression of nitric oxide synthase (Sato 
et al., 2007) which alters the ROS balance eand prevents the formation of fibrotic 
tissues (Ferrini et al., 2002). 
1.8.8 PRODUCING ANTI-FIBROTIC FACTORS 
MSCs release growth factors and cytokines characterised by their anti-fibrotic activities 
such as hepatocyte growth factor (HGF) and IL-10 (Li et al., 2009). HGF has been shown 
to down-regulate the expression of collagen type I and type III by fibroblasts therefore 
attenuating fibrosis and scar formation (Mou et al., 2009). Moreover, HGF impacts on the 
keratinocyte behaviour by promoting their migration, proliferation and expression of 
vascular endothelial growth factor A (VEGF-A), thereby generating a well granulated 
tissue with a high degree of vascularization and re-epithelialization (Jackson et al., 
2012a). 
1.8.9 ENHANCING DERMAL FIBROBLAST FUNCTION 
In response to the wounding process, fibroblasts present at the injury site produce 
additional quantities of extracellular matrix (ECM) to restore the integrity of the skin leading 
to scarred tissue (McAnulty, 2007). Also, many endothelial cells undergo epithelial-to-
mesenchymal transition (EMT) under the effect of transforming growth factor beta 1 (TGF-
β1) and become wound healing myofibroblasts (Jackson et al., 2012b). Both of these 
actions affect the function of dermal fibroblasts. Therefore, MSCs present in the wound 
site enhance dermal fibroblast function by producing HGF and PGE2 which both play a 
role in inhibiting epithelial-mesenchymal transition (EMT) (Zhang et al., 2006); and secrete 
biomolecules promoting the function of dermal fibroblast in wound healing (Smith et al., 
2010). MSCs therefore enable the cells present in the wound site to release ECM, similar 
to those produced by neighbouring dermal cells (Jackson et al., 2012a). 
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1.8.10 PROMOTING ANGIOGENESIS AND VASCULAR STABILITY 
It has been well documented that BM-MSCs play a major role in angiogenesis and 
microvascularisation via promoting proliferation, migration and differentiation of 
microvascular endothelial cells by producing basic Fibroblast Growth Factor (FGF) and 
VEGF-A (Renault et al., 2009).  
In the same way, more information about the skin and its structure is necessary in order 
for a better understanding of the healing process as discussed below. 
1.9 HUMAN SKIN 
Human skin represents the largest organ of human body since it constitutes approximately 
15 % of the total adult body weight (Kanitakis, 2002). It serves many vital roles, such as 
protection against foreign invader microbes, thermal insulation, sensation, as well as 
homeostasis regulation. Therefore, a body with injured or damaged skin cannot perform 
such important functions and consequently, will be at risk of numerous complications 
including infection and fluid loss (Kanitakis, 2002; Xie et al., 2010).  
1.9.1 HUMAN SKIN LAYERS 
Human adult skin is composed basically of three layers; epidermis, dermis, and 
hypodermis (subcutaneous) (Kanitakis, 2002; Banerjee and Sen, 2013) (Figure 1.5). 
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Figure 1.5 Simplified structure of human skin. 
Human skin is composed of three cellular layers; epidermis and dermis separated by the basement 
membrane; and a lower subcutaneous layer. The skin also contains glands such as sebaceous (oil) 
glands and sweat glands; in addition to blood vessels, hair follicles and nerves. (Adapted from 
www.thinglink.com with some amendments).  
1.9.1.1 EPIDERMIS 
The epidermis consists of four stratum layers, the skin surface, basal, spinosum, 
granulosum and stratum corneum (Banerjee et al., 2011) (Figure 1.6). Collectively, these 
layers constitute the epidermis, which represents the outer barrier of the human body. The 
keratinized stratified tissues provide a waterproof integral part of the body (Martin, 1997). 
The main cells present in the epidermis are keratinocytes, melanocytes, Langerhans cells 
and Merkel cells. Keratinocytes represent the dominant cell type in the epidermis since 
they constitute the vast majority of cells in the four epidermal sublayers. Keratinocytes in 
each layer express a panel of differential proteins which are used as biomarkers to detect 
keratinocyte differentiation. In the basal layer, basal keratinocytes express keratin 5 (K5), 
K14 and K15. During usual skin renewal, basal cells proliferate and differentiate into a 
spinous layer and express a different panel of proteins such as transglutaminase 1 & 5. 
The cells of spinous layer continue differentiating into a granular layer when cells express 
early differentiation markers such as K1, K2, K10, profilaggrin & transglutaminase 3. 
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Stratum corneum or the cornified layer is the late differentiating layer of epidermis. Cells 
in this layer express late differentiation markers such as loricrin, involucrin, trichohyalin, 
S100 proteins and small-molecules rich in protein (Chu and Weiss, 2002; Chu, 2008; 
Banerjee and Sen, 2013).  
  
Figure 1.6 Simplified structure of human epidermis. 
The epidermal layer is composed of four cell types; keratinocytes, melanocytes, Langerhans cells and 
Markel's cells. However, the epidermis does not contain blood vessels. [Adapted from (Visscher and 
Narendran, 2014) with some amendments]. 
1.9.1.2 DERMIS 
The dermis represents the second supportive layer of the skin located beneath the 
epidermis and connected to each other by the basal membrane (Chu, 2008). Connective 
tissues, collagen and elastic fibres are the primarily components of the dermis, which 
support the skin against stress and strain (Martin, 1997). Another supportive component 
of the dermis is its base which is made of a glycosaminoglycan-proteoglycan fraction 
which in turn is composed of macromolecules (polysaccharides and protein) which play a 
vital role in tissue remodelling and wound repair (Banerjee and Sen, 2013). The main 
dominant cell types in the dermis are fibroblasts, mast cells, macrophages and 
lymphocytes (Banerjee et al., 2011) in addition to blood  and lymphatic vessels and hair 
follicles (Chu, 2008). 
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1.9.1.3 HYPODERMIS 
The hypodermis is also termed subcutaneous tissue. It consists of elastin, connective 
tissue (mainly loose connective tissue) and fat which represent 50 % of the body’s fat. 
The primarily cells available in this layer are fibroblasts, adipocytes and macrophages 
(Chu, 2008). 
1.9.1.4 BASEMENT MEMBRANE 
The basement membrane is a type of extracellular matrix composed mainly of 
proteoglycans, glycosaminoglycans, collagen IV, and laminin, in addition to a wide 
spectrum of growth factors which regulate several cellular activities (Mao et al., 2015). It 
represents a junction between the dermis and the epidermis and binds to a variety of 
growth factors and cytokines to control the trafficking in both directions. It is therefore 
significantly involved during repair and remodelling (Iozzo, 2005).   
1.9.2 SKIN GLANDS 
Sebaceous glands are located all over the body, in the base of hair follicles, except the 
hands palms soles of the feet (Ro and Dawson, 2005). Their main function is 
thermoregulatory, when the skin is under cool or hot conditions keeping it emulsified by 
the action of sebum secreted by the glands (Porter, 2001). Sweat glands, primarily eccrine 
sweat glands are distributed all over the human body and concentrated mainly in the 
forehead, palms, soles of the feet and underarms. They contribute in re epithelialisation 
of wounded skin by generating outgrowths of keratinocytes which form a new epidermis 
(Rittie et al., 2013). 
1.9.3 SKIN PROTEINS 
The most abundant protein present in human skin is collagen, constituting up to 75% of 
human skin. It contributes to anti-ageing by fighting wrinkles and lines. Unfortunately, 
collagen production is affected by many factors such as ageing and environmental 
conditions (Igarashi et al., 1996; Tsukahara et al., 2002). Elastin is related to skin wrinkling 
and sagging and provides structure for skin and organs in association with collagen in the 
dermis (Igarashi et al., 1996; Tsukahara et al., 2002). Another skin protein is keratin, which 
provides skin rigidity and is the strongest protein in the skin (Igarashi et al., 1996). 
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1.9.4 OTHER SKIN COMPONENTS 
Blood vessels besides their function in keeping our bodies at stable temperature, also play 
a significant role in maintaining tissue and repairing wounds (Amoh et al., 2004). Hair 
follicles originate from fatty layers located in subcutaneous tissue and give rise to blood 
vessels thereby contributing to skin regeneration (Amoh et al., 2005b). Nerves of the skin 
are mainly, related to skin sensation. They consist of unmyelinated small sensory fibres. 
During nerve formation, the number of the axons decreases and the somatic fibres 
become myelinated (Chu, 2008). The skin pigments melanin and haemoglobin are able 
to absorb sunlight and are the main chromophores responsible for skin colour. Melanin is 
produced by specific cells located in the epidermis called melanocytes and their main 
function is protecting the skin by absorbing and dispersing UV light (Igarashi et al., 1996). 
In addition to skin cells, other cell types participate  in the healing process as described 
below. 
1.10 CELLS INVOLVED IN SKIN REGENERATION AND WOUND HEALING 
1.10.1 KERATINOCYTES 
The majority of cellular component of human epidermis are keratinocytes since they 
constitute 95 % of epidermal cells. They are found in the different layers of epidermis and 
referred to as the same name as the layer such as the basal keratinocytes. They are also 
found in the mucosa of the mouth and oesophagus and referred to as squamous 
keratinocytes. They tighten the nerves of the skin and serve as a junction between the 
epidermis and the dermis, keeping the epidermal Langerhans and the dermal 
lymphocytes in place (Pastar et al., 2014). In wounded skin, keratinocytes have several 
critical roles and are involved in the complicated mechanisms of inception, maintenance 
and healing. In chronic wounds, healthy keratinocytes cross-talk with other cell types, and 
remove and replace unhealthy cells from a quiescent wound edge (Santoro and Gaudino, 
2005). 
1.10.2 FIBROBLASTS 
Fibroblasts are a type of cells mainly present in the connective tissue of the body and 
responsible for producing ECM and collagen which together form the framework structure 
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of many tissues and play a pivotal role in tissue repair (Darby et al., 2014). These types 
of cells present in two alternative states, as inactive fibrocyte and active fibroblasts (Mine 
et al., 2009). The main function of the fibroblast is supporting the connective tissue and 
maintaining the integrity of tissue structures by secreting collagen, extracellular precursors 
and fibers (Eyden, 2005). Meanwhile, during angiogenesis, fibroblasts start migrating 
towards the wound site as the inflammatory phase terminates (two to five days post-
wounding) and become the most dominant cell type at the injury site (Hinz and Gabbiani, 
2003). Fibroblasts are important cells supporting the healing process and are involved in 
the main events such breaking down the fibrin clot, producing a new collagen structure 
and ECM to support other cells involved in the healing process and finally, in wound 
contraction (Darby et al., 2014). 
1.10.3 IMMUNE CELLS 
Immune cells (mast cells, neutrophils, macrophages and lymphocytes) play important 
roles in the healing process of both normal and pathological repair. The immune system 
is activated immediately after the injury and immune-inflammatory cells are recruited from 
the blood circulation, and start the inflammatory response (Zhang and Mosser, 2008; 
Abbas and Lichtman, 2010). The first immune response is the arrival of mast cells to the 
wound site. Mast cells are a type of granular white blood cells, which have originated from 
myeloid stem cells and perform several roles including defence against pathogens, 
participate in immune-tolerance and involved ultimately in wound healing and 
angiogenesis (da Silva et al., 2014; Polyzoidis et al., 2015). However, circulating 
neutrophils infiltrate the wound quicker than other cells and become the most abundant 
immune cells at the injury site during the first two days post wounding (Eming et al., 2007a; 
Wright et al., 2010). Concurrently, circulating monocytes infiltrate into the wound site and 
start to differentiate into mature macrophages which in turn start phagocytic activity 
against the pathogens and cell debris, in addition to secreting collagenases and elastases 
to break down the damaged tissues (Ariel et al., 2012). These macrophages also secrete 
mediators important to inflammation which activate many signals and act as 
chemoattractant to enhance leukocyte migration to the wound site (Sen et al., 2009b). 
The late inflammatory response includes T lymphocytes which appear at the injury site 
while the number of other immune cells diminish, indicating the end of the inflammatory 
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phase and the start of the remodelling and resolution phase of the healing process (Martin 
and Leibovich, 2005). The activities of immune cells due to the inflammatory roles and 
promoting cellular cross-talk via secretion of cytokines (Strbo et al., 2014) may have 
profound effects on the outcome of wound healing; in particular, fibrosis and scar 
formation (Martin and Leibovich, 2005). Understanding different  wound types  is also  
important for successful wound repair.   
1.11 TYPES OF SKIN WOUNDS 
Generally, wounds are classified on the basis of location, depth and tissue loss into three 
categories; superficial wounds where damage affects the epidermis only, partial thickness 
wounds when both the epidermis and dermis are involved, and full thickness wounds 
which involve the dermis, subcutaneous fats and sometimes, bone. However, depending 
on the normal healing trajectory there are two principal categories of skin wounds; acute 
and chronic (Monaco and Lawrence, 2003; Whitney, 2005). 
1.11.1 ACUTE SKIN WOUNDS 
Acute wounds arise either as a result of surgical incision or following traumatic accidents 
including abrasions, superficial burns, and partial thickness injuries with significant loss of 
tissues. Irrespective to their causes, the healing process of acute wounds is complex and 
utilises different types of cells and cytokines (Monaco and Lawrence, 2003). 
1.11.2 CHRONIC SKIN WOUNDS 
Wounds are defined as chronic when they fail to heal during one or all of the phases of 
the healing process causing an injury that cannot be repaired within the expected time 
period of normal wound repair (Maxson et al., 2012).  Chronic wounds mainly accompany 
disorders such as pressure ulcers, diabetes, burns, vascular insufficiency and vasculitis 
(Sen et al., 2009b). The chronic state of non-healing wounds is exacerbated by many 
factors including tissue hypoxia, microbial infection, necrosis, exudates, and an elevated 
ratio of inflammatory cytokines during the different healing stages (Guo and DiPietro, 
2010). Neutrophils also contribute by releasing excessive amounts of collagenase which 
leads to break down of the ECM (Diegelmann and Evans, 2004) and enzyme elastase 
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destroying important healing factors such as platelet-derived growth factor (PDGF) and 
TGF-β. Chronic wounds do not respond to therapy unless the prolonged inflammation is 
targeted (Maxson et al., 2012). Consequently, human skin, with its limited abilities, will fail 
to heal itself in cases of wounds penetrating the epidermis (Jackson et al., 2012a) due to 
the deficiency in growth factors and cytokines which are depleted during the healing 
process (Schönfelder et al., 2005). The mechanisms of wound repair, phases of the 
healing process, and types of wounds are discussed below.  
1.12 PHASES OF THE HEALING PROCESS OF SKIN WOUNDS   
Each wound undergoes a series of successive events for repairing and healing. These 
processes take from several minutes such as coagulation, several days such as 
inflammation to several months or years such as remodelling and can be divided into 
three, four or five overlapping phases and stages. Monaco and Lawrence stated that the 
wound healing process consisted of five distinct phases; (a) haemostasis, (b) 
inflammation, (c) cellular migration and proliferation, (d) protein synthesis and wound 
contraction, and (e) remodelling (Monaco and Lawrence, 2003). Others described the 
healing process as consisting of four highly integrated and overlapping phases: (a) 
haemostasis, (b) inflammation, (c) proliferation, and (d) tissue remodelling or resolution 
(Zhou et al., 2013; Marfia et al., 2015). Other scientists defined the normal wound healing 
mechanism is a dynamic and complex process involving a series of coordinated events, 
including (a) bleeding and coagulation, (b) acute inflammation, (c) cell migration, (d) 
proliferation, (e) differentiation, (f) angiogenesis, re-epithelialization and (g) synthesis and 
remodelling of ECM. Conversely, Maxson and colleagues reported that the healing 
process is a complex event occurring in three overlapping phases: (a) inflammatory, (b) 
proliferative, and (c) remodelling (Maxson et al., 2012). These phases and their bio-
physiological functions must occur in the proper sequence, at a specific time, and continue 
for a specific duration and intensity (Mathieu et al., 2006). There are many factors that 
can affect wound healing which interfere with one or more phases in this process, thus 
causing improper or impaired tissue repair (Guo and DiPietro, 2010). All in all, a successful 
healing process cannot be accomplished without any one of these processes; 
haemostasis, inflammation, angiogenesis, proliferation, contraction, re-epithelialization 
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and remodelling (Jorgensen, 2003). To better understand the healing process, the five 
phases are further discussed together with how they overlap. 
1.12.1 HAEMOSTASIS PHASE (COAGULATION) 
During blood circulation in an intact blood vessel, endothelial cells of the blood vessel 
secrete coagulation and aggregation inhibitors i.e. they release heparin like molecules to 
prevent blood coagulation and thrombomodulin to prevent platelet aggregation. 
Prostacyclin and nitric oxide are also involved in this process (Mendonça and Coutinho-
Netto, 2009). In contrast, the endothelial cells of broken blood vessels replace the 
secretions of clot inhibitors with a blood glycoprotein called von Willebrand Factor (vWF) 
which initiates haemostasis (Rasche, 2001; Mendonça and Coutinho-Netto, 2009). 
Haemostasis is the first phase of wound healing and consists of three successive steps; 
vasoconstriction, blockage of the wound by platelet aggregation and blood coagulation. 
When skin is injured, a blood extravasation begins to fill the injured site. Immediately after 
the skin injury and bleeding, the blood vessel contracts and reduces the blood flow to the 
wounded site thereby keeping the blood within the damaged vessel and causing bleeding 
to stop (Rasche, 2001; Versteeg et al., 2013). Not only do vessel contractions stop 
haemorrhage, but also, blood changing from a liquid phase to a gel phase forming a blood 
clot (coagulation) and platelet aggregation generates a haemostatic buffer (plasma) which 
is rich in fibrin, thereby stopping the haemorrhage and restoring a barrier protecting the 
wound from infection by invading microorganisms. This process constitutes a matrix that 
encourages cell migration (Eming et al., 2007b). In this phase, the role of platelets is not 
only restricted to blocking the damaged area and in clot formation, but also in the formation 
of a transient extracellular matrix by secreting adhesion molecules such as fibronectin and 
thrombospondin, as well as, growth factors such as epidermal growth factor (EGF), PDGF, 
TGF-α and TGF-β, and vascular endothelial growth factor (VEGF) (Streit et al., 2000). 
This matrix serves as a reservoir for growth factors and cytokines critical to the 
subsequent healing phases (Eming et al., 2007b). Collectively, the matrix, activated 
cascade coagulation, and parenchymatous cells make the injured vessel a chemotactic 
environment to attract inflammatory cells at the wound site and initiate the start of the 
inflammatory phase (Clark, 1996). 
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1.12.2 INFLAMMATORY PHASE 
An inflammatory reaction begins soon after the haemorrhage stops at the site of injury. 
This reaction promotes mobility of various cells toward the injured tissue giving rise to a 
multitude of complicated and successive series of reactions ending with rebuilding of a 
tissue like structure (Midwood et al., 2004).  The main advantages of this phase are 
isolating the injured tissues from the surrounding contaminated environment, cleaning out 
cell debris and damaged tissues and the initiation of the healing process (Abbas and 
Lichtman, 2010). The main reactivity observed in this phase is an increased migration of 
inflammatory cells from intravascular tissue towards the extracellular wound site due to 
increased vascular permeability. This permeability increases due to vasodilation when 
both fibrin and thrombin are activated by the coagulation cascade. Meanwhile, clot 
formation and their stimuli are dissipated and plasminogen converted to plasmin 
(Sherwood and Toliver-Kinsky, 2004). Three main cell types are involved in the 
inflammatory phase, neutrophils, macrophages, and lymphocytes whose activity is 
initiated within hours of injury (Midwood et al., 2004; Abbas and Lichtman, 2010). 
Neutrophils seem to be the most dominant cell type during the first 48 hours, cleaning the 
wound site from bacteria, cell debris and damaged tissue by releasing free radicals. 
However, they are not essential for the healing process (Eming et al., 2007b; Wright et 
al., 2010). Approximately 48 hours following the injury, stimuli for neutrophils no longer 
persist and neutrophil numbers cease when macrophages (monocyte-derived 
macrophages) penetrate the wound site via the blood and become the dominant cellular 
component of the inflammatory phase by phagocytosing cell debris and bacteria including 
expended neutrophils. Macrophages also secrete collagenases and elastases to break 
down the damaged tissues (Ariel et al., 2012). In contrast to neutrophils, the role of 
macrophages is not restricted to cleaning of the tissues, as they also play a crucial role in 
the healing process by secreting prostaglandins, which act as vasodilators increasing 
microvessel permeability and attracting other inflammatory cells into the wounded site 
(Tonnesen et al., 2000; Eming et al., 2007b). In addition, macrophages secrete fibroblast 
growth factors (FGF), PDGF, TGF-α, and VEGF which are important for proliferation and 
migration of fibroblasts as well as cytokines, which attract endothelial cells to the injury 
site promoting their proliferation and the development of a tissue (Swirski et al., 2009; 
Ariel et al., 2012). Within three days of the inflammatory phase, T-lymphocytes home to 
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the injury site by the activity of interlukin-1 and secret lymphokines such heparin-binding 
epidermal growth factor (HB-EGF) and basic fibroblast growth factor (bFGF), promoting 
fibroblast proliferation (Ross, 1994). 
1.12.3 PROLIFERATION PHASE  
The proliferation phase (epithelial proliferation phase) represents the main phase 
responsible for actual wound closure. In the case of skin wounds, endothelial non 
inflammatory cells such as keratinocytes and fibroblasts start to proliferate and migrate 
towards the edges of the wound producing collagen for the development of new tissues 
(Santoro and Gaudino, 2005; Bellayr et al., 2010). Within a few hours (between 6 and 24 
hours) of injury, TGF-ß and EGF act as mitogenic and chemotactic stimulators attracting 
keratinocytes which migrate towards the wound and start epithelialization (Usui et al., 
2008a). Fibroblasts are activated and start to differentiate into myofibroblasts which 
participate in reducing the wound size by contracting and secreting ECM proteins giving 
rise to healing of the connective tissue (Li and Wang, 2011; Li et al., 2011b). Meanwhile 
angiogenesis progresses, co-ordinating the transfer of nutrients and oxygen from newly 
formed capillaries to the wound site enhancing metabolic activity (Dvorak, 2002). 
Epithelisation,  fibroplasia and angiogenesis collectively comprise granulation tissue 
which covers the damaged tissues within four days of injury (Bellayr et al., 2010). 
1.12.4 CONTRACTION PHASE 
Wound contraction could be defined as mobility of the wound margins towards the wound 
core to facilitate closure. This phase begins when fibroblasts stop proliferating and 
undergo apoptosis within 5-15 days post injury which occurs concurrently with collagen 
synthesis (Eichler and Carlson, 2006; Hinz, 2006). The rate of movement of wound edges 
depends on tissue laxity and wound shape. For instance, the looser tissues tend to 
contract more rapidly than the compact tissues and squared wounds contract more quickly 
than rounded wounds. The contraction rate also depends on the availability of 
myofibroblasts and their proliferation and connection to the surrounding extracellular 
matrix (Newton et al., 2004). 
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1.12.5 REMODELLING PHASE (RESOLUTION) 
Remodelling or resolution is the last phase of the wound healing process. The biological 
processes observed in this step involve gradual resolution of the inflammatory phase, 
collagen deposition, complete coverage of the injured site by the new tissues and 
formation of scar tissue (Mora and Pessin, 2002). Successful remodelling requires stable 
collagen content, therefore, the important step in this phase is controlling collagen 
remodelling (Zhou et al., 2013). Although collagen synthesis is continuing during this 
phase, its level is restricted due to the activity of collagenases and metalloproteinases 
which aid in removing the excess collagen (Greenhalgh, 1998; Ruszczak, 2003). For 
optimal remodelling, collagen levels need to be balanced by the activity of 
metalloproteinases inhibitors secreted by tissue and which arrest the collagen lytic 
enzymes and balance the production of new collagen with that of the removed old collagen 
(Ruszczak, 2003). The outcome of this process is that collagen type III is replaced by 
collagen type I, hence replacing both hyaluronic acid and glycosaminoglycans by 
proteoglycans and the disappearance of fibronectin as well as resorbing water from scar 
tissues. These events start approximately 3 weeks after the injury and may last indefinitely 
as collagen fibres stack closer to each other decreasing scar thickness and increasing 
wound bursting strength “resistance to rupture” (McDougall et al., 2006).  
As described above, the main issues in the wound healing process are how cells are 
attracted to the site of injury and how their proliferation and differentiation is enhanced at 
the wounded region. These cells include inflammatory cells (neutrophils, macrophages 
and lymphocytes) and epithelial cells (fibroblasts and keratinocytes). All these activities 
are mainly regulated by growth factors and cytokines. In many cases these cells fail to 
migrate, proliferate and differentiate due to deficiency in growth factors and cytokines; 
consequently, the healing process will be impaired and chronic wounds will arise (Usui et 
al., 2008a). Therefore, in order to improve wound healing, there is a need for an alternative 
source of healing cytokines and growth factors to enrich the injury site. MSC-CM acts as 
a rich source of 36 growth factors, cytokines and chemokines which, collected from MSC 
in vitro under good manufacturing practice (GMP) could be used  as therapy for wounds 
in the future (Hwang et al., 2009). For further detail about the phases and events of the 
healing process see (Table 1.5). 
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Phase Haemostasis Inflammation 
Proliferation 
Migration 
Contraction Remodelling 
Starts 
post 
injury 
Immediately First hours Day 4 Day 5 Day 20 
Duration (minutes-hour) (3 days-14 days) (3 weeks) (10 days- 20 days) 
(Months-2 
years) 
Events 
Haemorrhage Phagocytosis 
Endothelial cells 
migration 
Fibroblast 
apoptosis 
Collagen 
control 
remodelling 
Vasoconstriction 
Growth factors 
secretion 
Epithelialization Wound edges pull  
Replacing 
collagen type 
III by  type I  
Platelet 
aggregation 
Cytokines 
secretion 
Fibroblast 
differentiate into 
myofibroblasts 
Wound Closure 
Disappearance 
of fibronectin 
Blood 
coagulation 
Synthesis of 
preliminary ECM 
ECM Production Scar maturation 
Immuno- 
modulation by T- 
lymphocytes 
Angiogenesis Collagen fiber cross linking 
Migration of inflammatory cells  Collagen production  
Activation of coagulation cascade Granulation  
 Fibroblast migration   
 Fibroblasia   
Healing 
Progress 
(A) Wound  
initiated 
(B) Healing not 
initiated 
(C) Progressive 
Healing  
(D) Healed 
(E) Healing 
Complete 
Table 1.5 The main phases and events of the wound healing process. 
Main phases and events of the wound healing process which are divided into five overlapping phases. 
(A) The wound is not healed and there is a possibility to reach a chronic state if the coagulation phase 
fails. (B) The wound is still not healed but it is progressing towards healing; however, if inflammation is 
not terminated, a chronic condition has a chance to be initiated. (C) The active healing process has 
been initiated. (D) Development of the healing process with less chance of progression to a chronic 
condition.  (E) Complete healing and remodelling. 
In addition to the cellular components of wound repair, micro molecules are also vital for 
the healing process, in particular, micro ribonucleic acids (microRNAs). 
1.13 ROLES OF MICRO RIBONUCLEIC ACIDS (MICRORNAS) IN WOUND HEALING 
Micro RNAs are single stranded, short sequence (19-24) nucleotides (ntds) in length 
originated from endogenous non-coding RNA genes. They target the 3′-untranslated 
region (3′UTR) of messenger RNA (mRNA) and suppress the expression of proteins 
produced by these coding genes (Aberdam et al., 2008; Banerjee et al., 2011; Schneider, 
2012; Mills et al., 2013). MicroRNAs were first discovered by (Wightman, et al, 1993) when 
they found that small sequences of lin-4 RNAs (miRNA-lin14) pairs to sites in the 3′UTR 
of lin-14 gene, formed multiple RNA duplexes and terminated the translation process 
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resulting in downregulation of the expression of the gene lin-14 in Caenorhabditis elegans. 
MicroRNAs are the major group of non-coding RNAs; approximately, 1000 microRNAs 
regulate gene expression of almost 33 % of the coding genes (Pritchard et al., 2012; Mills 
et al., 2013). These small sequences can regulate gene expression post-transcription by 
binding to their target mRNA resulting either in mRNA degradation or translation 
suppression or both (Wei et al., 2010; Banerjee et al., 2011). They may even suppress 
gene activation (Moura et al., 2014). Interestingly, more than one gene could be regulated 
by an individual microRNA and similarly, more than one microRNA could affect one gene 
(Li et al., 2015e). The main function of these highly conserved microRNAs is regulation of 
gene expression post transcription, therefore, they have been involved in many biological 
process such pathogenesis of disease and considered as promising therapeutic strategies 
and demonstrating great potential as diagnostic biomarkers for diseases (Moura et al., 
2014). In the field if dermatology, microRNA research is promising and the early findings 
are suggesting new strategies for developing effective therapies and providing novel 
opportunities for treating skin diseases and addressing major global health concerns such 
as chronic wounds (Sen and Roy, 2008; Banerjee et al., 2011). Moreover, microRNAs 
have been reported to serve as critical regulators in wound repair and skin regeneration 
by controlling cell division, differentiation and apoptosis of skin cells (Mills et al., 2013). 
However, investigating the key microRNAs in wound healing and their activities is still in 
its early stages and more studies are required to develop this field (Li et al., 2015e).     
1.13.1 BIOGENESIS OF MICRORNA 
MicroRNA synthesis is a highly regulated process with remarkably well coordinated steps 
which start at the nucleus and terminates in the cytoplasm by producing  mature-
microRNAs (Kim et al., 2004). As shown in (Figure 1.7), RNA polymerase III binds to 
microRNA coding genes, present in the human genome and transcribe long capped and 
polyadenylated fragments consisting of several kilobytes of nucleotides termed to primary 
microRNA (pri-miRNA). Drosha and two other microprocessor enzymes (RNase III and 
DGCR8) cleave the pri-microRNA into smaller sequences (approximately 70 nucleotides 
in length) referred to as premature microRNA (pre-microRNA). The export system 
transports this pre-microRNA from the nucleus to the cytoplasm by the action of Ran-
GTP-dependent nuclear export factor (exportin-5) where the Dicer, an RNA polymerase 
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enzyme, cleaves the pre-microRNA into shorter sequences (18-24 nucleotides in length) 
of double stranded RNA (dsRNA). Then, a microRNA-induced-silencing-complex (RISC) 
associates with dsRNA and degrades one of its strands resulting in single stranded RNA 
which is the mature microRNA (microRNA). This microRNA starts its activity to target 
specific mRNAs by binding to a complementary sequence at a certain site known as a 
seed sequence or 3’UTR (Ha and Kim, 2014; Melo and Melo, 2014). The outcome of this 
binding will be either mRNA degradation, translation inhibition or suppression of 
chromosome assembly, consequently, suppressing gene expression (Ha and Kim, 2014; 
Melo and Melo, 2014; Moura et al., 2014).    
 
Figure 1.7 Biogenesis of microRNA. 
This diagram explains microRNA biogenesis. In the nucleus, RNA polymerase III binds to microRNA 
coding genes and transcribes long fragments called primary microRNA (pri-microRNA). A group of three 
enzymes (RNase III, DROSHA and DGCR8) cleave the pri-microRNA into shorter sequences (∼70-nts-
long) to form the pre-mature microRNA (pre-microRNA). Then exportin-5 transport the pre-microRNA 
into the cytoplasm when another RNase enzyme called DICER split it into smaller double stranded 
RNAs (18-24 -ntds-long). The RISC associates with these double stranded RNAs and degrades one 
strand, while the other strand become the mature microRNA. These microRNAs start their activity by 
binding to a complimentary specific sequence called “seed sequence” on the target mRNAs and prevent 
ribosome assembly resulting in either degradation of mRNA or inhibition of translation, or both. 
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1.13.2 ROLES OF MICRORNAS IN SKIN DEVELOPMENT AND MORPHOGENESIS 
It has been well documented that microRNAs are responsible for regulating gene 
expression during skin development. Subsequently, they are important in development 
and maintenance of human skin including epidermis, dermis and adult skin stem cells 
(Pastar et al., 2012; Banerjee and Sen, 2013). Notably, Dicer, the main microRNA 
processing enzyme, is found in the epidermal layer and the hair follicle (Andl et al., 2006; 
Pastar et al., 2012). It has been found that mice lacking Dicer will die early to a lack of 
skin development (Schneider, 2012). Other evidence suggests that microRNAs play 
significant roles in skin morphogenesis, starting with organizing renewal of skin stem cells 
and their differentiation into basal epidermal cells and migration of these cells from the 
basal membrane to differentiate into other epidermal layers (Fuchs, 2008; Blanpain and 
Fuchs, 2009). The most highly expressed microRNAs in human skin are miR-16, miR-21, 
miR-27a, miR-27b, miR-30b, miR-34a, miR-125a, miR-125b, miR-126, miR-143, miR-
152, miR-191, miR-203, miR-205, miR-214; miR-19/-20 family including (miR-19b, miR-
20, miR-17-5p and miR-93); miR-199 family including (miR-199a and miR-199b) and miR-
200 family including (miR-200a, miR-200b, miR-200c, miR-141, and miR-429) (Banerjee 
et al., 2011). Many microRNAs have been shown to play a crucial role in skin development 
and morphogenesis. For example, miR-125b represses stem cell differentiation through 
silencing both B lymphocyte induced maturation protein 1 (Blimp1) and Vitamin D 
Receptor (VDR) (Zhang et al., 2011a). miR-125b has shown to play an important role in 
the development of stem cell progenitors, during the differentiation of epidermal cells, oil-
glands and hair-follicles (Yi et al., 2008). Another microRNA, miR-203 plays an important 
role in the differentiation of a single-layered epithelium into a stratified epidermal layer by 
suppressing p63 post-transcriptionally. It also maintains the proliferation potential of basal 
keratinocytes (Schneider, 2012; Lai and Siu, 2014). Interestingly, miR-203 performs the 
same functions both in zebrafish and man indicating its consistency and performance of 
a conserved function regardless of the species (Wienholds et al., 2005; Wei et al., 2010). 
On the other hand, overexpression of miR-203 in the epidermal basal layer of transgenic 
mice leads to formation of a thin epidermal layer with depletion in keratin 5 positive cells 
and frequent death shortly after birth (Yi et al., 2008; Wei et al., 2010). Therefore, the main 
function of miR-203 is thought to be to limit the proliferation potential of progenitor cells 
when they differentiate from the basal to the suprabasal layer by targeting the transcription 
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factor p63, shown to be the key player in maintaining stem cells in stratified tissues (Senoo 
et al., 2007). Interestingly, p63 regulates cell division and differentiation of keratinocytes 
by repressing miR-34 family members (Antonini et al., 2010). In addition, nine microRNAs 
have been shown to regulate differentiation of human keratinocytes and these include 
(miR-23b, miR-26a, miR-27b, miR-95, miR-200a, miR-210, miR-224, miR-328, and miR-
376a) (Banerjee et al., 2011; Hildebrand et al., 2011). In that case, microRNAs play 
different important roles during the healing process.  
1.13.3 ROLES OF MICRORNAS IN WOUND HEALING 
The significant roles played by microRNAs during skin morphogenesis and development, 
suggest that microRNAs are associated with skin pathologies, including cancer, and 
wound healing. They have therefore been considered as valuable regulators in wound 
healing (Banerjee et al., 2011; Pastar et al., 2012). Specific microRNAs have been 
reported to have changes in their expression during the cutaneous wound healing 
process. Up- and or down-regulation of these specific microRNAs may therefore play a 
crucial role in delayed wound healing (Shilo et al., 2007). In a mouse model study, 
microRNAs have been demonstrated to play significant roles in dermal wound healing, 
since down-regulation of specific microRNAs such as those of the miR-99 family including 
(miR-99a, miR-99b and miR-100) (Jin et al., 2013b) resulted in delayed wound healing. 
MicroRNAs could be involved in different phases of the healing process, participating from 
the early stages until the final phase. 
1.13.3.1 ROLE OF MICRORNAS IN THE COAGULATION PHASE  
MicroRNAs have been shown to play important roles during the haemostasis phase of the 
healing process. They can influence the main steps and events of the coagulation cascade 
including; platelet biogenesis and function, coagulation and anti-coagulation factors, and 
fibrinolysis (Teruel-Montoya et al., 2015). Landry and colleagues suggest that miR-223 
regulate the expression of platelet surface protein known as (P2Y12) which is very 
important in coagulation (Landry et al., 2009). In contrast, Leierseder and others explained 
that the role of miR-223 is restricted and minor during coagulation because the platelets 
of miR-223 deficient mice show normal reactivity and function (Leierseder et al., 2013). 
Another microRNA, miR-96 has been involved in regulation of vesicle-associated 
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membrane protein 8 (VAMP-8), which is a critical receptor involved in secretion of platelet 
granule (Shi et al., 2013). Also, miR-107, miR-200b and miR-495 possess suppressive 
activity on the proteins Circadian Locomotor Output Cycles Kaput (CLOCK), protein 
kinase type II-beta regulatory subunit (PRKAR2B) and Kelch Like Family Member 5 
(KLHL5) respectively (Nagalla et al., 2011). With respect to haemostatic factors, 
fibrinogen is the first coagulation factor targeted by microRNAs. Fibrinogen (FG) is 
composed of three nodules (Aα, Bβ and γ chains) encoded by three different genes 
(FGA, FGB and FGG) respectively. miR-409-3p targets FGB, while miR-29c targets FGA-
Αe. Whereas the miR-29 family including (miR-29a, miR-29b and miR-29c) target the 
three transcripts indirectly (Hatziapostolou et al., 2011; Fish and Neerman-Arbez, 2012). 
Moreover, members of miR-29 family play important role in fibrosis by targeting other 
coagulation factors such as collagen, elastin and fibrillin (van Rooij et al., 2008). Another 
coagulation factor, tissue factor (TF), the main initiator of blood coagulation, is encoded 
by the F3 gene which is by microRNAs. In in vitro studies miR-19 has been shown to bind 
to 3′-UTR of F3 while miR-20a and miR-106b bind to different sites of F3 and cause severe 
inhibition of TF in the breast cancer cell line and monocytic leukemia cell line, 
consequently, affecting the procoagulation activity of these cells (Teruel et al., 2011b). 
Regarding anticoagulation factors, miR-18a and miR-19b significantly affect the serine 
peptidase inhibitor clade 1 (SERPINC1) gene which encode the most important 
anticoagulant AT, thereby inhibiting both thrombin and Factor X (FaX) (Teruel et al., 
2011a). Another anticoagulant protein S (PS) which is critical during thrombosis of 
pregnancy is regulated by miR-494. miR-494 regulates PS expression by binding to its 
gene PROS1 (Tay et al., 2013). Moreover, miR-133a directly regulates anticoagulant 
targets in liver such as VKORC1 (vitamin-K 2,3-epoxide reductase complex subunit-1) 
(Teruel-Montoya et al., 2015). Many microRNAs also play important roles in the regulation 
of fibrinolysis. For example, plasminogen activator inhibitor-1 (PAI-1) encoded by serine 
peptidase inhibitor E1 (SERPINE1) is the primary inhibitor of the fibrinolytic cascade by 
targeting and inhibiting the activators of both tissue and uro-kinase type plasminogen 
(Iwaki et al., 2012). Both miR-30c and miR-421 directly inhibit PAI-1 by binding to the 3’ 
UTR of SERPINE1 mRNA (Marchand et al., 2012). 
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1.13.3.2 ROLE OF MICRORNAS IN THE INFLAMMATION PHASE 
As mentioned before, initiation and termination of successful inflammation is important for 
wound healing. The inflammatory response is highly regulated by pro-inflammatory and 
anti-inflammatory signals and cytokines (Banerjee and Sen, 2013). Many microRNAs 
mediate the inflammatory response during the course of wound healing and have shown 
significant regulatory roles during wound repair (Zhu et al., 2011; Ryan et al., 2012). Any 
failure in microRNA biogenesis will have a severe impact on the immune response leading 
to chronic non-healing wounds (Roy and Sen, 2012). Some studies have reported that 
miR-21, miR-146a, miR-146b, and miR-155 exert multi-axial roles and orchestrate the 
inflammatory response (Roy and Sen, 2012). Sonkoly and colleagues showed that some 
microRNAs serve as main regulators in human skin inflammation such as psoriasis and 
atopic eczema (Sonkoly et al., 2008). For example, miR-203 is highly expressed in the 
skin epithelium of psoriasis patients. miR-146a targets TNF-α and regulates innate 
immune responses during psoriasis. Also, miR-125b is involved in theTNF-α pathway 
during psoriasis and atopic eczema (Sonkoly et al., 2008). Additionally, miR-424 regulates 
the proliferation and differentiation of human monocyte and macrophages during 
inflammation via targeting the genes of the transcription factors unit protKB (PU.1) and 
nuclear factor IA (NFIA) (Lai and Siu, 2014). Also, miR-21 targets some inflammatory 
mediators including phosphatase and tensin homolog gene (PTEN) and programmed cell 
death protein-4 (PDCD-4) genes. Moreover, miR-146 targets interleukin-1 receptor-
associated kinase-1 (IRAK-1) and Cytochrome c oxidase subunit 2 (COX2), while miR-
155 targets the gene that encodes the multifunctional protein called SH2-containing 
inositol-5'-phosphatase-1 (SHIP1) which plays many roles in haematopoiesis of blood 
cells including their activation, proliferation and survival (Roy and Sen, 2012; Fernandes 
et al., 2013). Additionally; miR-155 targets suppressor of cytokine signalling (SOCS-1) 
and (IL-12) (Roy and Sen, 2012). Also, miR-105 serves as an inflammatory regulator in 
human oral keratinocytes by targeting and suppressing Toll-like receptor 2 (TLR-2) 
(Benakanakere et al., 2009). On the other hand, miR-147 may have anti-inflammatory 
activity and prevent excessive inflammatory events by terminating the inflammatory phase 
by targeting the gene that encodes the Toll-like receptors (TLRs) during the healing 
process (Lai and Siu, 2014). 
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1.13.3.3 ROLE OF MICRORNAS IN EPITHELIALISATION PHASE 
Epithelialisation also called re-epithelialization is a key phase during wound healing and 
the wound will be considered as non-healing if the tissues fail to re-epithelialise. As 
previously mentioned, re-epithelialization of a wound is an outcome of three overlapping 
biological process related to keratinocytes which are migration, proliferation and 
differentiation (Banerjee and Sen, 2013). Switching to the proliferative phase from the 
inflammatory phase is a critical step during the healing process and controlling this event 
and kinetics is very important to progress towards healing (Reinke and Sorg, 2012; 
Banerjee and Sen, 2013). It has been shown that miR-132 is highly expressed during the 
inflammatory phase and regulates many genes related to several immune responses such 
as the immune cell cycle. During the proliferative phase, miR-132 expression is 
predominant in epidermal keratinocytes and suppresses the nuclear factor kappa light 
chain enhancer of activated B cells (NF-κB) signalling pathway and increase the activities 
of both extracellular-signal-regulated kinase (ERK) and signal transducer and activator of 
transcription 3 (STAT3) signalling pathways. Silencing miR-132 in mouse and human ex 
vivo wounds results in delayed wound healing with a severe prolonged inflammatory 
phase suggesting that this microRNA is a pivotal regulator in transition from the 
inflammatory phase to the proliferative phase during wound healing (Landén et al., 2016). 
miR-21 is upregulated during wound healing and promotes keratinocyte migration via 
regulating the TGF-β1 signalling pathway since keratinocyte migration induced by TGF-
β1 is significantly attenuated when miR-21is knocked (Yang et al., 2011; Wang et al., 
2012b). miR-21 also regulates cell proliferation through the phosphatase and tensin 
homolog / phosphoinositide-3 kinase / alpha serine-threonine protein kinase (PTEN/PI-3 
K/Akt) signalling pathways (Li et al., 2015e) and showed that miR-21 is gradually 
overexpressed during wound healing when compared to intact skin, resulting in increased 
proliferation and migration of keratinocytes via direct targeting of the epithelial membrane 
protein 1 (EMP-1) gene. Another microRNA, miR-203, has a positive effect on migration 
and proliferation of keratinocytes via targeting two mRNA sequences which encode Ras-
related nuclear protein (RAN) and Ras-associated and pleckstrin homology domains-
containing protein 1 (RAPH-1), important for cell migration and proliferation. Therefore, 
miR-203 plays a pivotal role in epidermal wound re-epithelialization and haemostasis and 
hence re-establishing the injured skin (Viticchie et al., 2012). Additionally, miR-203 
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support the proliferative capacity of basal keratinocytes and maintains the stratification 
potential of epithelial cells (Banerjee et al., 2011). 
1.13.3.4 ROLE OF MICRORNAS IN ANGIOGENESIS 
Many studies have investigated the role of microRNAs in regulating angiogenesis and 
have shown that depletion of Dicer arrests microRNA biogenesis, resulting in arrested or 
incomplete formation of blood vessels (Sen et al., 2009a). One of the issues controlled by 
microRNAs in wound healing angiogenesis is regulating nicotinamide adenine 
dinucleotide phosphate (NADPH) oxidase to produce reactive oxygen species (ROS) 
(Shilo et al., 2008). miR-200b is a hypoxia-sensitive microRNA which plays a crucial role 
in angiogenesis during hypoxic conditions of wounds by targeting ETS-1 gene which 
encodes the transcription protein C-ets-1 in human mammary epithelial cells (HMEC) 
(Chan et al., 2011; Roy and Sen, 2012). Other microRNAs shown to target specific genes 
and regulate angiogenesis proteins include miR-17-5p which regulates tissue inhibitor of 
metalloproteinases (TIMP-1) (Otsuka et al., 2008), miR-17/miR-92 (TSP-1) (Dews et al., 
2006), miR-20a (VEGF) a potent regulator of angiogenesis (Hua et al., 2006), miR-92a 
(ITGB-5) which encodes Integrin beta-5 (Bonauer et al., 2009), miR-126  which encodes 
Sprouty-related, EVH1 domain-containing protein 1 (SPRED-1) (Fish et al., 2008) and 
miR-221/miR-222 (c-KIT or CD177) which play important roles in cell survival, 
proliferation, and differentiation (Poliseno et al., 2010). Additionally, there are many 
microRNAs such as miR-15a, miR-16 (Sun et al., 2013), miR-20b (Cascio et al., 2010), 
miR-101 (Zhao et al., 2015), and miR-206 (Zhang et al., 2011b) that increase the 
angiogenic activity through regulating VEGF in cancer cells. Therefore controlling these 
microRNAs may be of importance in regulating VEGF and promoting angiogenesis during 
wound repair (Lai and Siu, 2014).         
1.13.3.5 ROLE OF MICRORNAS IN THE CONTRACTION AND REMODELLING PHASE  
As previously mentioned, collagen deposition is a critical step for the remodelling phase 
during wound healing. Many microRNAs have been shown to regulate collagen deposition 
such as miR-21 (Lai and Siu, 2014), miR-29a, miR-29b, miR-29c and miR-192 (Cheng et 
al., 2010). Both miR-29b and miR-29c target and silence specific genes responsible for 
producing many extracellular matrix proteins such as anti-fibrotic TGF-β, β-catenin and 
small mother against decapentaplegic (SMAD) like proteins which are involved in collagen 
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regulatory signalling pathways during remodelling (van Rooij et al., 2008). Whereas, miR-
129 targets smad interacting protein-1 (SIP-1) which encodes the expression of both 
collagen type I and type II (Kato et al., 2007). Additionally, miR-21 is involved in wound 
contraction via mediating the TGF-β-signalling pathway (Wang et al., 2012b; Lai and Siu, 
2014). 
Based on the observations mentioned above, regulation of microRNA levels at the wound 
site makes microRNAs attractive candidates for treating non-healing wounds via novel 
strategies (microRNA-therapies) to overcome this global burden. The unique concept that 
microRNA-therapies could regulate more than one gene in the pathway gives them 
advantage over the conventional gene therapy (Banerjee and Sen, 2013). 
Conversely, Pastar and others explained that some microRNAs affect wound healing 
negatively (Pastar et al., 2012). For example, miR-210 inhibits wound healing in ischemic 
wounds of a murine model, by repressing keratinocyte proliferation (Biswas et al., 2010). 
Other microRNAs expressed differentially during rat and human venous ulcers can delay 
the healing process such miR-16, miR-20a, miR-21, miR-106a, miR-130a, and miR-203 
since these microRNAs target growth factor signalling and suppress the re-
epithelialisation process and formation of granulation tissue (Pastar et al., 2012). Also, 
miR-125b reduces the proliferative ability of keratinocytes via regulation of fibroblast 
growth factor-2 receptor (FGFR2) (Schneider, 2012). Additionally, miR-198 significantly 
prevents keratinocyte migration and re-epithelialisation resulting in chronic wounds 
(Sundaram et al., 2013). 
Recently, it has been shown that cellular receptors are important for granulation tissue 
formation, appropriate tissue regeneration and wound repair (Feoktistov et al., 2009).   
1.14 RECEPTORS OF GROWTH FACTORS AND CYTOKINES AND THEIR ROLES IN WOUND 
HEALING 
The potential to recognize tissue damage and initiate a proper repair mechanism is carried 
out by biological molecules that mediate signal transduction and make structural changes 
in the cellular environment, enhancing the cellular response and restoring function such 
as inflammation and wound healing. These molecules are termed recognition receptors 
(Dasu and Rivkah Isseroff, 2012). Interestingly, cell receptors such as Toll-like receptors 
can recognize pathogens upon injury, trigger immune responses (Jiang et al., 2005) and 
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induce inflammation (Sims et al., 2010). Secretion of these receptors is not only restricted 
to the immune cells, but they are also present on non-myeloid cells such as endothelial 
and epithelial cells and thus involve them in the wound healing process (Grote et al., 
2011). 
Upon binding of growth factors or cytokines to receptors on the target cell, many signalling 
pathways are activated and several cellular responses evoked, such as cell division, 
proliferation, migration, differentiation, survival or apoptosis and many other cellular 
functions (Manavalan et al., 2011) (Figure 1.8). 
 
Figure 1.8 Interaction between growth factors and their receptors expressed by primary 
keratinocytes. 
Upon binding of one or more growth factors and cytokines to their particular receptor on the target cell, 
specific signaling pathways will be evoked leading to activation of the cell response such as cell division 
and proliferation, migration, differentiation and apoptosis.  
1.14.1 C-MET: HGF RECEPTOR 
c-Met is the receptor of HGF and scatter factors (SFs) and participates in signalling 
pathways enhancing proliferation and mobility of epithelial cells (Bottaro et al., 1991; 
Birchmeier et al., 2003). The signalling pathway mediated by HGF and its tryrosine kinase 
proto-oncogene receptor (c-Met) is very important for vertebrate embryogenesis since 
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these mediators control several cellular activities including formation of the placenta as 
well as proliferation and survival of hepatocytes (Dietrich et al., 1999). Therefore, c-Met is 
essential for liver repair and regeneration (Borowiak et al., 2004; Taub, 2004). 
Interestingly, c-Met expression is increasingly observed after injury of other tissues such 
as heart, kidney and skin (Cowin et al., 2001). Therefore, expression of HGF, SFs and c-
Met could be upregulated during response to tissue damage and repair by the activity of 
IL-1 and IL-6, when both are activated via transcription of HGF and SFs (Michalopoulos 
and DeFrances, 1997). Interestingly, c-Met in the epidermis of mutant mice are unable to 
participate in re-epithelialization of skin wounds and wound closure is slightly attenuated 
since the closure process is enhanced only by the few keratinocytes which escaped the 
mutation. Additionally, c-Met mutant primary keratinocytes grown in vitro failed to close 
the scratched area and only c-Met positive cells that escaped the mutation participated in 
wound healing suggesting that c-Met is an important signalling pathway not only for cell 
growth and migration but also for proliferation and regeneration of skin during wound 
healing (Chmielowiec et al., 2007). 
1.14.2 PDGFR: RECEPTOR OF PDGFA, PDGFB, PDGFAB, PDGFCC.  
PDGF is the primary growth factor that appears at the injury site and is secreted by the 
platelets (Martin, 1997). It presents in three classic isoforms, which are composed of 
polypeptide A and B units, forming two homodimers PDGF-AA, PDGF-BB and one 
heterodimer PDGF-AB (Heldin and Westermark, 1999). The physiological action of these 
three isoforms of PDGF are evoked by binding to two specific tyrosine kinases cell surface 
receptors (α and β) (Heldin et al., 1988). Additionally, two homodimers of PDGF have 
been recognized; PDGF-CC and PDGF-DD (Bergsten et al., 2001). The α receptor has 
the ability to bind to PDGF-AA, PDGF-BB, PDGF-AB and PDGF-CC isoforms, whereas 
the β receptor can bind to PDGF BB and PDGF-DD isoforms (Heldin and Westermark, 
1999; Bergsten et al., 2001). Genetic studies showed that the PDGFR-α signalling 
pathway is important for palatogenesis, somites formation and patterning of mesodermal 
tissue (Ding et al., 2004). Additionally, both PDGF-α and -β receptors trigger mitogenic 
signals and enhance cell motility and actin filament production. Mutations in PDGF-B- and 
its receptor (PDGFR-β) results in failure to recruit pericytes and smooth muscle cells to 
initiate primary blood vessels leading to widespread haemorrhaging and death in utero  (a 
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term used to describe the state of the foetus in the womb). Moreover, PDGFR-β inhibition 
leads to delayed wound healing and reduced wound closure which is accompanied by 
significant reduction in myofibroblast recurrence, fibronectin expression, collagen type I 
synthesis and distribution of collagen-producing cells at the edges of the wound, arresting 
proliferation and migration of fibroblast and  inhibition of pericyte proliferation and 
migration in vitro at the early stages of the wound healing process (Rajkumar et al., 2006). 
1.14.3 FGFR2: KGF RECEPTOR 
Fibroblast growth factor receptor-2 (FGFR-2) also known by other names such as 
keratinocyte growth factor receptor (KGFR) and CD332, is a transmembrane receptor 
tyrosine kinase encoded by the FGFR2 gene (Abuharbeid et al., 2006). There are many 
slight differences in FGFR-2 isoforms such as FGFR-1, FGFR-2, FGFR-3, FGFR-4, 
FGFR-7 and FGFR-10 which spread around the different tissue types in the body and 
change during growth and development (Ornitz and Itoh, 2001).  It is involved in many 
important cell activities including division, growth and maturation of the cell, formation of 
blood vessels, embryogenesis, healing of chronic wounds and tissue repair. Lack of 
binding to their transmembrane receptor, causes the FGF family including KGF unable to 
regulate proliferation, migration, survival and differentiation of many cell types in both 
normal and wounded skin (Gartside et al., 2009; Werner, 2011). Structurally, FGFR-2 is 
composed of two domains, one remains inside the cell and the other spans the cell 
membrane, to allow the receptor to bind and interact with specific ligands and growth 
factors outside the cells triggering a cell response to the extracellular environment. For 
instance, when a growth factor binds to the FGFR2 protein, the receptor acts as a signal 
transducer and initiates a series of chemical reactions that evoke signalling cascades 
inside the cell which in turn inform the cell to perform special functions such as growth, 
migration, proliferation and differentiation or participate in the development of embryonic 
cells to become more specialized cells of other tissues (Gartside et al., 2009). 
1.14.4 TGFß-R1: TGFß-1 RECEPTOR 
Transforming growth factor beta in its three isoforms (TGF-β1, TGF-β2, and TGF-β3) are 
members of a superfamily of cytokines. All three isoforms participate in the wound healing 
process; however, TGFβ-1 is the most influential and dominant isoform since it is secreted 
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by many cell types such as platelets, monocytes and macrophages to initiate the 
inflammatory response. It is also secreted by keratinocytes and fibroblasts to enhance 
granulation tissue formation (Barrientos et al., 2008b). Receptors of TGF-β are 
transmembrane receptors characterised by dual specificity, firstly, they are unique in 
their ability in man to strongly bind to serine/threonine kinases (Huminiecki et al., 2009). 
Secondly, they weakly bind to tyrosine kinases (Heldin et al., 2009; Huminiecki et al., 
2009). They could be divided into three types; (TGFβ-1R; which is also known as activin 
like kinase /ALK), TGFβ-2R) and TGFβ-3R). All TGFs-β cannot perform their functions 
in the target cell independently without binding to their specific receptors. First of all, 
TGFβ is released and its ligand binds to the active TGFβ-2R which then binds to TGFβ-
1R (Goumans et al., 2009) and forms TGFβ-1R phosphorylate (Heldin et al., 2009). 
Then, TGFβ-3R regulates the receptor activity by mediating the binding of specific TGF-
β isoforms (Moustakas and Heldin, 2009). After activation, the ligand-receptor complex 
evokes intracellular cascades and activates canonical and non-canonical signalling 
pathways including both R-Smad dependent pathways (Smad2/3), and R-Smad 
independent pathways (ERK1/2) which are well documented to enhance epidermal and 
dermal cell migration during the wound healing process (Bandyopadhyay et al., 2011) as 
well as their important roles in angiogenesis and fibrosis (Maring et al., 2012). 
1.14.5 MSTR1: MSP-1 RECEPTOR (ALSO KNOWN AS RON; PTK8; CD136; CDW136) 
MSTR1 is a tyrosine kinase receptor which binds to extracellular signals and transfers 
them through the cell membrane into the cytoplasm and induces RON (Recepteur 
d'Origine Nantais) auto-phosphorylation to initiate intracellular cascades and enhance 
physiological process such as cell survival, proliferation, migration and differentiation of 
epithelial cells into the wound site. Additionally, RON restores downstream signaling 
molecules which regulate macrophage migration and phagocytic activities involved in the 
immune response (Côté et al., 2007; Feres et al., 2008). It has been shown that RON 
possess anti-inflammatory activity, since it mediates the transduction of signals that 
suppress the production of inflammatory mediators by the NF-kβ pathway by blocking 
lipopolysaccharides (LPS) (Wang et al., 2002; Kretschmann et al., 2010). In addition, 
MSP/RON signalling are strongly involved in the different steps of the healing process and 
are significantly increased during the first 7 and 21 days. Interestingly, in RON deficient 
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mice suffering from lung injury the wounds become significantly chronic and lead to poor 
survival (Kretschmann et al., 2010). 
1.14.6 CXCR4: SDF-1Α RECEPTOR   
Cellular migration is generally regulated by chemokines (Gillitzer and Goebeler, 2001). It 
has been shown that the CXCR4/SDF-1 signalling pathway is implicated in many 
disorders such as skin wound healing, tumour angiogenesis, basal cell carcinoma and 
systemic lupus erythematosus (Bollag and Hill, 2013). SDF-1α and its receptor CXCR4 
represent the most effective chemotactic pathway for cellular mobility of MSCs and 
monocytes towards the damaged tissue (Ding et al., 2011; Sánchez-Martín et al., 2011). 
Therefore, SDF-1α/CXCR4 signalling pathway not only facilitate MSC migration from the 
bone marrow towards the wound site, but also represent the crucial migratory mechanism 
during the inflammation and proliferation phase of the healing process (Hu et al., 2013; 
Campeau et al., 2015). CXCR4 expressing cells are attracted by SDF-1α (CXCL12) and 
migrate to the peripheral tissue and initiate the CXCR4 dependent signalling pathway 
(Miller et al., 2008; Campeau et al., 2015). It has been reported that SDF-1 and/or CXCR4 
are up-regulated during burns and excisional wounds in skin epidermis indicating their 
involvement in the wound healing process (Avniel et al., 2006; Toksoy et al., 2007). Avniel 
et al reported that CXCR4 and its ligand SDF-1α are upregulated in skin burns of man, 
pigs and rats where SDF-1α was mainly released by dermal fibroblasts but not the 
keratinocytes which instead secreted its receptor CXCR4 (Avniel et al., 2006). Several 
cell types are shown to express CXCR4 at the wound site including vascular endothelial 
cells and infiltrating immune cells (Avniel et al., 2006; Bollag and Hill, 2013) as well as 
embryonic and adult stem cells (Miller et al., 2008). 
To date, the vast majority of cell based assays are tested in traditional two-dimensional 
cell culture (2DCC), however, new techniques have been developed that mimic the in vivo 
environment by growing the cells in a three-dimensional cell culture (3DCC) (Edmondson 
et al., 2014).  
1.15  TWO-DIMENSIONAL AND THREE-DIMENSIONAL CELL CULTURE 
The majority of biological studies on experimental skin have been conducted in standard 
two-dimensional cell culture (2DCC), whereas, accumulating evidence has suggested that 
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the behaviour of the cells in the 2DCC is quite different from their behaviour when they 
are grown in three-dimensional cell culture (3DCC) (Li et al., 2011a). Therefore, in vitro 
cell culture has recently developed from 2DCC to 3DCC, characterised by cultured cells 
with an environment which significantly mimics the in vivo niche by growing the cells as a 
floating mass (Wozniak and Keely, 2005). The 3DCC design is provided by a collagen 
matrix and emulates the ECM, and mimics a natural environment for cell growth.(Wozniak 
and Keely, 2005). Recently, scientists have developed 3D human skin constructs 
consisting of epidermis represented by stratified, differentiated keratinocytes, dermis 
composed of fibroblasts embedded in a collagen I matrix and functional basement 
membrane separating the two layers thus, enabling investigations into the interactions 
between different cell types and cell matrix compositions. Moreover, in other research 
experiments, the constructed skin has contained melanocytes located in the basement 
membrane as shown in vivo (Li et al., 2011a). Recently, applications of 3D culture has 
involved developing  3D skin models for a variety of purposes, including wound healing 
studies and drug screening investigations. The majority of drug testing assays including 
drug discovery, cytotoxicity and wound healing assays, rely on 2D culture-based 
techniques involving the seeding of cells on naked or coated plastic and glass flat surfaces 
in tissue culture plates. Although, these assays are advantageous in terms of simplicity, 
quick, and inexpensive when compared to large-scale cell culture, they still have many 
disadvantages when compared to 3D culture (Edmondson et al., 2014). For instance, cells 
in 2D culture differ morphologically and physiologically from cells in 3D culture (Baharvand 
et al., 2006). Also, cells in 2D culture lack the criteria of being surrounded by cellular 
elements and extracellular matrix as in an in vivo environment, whereas 3D culture mimics 
this habitat and offers the cultured cells, to some extent, an environment mimicking in vivo 
conditions including the growth of cells floating in culture media (Bhadriraju and Chen, 
2002). Additionally, 2D culture does not enable adequate exposure of the cells to the 
tested drug or substance of interest resulting in false, non-predictive and misleading data 
(Birgersdotter et al., 2005). Moreover, wound healing studies require testing the ability of 
the compound to enhance the motility of cell mass or cell sheets in the damaged area as 
in an epithelial wound which cannot be performed in 2D culture since the cells may migrate 
as single cells in two dimensions (Poujade et al., 2007). Furthermore, to mimic cutaneous 
wounding, cultured skin equivalents require exposure to the air-liquid interface, which is 
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not applicable to 2D culture. In addition, some experiments require a shrinkable substrate 
to form an even organotypic culture, which is again not applicable to 2D culture (Laco et 
al., 2009; Ma et al., 2009) while it is easily achieved in 3D culture through the use scaffolds 
such as the Alvetex® scaffold. 
1.16 SKIN EQUIVALENT MODEL 
Due to the limitations and lack of knowledge in understanding of the biological 
mechanisms involved in wound repair and for furthering human skin research, significant 
efforts have been made to establish in vitro and ex vivo skin models (Xie et al., 2010). In 
the early 1980s, the first human skin-like structure was developed by Bell and colleagues 
(Bell et al., 1981) when they attempted to treat burns and chronic wounds. Although, all 
constructed skin models are based on the same protocols and principles, some 
modifications have been made and a skin model consisting of fibroblasts and collagen 
matrix overlaid with epidermal keratinocytes has been constructed (Carlson et al., 2008). 
Recently, skin constructs have been improved and developed models have been 
produced such as pigmented, vascularised, innervated skin and immune competent-
containing skin (Roggenkamp et al., 2013). However, the majority of constructed skin 
models are insufficient to meet the relative complexity of human skin because they include 
only one or two cell types and lack skin appendages (Guo et al., 2013b). In dermatology, 
many attempts were made in the early 1990s to establish skin equivalents in vitro, starting 
with cultured epidermal sheets, an organotypic culture for cytotoxicity assays and then, 
an advanced living skin equivalent consisting of collagen lattice of fibroblasts covered with 
an epidermal layer (Parenteau et al., 1991). In 1993, companies started to develop skin 
models such as Advanced Tissue Sciences / USA, which launched two successful 
versions of the 3D skin equivalent, branded as ‘Skin²TM ZK1300 and ZK1350, used 
worldwide for many tasks such as toxicological tests, skin irritation and dermal absorption. 
In 1995, these models were replaced by a developed clinical skin equivalent (Dermagraft-
TC), which was mainly used for wound therapy in patients with cutaneous burns (Stoppie 
et al., 1993). Later, other models were developed such as The EpiSkin™ and SkinEthic 
RHE™ skin models in France, which contained a collagen lattice and collagen IV (Tinois, 
1991) and The EpiDerm™ skin models in the USA (Cannon et al., 1994), The Vitrolife-
SKIN™ skin model, Japan (Noriyuki Morikawa, 2007), The Phenion® Full-Thickness Skin 
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Model and the OS-REp model, Germany (Mewes et al., 2007) and The LabCyte™ skin 
model, Japan (Niwa (Niwa et al., 2009) et al., 2009). More recently, attempts have been 
made to establish a 3D skin model that mimics real skin for many purposes such as skin 
disorders, cytotoxicity assessment and wound healing. All these models have utilised 
different substances and materials of non-human origin. For instance (Vörsmann et al., 
2013; Klimkiewicz et al., 2017) developed a 3D model which contained collagen I isolated 
from rat-tails for studying melanoma metastasis. In addition, 3D models have been 
developed using a scaffold and collagen gels generated from bovine collagen I to study 
melanoma metastasis (Li et al., 2011a) and wound healing (Marquardt et al., 2015). 
Laterally, a 3D skin equivalent for melanoma studies, that does not require collagen has 
been developed that relies on the production of its own extracellular matrix, improving its 
overall longevity (Hill et al., 2015). 
1.17 AIMS OF THE STUDY 
1.17.1 THE PROBLEM 
In many cases, skin wounds fail to heal normally due to two main causes; the first one is 
alteration of the characteristics of the keratinocytes at the injury site which in turn are 
unable to cross talk with other cell types and participate in the healing process. The 
second factor is deficiency in growth factors and cytokines required for the initiation and 
termination the different phases of the healing process such as homeostasis, 
inflammation, cell migration and proliferation, and re-epithelialization. These problems 
lead to the development of chronic wounds (Pastar et al., 2008). 
1.17.2 HYPOTHESES 
In this study, three hypotheses were proposed and addressed. Firstly, the hypothesis that 
MSC secretions contain growth factors and cytokines which could be collected from in 
vitro culture to promote proliferation and migration of skin cells into the wounded area in 
both 2D and 3D cultures. Secondly, the hypothesis that bone marrow derived stem cells 
(BM-MSCs) migrate and differentiate into skin cells in vivo. Herein, this hypothesis was 
tested in vitro using both 2D and 3D cultures. The third hypothesis is that small non-coding 
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RNAs could participate in regulating the healing process. This hypothesis was tested via 
microRNA profiling during wound healing using a developed 3D skin model. 
1.17.3 AIMS OF THE STUDY 
This project aims to address how MSCs and their secretions promote migration, 
proliferation and / or differentiation of skin cells into the injury site. To this aim, the specific 
objectives are: 
1. Isolate MSCs from bone marrow, establish their maintenance in cell culture in vitro 
and define their secretory profile of growth factors and cytokines. 
2. Determine the effect of growth factors and cytokines secreted by MSCs on wound 
healing in 2D culture using an established in vitro scratch assay using human 
keratinocyte cell lines (HaCat), human primary keratinocytes and human dermal 
fibroblasts. 
3. Reproduce a 3D human skin equivalent model and validate epidermal and dermal 
biomarker expression.  
4. Develop a prototype of the 3D skin model for wound healing studies and study the 
effect of MSC or MSC derived secretions, containing specific growth factors or 
cytokines on this wound healing model. 
5. Use the developed 3D skin model to study the molecular mechanisms of wound 
healing using microRNA profiling. 
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CHAPTER TWO: MATERIALS AND METHODS 
2.1 ETHICS AND CONSENT 
All human MSC samples used in this study were obtained with donor informed consent. 
The research was approved with full Local Research Ethics approval (NRES Newcastle 
and North Tyneside 1 REC reference 14/NE/1212) which was obtained on 5th December 
2014. For more information about the approvals (See Ethics Approval Page 315). 
2.2 MATERIALS AND EQUIPMENT  
A variety of reagents, substances, tools, equipment and systems were used in this study. 
All information about these materials and their providers are listed in the Tables depending 
on their type and use during the experiments, to avoid repetition in the text.  
2.2.1 CULTURE MEDIA 
Item Catalogue # Company Origin 
Dulbecco’s Modified Eagle’s Medium - high glucose D6546-500ML Sigma-Aldrich UK 
Keratinocyte-SFM (1X), without calcium chloride 37010022 ThermoFisher Scientif ic  UK 
EpiLife® Medium, with 60 µM calcium MEPI500CA EpiLife UK 
MCDB153 with L-Glutamine, 28 mM HEPES M7403-10L Sigma-Aldrich UK 
Nutrient Mixture F-12 Ham N6658-500ML Sigma-Aldrich UK 
Roswell Park Memorial Institute-1640 (RPMI-1640) R0883-500ML Sigma-Aldrich UK 
StemMACS MSC Expansion Media, human 130-091-680 Miltenyi Biotec Germany 
StemMACS™ AdipoDiff Media, human  130-091-677 Miltenyi Biotec Germany 
StemMACS™ ChondroDiff Media, human  130-091-679 Miltenyi Biotec Germany 
StemMACS™ OsteoDiff Media, human  130-091-678 Miltenyi Biotec Germany 
X-VIVO™ 10 Chemically Defined, Serum -free 
Haematopoietic Cell Medium 
04-380Q Lonza (SLS) UK 
Table 2.1 Types of media used for culturing different cell types. 
2.2.2 MSC PHENOTYPIC CHARACTERISATION KIT 
Item Catalogue # Company Origin 
PE Mouse Anti-Human CD73  Clone  AD2  (RUO) 550257 BD Bioscience UK 
PerCP-Cy™5.5 Mouse Anti-Human CD90  Clone  5E10  (RUO) 561557 BD Bioscience UK 
APC Mouse Anti-Human CD105  Clone  266  (RUO) 562408 BD Bioscience UK 
FITC Mouse Anti-Human CD14  Clone  M5E2  (RUO) 555397 BD Bioscience UK 
FITC Mouse Anti-Human CD19  Clone  HIB19  (RUO) 555412 BD Bioscience UK 
FITC Mouse Anti-Human CD34  Clone  581  (RUO) 555821 BD Bioscience UK 
FITC Mouse Anti-Human CD45  Clone  HI30  (RUO) 555482 BD Bioscience UK 
APC-H7 Mouse Anti-Human HLA-DR  Clone  G46-6  (RUO) 561358 BD Bioscience UK 
CD14 FITC  Clone  MφP9   (CE/IVD) Isotype 345784 BD Bioscience UK 
CD19 FITC  Clone  4G7   (CE/IVD) Isotype 345776 BD Bioscience UK 
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Anti-HLA-DR APC-H7  Clone  L243   (CE/IVD) Isotype 641411 BD Bioscience UK 
DAPI [4,6-Diamidino-2-phenylindole, dihydrochloride]  564907 BD Bioscience UK 
Table 2.2 Antibodies and isotypes used for phenotypic assay of MSCs. 
2.2.3 ELISA KITS 
Kit Catalogue # Company Origin 
HGF ELISA Kit, Human KAC2211 Lifetechnologies USA 
PDGF-AB ELISA Kit, Human EHPDGFAB Lifetechnologies USA 
TGF beta 1 ELISA Kit, Multispecies  KAC1688 Lifetechnologies USA 
SDF-1a (CXCL12A) ELISA Kit, Human EHCXCL12A Lifetechnologies USA 
MSP (MST1) ELISA Kit, Human EHMST1 Lifetechnologies USA 
FGF-7 (KGF) ELISA Kit, Human EHFGF7 Lifetechnologies USA 
Table 2.3 ELISA kits used to measure the concentrations of growth factors and cytokines in MSC-
CM. 
2.2.4 IMMUNOFLUORESCENCE ANTIBODIES AND STAINS 
Antibody Catalogue # Company Origin 
Alexa flour 568 goat anti -rabbit IgG (H+L) secondary 
antibody 
A-11036 Life Technologies UK 
Alexa fluor 488 goat anti -mouse IgG (H+L) secondary 
antibody   
A11001 Life Technologies UK 
Anti-BrdU antibody ab152095 Abcam UK 
Anti-collagen IV antibody [COL-94] ab6311 Abcam UK 
Anti-Cytokeratin 10 antibody ab111447 Abcam UK 
Anti-Cytokeratin 14 antibody [LL002]  ab7800 Abcam UK 
Anti-involucrin antibody [SY5] ab68 Abcam UK 
Anti-Loricrin antibody ab85679 Abcam UK 
BrdU (5-bromo-2'-deoxyuridine) ab142567 Abcam UK 
Donkey Anti-Rabbit IgG H&L (Alexa Fluor® 488) ab150073 Abcam UK 
Dibutylphthalate Polystyrene Xylene (DPX) mounting 
medium 
1.00579.0500 VWR International UK 
Fluoroshield Mounting Medium (20 ml) ab104135 Abcam UK 
Goat Anti-Mouse IgG H&L (Alexa Fluor® 488) preadsorbed ab150117 Abcam UK 
Mouse mAb to collagen III [1E7-D7/col3] ab23445 Abcam UK 
Loricrin Polyclonal Antibody, Purified 
(Formerly Covance PRB-145P-100) 
905101 
Cambridge 
Bioscience 
UK 
Table 2.4 Primary and secondary antibodies and other reagents used for immunofluorescence 
staining. 
2.2.5 MATERIALS AND REAGENTS OF GENE EXPRESSION 
Item Catalogue # Company Origin 
High-Capacity cDNA Reverse Transcription Kit with 
RNase Inhibitor 
4374967 ThermoFisher Scientif ic USA 
High-Capacity cDNA Reverse Transcription Kit with 
RNase Inhibitor 
4374966 ThermoFisher Scientif ic  USA 
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MicroAmp® Optical Adhesive Film 4360954 ThermoFisher Scientif ic  USA 
Nuclease-Free Water (not DEPC-Treated) AM9938 ThermoFisher Scientif ic  USA 
RNeasy Micro Kit (50) 74004 QIAGEN USA 
RNeasy Mini Kit (50) 74104 QIAGEN USA 
TaqMan® Gene Expression Assay / CXCL12, hCG25667 4331182 ThermoFisher Scientif ic  USA 
TaqMan® Gene Expression Assay / FGF2, Hcg37365  4331182 ThermoFisher Scientif ic  USA 
TaqMan® Gene Expression Assay / GAPDH  
Hs02758991_g1 
4331182 ThermoFisher Scientif ic  USA 
TaqMan® Gene Expression Assay / MET, Hcg38705  4331182 ThermoFisher Scientif ic  USA 
TaqMan® Gene Expression Assay / MST1R, hCG95986 4331182 ThermoFisher Scientif ic  USA 
TaqMan® Gene Expression Assay / PDGFRA, Hcg22159 
(20X) 
4331182 ThermoFisher Scientif ic  USA 
TaqMan® Gene Expression Assay / TGFBR1, hCG30154  4331182 ThermoFisher Scientif ic  USA 
TaqMan® Gene Expression Master Mix  4369016 ThermoFisher Scientif ic  USA 
TaqMan® Gene Expression Master Mix  4369514 ThermoFisher Scientif ic  USA 
Table 2.5 Reagent and substances used for gene expression assay. 
2.2.6 MICRORNA PROFILING KITS 
Item Catalogue # Company Origin 
Agilent Small RNA Kit  5067-1548 Agilent Technologies Germany 
mirVana™ microRNA Isolation Kit, with phenol  AM1560 ThermoFisher Scientif ic  Lithuania 
nCounter Human v3 microRNA Expression 
Assay Kit 
GXA-MIR3-12 NanoString Technologies USA 
RNAlater® Stabilization Solution AM7020 ThermoFisher Scientif ic  USA 
Table 2.6 Kits and reagents used for microRNA analysis. 
2.2.7 STAINS AND STAINING REAGENTS 
Different stains and reagents were used to stain the cells and the 3D skin model during 
this study and are listed in (Table 2.7). 
Item Catalogue # Company Origin 
Alcian Blue 8GX A5268-10G Sigma-Aldrich UK 
N,N-Dimethylformamide 227056-100ML Sigma-Aldrich UK 
Eosin Stain 6766007 Thermo UK 
Fast Blue RR  201545-5G Sigma-Aldrich UK 
Haematoxylin satin HS315-1L Cell Path UK 
Methylene Blue Dye 556416-1G Sigma-Aldrich UK 
Naphthol AS-MX phosphate disodium salt (phosphatase 
substrate) 
N5000-100MG Sigma-Aldrich UK 
Oil Red O O0625 Sigma-Aldrich UK 
Tris base TRIS-RO Sigma-Aldrich UK 
Trypan Blue Dye 302643-25G Sigma-Aldrich UK 
Table 2.7 Stains and reagents used during the different staining protocols. 
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2.2.8 GENERAL REAGENTS 
Item Catalogue # Company Origin 
3,3′,5-Triiodo-L-thyronine sodium salt (T3) T6397-100MG Sigma-Aldrich USA 
4% Paraformaldehyde 1 * 500 ml BSBTAR1068 VWR UK 
Amphotericin B solution A2942-50ML Sigma-Aldrich USA 
Calcium chloride solution volumetric, 1.0 M CaCl2  21114-1L Sigma-Aldrich USA 
CellTiter 96® AQueous One Solution Cell Proliferation Assay  G3580 Promega UK 
200 mM L-Glutamine Solution G7513-100ML Sigma-Aldrich UK 
Bovine Serum Albumin A2153-50G Sigma-Aldrich UK 
Chelex® 100 Chelating Resin, biotechnology grade, 100–200 
mesh, sodium form, 100 g 
1432832 BioRad UK 
Cholecalciferol (Vitamin D3) 
PHR1237-
500MG 
Sigma-Aldrich UK 
Coomassie Plus protein assay reagent  10495315 
Thermo 
Scientif ic Pierce 
UK 
CXCL12 (SDF-1) Recombinant Human Protein, N-His Tag 13511-H07E-50 
Thermofisher 
Scientif ic 
UK 
Dispase 07923 
Stem Cell 
Technologies 
UK 
Donkey Serum D9663-10ML Sigma-Aldrich UK 
Dulbecco’s Phosphate Buffered Saline (PBS) D8537-500ML Sigma-Aldrich UK 
Foetal Bovine Serum 10270106 Gibco UK 
Human Keratinocyte Growth Supplement (HKGS)  S-001-5 
Thermofisher 
Scientif ic 
UK 
Human/Mouse CXCL12/SDF1 Antibody MAB310-500 R & D Systems USA 
Hydrocortisone H0888-1G Sigma-Aldrich UK 
Insulin, Recombinant Human 91077C-100MG Sigma-Aldrich UK 
Insulin-Transferrin-Selenium (ITS -G) (100X) 41400045 
Thermofisher 
Scientif ic 
UK 
L-Ascorbic acid A5960-100G Sigma-Aldrich UK 
Lymphoprep 1114547 Axis-Shield UK 
Mitomycin C (MMC) ab120797 Abcam UK 
Penicillin – Streptomycin P4333-100ML Sigma-Aldrich UK 
Rabbit serum R9133-10ML Sigma UK 
Tris (Hydroxymethyl)-methylamine 77-86-1 Fisher Scientif ic UK 
Triton™ X-100 X100-100ML Sigma-Aldrich UK 
Trypsin inhibitor from Glycine max (soybean) T6522-250MG Sigma-Aldrich UK 
Trypsin-EDTA Solution T3924-100ML Sigma-Aldrich UK 
Table 2.8 General reagents and materials used during the study. 
2.2.9 EQUIPMENT AND MACHINES 
Item Company Origin 
2720 Thermal Cycler Applied Biosystems USA 
7900HT Fast Real-Time PCR System Applied Biosystems USA 
Agilent 2100 Bioanalyzer Agilent Germany 
Galaxy B CO2 Incubator  (Model 150-400) Scientif ic Supplies Ltd UK 
Cooled Centrifuge accuSpinTM 3R Fisher Scientif ic USA 
CytoMAT Pharmaceutical Safety Cabinet  CytoMAT Medical Air Technology Ltd.  USA 
DRI-BLOCK DB.2A Heater Techne UK 
ELISA Reader (Multiskan Ascent)  Thermo Lab systems USA 
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Floating–out Bath Gallenkamp  UK 
FACS Canto II FlowCytometry BD Biosciences USA 
Freezer (-80) Cool Repair UK Ltd UK 
Heraeus Megafuge 8 Centrifuge Thermo Scientific UK 
NU-5841 Hypoxic and Humidity Controlled CO2 
Incubator 
TripleRed USA 
IKA MS 3 basic S36 Agilent  Agilent Germany 
Labnet MPS 1000 Mini plate spinner Labnet UK 
MicroCL 17 Centrifuge Thermo Electron Corporation USA 
Mini see-saw rocker SSM4 Stuart UK 
 NanoDrop Spectrometry NanoDrop 1000 ThermoFisher Scientif ic  USA 
Oven MIDIS/1/SS/G/F GENLAB UK 
pH Meter Mettler Toledo UK 
Sartorius analytic Balance  Sartorius Germany 
Shandon Finesse 325 Microtome  ThermoFisher Scientif ic  USA 
Vortex-Genie 2 Scientif ic Industries USA 
Water Bath JB Aqua 5 Grant UK 
Table 2.9 Systems and machines used to carry out experiments during the study. 
2.2.10 PLASTIC AND GLASS WARES 
Item Catalogue # Company 
0.2 ml PCR Tube, Flat Cap (mixed)  I1402-8108 Start Lab 
8-well on glass detachable 94.6170.802 Sarstedt 
Alvetex 12 Well Insert Format  AVP005-12 Reprocell / Reinnervate  
Cover Glasses for Slides 18 mm × 18 mm (200)  12343138 Fisher Scientif ic 
Cryotube 1.8 ml SI INT. ROUND 363401 Thermo Scientific 
Flasks (25 cm2, 75 cm2, 175 cm2)  660175-TRI Greiner  
MicroAmp® Optical 96-Well Reaction Plate N8010560 Thermofisher Scientif ic  
Serological Pipettes Different Sizes (5 ml, 10 ml and 25 ml)  760107 Greiner 
Superfrost™ Ultra Plus Adhesion Slides, size 25 mm × 75 mm (50)  1014356145 Fisher Scientif ic 
Tissue Culture plates (6-wells, 12 wells, 24 wells, 48 well and 96 
wells) 
657160 Greiner 
Tissue Culture Test Plate 6 92006 TPP / Switzerland 
Well Insert Holder in Deep Petri Dish for Alvetex Well Insert  AVP015-2 Reprocell / Reinnervate 
Table 2.10 Consumables used for general techniques throughout the study. 
2.2.11 OTHER TOOLS 
Item Catalogue # Company 
Acrodisc 32 Syring Filter with 0.2 µm Supor Membrane  4652 Pall Corporation 
Disposable Scalpels Sterile R 0525 Swan Morton 
Falcon® 100µm Cell Strainer, Yellow, Sterile  352360 Falcon A Corning Brand 
Premier Disposable Microtome Blade, 34° cutting angle  MB35 Thermofisher Scientif ic  
Stiefel Biopsy Punch 3mm (pack of 10)  BC-BI-1000 SCHUCO 
Table 2.11 Other tools used for different lab purposes. 
 
Chapter 2                                                                                                                     Materials and Methods 
67 
 
2.2.12 BIOIMAGING MACHINES 
Different microscopes listed in (Table 2.12) below were used to investigate cells including 
MSCs, HaCat cell lines, primary keratinocytes and primary fibroblasts and their behaviour 
such as migration, proliferation and differentiation under different conditions and at 
different time points.  All bioimaging machines used in this study were available at the 
Medical School / Newcastle University. 
Machine Purpose Location 
Olympus CK2 Microscope Regular Monitoring of Cell Culture  
Academic 
Haematology 
Carlzeiss Jena Jenamed 2 
Microscope 
Regular Cell count 
Academic 
Haematology 
Leica DM IRB 
Imaging MSC Morphology 
BioBank 
MSC Differentiation into Tri-lineages 
Nikon BioStation Cell Migration (Scratch assay)  BioImaging Unit 
Nikon TiE Multi-Modality (WF, BF, 
TIRF, SD Confocal (invert))  
Cell Migration (Scratch assay)  BioImaging Unit 
Zeiss AxioImager with Apotome 
(wide field fluorescence, upright)  
Keratinocyte Differentiation Markers 
Immunofluorescence (IF)    
BioImaging Unit 
MSC Differentiation into Skin-like Cells 
Immunofluorescence (IF)    
3D Skin Model Immunofluorescence (IF)  
3D Skin Model Bright Field (BF) 
Table 2.12 Microscopes used to image the live cells, dead stained cells and 3D skin equivalent 
models (3D-SEM). 
2.2.13 PREPARATION OF CULTURE MEDIA 
Culture media and reagents required addition of supplements at specific concentrations 
and volumes before use. Therefore, two main equations (Equation 2.1 and Equation 2.2) 
were used to prepare the correct amount of these additives. 
𝑴𝒐𝒍𝒂𝒓𝒊𝒕𝒚 (𝑴) =
𝑾𝒆𝒊𝒈𝒉𝒕 (𝑾)
𝑴𝒐𝒍𝒆𝒄𝒖𝒍𝒂𝒓 𝑾𝒆𝒊𝒈𝒉𝒕 (𝑴𝒘𝒕)
× 𝑽𝒐𝒍𝒖𝒎𝒆 (𝑽) . . . . . . . Equation 2.1 
   
𝑪𝟏 ×  𝑽𝟏 = 𝑪𝟐 ×  𝑽𝟐 . . . . . . . Equation 2.2 
When: 
C1 V1= Start concentration and start volume. 
C2 V2= Final concentration and final volume. 
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2.2.13.1 STEM CELL CULTURE MEDIA 
This media was used as complete media already supplemented with foetal calf serum and 
L-Glutamine. Before use, it was supplemented with 5 ml of 100IU/ml penicillin - 100 µg/ml 
streptomycin and used to grow and expand MSCs. 
2.2.13.2 STANDARD CULTURE MEDIA 
This media was used to grow HaCat cell lines and primary fibroblasts. It was also used to 
suspend and seed fibroblasts onto the Alvetex® in the 3D skin equivalent model (3D-SEM) 
and referred to as media A. The ingredients of this media are detailed in (Table 2.13). 
Item Volume (ml) Concentration 
Dulbecco’s Modified Eagles Media (DMEM)  500 --- 
FCS or FBS 50 10 % 
200 mM L-Glutamine 20 4 % 
100 IU/ml penicill in, 100 µg/ml streptomycin (PS)  5 1% 
Table 2.13 Components of standard culture media. 
2.2.13.3 MCDB MEDIA 
This media was used to grow primary keratinocytes. It is composed of the following 
ingredients listed in (Table 2.14).  
Ingredients Volume / Concentration Final Concentration 
MCDB153 with L-glutamine, 28 mmol/L HEPES 500 ml ------ 
Histidine 18.65 mg 240 μmol/L 
Isoleucine 49.2 mg 750 μmol/L 
Methioninen 6.7 mg 90 μmol/L 
Phenylalanine 7.45 mg 90 μmol/L 
Tryptophan 4.6 mg 45 μmol/L 
Tyrosine 9.775 mg 100 μmol/L 
Ethanolamine (98% w/v) 3.05 μL 100 μmol/L 
Phosphorylethanolamine 7.05 mg 100 μmol/L 
Calcium chloride (1 mol/L) 20 μL 40 μmol/L 
Sodium bicarbonate 588 mg 15 mmol/L 
Human keratinocyte growth supplement  5 mL ≈1% 
Penicillin/streptomycin/amphotericin  (PSA) 5 mL ≈1% 
Table 2.14 Constituents of MCDB media. 
2.2.13.4 CONDITIONED MEDIA 
This media was used to collect MSC secretions. Two types of conditioned media were 
used; high calcium level (which is a DMEM based formula and used to collect MSC 
secretions for experiments involving HaCat cells and fibroblasts) and low calcium level 
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(which is MCDB based formula and used to collect MSC secretions for primary 
keratinocyte experiments). For both media, 1% of insulin-transferrin-selenium (ITS) was 
added to support MSC growth. The ingredients of these media are listed in (Table 2.15). 
Media Type Formula based Purpose Ingredients Volume 
High-Calcium Conditioned 
Media (HC-CM) 
DMEM 
experiments involving HaCat 
cells and fibroblast  
DMEM 500 ml 
PS 5 ml 
L-Glutamine 20 ml 
ITS 5 ml 
Low-Calcium Conditioned 
Media (LC-CM) 
MCDB keratinocyte experiments 
MCDB 500 ml 
PSA 5 ml 
L-Glutamine 20 ml 
ITS 3ml 
Table 2.15 Types of media used to collect MSC secretions. 
2.2.13.5 EPIDERMAL DIFFERENTIATION MEDIA (EDM) 
This media was used to grow MSCs and test their ability to differentiate into skin-like cells. 
It is composed of the following ingredients listed in (Table 2.16) below: 
Item Volume (ml) Concentration 
Dulbecco’s Modified Eagles Media (DMEM)  375 ml --- 
Ham's F12 Nutrient Mixture 125 ml --- 
Chelex-treated Foetal Calf Serum 25 ml 5 %  
200 mM L-Glutamine 20 ml 4 % 
100 IU/ml Penicil lin, 100 µg/ml Streptomycin (PS) 5 ml 1 % 
250 μg/ml Amphotericin B 5 ml 2.5 % 
Recombinant Human Epidermal Growth Ffactor (0.2 mg/ml)  50 µl 10 ng/ml 
Adenine (6 mg/ml) 2 ml 24 μg/ml 
Cholecalciferol (Vitamin D3) 10 µl 1 μM 
Cholera toxin (0.85 mg/ml)  5 µl 8.5 ng/ml 
3,3′,5-Triiodo-L-thyronine sodium salt (T3) 200 µl 1 nM  
Hydrocortisone (0.5 mg/ml)  400 µl 0.5 µg/ml 
Insulin, Recombinant Human (10 mg/ml) 250 µl 5 μg/ml 
Transferrin (10 mg/ml)   250 µl 10 ng/ml 
L-Ascorbic acid (10 mg/ml) added fresh 100 μl per 10 ml media  100 μg/ml 
Table 2.16 Ingredients of epidermal differentiation media. 
2.2.13.6 MEDIA OF 3D SKIN EQUIVALENT MODEL (3D-SEM) 
According to the methods of Hill and colleagues (Hill et al., 2015), four types of media 
were used to feed the 3D-SEM during the different phases of the model construction as 
shown below. 
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2.2.13.6.1 STANDARD CULTURE MEDIA (MEDIA A)  
This is the same standard culture media listed in 2.2.13.2. It was used to suspend the 
fibroblasts and seed them on to the Alvetex®.  
2.2.13.6.2 DERMAL LAYER FEEDING MEDIA (MEDIA B) 
This is a DMEM based formula with the additives listed in (Table 2.17) below. It was used 
to feed first and second fibroblast layers of the 3D-SEM for three weeks. 
Item Volume (ml) Concentration 
Dulbecco’s Modified Eagles Media (DMEM)  500 --- 
FCS or FBS 50 10 % 
200 mM L-Glutamine 20 4 % 
100 IU/ml Penicil lin, 100 µg/ml Streptomycin (PS)  5 1 % 
100 IU/ml Amphotericin B 5 1 % 
L-ascorbic acid (10 mg/mL) added fresh  100 µl per 10 mL media 100-μg/ml 
Table 2.17 Components of dermal layer feeding media (media B). 
2.2.13.6.3 KERATINOCYTE CHELATING MEDIA (MEDIA C) 
The serum of this media was treated with chelex by dissolving 1 g of chelex in 25 ml FCS, 
centrifuged for 12 hours at 2500 rpm, filtered via 0.22-µm filter and added to the remainder 
of the media component. This media was used for co-culture of keratinocytes over the 
dermal fibroblast layer of the 3D skin model. These co-cultures were fed with this media 
for three days with a daily change. The ingredients of this media are listed in (Table 2.18). 
Item Volume (ml) Concentration 
Dulbecco’s Modified Eagles Media (DMEM)  375 ml --- 
Ham's F12 Nutrient Mixture 125 ml --- 
Chelex-treated Foetal Calf Serum 25 ml 5 % 
200 mM L-Glutamine 20 ml 4 % 
100 IU/ml Penicil lin, 100 µg/ml Streptomycin (PS) 5 ml 1 % 
100 IU/ml Amphotericin B 5 ml 1 % 
Recombinant Human Epidermal Growth Factor (0.2 mg/ml) 50 µl 10 ng/ml 
Insulin, Recombinant Human (10 mg/ml) 250 µl 5 μg/ml 
Adenine (6 mg/ml) 2 ml 24 μg/ml 
Cholera toxin (0.85 mg/ml)  5 µl 8.5 ng/ml 
Hydrocortisone (0.5 mg/ml) 400 µl 0.5 µg/ml 
L-ascorbic acid (10 mg/mL) added fresh 100 µl per 10 mL media 100μg/ml 
Table 2.18 Constituents of keratinocyte chelating media (Media C). 
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2.2.13.6.4 AIR-LIQUID INTERPHASE MEDIA (MEDIA D) 
This media was used to feed the dermal fibroblast layer of the 3D-SEM after exposure of 
the model to the air-liquid interface with 6 changes for two weeks. The ingredients of this 
media are listed in (Table 2.19). 
Item Volume (ml) Concentration 
Dulbecco’s Modified Eagles Media (DMEM)  375 ml --- 
Ham's F12 nutrient mixture 125 ml --- 
FCS or FBS 50 ml 10 % 
200 mM L-Glutamine 20 ml 4 % 
100 IU/ml Amphotericin B 5 ml 1 % 
100 IU/ml penicill in, 100 µg/ml streptomycin (PS) 5 ml 1 % 
Recombinant Human Epidermal Growth Factor (0.2 mg/ml) 50 µl 10 ng/ml 
Transferrin (10 mg/mL) 250 µl 250 μg/ml 
Cholera toxin  5 µl 0.85 mg/ml 
Hydrocortisone (0.5 mg/ml)  400 µl 0.5 µg/ml 
L-ascorbic acid (10 mg/mL) added fresh 100 µl per 10 mL media 100*μg/ml 
Table 2.19 Ingredients of air-liquid interphase media (Media D). 
2.2.13.7 FREEZING SOLUTIONS 
Different solutions were used to freeze the different cell types as shown in (Table 2.20). 
Freezing Solution Ingredients Cell Type 
Freezing Solution A 70% RPMI + 20% FCS + 10% DMSO HaCat cell line 
Freezing solution N 90% FCS or FBS + 10% DMSO MSCs and Fibroblast 
Kers Freezing Solution 90% MCDB + 10% DMSO Primary keratinocytes 
Table 2.20 Freezing solutions of different cell types. 
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2.3 METHODS 
2.3.1 GENERAL PROTOCOLS OF CELL CULTURE 
All cell culture was performed in class II cabinets to reduce the risk of infection and 
contamination. Then, all the cells and skin models were incubated at standard culture 
conditions (SCC) which were provided by humidified incubator adjusted to 37oC, ≈20%O2 
and 5% CO2. Unless otherwise stated, all culture conditions set out in in this study for cell 
culture and cell experiments were SCC. 
2.3.1.1 SPLITTING PROTOCOL FOR MONOLAYER CELLS 
Old media was aspirated and cells were rinsed with PBS, trypsinised with trypsin 1X and 
incubated for 10 minutes. A quantity of 10 ml of DMEM with 10 % FCS was added to 
prepare the cell suspension and centrifuged at 1500 rpm for 5 minutes. The supernatant 
was discarded and cells were counted and a cell number of 5×105 to 1×106 was seeded 
into a T75 flask. A quantity of 15-20 ml of fresh growth medium (4mM L-glutamine, 4500 
mg glucose / L, 1500 mg/L sodium bicarbonate, FCS (110 ml), 10,000 I.U./ml penicillin, 
10,000 (ug/ml) streptomycin) were added to the flask and incubated under SCC (Sandell 
and Sakai, 2008). 
2.3.1.2 CELL COUNT 
Methylene blue stain was used to stain mononuclear cells to assess their total count 
during MSC isolation. Trypan blue stain was used to assess viability of all cells including 
MSCs, HaCat cells, fibroblasts and primary keratinocytes. In both stains, a volume of each 
was mixed with an equal volume of cell suspension. A quantity of 10 μl of this mixture was 
transferred to a Neubauer chamber and covered with a cover slip prior to counting under 
the microscope (Sandell and Sakai, 2008). (Equation 2.3) and (Equation 2.4) were used 
to calculate cell count and cell viability. 
𝑻𝒐𝒕𝒂𝒍 𝑪𝒆𝒍𝒍 𝑪𝒐𝒖𝒏𝒕 = 𝑵𝒐 𝒐𝒇 𝒄𝒆𝒍𝒍𝒔 𝒊𝒏 𝟐𝟓 𝒔𝒎𝒂𝒍𝒍 𝒔𝒒𝒖𝒂𝒓𝒆 × 𝑫𝒊𝒍𝒖𝒕𝒊𝒐𝒏 𝑭𝒄𝒂𝒕𝒐𝒓 × 𝟏𝟎𝟒 …. Equation 2.3 
  
𝑪𝒆𝒍𝒍 𝑽𝒊𝒂𝒃𝒊𝒍𝒊𝒕𝒚 =
𝑵𝒐 𝒐𝒇 𝒗𝒊𝒂𝒃𝒍𝒆 𝒄𝒆𝒍𝒍𝒔 𝒊𝒏 𝟐𝟓 𝒔𝒎𝒂𝒍𝒍 𝒔𝒒𝒖𝒂𝒓𝒆
𝑻𝒐𝒕𝒂𝒍 𝒄𝒆𝒍𝒍 𝒄𝒐𝒖𝒏𝒕 (𝑳𝒊𝒗𝒆 + 𝒅𝒆𝒂𝒅 𝒄𝒆𝒍𝒍𝒔)
 × 𝟏𝟎𝟎 % . . . . . Equation 2.4 
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2.3.1.3 CRYOPRESERVATION 
HaCat cells, fibroblasts and primary keratinocytes were frozen when they reached 80 % 
confluency at each passage (P1, P2 and P3). After trypsinisation with trypsin-EDTA 1X, 
cells were washed twice with PBS, suspended in 1 ml of growth medium and counted 
after staining with trypan blue. The cell suspension was centrifuged for 5 min at 2500 rpm 
and the supernatant was discarded. HaCat cells were re-suspended in the freezing 
solution A (70% RPMI, 20% FCS, and 10% DMSO), fibroblasts were re-suspended in the 
freezing solution N and primary keratinocytes were re-suspended in the Kers-freezing 
solution. A cell number of 0.5 ×106 to 3×106 cells was seeded per 1.8 ml cryotube and 
stored in -80 freezer until use (Sandell and Sakai, 2008). 
2.3.2 ISOLATION OF MSCS FROM BONE MARROW (PRIMARY CULTURE) 
All the hip joints were obtained from Musculoskeletal Research Lab (Newcastle University, 
Institute of Cellular Medicine). The marrow from the femoral head of the hip joint was 
dislodged into a sterile tissue culture dish using sterilised pliers. After harvesting the 
marrow, it was mixed with 10 ml sterile PBS and filtered using a BD sieve to release cells. 
The bone marrow suspension was layered onto Lymphoprep into a 50 ml falcon tube with 
a dilution ratio of 15 ml lymphprep: 35 ml diluted BM then the mononuclear cells (MNC) 
were separated by density gradient centrifugation at 800 g at 20oC for 15 minutes followed 
by collecting Lymphoprep-plasma interface which was washed twice in PBS at 500 g for 
5 minutes each. The cell pellet was re-suspended in 1 ml non-haematopoietic medium 
(NH) and counted with methylene blue dye. A total count of 3 × 107 – 8 × 107 MNCs was 
seeded per T25 flask and incubated lying horizontally under SCC. The medium was 
changed every three days and cells were split when they reached 80 % confleunce 
(Quiroz et al., 2013). 
2.3.3 EXPANSION OF MSCS IN VITRO 
The old medium was discarded and the cells were rinsed with PBS, followed by addition 
of 4 ml Trypsin-EDTA for a T25 flask or 7 ml for a T75 flask and incubated at 37°C for 5 
minutes. When cells were completely detached from the flask surface, a quantity of FCS 
(0.5 ml to T25 and 1.0 ml to T75) was added to deactivate Trypsin–EDTA activity, followed 
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by washing the cells twice with PBS. The cell pellet was re-suspended in 1 ml NH medium 
and counted using trypan blue dye. A total count of 1x105 to 2x105 cells was seeded into 
a T25 flask in 10 mls of medium or 3x105 to 5x105 cells into T75 flasks in 20 mls of medium 
depending how quickly the cells were needed for the assays (Jung et al., 2012). Both 
population doubling (PD) and doubling time (DT) were measured according to (Mareschi 
et al., 2012) by applying (Equation 2.5) and (Equation 2.6) respectively. 
 𝑷𝑫 =
𝒍𝑶𝑮 (𝑯) − 𝑳𝒐𝒈 (𝒔)
𝑳𝒐𝒈 (𝟐)
 . . . . . Equation 2.5 
 
 𝑫𝑻 =
𝜟𝑻 𝑳𝒐𝒈 (𝟐)
𝒍𝑶𝑮 (𝑯) − 𝑳𝒐𝒈 (𝒔)
 . . . . . Equation 2.6 
When: 
S= Number of Seeded cells.  
H= Number of Harvested cells.  
ΔT= Time from seeding to harvesting (time required to reach 80% confluence at a given passage). 
2.3.4 CRYOPRESERVATION OF MSCS 
All MSC samples were frozen when they reached 80% confluence at each passage (P1, 
P2 and P3). MSCs were detached and counted as mentioned above in expansion 
protocol, but, instead of seeding cells into a culture flask, a cell number of 105 cell / ml was 
transferred into cryogenic vials (2 ml Nalgene)and centrifuged for 5 min (1000 rpm at room 
temperature) to obtain a cell pellet. The medium was discarded and 1 ml of freezing 
solution (90% FCS, 10% DMSO) was slowly added. All vials were stored at –80°C freezers 
until needed (Naaldijk et al., 2012). 
2.3.5 CHARACTERISATION OF MSCS 
Isolated MSCs were tested for the minimal criteria defining h-MSCs stipulated by the ISCT 
in 2006 (Jung et al., 2012). These tests were the following:- 
2.3.5.1 MORPHOLOGICAL CHARACTERISATION TEST 
The isolated cells were tested for their morphology by monitoring their shape and the 
ability to attach to the plastic surface of the culture flask (Jung et al., 2012).
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2.3.5.2 PHENOTYPIC CHARACTERISATION TEST 
All isolated MSCs were analysed for their phenotypic characteristics at passage 3 (P3). 
AMSC suspension consisting of 2×106 cell / ml was prepared by suspending MSCs in 
FACS buffer (10 ml of FBS or FCS + 1 ml of 1 mM EDTA in 500 ml Dulbecco’s PBS) 
(Pravdyuk, Petrenko et al. 2013). As demonstrated in (Table 2.21), the suspension was 
equally divided (300 μl/tube) into five different tubes, isotype stained tube-1, Ab stained 
tube-2, HLA-DR isotype tube-3, HLA-DR ab-4 and negative control tube-5. The following 
isotypes were added to tube-1 (7μl FITC mlgG1, 2μl FITC mlgG2b, 1 μl PE mlgG1, 0.5 μl 
perCPCymlgG1 and 1 μl APC mlgG1). Tube-2 contained the following antibodies (4μl 
CD73-PE, 2μl CD105-APC, 2μl CD90-PerCPCy5.5, 4μl CD14-FITC, 4μl CD19 FITC, 4μl 
CD34 FITC and 4μl CD45 FITC). In addition, 0.25μl APC-H7mlgG2a was added to tube-
3, and 1μl HLA-DR APC H7 to tube-4. While neither isotype nor antibody were added to 
the negative control (Jung et al., 2012). All tubes were incubated at 4oC for 20 minutes. 
After the incubation period, 2 ml of FACS buffer was added to each tube and centrifuged 
for 5 min at 500 g to remove unbound antibodies. The washing buffer was removed and 
the cells were re-suspended in 400 μl FACS buffer prior to analysis on the Fluorescent 
Activated Cell Sorter (FACS Canto II). Immediately prior to running the tube on the FACS 
Canto II, 50 ul DAPI were added to assess viability (Akiyama et al., 2012; Pravdyuk et al., 
2013). 
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Tube No & 
Conditions 
→ 
Tube 1 
Isotype Stained 
Tube 2 
Ab Stained 
Tube 3 
HLA-DR Iso 
Tube 4 
HLA-DR Ab 
Tube 5 
Unstained 
Steps ↓ 
     
MSCs 
300 μl 
0.15 × 106 cell 
300 μl 
0.15 × 106 cell 
300 μl 
0.15 × 106 cell 
300 μl 
0.15 × 106 cell 
300 μl 
0.15 × 106 cell 
Ab  
------- 
 Isotype 
7μl FITC mlgG1 
2μl FITC mlgG2b  
1 μl PE mlgG1  
0.5 μl perCPCy  
mlgG1 
1 μl APC mlgG1 
4μl CD73-PE 
2μl CD105-APC 
2μl CD90-
PerCPCy5.5 
4μl CD14-FITC 
4μl CD19-FITC 
4μl CD34-FITC 
4μl CD45-FITC 
0.25μl 
APC-H7mlgG2a 
1μl 
HLA-DR APC 
H7 
None 
Incubation All tubes were incubated at 4 ̊ C for 20 minutes 
FB 2000 μl 2000 μl 2000 μl 2000 μl 2000 μl 
Spinning centrifuged for 5 min at 500 g 
FB 400 μl 400 μl 400 μl 400 μl 400 μl 
DAPI 50 μl 50 μl 50 μl 50 μl 50 μl 
Table 2.21 Summary of MSC phenotyping assay. 
The MSC phenotypic assay consists of 7 steps as detailed before starting the assay, five tubes were 
labeled; Tube 1 Isotype stained, Tube 2-Antibody stained, Tube 3-HLA-DR Isotype, Tube 4-HLA-DR 
Antibody and Tube 5 Unstained cells. 300 μl of MSCs were added at a cell count 0.15×106 cell in each 
tube as shown in step 1. Conjugated antibodies and isotypes were added at the stated volumes in step 
2 then, cells were incubated at 4°C for 20 minutes in step 3. Followed by addition of 400 µl of FB and 
cells were centrifuged for 5 minutes at 500g as in step 5. Then at step 6, cells were suspended in 400 µl 
of FB and mixed with 50 µl of DAPI immediately before assessment by the FACS Canto II. FITC= 
fluorescein isothiocyanate, PE= phycoerythrin, perCPC= peridinin chlorophyll protein, APC= 
Allophycocyanin, FB= FACS Buffer= (10 ml of FBS or FCS + 1 ml of 1 mM EDTA in 500 ml Dulbecco’s 
PBS) 
2.3.5.3 ASSESSMENT OF MSC DIFFERENTIATION POTENTIAL 
When MSCs reached 80 % confluence at P3, they were trypsinised with trypsin-EDTA 
and counted prior to testing for their differentiation potential. (Table 2.22) summarises the 
steps of MSC differentiation into tri-linages; adipocyte, osteoblast and chondroblast.    
2.3.5.3.1 ADIPOGENESIS ASSAY 
2 x105 MSCs per well were seeded into 6-well plates followed by addition of 2 ml NH 
medium. The plate was incubated under SCC until confluent. When a confluent monolayer 
was formed, the NH medium was replaced with fresh Lonza adipogenic differentiation 
medium (ADM) with a sequential medium change of ADM every three days for 15-18 days. 
Cells were then fed with ADM for 3 days at SCC to reach confluence (roughly 18-21 days) 
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and stained with oil red stain to assess the accumulation of cytoplasmic lipid droplets 
under light microscopy (Vishnubalaji et al., 2013). The control wells contained the same 
cell number and the NH medium was changed every three days. 
To stain the cells, the media was removed and the cells were rinsed with PBS and fixed 
with 2 ml 10% formalin and left for 30-60 minutes. The formalin was then removed and 
cells rinsed with distilled water (DW), followed by addition of 2 ml 60% isopropanol to the 
well and left for 5 minutes. The isopropanol was then completely removed and 2 ml of 
0.3% Oil Red O working solution was added and left for 5 minutes. Cells were rinsed with 
distilled water until the water ran clear and assessed using an inverted microscope.   
2.3.5.3.2 OSTEOGENESIS ASSAY  
Cell count of 3×104 MSCs per well were seeded in duplicate into a 6 well plate followed 
by addition of 2 ml of osteogenic differentiation medium (ODM). The negative control well 
contained the same cell number but was supplemented with NH medium. The plate was 
incubated under SCC and after 24 h, both the test and the negative control wells were 
enriched with fresh ODM and NH media respectively every three days. Twenty-one days 
later, cells were stained with alkaline phosphatase (ALP) and Von Kossa stain for further 
assessment by light microscopy (Akiyama et al., 2012).. 
The staining protocol required preparation of alkaline phosphate substrate solution 
(ALSS) which was prepared by diluting 6 mg of Napthol AS phosphate in 0.1 ml of 
dimethylformamide, then mixed with 20 ml of Tris HCl buffer (0.2M), followed by addition 
of 2 mg of fast blue dye and filtered before use. 
For staining cells, the media was removed and the cells rinsed with 2 ml of PBS to remove 
any residual media.  Cells were then fixed with 10% formalin for at least 10 minutes at 
37oC. The formalin was removed and cells washed twice with 0.2M Tris HCl buffer and 
then with DW,followed by staining with filtered ALSS overnight in a 37oC. ALSS was then 
discarded and the cells washed with double DW three times and covered with 2 ml of Von 
Kossa stain (3% silver nitrate “AgNO3”) and left for at least one hour under a white light 
lamp. Silver nitrate was then discarded and cells washed with double DW three times, 
covered with water and assessed under light microscopy. 
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2.3.5.3.3 CHONDROGENESIS ASSAY  
0.25x106 MSCs were suspended in 1 ml NH medium in a 15 ml polypropylene conical 
tube and centrifuged for 5 minutes at 150 g at room temperature. The supernatant was 
completely aspirated and a fresh pre warmed chondrogenic differentiation medium (CDM) 
was added and centrifuged for 5 minutes at 150g, at room temperature. The tube was 
incubated upright under SCC keeping the cap loose without disturbing the cell pellet. CDM 
was replaced every three days for 21 days. At day 21, the supernatant was removed and 
the pellet was fixed with 10% formalin for three hours at room temperature. The formalin 
was then discarded and the pellet was embedded in paraffin before taking thin sections 
for slide preparation and staining for further microscopic examination (Akiyama et al., 
2012). 
After 21 days, the culture supernatant was discarded and chondrogenic pellets washed 
with PBS and fixed in 10% formalin for a minimum of 3 hours at room temperature. 
Formalin was then discarded and cells were stored in 70% ethanol at room temperature 
(RT) and embedded in paraffin wax (Biobank Service) and  sectioned (5 µm) on slides. 
The slides were deparaffinised by soaking in xylene for 10 minutes, 100% ethanol for 5 
minutes, 95% ethanol for 5 minutes, 70% ethanol for 5 minutes, washed in 0.1N HCl for 
1 hour and stained with 0.1% alcian blue solution overnight. On the next day, the slides 
were washed in 0.1N HCl and assessed for proteoglycan staining using a bright field Leica 
microscope. 
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Step 
Period 
(Days) 
Lineage Manipulation 
Adipogenesis Osteogenesis Control Chondrogenesis 
1 0 
0.2×106 cells 
Plate (*NH) 
0.03×106 cells 
Plate (ODM*) 
0.2×106 cells 
Plate (NH) 
0.25×106 cells in 15 ml Vial 
(1 ml CDM*) 
2 1 ----- ODM after 24h ------ ------ 
3 3 Change *ADM Change ODM Change NH Change CDM 
4 6 Change ADM Change ODM Change NH Change CDM 
5 9 Change ADM Change ODM Change NH Change CDM 
6 12 Change ADM Change ODM Change NH Change CDM 
7 15 Change ADM Change ODM Change NH Change CDM 
8 18 
Staining with Oil 
Red 
Change ODM Change NH Change CDM 
9 21 *ALP / Von Kossa ---------- 
Formalin fixation Paraffin 
embedding Alcian Staining 
Table 2.22 Summary of MSC differentiation assays. 
This table explains the steps of manipulating MSCs during the differentiation assay into tri-lineages. At 
day zero, a cell count of 0.2×106 cells/well of MSCs were seeded into six-well plates, labelled as 
adipocytes and fed with NH media for three days followed by feeding with ADM until day 18 and then 
stained with oil red. For osteoblasts, 0.03×106 MSC cells/well were seeded into six-well plates in ODM 
for 24 hours followed by changing the media every three days for 21 days and then stained with ALP / 
Von Kossa satin. For chondrogenesis, MSCs were seeded at a density of 2.5×106 cells/wells in 1 ml 
CDM in a 15 ml tube and fed with CDM for three weeks followed by fixation of the pellet with 10% 
formalin, paraffin embedding, sectioning, slide fixation and staining with Alcian satin. The control cells 
for each lineage were treated the same as the test cells but fed with only NH media. NH*= Non-
haematopoietic Medium, ADM*= Adipogenic Differentiation Media, ODM*= Osteogenic Differentiation 
Medium, CDM*= Chondrogenic Differentiation Medium, ALP*= Alkaline Phosphatase 
2.3.6 PREPARATION OF MSC CONDITIONED MEDIA (MSC-CM) 
MSC conditioned medium (MSC-CM) was collected when the cells reached 80 % 
confluence by discarding the NH medium, washing the cells with PBS twice and adding 
20 ml of either fresh serum free medium with standard calcium levels (1.8 mM/L) (DMEM 
based formula for HaCat and fibroblasts) or low calcium levels (0.07 mM/L) (MCDB based 
formula for primary keratinocytes). Both media were supplemented with 1 % insulin-
transferrin-selenium (ITS) to support MSC growth (Walter et al., 2010), 20 ml L-glutamine 
and streptomycin-penicillin. MSC-CM was collected after 24, 48 and 72 hours and referred 
to as (CM24, CM48 and CM72)  and centrifuged at 3,000 rpm for 5 minutes to remove cell 
debris, filtered through a 0.2 µm filter and stored at -80oC until needed (Walter et al., 2010; 
Hsiao et al., 2012; Tamama and Kerpedjieva, 2012; Moghadasali et al., 2013). 
2.3.6.1 PROTEOMIC ANALYSIS OF MSC-CM 
ELISA kits from Lifetechnologies Company were used to detect the protein content of 5 
MSC-CM samples. The most important growth factors and cytokines which were well 
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documented to possess a positive effect on wound healing were studied and were; KGF, 
HGF, EDGF, PDGF-α, TGF-1β, SDF-1α, and MSP-1. An example of an ELISA kit is 
shown in (Table 2.23). 
Item Quantity Preparation 
Anti-Human GF Precoated 96-well Strip Plate 1 Ready to use 
Assay Diluent, 5X concentrated buffer  15 mL 
Diluted 5 times in DDW to get 1X assay diluent  
(1X AD) 
Lyophilized Recombinant Human GF Standard  2 vials 
Diluted in 400 µl 1X AD. See 2.3.11.1 for more 
details 
20X Wash Buffer 25 mL 
Dilute 20 times in DDW to get 1X wash buffer 
(WB) 
Biotinylated Antibody Reagent  2 vials 
Dilute in 100 µl 1X AD then, diluted  80 times 
in 1X AD 
Streptavidin-HRP Reagent 200 µL Dilute 200 times in 1X AD 
TMB Substrate 12 mL Ready to use 
Stop Solution, contains 0.2M sulfuric acid 8 mL Ready to use 
Adhesive Plate Sealer 2 Ready to use 
Table 2.23 An example of an ELISA kit and reagent preparation. 
2.3.6.2 PREPARATION OF STANDARDS AND SAMPLES 
All kit reagents and samples (MSC-CM and controls) were brought to room temperature 
(18-25ºC) before use. 1X assay diluent was used to dilute the MSC-CM and controls up 
to 2 fold. For preparation of standards, 400μL 1X assay diluent was added into the 
lyophilized standard of a given growth factor and used as the starter standard (SS) which 
was then used to prepare serial dilutions of the lower concentrations as shown in (Figure 
2.1). 
 
Figure 2.1 Preparation of ELISA standards. 
Preparing standards of the ELISA kit. The lyophilised standard was diluted with 1X assay diluent to give 
the standard solution (SS) which differed depending on the growth factor (see Table 2.24 below). After 
dissolving the lyophilised standard, a specific volume was taken from the SS and added to a vial 
containing a specific volume of 1X assay diluent to make standard no 8. Other standards (7-2) were 
prepared by serial dilution of the standards in the same volume of 1X assay diluent. Standard number 1 
represents 1X assay diluent only at 0 pg/ml.         
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The concentrations of standards were different depending on the growth factor; therefore, 
the required volumes to prepare each standard concentration were different as showed in 
(Table 2.24). 
GFs 
Assay 
Diluent 
Volume 
(µl) 
Concentration of 
Starter Standard 
(ng/ml) 
Stand 
8 
Pg/ml 
Stand 
7 
Pg/ml 
Stand 
6 
Pg/ml 
Stand 
5 
Pg/ml 
Stand 
4 
Pg/ml 
Stand 
3 
Pg/ml 
Stand 
2 
Pg/ml 
Stand 
1 
Pg/ml 
HGF 1000 20 8000 4000 2000 1000 500 250 125 0 
KGF 400 50 400 133.3 44.44 14.81 4.94 1.65 0.55 0 
TGF-β1 1000 10 2000 1000 500 250 125 62.5 31.2 0 
SDF-1 400 17 6000 3000 1500 750 375 187.5 93.75 0 
PDGF-AB 400 50 2500 1000 400 160 64 25.6 10.24 0 
MSP-1 400 50 ------- 2000 666.7 222.2 74.07 24.69 8.23 0 
Table 2.24 Concentrations of standards differ depending on growth factors. 
ELISA kits designed for estimating the concentration of growth factor are provided with standards 
specific for each growth factor. The concentrations of these standards vary depending on the 
concentration of the growth factor found in human serum and other body fluids. The standard range 
was above and below the standard level of the growth factor.    
To prepare the biotinylated antibody working reagent, 100 μl of 1X assay diluent was 
added to the biotinylated antibody stock reagent, and diluted 80 fold with 1X assay diluent. 
The streptavidin-HRP working reagent was prepared by diluting 200-fold with 1X assay 
diluent as shown in (Table 2.23).  
2.3.6.3 GENERAL ELISA PROTOCOL 
The summary steps of an ELISA protocol are shown in (Figure 2.2). Briefly, 100 μl of the 
standards and MSC-CM were added into appropriate wells, covered and incubated for 
2:30 hours at room temperature with gentle shaking. After the incubation time, the content 
of each well was discarded and washed four times with 1X washing buffer, which was 
then discarded and the wells inverted over clean absorbance tissue to remove any 
remaining wash buffer. 100 μl of 1X prepared biotinylated antibody working reagent was 
then added to each well and incubated for 1 hour at room temperature with gentle shaking. 
Well contents were discarded and the well was washed with wash buffer before addition 
of 100 μl of prepared streptavidin-HRP working reagent and a further incubation of 45 
minutes at room temperature with gentle shaking. The wells were washed before addition 
of 100 μl of tetramethylbenzidine (TMB) substrate and a further incubation of 30 minutes 
at room temperature in the dark with gentle shaking. The final step was stopping the 
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reaction by adding 50 μl of stop solution (sulphuric acid) to each well and the absorbance 
was read at 450 nm using an ELISA reader within 30 minutes of stopping the reaction. 
Data were analysed by plotting the optical densities (ODs) of each standard to generate 
a standard curve for the standard concentrations. Then, the ODs of each MSC-CM were 
compared to the ODs of the standards and the concentrations of growth factors in MSC-
CM were determined by comparing and plotting against the concentrations of each 
standard.  
 
Figure 2.2 Explanatory scheme of ELISA protocol. 
This flow chart summaries a general ELISA protocol. Standards and MSC-CM are added and incubated 
for 2:30 hours followed by washing with washing buffer (WB) four times. Then biotinylated antibody are 
added and incubated for one hour at room temperature followed by discarding and washing. The third 
addition is streptavidin reagent and incubation for 45 minutes at room temperature followed by 
discarding and washing. The next step is the addition of TMB and incubation for 30 minutes in dark at 
room temperature. The final step is stopping the reaction by addition of stop solution. The optical density 
(OD) of both standards and MSC-CM are measured at 450 nm and compared to each other to determine 
the relative concentration. 
ELISA readings showed consistent optical densities proportional to the corresponding 
concentrations of standards of a given growth factor as explained in (Figure 2.3). 
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(A) (B) 
  
(C) (D) 
  
(E) (F) 
Figure 2.3 Standards curves of growth factors and cytokines. 
Each growth factor has specific serial concentrations that differ from the others. All standards were 
read at 450 nm and their absorbance were plotted against the corresponding standard concentration 
which are presented in picogram / ml unit. (A) Standard curve of hepatocyte growth factor (HGF) which 
has serial standards (8000, 4000, 2000, 1000, 500, 250, 125 and 0.0) pg/ml. (B) Standard curve of 
keratinocyte growth factor (KGF) with serial standards (400, 133.3, 44.44, 14.81, 4.94, 1.65, 0.55 and 
0.0) pg/ml. (C) Standard curve of platelet derived growth factor α and ß (PDGF-AB) with serial 
standards (1000, 400. 160, 64, 25, 10.0 and 0.0) pg/ml. (D) Standard curve of transforming growth 
factor ß1 (TGF- ß1) with serial standards (1000, 500, 250, 125, 62.5, 31.2, 15.6 and 0.0) pg/ml. (E) 
Standard curve of stromal derived factor-1 (SDF-1) with serial standards (6000, 3000, 1500, 750, 375, 
187, 93.75 and 0.0) pg/ml. (F) Standard curve of macrophage stimulating protein-1 (MSP-1) with serial 
standards (2000, 666.7, 222.2, 74.07, 24.69, 8.23 and 0.0) pg/ml. 
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2.3.7  HUMAN SKIN PRIMARY CELLS AND CELL LINES 
2.3.7.1 CONSENT AND ETHICS 
Human skin cells including (keratinocyte and fibroblast) used in this study were obtained 
with agreement and consent of each donor. Approval for the study was given by the Local 
Research Ethics Committee (NRES Newcastle and North Tyneside 1 REC 
08/H0906/95+5) which was obtained on the 10th March 2014. 
2.3.7.2 ISOLATION OF SKIN CELLS  
A volume of 1 ml of dispase was mixed with 1 ml Penicillin-Streptomycin-Amphotericin 
(PSA) then the mixture was added to 8 ml of PBS in a universal tube labelled with name 
or the code of the corresponding skin. The skin bioposy was transferred to a petri dish 
containing PBS. Scratches along and across the epidermal side of the skin were made in 
the skin biopsy to allow dispase to penetrate and embed the cocktail of Dispase-PSA-
PBS solution. The biopsy was incubated under SCC for at least 4 hours to allow 
separation of the dermal layer from the epidermal layer. After the incubation period, skin 
cells were isolated as detailed below.  
2.3.7.2.1 KERATINOCYTE ISOLATION 
The scratched skin was removed from the universal and placed in a petri dish containing 
PBS and the epidermis peeled off using forceps and soaked in 5 ml trypsin-EDTA and 
incubated for 5 minutes under SCC. The Trypsin-EDTA was then neutralized by 15 ml of 
10% FCS-DMEM and centrifuged at 3000 rpm for 5 minutes. The supernatant was 
discarded and the pellet was mixed with 20 ml MCDB, and transferred to a 175 cm2 culture 
flask and incubated at SCC overnight to allow keratinocytes to adhere. On the next day, 
the MCDB media was discarded and 20 ml of fresh MCDB medium were added.  MCDB 
media was changed until splitting at passage 1.    
2.3.7.2.2 FIBROBLAST ISOLATION 
The remaining dermis was cut into small sections using a scalpel and placed over a tissue 
wet with 70% ethanol for 2 minutes and each section was transferred into a well of a 6 
well plate, covered with FBS incubated at SCC for overnight. On the next day, a volume 
Chapter 2                                                                                                                     Materials and Methods 
 
85 
 
of 5 ml of DMEM was added to each well. The dermal sections were kept in the wells with 
a regular change of media until splitting at passage1.     
2.3.7.3 HACAT CELL LINE 
HaCat cell line is an immortalised human keratinocyte cell line isolated from adult human 
skin. It is characterised for its ability to proliferate and differentiate in vitro therefore and it 
is widely used in scientific research.  
2.3.7.4 HELA CELLS 
HeLa cells showed in (Figure 2.4) are an immortalised cervical adenocarcinoma cancer 
cell line. The name HeLa was derived from the patients’ name Henrietta Lacks (Scherer 
et al., 1953). Dr Amy Anderson / Musculoskeletal Research Group, the Faculty of Medical 
Sciences, Newcastle University kindly provided these cells at passage 38 and they were 
used as a positive control in the experiments assessing proliferation markers. 
 
Figure 2.4 HeLa cell line in culture at different densities (Adopted from ATCC). 
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2.3.8 ASSESSMENT OF CELL MIGRATION 
The scratch assay was applied to assess cell migration by measuring the area of the 
scratch during different periods utilising the protocol described by (Walter et al., 2010) with 
some modifications. Briefly, three cell types were assessed in this test for their ability to 
migrate under the effect of MSC-CM, namely, the human keratinocyte cell line (HaCat), 
human primary keratinocytes and human primary fibroblasts. Each cell type was seeded 
in 48 well plates at a density of 0.05×106 cells per well and incubated at SCC overnight 
to allow cell adherence (Figure 2.5). On the second day, each confluent monolayer was 
scratched with a sterile yellow tip making a scratch of ≈ 0.4–0.5 mm in width along the 
diameter of each well. The medium was removed and replaced with test substances; 
MSC-CM and controls (cells treated with DMEM in case of HaCat cells and fibroblasts, or 
with MCDB media in the case of primary keratinocytes) as shown in (Figure 2.5) below. 
The plate was re-incubated under an inverted microscope (Nikon ECLIPSE Ti) under SCC 
to monitor wound closure by taking images every two hours. The scratch assay was also 
performed for primary keratinocytes under hypoxic conditions (1% O2, 5% CO2, 37°C). 
To investigate whether MSC-CM enhance migration or proliferation,  experiments also 
included inhibition of keratinocyte proliferation using 10 µg/ml  mitomycin c (MMC) for 3 
hours before making the scratch. The area of each single scratch was measured at 
different time points using image J software. 
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Figure 2.5 Design of scratch assay. 
In the scratch assay of each cell type (HaCat 
cells, fibroblast and keratinocytes) 48 well 
plates was used separately. Each cell type 
was assessed in quadruplicate and the plate 
was divided into four quarters; each quarter 
contained 12 wells which were specified to 
fulfil four conditions which were (CM24, 
CM48, CM72 and Control) for the same 
donor. 4 different donors were assessed per 
one assay. When the cells formed a 
confluent monolayer, a scratch was made in 
each cell layer using a sterile yellow tip. The 
cells then treated with MSC-CM and the 
plate was incubated at the SCC for three 
days under an inverted NIKON microscope 
to monitor cell migration by capturing 
images every two hours. 
In addition, a scratch assay was performed by adding 0.02 µg/ml of SDF-1 antibody 
(MAB310-500) (Guo et al., 2015) to the confluent monolayer for 30 minutes to block SDF-
1α receptor (CXCR4) prior to inducing the scratch. The positive controls consisted of 
addition of 0.2 µg/ml SDF-1α human recombinant protein to the monolayer (Wang et al., 
2014), whereas keratinocyte growth media (KGM) alone represented the negative control. 
The plate was incubated under SCC for three days and time-lapse images were taken 
every two hours. 
2.3.9 DETECTION OF PROLIFERATION MARKERS 
To test whether keratinocytes migrate or proliferate during the wound closure process, a 
proliferation marker was incorporated by labelling the cells with BrdU synthetic nucleoside 
(see the following sections). 
2.3.9.1 SEEDING CELLS 
Primary keratinocytes were seeded at a density 0.05×106 cells per well in 8-glass well 
chambers in keratinocyte growth media (KGM) (N=3). The chamber was then incubated 
under SCC overnight to allow cell adhesion. Next day, a scratch was induced onto the 
monolayer followed by treatment with MSC-CM. Other wells of keratinocytes were 
scratched on the day of imaging and used as a time zero scratch control. HeLa cells were 
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used as a control and seeded at a density 0.1×106 cells per well in DMEM-10%-FCS and 
incubated for 4 hours under SCC to allow cell attachment. 
2.3.9.2 LABELLING WITH BRDU  
A stock solution of BrdU (10 mM) was prepared by dissolving 3 mg of BrdU powder in 1 
ml water and filtered through 0.22-µm filter under sterile conditions. The working solution 
(3 µg/ml BrdU) was prepared by mixing 10 µl of BrdU stock solution with 1 ml MSC-CM 
and used to treat primary keratinocytes and HeLa cells overnight. The next day, BrdU 
labeling solution was discarded and cells washed 3 times with PBS for 5 minutes for each 
wash.  
2.3.9.3 FIXATION AND PERMEABILISATION  
The cells were then fixed with 4% ice-cold paraformaldehyde (PFA) for 15 minutes at room 
temperature, washed 3 times with PBS and permeabilised with 0.2% Triton X for 10 
minutes at room temperature and again washed 3 times with PBS.        
2.3.9.4  DNA HYDROLYSIS (DNA DENATURATION)  
A volume of 83.3 ml of 1% PBS-T (3 ml Tween-20 + 97 ml PBS) was mixed with 16.7 ml 
concentrated HCL to prepare the DNA hydrolysis buffer (2 M HCL). The cells were 
incubated with this buffer for 15 minutes at 37°C and washed 3 times with PBS. 
2.3.9.5 BLOCKING AND STAINING WITH ANTI-BRDU-ANTIBODY  
Nonspecific binding was blocked with blocking buffer (1% BSA) (1 g bovine serum albumin 
+ 100 ml PBST) for 60 minutes at room temperature followed by incubation with 120 µl 
anti-BrdU-antibody (1:60) diluted in 1% BSA  and left in the dark for 1 hour at room 
temperature. Cells were then washed three times in PBS followed by incubation with the 
secondary antibody (Donkey Anti-Rabbit IgG H&L (Alexa Fluor® 488) (1:250) in (1% BSA) 
for a further 2 hours in the dark. The  cells  were then washed 3 times in PBS and stained 
with (DAPI 1:1000) in 1% BSA in the  dark for 30 minutes at room temperature and washed 
3 times in PBS. The cells were then covered with 50 µl mounting medium on a coverslip 
and visualised by fluorescence field microscopy.  
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2.3.10 VIABILITY AND PROLIFERATION ASSAY 
MSC-CM were tested for their effect on survival and proliferation activity of skin cells 
including HaCat cells, primary fibroblasts and primary keratinocytes. Figure 2.6 shows the 
design of the proliferation assay in 96 well plates. Briefly, a cell count of 0.01×106 cell / 
well of each cell type were seeded into the 96 well plates in 1 ml suitable culture media 
(DMEM for HaCats and fibroblasts, MCDB for primary keratinocytes) and incubated for 4 
hours under SCC to allow cell adherence. After the incubation time, cells were washed 
twice in serum free medium followed by addition of 1 ml of MSC-CM and suitable control 
(LC-CTRL in case of primary keratinocytes and HC-CTRL in case of HaCat cells and 
fibroblasts) as shown in (Figure 2.6. A) and incubated at SCC. A volume of 20 µl of (3-
(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium 
(MTS) was added to the wells after 24, 48 and 72 hours. The plate was then incubated 
for 3 hours to allow the viable cells to reduce the tetrazolium and release the coloured 
formazan compound into the culture media giving a colour depending on cell viability, 
which was then read at a wavelength of 490 nm using an ELISA reader. Both HaCat cells 
and fibroblasts were treated with HC-CM, while primary keratinocytes were treated with 
HC-CM as well as LC-CM. Controls included DMEM-SF media and MCDB media. Each 
condition was tested on four different donors for both fibroblasts and keratinocytes.  
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Figure 2.6 Design of proliferation assay. 
In the proliferation assay, skin cells including HaCat cell lines, primary fibroblasts and primary 
keratinocytes were seeded  at a density of 0.01×106 cell / well in 96 well plates and incubated for 4 
hours under SCC to allow cell attachment as shown above. Then they were treated with absolute and 
50 % diluted MSC-CM. HaCat cells and fibroblasts were treated with HC-CM only, whereas primary 
keratinocytes were treated with both HC-CM and LC-CM. then, the plates were incubated under SCC 
and their viability measured after 24, 48 and 72 hours using MTS solution. The optical density was 
measured at 490 nm using an ELISA reader.      
2.3.11 DIFFERENTIATION OF MSCS INTO EPIDERMAL-LIKE CELLS 
MSCs were seeded on sterile cover slips in NH media in 6-well plates at a density of 
0.01×106 cells / well. The plates were incubated at SCC of for 24 hours to allow cell 
adherence. Then cells were then fed with epidermal differentiation media (EDM) for 
different time points to investigate their ability to express skin markers. For instance, after 
7 days of treatment with EDM, MSCs were tested for their ability to express cytokeratin 
K14 (K14), after 10 days for K14 and cytokeratin 10 (K10) and after 17 days for K10 and 
loricrin.    
Chapter 2                                                                                                                     Materials and Methods 
 
91 
 
2.3.12 IMMUNOFLUORESCENCE OF SLIDE FIXED CELLS 
After the treatment period, MSCs were washed with PBS 3 times for 5 minutes each, fixed 
with 4% iced cold paraformaldehyde for 15 minutes at room temperature. The fixative was 
aspirated and cells washed as before. For permeabilisation, cells were treated with 0.2% 
Triton-X (200 µl Triton-X +99.800 ml PBS) for 10 minutes at room temperature, then 
washed 3 times with PBS for 5 minutes each. To block non-specific binding, MSCs were 
incubated with blocking buffer (10% FBS in PBS) for 60 minutes. Cells were separately 
stained with 100 µl of 1:200 diluted primary antibodies such as keratin 14, keratin 10 and 
loricrin and incubated overnight at 4°C. On the next day, cells were rinsed 3 times with 
PBS for 5 min each. The cells were then stained with 100 µl diluted 1:200 Alexa Fluor-
488 secondary antibody and incubated for 1 hour in the dark at room temperature, 
followed by rinsing 3 times with PBS for 5 minutes each. DAPI (1/2000) was then added 
and the cells incubated in the dark for 30 minutes at room temperature and rinsed again 
as before. The cells were then covered with 50 µl mounting medium and visualized using 
a confocal microscope. 
2.3.13 DETECTION OF GROWTH FACTOR RECEPTORS IN PRIMARY KERATINOCYTES  
2.3.13.1 CONDITIONS 
As shown in (Figure 2.7) four samples of primary keratinocytes were seeded in MCDB 
media in 15 ml petri dishes and incubated under SCC until reaching confluent. All samples 
were subjected to the same conditions; no scratch (NS), scratched non-treated with MSC-
CM (SNT) and scratched treated with MSC-CM (ST-CM). Then, cells of each condition 
were harvested after different time points; 24, 48 and 72 hours for RNA extraction. 
Detection of the receptors,FGF-R2, c-Met, TGFR-β1, PDGR-A, CXCL12 and MST-R1 
which are receptors for KGF, HGF, TGF-1β, PDGF-α, SDF-1α and MSP-1 respectively 
was carried out using gene expression profiling . 
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Figure 2.7 Conditions applied to primary keratinocytes for further gene expression of growth 
factor receptors. 
Four samples of human primary keratinocytes were seeded into 15 ml petri dishes and incubated under 
SCC to reach confluence. Each sample was subjected to three conditions; non-scratched cells (NS), 
scratched cells without any treatment (SNT) and scratched cells treated with MSC-CM (ST-CM). Cells 
were harvested after different time points (24, 48 and 72 hours) for further RNA extraction.  
To detect gene expression, three sequential protocols were followed; total RNA isolation, 
synthesis of complementary DNA (c-DNA) and quantification of gene expression using 
TaqMan assay by real time-polymerase chain reaction (RT-qPCR). These steps are 
summarised in (Figure 2.8). 
 
Figure 2.8 Steps of gene expression assay. 
Gene expression could be detected by using the real time reverse transcriptase polymerase chain reaction 
(RT-PCR) technique which involved three main steps; A. total RNA extraction from cell lysate, B. cDNA 
synthesis using reverse transcription and D. Quantification of gene expression by real time PCR.  
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2.3.13.2 TOTAL RNA ISOLATION 
RNeasy Micro Kit from QIAGEN was used to extract RNA from primary keratinocytes. The 
content of the kit and reagent preparation are explained in (Table 2.25). 
Item Quantity Preparation 
RNeasy MinElute® Spin 
Columns (each in a 2 ml 
Collection Tube) 
50 Ready to use 
Collection Tubes (1.5 ml)  50 Ready to use 
Collection Tubes (2 ml)  100 Ready to use 
Buffer RLT 45 ml 10 ml  RLT mixed with 100 μ l β-mercaptoethanol (β-ME)  
Buffer RW1 45 ml Ready to use 
Buffer RPE (concentrate)  11 ml Mixed with 44 ml (Absolute Ethanol 96-100 %) 
RNase-Free Water 3 x 10 ml Ready to use 
Carrier RNA, poly-A 310 µg Ready to use 
RNase-Free DNase Set  
RNase-Free DNase I 
(lyophilized) 
1500 
units 
The lyophilized DNase I dissolved in 550 μ l RNase-free water 
mixed gently and stored as single-use aliquots at –80°C for up 
to 9 months.  
Buffer RDD 2 x 2 ml 
70 μ l Buffer RDD mixed with 10 μ l DNase I stock solution to 
prepare DNase I incubation mix (80 μ l). 
RNase-Free Water 1.5 ml Ready to use 
Table 2.25 Content of RNeasy micro kit and their preparation. 
All steps of RNA isolation were completed according to the manufacturer’s protocol 
(QIAGEN) in the presence of RNase inhibiting reagents to avoid unwanted changes in the 
gene expression profile. In addition, samples were either processed immediately after 
harvesting or kept in RNA stabilising solution (RNA later) in – 80°C until use. Briefly, a 
maximum of 5×105 cells were harvested and directly treated with 350 μl tissue and cell 
lysis buffer for RNA extraction (RLT) working solution to lyse the cell plasma membrane. 
Cell lysate was then homogenised using a 2G sterile needle to shear high molecular 
weight (HMW) genomic DNA and other HMW cellular components to reduce the viscosity 
of the lysate and create a homogenous lysate. RNA purification was done by addition of 
one volume of 70% ethanol (350 μl) to the lysate, transferred to RNeasy MinElute columns 
in 2 ml collection tubes and centrifuged for 15 seconds at ≥ 8000g with closed lid and the 
flow-through was discarded. The next addition was 350 μl buffer RW1 to the RNeasy 
MinElute spin column, which was centrifuged for 15 seconds at ≥8000g and the flow-
through discarded. Then, DNase I incubation mix (80 μl) was directly added to the RNeasy 
MinElute column membrane and placed on the benchtop for 15 minutes at room 
temperature (20–30°C) to allow full digestion of the DNA. The next addition was 350 μl 
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buffer RW1 to the RNeasy MinElute spin column and centrifuged as before. The RNeasy 
MinElute spin columns were placed in a new 2 ml collection tube and 500 μl buffer RPE 
were added to the spin column and centrifuged as above. A volume of 500 μl of 80% 
ethanol were added to the RNeasy MinElute spin column and centrifuged for 2 minutes at 
≥8000g. The collection tubes were discarded and the RNeasy MinElute spin columns were 
placed in a new 2 ml collection tube, centrifuged at 15000g for 5 minutes with an open lid 
to dry the membrane and remove any ethanol residue which may interfere with 
downstream reactions. The flow-through and collection tube were discarded and the 
RNeasy MinElute spin columns were placed in new 1.5 ml collection tubes. The final 
addition was 14 μl RNase-free water added directly to the centre of the spin column 
membrane and centrifuged for 1 minute at 15000 g to elute the RNA. Then, RNA 
concentrations were quantified and analysed for purity using Nanodrop spectrometry and 
stored at – 80 until use.  
2.3.13.3 CDNA SYNTHESIS BY REVERSE TRANSCRIPTASE PCR (RT-PCR) 
High capacity cDNA Reverse Transcription Kit from Applied Biosystems was used to 
synthesise complementary DNA. The materials of the kit and their volumes for specific 
number of reactions are shown in (Table 2.26). The first step was preparation of 2X 
reverse transcriptase master mix (2X-RT-MM). Briefly, all kit components were allowed to 
thaw on ice followed by mixing the volumes as listed in (Table 2.26). 
Item Quantity 
Preparation of 2X-RT-MM 
Volume (µl) / Reaction(s) Volume / 6 tubes 
(10 µl / tubes) 1 Reaction 30 Reactions 
10✕ RT Buffer 1.0 ml 2 tubes 2.0 60 14 
10✕ RT Random Primers, 1.0 ml 2 tubes 0.8 24 5.6 
25✕ dNTP Mix (100 mM) 1.0 ml 1 tube 2.0 60 14.0 
MultiScribe™ Reverse Transcriptase, 50 
U/µL, 1.0 ml 
1 tube 1.0 30 7.0 
RNase Inhibitor‡, 100 µL  
10 
tubes 
1.0 30 7.0 
Nuclease-free H2O 100 ml 1 bottle 3.2 96 22.4 
Total per Reaction --- 10.0 300 70.0 
Table 2.26 Content of high capacity cDNA reverse transcription kit and their preparations. 
To prepare the cDNA reverse transcription reaction, 10 µl of 2X-RT-MM were pipetted into 
single tubes followed by addition of 10 µl of RNA, mixed well and kept on ice until loaded 
into the thermal cycler which was adjusted to the conditions shown in (Table 2.27). 
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Reaction volume 20 µl 
Conditions Step I Step II Step III Step IV 
Temperature (°C) 25 37 85 4 
Time (Minutes) 10 120 5 ∞ 
Table 2.27 Conditions of the thermal cycler for reverse transcriptase PCR. 
After finishing the run, cDNA purity was assessed using NanoDrop spectrometry and 
stored at -80°C or immediately used for gene expression evaluation using the TaqMan® 
technique.   
2.3.13.4 ASSESSMENT OF NUCLEIC ACID PURITY 
Extracted RNAs and synthesised cDNA were analysed for any contamination that could 
interfere the purity of RNA and DNA such as phenol or other contaminants. NanoDrop 
spectrometry (NanoDrop 1000, Thermo Scientific) was used to measure A260/A280 
which should generally be 2.0 for RNA and 1.8 for DNA to be accepted as “pure” according 
to the ThermoFisher guidelines. In addition, the A260/230 ratios, which should range from 
2.0 – 2.2 for pure nucleic acids were measured to detect any impurities that could be 
absorbed at 230 nm as shown in the explanatory figure (Figure 2.9). Briefly, 1 µl of a 
nucleic acid sample was placed on the sensor and the lid was placed on the NanoDrop 
and then the software was used to analyse the sample for any interfering contaminants. 
(A) 
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(B) 
 
Figure 2.9 Explanatory images of assessing nucleic acid purity. 
Samples of nucleic acids analysed for purity and measured for concentration by NanoDrop 1000. Each 
line in the plot of each image represents a single sample. Data in the right hand side of each image 
represents one sample which could be selected manually by the software.  A- An RNA sample shows 
that the concentration of total RNA in the sample is 1022.94 ng/μl with a ratio of 260/280=2.11 and 
260/230=2.01. B- A DNA sample shows that it contains a concentration of DNA = 431.60 ng/μl with a 
ratio 260/280=2.08 and 260/230=1.72. Thermofisher Scientific guidelines state that a ratio of ~1.8 is 
generally accepted as “pure” for DNA and a ratio of ~2.0 is generally accepted as “pure” for RNA. So, 
these samples could be classified as pure. 
2.3.13.5 TAQMAN GENE EXPRESSION BY RT-PCR 
The first step in RT-qPCR is preparation of the PCR reaction mix (PCR-RM). Each 
condition was run in quadruplicate and the volumes for preparing the PCR-MM are shown 
in (Table 2.28). 
Component of PCR Master Mix 
Volume per 20 (µl) Reaction (µl) 
1 Reaction Quadruplicate 10 Reactions 
2✕ TaqMan® Gene Expression Master Mix  10.0 50.0 100.0 
cDNA template (1 to 100 ng) 4.0 20.0 40.0 
RNase-free water 5.0 25.0 50.0 
20✕ TaqMan® Gene Expression Assay 1.0 5.0 
10.0 (Added as 1.0 µl to the 
Plate later) 
Table 2.28 The components of PCR master mix and their preparations. 
This table shows the components required for the RT-PCR reaction. These volumes vary depending 
on the number of samples processed per single run and the number of replicates. For example, in the 
experiments two genes and one housekeeping gene (GAPDH) were analysed in triplicate; in total 9 
wells. Volumes for 10 reactions were prepared to avoid lost volumes during pipetting.  
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Then, 19 µl of PCR-RM were added to the corresponding wells of a MicroAmp Optical 96-
Well Reaction Plate, followed by addition of 1.0 µl of 20✕ TaqMan® Gene Expression 
Assay of the gene of interest. GAPDH was used as a housekeeping gene control and 
used at the same volume prepared for the test genes for quantitative evaluation. 
Additionally, non-treated controls (NTC) were included which were Nuclease Free H2O+ 
PCR-RM to detect any contamination that may interfere with the results as shown in 
(Figure 2.10). 
 
Figure 2.10 Flowchart of preparing RT-PCR reaction and PCR plate. 
As mentioned in Table above, the PCR reaction required preparation of specific volume of PCR-MM 
depending on the number of samples and duplicates. These volumes were added to the corresponding 
wells. MicroAmp Optical 96-Well Reaction Plate was used to process 9 conditions in triplicate for two 
genes and one houskeeping gene (GAPDH).In addition, the plate included triplicates of non-treated 
controls (NTC) for each single gene and GAPDH. 
The plate was centrifuged briefly using Labnet MPS 1000 Mini plate spinner and loaded 
onto the RT-PCR machine (Applied Biosystems 7900HT Real-Time PCR System) with 
the settings as shown in (Table 2.29). 
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System Run 
Reaction 
Plate 
Experiment 
Parameters 
Thermal Cycler Conditions 
Step Temperature (°C) Time (mm:ss) 
Applied Biosystems 
7900HT Real-Time 
PCR System 
Fast 
96-well 
plate 
Rxn. Volume: 20 µl Hold 50 2:00 
Ramp Rate: Fast Hold 95 0:22 
Table 2.29 Conditions of RT-PCR system required for TaqMan gene expression 
Information obtained from the PCR machine were generated as numeric data in SDS 
software (2.4) then exported into an excel sheet for further calculation and quantification 
of gene expression using (Equation 2.7) and (Equation 2.7). 
∆𝑪𝒕 = 𝑪𝒕 (𝒈𝒆𝒏𝒆) −  𝑪𝒕 (𝒄𝒐𝒏𝒕𝒓𝒐𝒍) . . . . . Equation 2.7 
   
𝑹𝒆𝒍𝒂𝒕𝒊𝒗𝒆 𝑸𝒖𝒂𝒏𝒕𝒊𝒇𝒊𝒄𝒂𝒕𝒊𝒐𝒏 (𝑹𝑸) = 𝟐−∆𝑪𝒕 . . . . . Equation 2.8 
When: 
Ct= cycle threshold: number of cycles required by fluorescence signal of the target gene and reference 
gene to exceed the background signal in PCR. 
2.3.14 CONSTRUCTION OF 3D SKIN EQUIVALENT MODEL (3D-SEM)   
Hill and colleagues developed a 3D skin model for melanoma invasion studies (Hill et al., 
2015). Based on this model, we developed the same model in our lab for further 
developing a prototype 3D model for wound healing studies. The basis of this model is 
the Alvetex®scaffold explained in Figure 2.11 A. Before seeding cells, Alvetex® was 
activated with 70 % ethanol for 30 seconds, treated with media A (Section 2.2.13.6.1) for 
30 seconds, fixed in 6 well plates and incubated under SCC until required. To form the 
dermal equivalent of the model, 2×106 fibroblasts were suspended in 100 µl media A and 
seeded onto the Alvetex® and incubated at SCC for 90 minutes. 9 ml of media B (Section 
2.2.13.6.2) was added to each Alvetex® well and incubated under SCC with a change of 
media B every two days for 18 days (Figure 2.11 B). The epidermal layer was prepared 
by seeding 100 µl of media C containing 2×106 keratinocytes over the dermal fibroblast 
layer and incubated under SCC for 3 hours to allow cell adherence. Concurrently, the 
dermal layer was fed from the bottom with 4 ml media C (2.2.13.6.3). After the incubation 
time, the whole model was covered with media C for three days with a daily change of 
media C as demonstrated in Figure 2.11 C. Stratification of the model was enhanced by 
subjecting the epidermal layer to the air liquid interface for 14 days while feeding the 
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dermal layer with air-liquid interface media (media D) (Section 2.2.13.6.4) with two day 
changes of media D (Figure 2.11 D). 
 Step Real Model Explanatory Image Media Period 
(A) 
Alvetex 
Activation  
  
70 %OH 30 Sec 
Media A 30 Sec 
(B) 
Dermal 
Equivalent 
Formation 
(1st 
Fibroblast 
Layer) 
Seed 2×106  
Fibroblast 
  
Media B 
18 
days 
(C) 
Epidermal 
Equivalent 
Formation 
Seed 2×106 
keratinocytes 
  
Media C 3 days 
(D) 
Exposure to 
Air-Liquid 
Interface 
 
 
Media D 
14 
days 
Figure 2.11 Generation of a 3D skin equivalent model (3D-SEM) using the Alvetex®. 
(A) Alvetex® activated by rinsing in 70 % ethanol for 30 seconds and soaked in media A for 30 seconds 
again, then every single Alvetex® was fixed in a single well of 6 well plates until fibroblasts are ready 
for seeding. (B) Formation of dermal layer in media B on the Alvetex® under SCC for 18 days with 3 
changes of media B per week. (C) Generation of the epidermal layer over the dermal fibroblast layer 
incubated under SCC with 9 ml of media C for three days. (D) Exposure to the air-liquid Interface for 14 
days and feeding the dermal layer with media D while leaving the epidermal layer exposed to the air 
without media. 
2.3.15 DIFFERENTIATION OF MSCS INTO EPIDERMAL-LIKE STRUCTURE IN 3D CULTURE  
After testing their ability to differentiate into skin like cells in a 2D culture, MSCs were 
tested for their ability to differentiate into epidermal-like structures. The same protocol 
used to construct a 3D-SEM using fibroblasts and keratinocytes (Section 2.3.14) was used 
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to examine the ability of MSCs to differentiate into epidermal-like layers with some 
modification in terms of the media used. Briefly, the dermal layer was generated as 
described in the protocol above (Section 2.3.14). When the dermal layer was obtained, 
2×106 MSCs were suspended in 100 µl of epidermal differentiation media (EDM) (Section 
2.2.13.5) and seeded over the dermal fibroblast layer and incubated for 3 hours under 
SCC to allow cell attachment. The skin equivalent was then fed with EDM supplemented 
with vitamin C for three weeks. The model was subjected to the air liquid interface in EDM 
to enhance epidermal stratification and with a regular change of media every 3 days.     
The constructed models from keratinocytes in (Section 2.3.14) and from MSCs in this 
section were validated structurally by haematoxylin-eosin (H-E) staining (this service was 
carried out in the Department of Pathology/ RVI) and by detection of dermal and epidermal 
differentiation markers as described in the following protocol. 
2.3.16 DEVELOPING A PROTOTYPE 3D SKIN EQUIVALENT MODEL (3D-SEM) FOR WOUND 
HEALING STUDIES  
In this study, a robust method was developed to evaluate wound healing using a fully 
humanised skin model which was generated in (section 2.3.14). The aim of this protocol 
was to establish a model to mimic the environment of a cutaneous wound in which the 
skin cells at the injury site such as fibroblasts and keratinocytes could migrate over 
another cellular layer such as dermal fibroblast layer. The idea of the protocol was to allow 
the cells at the wound site of the model to migrate over another intact cellular layer of 
fibroblasts. Therefore, a second fibroblast layer was prepared on a new Alvetex® (Figure 
2.12 A) by following the same steps of preparing the first dermal fibroblast layer. When 
the full skin model was constructed it was washed twice with PBS, taken out of the 
Alvetex® using a circular cutter, and transferred to a sterile Petri dish (Figure 2.12 B). A 3 
mm punch was made in the model using a sterile 3 mm punch (Figure 2.12 C). The 
punched model was then transferred over the second fibroblast layer and fed with media 
B and left for 3 hours to allow attachment of the first fibroblast layer to the second one. 
(Figure 2.12 D). Then all punched models were treated with MSC-CM for different time 
points; 1 week, 2 weeks and 4 weeks with three changes of MSC-CM per week (Figure 
2.12 E). Control models were treated with media B with a regular change of media every 
two days. Allogenic models (unmatched dermal and epidermal layer) were used for wound 
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healing visualisation by (H-E), while autologous models (matched dermal and epidermal 
layers) were used for microRNA profiling. 
 Step Real Model Explanatory Images Media  Period 
(A) 
Generation of 
2nd Fibroblast 
Layer 
(Seed 2×106  
fibroblasts) 
  
Media B 18 days 
(B) 
Take the full 
model out of 
the Alvetex® 
 
 
---- ---- 
(C) 
Make a 3 mm 
punch 
 
 
---- ---- 
(D) 
Place the 
punched model 
over the 2nd 
fibroblast layer 
  
Media B 5 hours 
(E) 
Treatment with 
MSC-CM 
  
1:1 v/v 
MSC-CM 
Media B 
7 Days 
14 Days 
28 Days 
Figure 2.12 The developed protocol for wound healing using a fully humanised 3D kin equivalent 
model (3D-SEM). 
Explanatory figure showing the developed protocol for wound healing using a 3D-SEM. (A) Formation 
of the second dermal layer to act as a bed to support migration of the epidermis of the wounded model. 
(B) The previously constructed model was taken out the Alvetex® and placed in sterile petri dish. (C) 
The model was punched using a 3 mm punch biopsy. (D) Placing the punched model over the second 
fibroblast layer and left for 5 hours at SCC to allow adherence and feeding only the second layer with 4 
ml media B. (E) Treating the punched model with MSC-CM and media B (1:1 v/v) for different time 
points (1,2 and 4 weeks). 
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2.3.17 EVALUATION OF WOUND HEALING  
The evaluation of wound healing was carried out by using two main techniques; the first 
one was monitoring migration of dermal and epidermal layers at the wound edges towards 
the wound centre which was detected by Haematoxylin-eosin (H-E) staining. The other 
technique was detecting the epidermal and dermal differentiation markers at the wounded 
site using immunofluorescence primary and secondary antibodies. 
2.3.18 IMMUNOFLUORESCENCE STAINING OF THE 3D SKIN EQUIVALENT MODEL (3D-SEM) 
2.3.18.1 SECTIONING USING MICROTOME AND SLIDE PREPARATION 
Paraffin embedded skin model tissues were always kept on ice during sectioning to ensure 
effective sectioning. The microtome was adjusted to 4 µm and sections were kept in a 
water bath adjusted at 40oC for 2-3 minutes before transferring to slides. The slides were 
then heated in an oven at 60oC overnight and the next day, dehydrated by washing for 5 
minutes in each xylene, 100% ethanol, 95% ethanol, 70% ethanol and distilled water. 
2.3.18.2 ANTIGEN RETRIEVAL 
For antigen retrieval, slides were placed in previously heated 10 mM citrate buffer, pH 6.0, 
in a microwave for 1 minute and then left to cool at room temperature for 30 minutes, and 
washed in 5 mM Tris buffered saline (TBS) pH 7.6 for 5 minutes. Permeabilisation of the 
slides was performed in 0.2% Triton-X for 10 minutes at room temperature. 
2.3.18.3 SINGLE IMMUNOSTAINING   
All sections were blocked by 10% goat serum in PBS for 10 minutes at room temperature 
and washed with Tris base solution (TBS) four times to remove the goat serum. The 
sections were stained with 100 µ of the following primary antibodies which were diluted 
before use; (K14 1:250, K10 1:200, Loricrin 1:200, Involucrin 1:250, collagen III 1:50) and 
incubated in a moist chamber at 4oC overnight. Control slides were not stained but were 
incubated with blocking solution instead. The following day the sections were washed four 
times in TBS for 2 minutes each and incubated with100 µl of secondary antibody-DAPI 
mix at a dilution of 1:250 and 1:1000 respectively for 2 hours at 37oC in a moist chamber 
in the dark. Sections were then washed four times in TBS for 2 minutes, covered with 
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DPX, left in the dark at room temperature overnight, and analysed the next day using 
confocal microscopy. 
2.3.18.4 MULTIPLE IMMUNOSTAINING (SEQUENTIAL FLUORESCENCE STAINING) 
In order to detect more than one biomarker in one slide at the same time and to clarify the 
spatial-temporal order of the epidermal layers, a sequential labelling protocol was used. 
Briefly, firstly the blocking was carried out by incubation with serum compatible with the 
first secondary antibody. Sections  were then incubated with K14 antibody (1:250) for one 
hour at room temperature (RT) and then washed three times with TBS followed by 
incubation with  a secondary antibody specific for K14 for one hour at RT. Sections were 
then washed three times with TBS and re blocked with  a second serum corresponding to 
the second secondary antibody. Sections were then re-incubated with K10 antibody 
(1:200) for 1 hour at RT and washed 3 times with TBS followed by incubation with a 
secondary antibody specific for K10 for 1 hour at RT. The same steps (blocking and 
washes) under the same conditions (RT and incubation times) were followed to for 
staining with involucrin (1:250) antibodies and their corresponding secondary antibodies. 
2.3.19 MICRORNA PROFILING DURING WOUND HEALING USING 3D-SEM 
mirVana™ microRNA Isolation Kit was used to extract microRNAs from the skin models 
and the kit  contents are listed in (Table 2.30). 
Item Quantity 
microRNA Wash Solution I  
30 ml (To prepare working reagent, mixed with 21 mL 100% 
ethanol before use) 
Wash Solution 2/3 
50 ml (To prepare working reagent, mixed with 40  mL 100% 
ethanol before use) 
Collection Tubes 80 
Filter Cartridges 40 
Lysis/Binding Buffer 100 ml 
microRNA Homogenate Additive 10 ml 
Acid–Phenol: Chloroform (APC) 100 ml 
Gel Loading Buffer II  1.4 ml 
Elution Solution 5 ml 
Table 2.30 Contents of microRNA isolation kit (mirVanaTM) 
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2.3.19.1 ISOLATION OF SMALL RNAS INCLUDING MICRORNAS  
The first step in microRNA extraction is lysis of the sample (punched and intact 3D-SEM) 
in 300 µl of a denaturing lysis buffer (LB) with continuous chopping and teasing with a 
scalpel blade for 3-5 minutes until the tissue is broken down. Cells were lysed immediately 
with 300 µl of lysis buffer. The organic extraction step was completed by addition of 30 µl 
of RNA homogenate to the samples, which were then vortexed and incubated on ice for 
10 minutes. For a robust initial purification and DNA removal, 300 µl of acid–phenol-
chloroform (APC) were added to the model in a fume hood, mixed by vortex for 30-60 
seconds and centrifugation for 5 min at 10,000g. Again, in the fume hood, 100 µl (in 5 
times; 20 µl each) of the upper (aqueous phase) was carefully extracted without disturbing 
the phenol phase and transferred to a new Eppendorf vial.  For the final purification, the 
lysate/ethanol was mixed with 375 µl of absolute ethanol making a colourless mixture and 
passed through a filter cartridge containing a glass-fiber filter to immobilise the RNA, then, 
centrifuged for 15 seconds at 10,000g followed by discarding the flow through. The 
washing step was performed three times; the first one with 700 µl of microRNA wash 
solution I was added and centrifuged for 10 seconds at 10,000g followed by discarding 
the flow through again. The second and the third washes were with volumes of 500 µl of 
microRNA wash solution and centrifuged. After discarding the flow through from the final 
wash, the assembly was spin for 1 minute at 10,000 g to remove any residual fluid and to 
dry the filter. The filter cartridge was then transferred to a new labelled collection tube and 
the final step was elution with a low ionic-strength solution such as 100 µl of pre heated 
(95°C) nuclease free water added to the centre of the filter and spun at maximum speed 
for 20 to 30 seconds to recover the RNA which was stored at – 80 until use.       
2.3.19.2 DETERMINATION OF MICRORNA INTEGRITY NUMBER 
Agilent RNA 6000 Nano Kit was used to analyse the microRNA integrity number, which is 
composed of the following reagents and tools as listed in (Table 2.31). 
 
 
 
Content Quantity Preparation / Explanation 
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RNA 6000 Nano Ladder 1 vial 
The ladder vial was spin down, denatured by heating for 2 min 
at 70ºC and Immediately cooled on ice. It then dispensed in 
aliquots and stored at -70ºC until use. Before use, the ladder 
aliquots were thawed on ice avoiding  extensive warming      
RNA 6000 Nano Gel 
Matrix 
2 vials 
A volume of 550 µl of the gel matrix was pipetted into a spin 
filter  showed in red  in Figure 2.13 B, centrifuged at 10000g for 
15 minutes at room temperature and aliquoted  in 0.5 ml RNAse 
free micro centrifuge tubes and stored at 4ºC until use within 
one month.    
RNA 6000 Nano Chips 25 As shown in Figure 2.13 A 
Electrode Cleaners 2  
Syringe Kit  1  
Eppendorf Tubes 30 
Safe-Lock Eppendorf Tubes PCR clean (DNase/RNase free) for 
gel-dye mix 
RNA 6000 Nano Dye 
Concentrate 
1 vial 
Before use, RNA 6000 Nano Dye Concentrate was allowed to 
equilibrate at room temperature for 30 minutes, then vortexed 
and for 10 seconds at 10000 g.  
RNA 6000 Nano Marker 2 vials  
Spin Filters 4  
Table 2.31 Content and reagents of Agilent RNA 6000 Nano kit. 
All reagents were brought to equilibrate to room temperature for 30 minutes before starting 
the experiment. 
2.3.19.2.1 PREPARING THE GEL-DYE MIX (GDM) 
Dye concentrate was vortexed for 10 seconds and spin down at 10000 g followed by 
pipetting 1 µl of dye into 0.5 mL RNase free micro tubes containing 65 µL of filtered gel 
and mixed by vortex for 10 seconds until the dye was distributed equally and the mixture 
became homogeneous, and then spun at 13000 g for 10 min at room temperature. 
2.3.19.2.2 LOADING THE GEL-DYE MIX (GDM) 
A volume of 9 µL of GDM was loaded in the chip well- labelled pink in (Figure 2.13 C). 
The plunger was pressed until it was held by the clip and released after 30 seconds. Then, 
9 µL of GDM were added in the wells- labelled pink in (Figure 2.13 D). 
2.3.19.2.3 LOADING THE MARKER 
A volume of 5 µL of RNA marker was added into all 12 sample wells as well as the ladder 
well - labelled green in (Figure 2.13 E). 
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2.3.19.2.4 LOADING THE LADDER AND SAMPLES  
A volume of 1 µL of prepared ladder was pipetted into the yellow well in (Figure 2.13 F), 
and 1 µL of each sample was pipetted in each of the 12 sample wells labelled as blue in 
(Figure 2.13 G). For unused sample wells, 1 µl of RNA Marker was pipetted in each well. 
The chip then was then placed horizontally in the IKA vortexer and vortexed for 1 minute 
at 2400 rpm followed by running the chip in the Agilent 2100 Bioanalyzer instrument within 
5 minutes. 
    
(A) (B) (C) (D) 
   
(E) (F) (G) 
Figure 2.13 Summary of protocol for determining microRNA integrity number. 
The Figure was adapted from Agilent RNA 6000 Nano Kit Guide with modification. Agilent RNA 6000 
Nano Kit Guide and Agilent RNA chips were used to determine RNA integrity number. (A) A 6000 RNA 
Nano chip with labelled wells. (B) Preparing the GDM by mixing 1 µl of dye concentrate with 65 µl filtered 
gel. (C) Addition of 9 µl GDM to the well  labelled pink and pressing the plunger until being held by 
the clip for 30 seconds. (D) Releasing the plunger and addition of 9 µl GDM to the wells G labelled pink 
colour. (E) Addition of 9 µl of RNA marker to the wells 1-12 (green colour) in addition to the well labelled 
as ladder (green colour). (F) Addition of 1 µl of the ladder to the ladder well (yellow colour). (G) Addition 
of 1 µl of each sample to the wells 1-12 (blue colour).   
The bioanalyzer is a very productive machine utilised to analyse nucleic acids and protein 
utilising a chip-based technique. It provides information with high sensitivity about the 
sample of interest. The bioanalyzer cab utilise different sizes of chips; 11 samples or 12 
samples depending on the kit type, which in turn is determined by the molecule to be 
analysed such as small RNAs, DNA, exosomes or protein. As explained in (Figure 2.14), 
Chapter 2                                                                                                                     Materials and Methods 
 
107 
 
the analysis provided information about the RNA Integrity Number (RIN), electrophoresis, 
time required to detect and analyse the sample, microRNA concentration and microRNA 
size or length (in nucleotide) of the detected molecule. 
(A) 
 
(B) 
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(C) 
 
Figure 2.14 Evaluation of microRNAs using bioanalyzer. 
Twelve samples could be run per chip. (A) Output of the analysis showed that all samples have high 
RNA integrity number (RIN) indicating that these samples contained intact and not degraded RNAs 
suitable for further analysis by NanoString technology. (B) Explains electrophoresis and bands of 
microRNAs depending on the concentrations of microRNA in each sample in comparison to the ladder 
bands. (C) Provides more information about each sample such as the time required to detect 
microRNAs peaks; mainly between 40 and 50 seconds to detect small RNAs between 18 and 28 
nucleotides and the concentration of microRNAs in each sample. 
2.3.19.3 MICRORNA PROFILING USING NANOSTRING TECHNOLOGY 
Two main steps were utilised in this technology; preparation and microRNA hybridisation 
protocol.  The preparation step includes setting the thermocycler temperature and sample 
preparation for annealing, ligation and purification.   
2.3.19.3.1 THERMOCYCLER SETTING  
Before starting the microRNA profiling using NanoString technology, the thermocycler was 
programmed to warm up for each protocol as shown in (Table 2.32). 
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Annealing protocol 
 
Ligation Protocol 
 
Purification Protocol 
Temperature Time Temperature Time Temperature Time 
94 ºC 1 minute 48 ºC 3 minutes 37 ºC 2 hours 
65 ºC 2 minutes 47 ºC 3 minutes 70 ºC 10minutes 
45 ºC 10 minutes 46 ºC 3 minutes 4 ºC Hold 
48 ºC Hold 45 ºC 5 minutes 
Total Time 2 hours+10 min 
Total Time 13 minutes 
65 ºC 10 minutes 
4 ºC Hold 
Total Time 24 minutes 
Table 2.32 Temperature setting of the thermocycler for annealing, ligation and purification 
protocols during microRNA profiling technique using NanoString technology. 
2.3.19.3.2 ANNEALING PROTOCOL 
All RNA samples were normalised to 33 ng/μl using RNAse-free water. MicroRNA Assay 
controls were used at a dilution of 1:500 by mixing of 499 μl DEPC H20 with 1 μl of the 
microRNA Assay Controls were placed in a sterile micro-centrifuge tube, mixed by 
vortexing and spun down and kept on ice during the procedure. Annealing master mix 
(AMM) was prepared by combining 13 μl of Annealing Buffer, 26 μl of nCounter microRNA 
Tag Reagent and 6.5 μl of the 1:500 dilution microRNA Assay Control. All the contents 
were mixed by pipetting up and down. A volume of 3.5 μl of the AMM was aliquoted into 
each tube of a 12×0.2 ml strip tube. Then, a volume of 3 μl (100 ng) of RNA sample was 
added to each tube and mixed by gentle flicking and spinning down followed by initiating 
the annealing protocol with temperature and time setting as shown in (Table 2.32).  
2.3.19.3.3 LIGATION PROTOCOL 
Ligation Master Mix (LMM) was prepared by combining 19.5 μl PEG and 13 μl ligation 
buffer and mixing by pipetting up and down to ensure accurate transfer of the total volume 
of the viscous PEG. When the thermocycler reached 48ºC, after completion of the 
annealing process, 2.5 μl of LMM  was added to each tube and  mixed  well by gentle 
flicking and spinning down followed by returning the tubes to the thermocycler and 
incubation at 48ºC for 5 minutes. After 5 minutes, the cap of each tube was removed 
carefully and the strips were left on the heat block followed by addition of 1 μl of ligase 
directly to each tube while they were still incubated on the heat block at 48ºC. After 
addition of ligase to the final tube, all tubes were re capped while they still on the heat 
block, the lid was closed and the ligation protocol initiated with the setting as shown in 
(Table 2.32).  
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2.3.19.3.4 PURIFICATION PROTOCOL 
The purification protocol was initiated by addition of 1 μl of Ligation Clean-Up Enzyme to 
each reaction with gentle mixing by flicking and spinning down and the tubes were 
returned to the thermocycler and the purification initiated with the settings shown in (Table 
2.32). After completion of the purification protocol, 40 μl DEPC (or RNAse-free), water 
was added to each sample, mixed well and spun down. A denaturation step was 
performed before adding the prepared sample to the hybridisation protocol as explained 
in the sections below. 
2.3.19.3.5 CODESET HYBRIDISATION PROTOCOL 
Reporter CodeSet and Capture ProbeSet reagents were thawed and kept on ice, inverted 
several times to mix well and briefly spin down at <1000 rpm for 30 seconds. The final 
hybridization reaction (FHR) composed of 10 μl Reporter CodeSet, 10 μl hybridisation 
buffer, a 5 μl aliquot from the microRNA Sample Preparation Protocol, and 5 μl Capture 
ProbeSet. To prepare the master mix (MM), 130 μl of hybridisation buffer was added to a 
tube containing 130 μl of the Reporter CodeSet, mixed well by inverting and spinning 
down. Twelve tube strips were cut in half to fit in the picofuge and labelled with the 
corresponding samples numbers, followed by addition of 20 μl of master mix (MM) to each 
of the 12 tubes. Samples from the microRNA sample prep protocol were denatured at 
85ºC for 5 minutes, and quickly-cooled on ice, followed by addition of 5 μl aliquots from 
the microRNA Sample Preparation Protocol into each tube. At this time, the  thermocycler 
was pre-heated to 65ºC using  a 30 μl volume, calculated temperature, heated lid and 
“forever” time setting. Before placing samples at 65ºC, 5 μl of Capture ProbeSet were 
added to each tube and immediately capped and mixed by inverting the strip tubes several 
times and flicking to ensure complete mixing. They were then spun down at <1000 rpm 
and the strip tube was immediately placed in the 65ºC thermocycler. The hybridisation 
assays were left at 65ºC until ready for processing, and then incubated for at least 12 
hours. Once removed from the thermocycler, post-hybridisation processing with the 
nCounter Prep Station was performed. 
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2.4 DATA COLLECTION AND STATISTICAL ANALYSIS 
Several types of software were used to collect, export and analyse data throughout the 
study. FlowJo (7.5) was used for fluorescence-activated cell sorting (FACS) of the 
phenotypic markers of MSCs. Both NIS-Elements Viewer (4.2) and Image J (1.49t) were 
used to export images obtained from the NIKON microscope for measuring the scratch 
area. Ascent software for multiskan ascent (2.6) was used to export data from the 
microplate reader, which was used for the estimation of protein concentration and 
evaluating cell viability in the MTS assay. ND-1000 software was used to export data 
generated by NanoDrop, for the nucleic acid purity and concentration. While, SDS (2.4) 
was used to export data generated from the PCR machine during gene expression 
analysis. 2100 Expert (2.3) was a software used to export data obtained from the 
bioanalyzer, for analysis of microRNA concentration and integrity. Other software was 
used for microRNA analyses such nSolver (3.0) to export and normalise data obtained 
from NanoString machine and R studio which was used to create images and figures of 
microRNA analyses as well as to assess significant variations between groups. Finally, 
Prism software (6.0) from Graphpad was the most commonly used software for statistical 
analyses. 
2.4.1 DATA TYPES AND CHOOSING OF STATISTICAL TEST 
Data of this study were variable depending on the type of experiment. In order to choose 
the most suitable statistical test, data were divided into related and unrelated data. 
2.4.1.1 RELATED DATA 
These data were produced from repetitive measurements and matched pairs. Examples 
of these data include percentages of MSCs that express specific markers (CD+MSCs %), 
protein concentration (pg/ml), scratch area (µm2), cell viability (%), migrating cells (%), 
proliferating cells (%) and gene expression which are all types of quantitative continuous 
data. This type of data (quantitative continuous data) was analysed by using 
means ± standard error of the mean (SEM) and a Two-way RM ANOVA test to determine 
significant differences between samples (when P values were less than 0.05). Multiple 
comparisons were required to find differences between pairs of means with appropriate 
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adjustment for multiple testing in every single condition during different time points in each 
separate experiment. Tukey's multiple comparisons test was used to detect variations, 
which were considered as significant when the P value was less than 0.05. 
2.4.1.2 UNRELATED DATA 
These data were produced from different independent groups of non-related variables. To 
find significant variations between the variables in this type of data, Sidak’s multiple 
comparison test was used. For instance, comparing two groups of unrelated variables at 
different time points. For example, comparing cell doubling which was measured by fold 
change and doubling time which was measured in days for the same population at 
different time points. Another example was comparing the ratio of proliferating cells to the 
ratio of migrating cells in the same population at different time points.  
For both types, Prism software version 6 from Graphpad was used in this study. 
2.4.2 STATISTICAL ANALYSIS OF MICRORNA PROFILING  
Data of microRNA profiling were generated as comma-separated values (CSVs) from 
nCounter digital analyser to nSolver (3.0) for normalisation. Data analysis was set to 
compare the correlation between microRNA signatures in the 3D model in relation to 
microRNA signatures of real skin. In addition, microRNA signatures at different time points 
in the punched models were compared in relation to microRNA signatures of intact models 
for further analysis of differentially expressed microRNAs during the healing process. 
Normalised data along with the fold change data were imported into R software (3.3.3) 
from The R Project for Statistical Computing. A two-tailed t-test was used to find significant 
variations of differentially expressed microRNAs between groups (P<0.05). While ggplot2 
(2.1.0) was used to generate functions and create volcano plots. Additionally, based on 
an unsupervised clustering of the normalised expression counts, gplots” (2.17.0) and 
“RColorBrewer” (v1.1-2) with a Euclidean 2 from (www.ingenuity.com) were utilised to 
construct heatmaps (L2 norm) space measure and complete as the agglomeration 
method. All scripts and analysis pipelines were developed by Dr Rachel Crossland, 
Haematological Sciences, Institute of Cellular Medicine, Faculty of Medical Silences, 
Newcastle University, UK.  
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CHAPTER THREE: CHARACTERISTICS OF MESENCHYMAL STEM CELLS AND DEFINING 
THEIR SECRETIONS  
3.1 INTRODUCTION 
Despite the numerous sources for isolating MSCs, bone marrow represents the most 
suitable cell source to generate MSCs (BM-MSCs) for tissue engineering and potential 
therapeutic application (Liu et al., 2009; Mafi et al., 2011). BM-MSCs have the potential 
to differentiate into mesodermal lineages such as adipocytes, osteoblasts (Pittenger et al., 
1999), chondrocytes (Johnstone et al., 1998), tenocytes, skeletal myocytes, and visceral 
mesodermal cells (Jiang et al., 2002) astrocyte (Kopen et al., 1999). They can also 
differentiate into endodermal and ectodermal cell types and tissues such as 
cardiomcyocytes (Fukuda, 2002), hepatocytes (Qu-Petersen et al., 2002), mesangial cells 
(Ito et al., 2001), muscle (Ferrari et al., 1998) (Tamama et al., 2008), neurons (Azizi et al., 
1998), stromal cells (Majumdar et al., 2000), embryonic tissue (Stott et al., 1999) and 
multiple skin cell types (Sasaki et al., 2008). MSCs therefore have the potential to become 
the basis of tissue repair (Phinney and Prockop, 2007). This therapeutic potential to repair 
damaged tissues could be attributed not only to their transdifferentiation ability but also to 
the biomolecules secreted by these cells which alter the microenvironment of the injured 
tissue and are involved in a wide range of biological processes such as inflammation, 
angiogenesis, migration, proliferation and cell differentiation (Mafi et al., 2011). Since the 
main secretions of MSCs are proteins such as growth factors and cytokines, the best 
technique to detect these biomolecules is by the use of an enzyme linked immunosorbent 
assay (ELISA) or enzyme immunoassay (EIA). With regard to wound healing and skin 
repair, MSCs have several roles. They can differentiate into skin like cells to compensate 
for cell loss during tissue damage and they can secrete a broad range of growth factors 
and cytokines which can initiate cellular functions such as migration, proliferation and 
differentiation of skin cells as well as an inflammatory response. (Sasaki et al., 2008). The 
International Society for Cell Therapy (ISCT) has stipulated the main characterstics of 
MSCs. They should be fibroblast like cells with the ability to expand in vitro in non 
haematopoietic media and should possess the ability to differentiate into three lineages; 
adipocyte, chondroblasts and osteoblasts when grow in appropriate differentiation media. 
They should also be positive for the expression of the stem cell markers, CD73, CD90 
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and CD105 while negative for the expression of the haematopoietic stem cell markers, 
CD14, CD19, CD34, CD45 and HLA-DR (Dominici et al., 2006). Their ability to express 
these markers  can be detected using the fluorescence activated cell sorting (FACs) 
technology. FACs is used to analyse the phenotype of cells at the single cell level and 
particle size of 0.2-150 μm. FACs analysis includes cell counting, cell sorting, detection of 
phenotypic biomarkers to reveal heterogeneity in a population and protein engineering 
depending on the chemical and physical characteristics of the cells. It is composed of 
three systems; fluidic, optic and electronic. Each system performs a specific function; the 
fluidic part passes the cells or particles through a fluidic stream and transports them to the 
optical part where the laser beams illuminate the stained cells depending on the type of 
flourochome used during the cell staining. Any fluorescent molecules in the stream scatter 
the light in proportion to the signals and emit fluorescence which is then detected by 
specific lenses and directed by optical filters to detectors where the electronic system 
changes these light signals to electronic pulses and then computer analysis. 
One of the most important ingredients required for MSC growth and expansion in vitro is 
that the calcium level is equal to 1.8 mM/L. Lower calcium concentrations significantly 
reduce the ability of MSCs to proliferate and expand in vitro (Liu et al., 2009). The media 
used to grow MSCs and expand them successfully is complete non haematopoietic media 
with standard (high) calcium level (HC-Media) and is the optimal media for the cells to 
secrete their biomolecules for wound healing purposes (Hwang et al., 2009; Walter et al., 
2010; Tamama and Kerpedjieva, 2012). However, collection of MSC secretions from their 
in vitro culture in complete media is unsatisfactory due to the serum content, which 
interferes with effect of MSC secreted molecules when tested on skin cells during 
migration and proliferation assays. The conventional method to collect MSCs secretions 
is using serum free media (DMEM based formula) enriched with some suppliments that 
support MSC growth and propagation (Walter et al., 2010). However, collection of MSC 
secretions from their in vitro culture using this method is again unsatisfactory when the 
used cells are primary keratinocytes due to the HCL which would enhance their 
differentiation and therefore arrest their migration and proliferation. Therefore, a new 
method is required to collect MSC secretions for use in wound healing studies. 
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3.2 SPECIFIC AIMS OF CHAPTER THREE  
1. To characterise isolated human MSCs from the femoral heads of human hip joints in 
terms of morphology, phenotypic markers and differentiation potential. 
2. To test the ability of MSCs to grow in serum free media in both standard (high) and 
low calcium concentrations and to compare MSC characteristics under these 
conditions.  
3. To collect MSC secretions under serum free media with low and standard (high) 
calcium level) conditions and analyse their protein content by ELISA. Use and compare 
these secretions in wound healing experiments including testing their effects on 
migration proliferation and differentiation of human skin cells such as primary 
keratinocytes and primary dermal fibroblasts. 
4. To test the potential of MSCs to differentiate into epidermal-like cells in 2D culture. 
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3.3 RESULTS 
3.3.1 DONORS AND SAMPLE COLLECTION 
As mentioned in the methods chapter (Chapter 2), MSCs were isolated from hip joints 
from 12 osteoarthritis patients after informed consent. The patients consisted of 5 males 
aged 64 and 94 years and 7 females aged between 55 and 82 years. Isolated MSCs were 
referred to as BB92, BB93, BB95 and BB95a, BB100, BB103, BB104, BB105, BB106, 
BB107, BB108 and BB109). One sample failed to generate MSCs (BB104). Two samples; 
BB103 and BB106 were unable to grow and expand under standard growth conditions 
during in vitro expansion as shown in (Table 3.1) and (Figure 3.1). 
Collection and 
Processing Date 
DTOS # 
MRG 
N# 
Haem 
BB# 
G 
Age 
(Yr) 
Hip Condition Notes 
30.04.14 5189 N3476 BB92 F 56 L OA* Characterised and utilised 
08.05.14 5212 N3485 BB93 F 74 R OA Characterised and utilised 
03.06.14 5256 N3515 BB95 M 82 L OA Characterised and utilised 
03.06.14 5256 N3515 BB95a M 82 L OA Characterised and utilised 
07.08.14 5385 N3599 BB100 F 65 R OA Characterised and utilised 
29.10.14 5514 N3669 BB103 F 75 L OA Failed to expand at P1 
06.11.14 5527 N3672 BB104 F 75 R OA No cells obtained 
19.11.14 5555 N3687 BB105 F 63 L OA Characterised and utilised 
20.11.14 5553 N3688 BB106 M 64 R OA Failed to expand at P2 
20.11.14 5554 N3689 BB107 M 94 R OA Characterised and utilised 
20.11.14 5556 N3690 BB108 F 55 L OA Characterised and utilised 
26.11.14 5567 N37 BB109 M 67 R OA Characterised and utilised 
Table 3.1 Information about MSCs used in the study. 
This table shows MSC samples isolated from the femoral head of human hip joints. Twelve samples 
were isolated at different times from male and female donors aged between 55 and 94 years. The 
isolated cells were given different numbers and anonymised codes depending on the department 
storing the samples. In Academic Haematology, they are given a BB number, which was the code and 
ID for MSCs in this study. Two samples; BB103 and BB106 were lost during processing at P1 and P2 
respectively, while no cells were obtained from BB104. Other samples were processed and yielded 
MSCs successfully and further used in the study. MRG= Musculoskeletal Research Group, Haem= 
Haematological Sciences Unit, G= Gender, Yr=Year, L= Left, R= Right, OA=Osteoarthritis. 
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3.3.2 CHARACTERISTICS OF HUMAN MSCS 
3.3.2.1 MORPHOLOGICAL CHARACTERISTICS AND EXPANSION ABILITY 
Under standard growth conditions, MSCs have a small cell body with a nucleus located in 
the middle of the cell body and long and thin processes. They are mainly spindle-shaped 
elongated cells i.e. fibroblast like cells. However, they can appear in two more shapes; 
e.g. star-shaped cells (cuboidal and stellate) and triangular-shaped cells with the ability to 
propagate and expand in vitro when grown in non-haematopoietic (NH) media (Banik et 
al., 2016) (Figure 3.1 A, B, C and D). They have the ability to attach to plastic surface after 
24 hours of isolation from bone marrow. (Figure 3.1 A). Interestingly, MSCs have the 
ability to grow under other culture conditions such as serum free media and low calcium 
media (LC-Media) for three days retaining their spindle shape morphology but losing their 
expansion ability (Figure 3.1 E and F). 
  
(A) (D) 
  
(B) (E) 
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Figure 3.1 Morphology and shapes of MSCs at different time points and different growth 
conditions. 
Representative images of isolated MSCs mentioned in (Table 3.1). (A) MSC sample (BB100) are 
generally spindle-shaped cells with the ability to adhere to plastic after 24 hours of isolation from the 
bone marrow. (B) MSCs (BB100) at 50 % confluence, they are mainly spindle-shaped. (C) MSCs 
(BB100) at 80 % confluence. (D) MSCs (BB100) appear as star shapes and triangular shapes (Yellow 
arrows). (E) MSCs (BB100) grown in serum free media with a calcium level of 1.8 mM/L can retain their 
morphology but lose their expansion ability. (F) MSCs (BB105) grown in serum free media containing 
low calcium levels (0.04 mM/L) for three days lost their expansion ability but retained their spindle 
shaped morphology. Scale Bar: A-C: 100 µm, D-E; 200 µm. 
In term of expansion ability, MSCs are able to expand in vitro under standard culture 
conditions (SCC) in NH medium (supplemented with 10% FBS, 1.8 mM/L calcium level, 
200 mM L-glutamine and 1% penicillin-streptomycin). In vitro expansion ability was 
measured by calculating proliferation indices; the cell count of harvested cells, doubling 
time (DT) and population doubling (PD) for each passage. The cell count significantly 
increased from 0.96×106 ± 0.17×106 at passage 1 to 1.565×106 ±0.285×106  at passage 2 
and 3.505×106 ±0.105×106  at passage 3 (P>0.01 and P>0.001) respectively (Figure 3.2 
A). On the other hand, DT was reduced from 4 days at passages one and two to 1 day 
and half days at passage three (Figure 3.2 B).  
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Figure 3.2 Expansion indices of MSCs. 
(A) Numbers of harvested MSCs significantly increased when passage number increased. (B) MSC 
doubling time reduced at later passages i.e. MSCs took 4 days to double their number at passage 1 
while they duplicated their count within one and half days at passage 3. Columns in (A) represent means 
of the cell count at the assigned passage (N=3), Columns in (B) Black columns in (B) represent means 
of the doubling time (DT) (N=3), Gray columns in (B) represent means of the population doubling (PD) 
(N=3), Error bar= standard error of the mean (SEM).   
3.3.2.2 PHENOTYPIC CHARACTERISTICS OF MSCS 
After staining cells with specific CD markers and analysing using the FACScan analyser 
(Canto II) (Chapter 2, Section 2.3.5.2), Flow Jo software was used to gate cells depending 
on their stain. Briefly, cell debris were excluded from the total analysed cells. Live cells 
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(DAPI negative) were used to segregate other cells that express specific CD marker 
depending on the dye wave length. 
Under standard conditions for MSCs (N=9), 97±0.55 % and over of the isolated MSCs 
expressed the stem cell markers CD73 (97.0±0.55 %), CD90 (97.8±0.55 %) and CD105 
(97.5±0.54 %). These samples minimally expressed CD14, CD19, CD34, CD45 
(0.90±0.15 %) and human leucocyte antigen (HLA-DR) (2.3±0.96 %). In another words, 
more than 98% of MSCs were negative for the expression of CD14 (which is expressed 
by monocytes, macrophages and endothelial progenitor cells), CD19 (a B-lymphocyte 
antigen), CD34 (a marker expressed by primitive haematopoietic stem cells), CD45 (a 
marker of all haematopoietic cells) and HLA-DR (Figure 3.3). 
(A) 
    
           All Cells               Live Cells               Isotype                  Antibody 
  
(B) 
 
 
    
 CD73 CD90 CD105 CDs14 19 34 45 HLA-DR 
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Figure 3.3 Phenotypic characteristics of MSCs at standard (high) calcium media (HC-Media). 
All isolated MSCs (N=9) were stained with specific antibodies for each marker such as PE Mouse Anti-
Human CD73  Clone  AD2  (RUO), PerCP-Cy™5.5 Mouse Anti-Human CD90  Clone  5E10  (RUO), 
APC Mouse Anti-Human CD105  Clone  266  (RUO), FITC Mouse Anti-Human 
CD14  Clone  M5E2  (RUO), FITC Mouse Anti-Human CD19  Clone  HIB19  (RUO), FITC Mouse Anti-
Human CD34  Clone  581  (RUO), FITC Mouse Anti-Human CD45  Clone  HI30  (RUO) and APC-H7 
Mouse Anti-Human HLA-DR  Clone  G46-6  (RUO) for 20 minutes at 4ºC then stained with DAPI and 
sorted in FACs. (A) Gating strategy showing that all stained cells were analysed and then gated on live 
cells  versus specific  antibody. (B) Gating strategy of representative overlapping antibody stained cells 
(blue line) and isotype stained cells (red line) for the given marker. (C) Statistical analysis showing the 
ratio of MSCs expressing CD markers presented as the mean on cell percentages. Error bars= standard 
error of the mean (SEM), (N=9). 
MSCs where grown in low calcium media (LC-Media), 0.04 mM/L, for 3 days. LC-Media 
medium is a new potentially stressful environment for MSCs; with the possibility that it 
may cause a change their biological behaviour in particular their stemness, phenotypic 
features and differentiation potential. The phenotypic characterisation was therefore 
repeated under LC-Media. Again, MSCs showed the ability to grow in LC-Media for 3 days 
keeping their morphology as fibroblast like cells as shown in (Figure 3.1 F) but they lost 
their expansion ability. In addition, over 96% of the cells expressed CD73 (96.9±0.65 %), 
CD90 (99.3±0.18 %) and CD105 (96.9±0.97 %) and minimal number of cells were positive 
for the expression of the haematopoietic stem cell markers CD14, CD19 CD34, CD45 
(1.65±0.87 %) and HLA-DR (1.00±0.10 %) i.e. over 98 % were negative for these markers 
(Figure 3.4). Therefore, MSCs can retain the criteria stipulated by the International Society 
for Cell Therapy (ISCT) when grown in LC-Media for three days. 
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(A) 
    
 All Cells Live Cells Isotype Antibody 
     
(B) 
 
 
    
 CD73 CD90 CD105 CDs14 19 34 45 HLA-DR 
      
(C) 
 
Figure 3.4 Phenotypic characteristics of human MSCs at low calcium media (LC-Media). 
Four samples of isolated MSCs were analysed for their ability to express the CD marker panel after 
growth in LC-Media (0.04 mM/L) for 72 hours. Cells then stained with the same antibodies as explained 
in the legend of (Figure 3.3). (A) Gating strategy showing that all stained cells were analysed and used 
to generate positive cells for specific antibody. (B) Gating strategy of representative overlapping antibody 
stained cells (blue line) and isotype stained cells (red line) for the given marker. (C) Statistical analysis 
showing the ratio of MSCs expressing CD markers presented as the mean on cell percentages. Error 
bars= standard error of the mean (SEM) (N=4). 
When the ratio of CD markers expressed by MSCs at both high and low calcium 
concentrations were compared, there was no significant difference (P>0.05) and the 
MSCs kept their phenotypic characteristics as shown in (Figure 3.5). Over 98% of the cells 
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expressed CD73, CD90 and CD105 and were negative for the expression of the 
haematopoietic stem cell markers CD14, CD19 CD34, CD45 and HLA-DR. Therefore, 
MSCs can retain the criteria stipulated by the ISCT when grown in LC-Media for three 
days. 
 
Figure 3.5 Comparison between MSC phenotypic markers expressed at standard high calcium 
media (HC-Media) and low calcium media (LC-Media). 
MSCs grown in HC-Media and LC-Media expressed the phenotypic markers stipulated by the ISCT. 
MSCs at both HC-Media (Black columns) and LC-Media (Gray columns) expressed CD72, CD90 and 
CD105 with a ratio more than 97% with no significant variation (P>0.05). Also, more than 98% of MSCs 
at HC-Media and LC-Media were negative for the expression of CD14, CD19, CD34, CD45 and HLA-
DR with no significant differences between samples (P>0.05). Data presented in columns as mean of 
percentages of MSCs that express specific marker. Error bars= standard error of the mean (SEM), 
(N=4). 
3.3.2.3 DIFFERENTIATION POTENTIAL OF MSCS 
Four MSC samples were analysed for their differentiation potential. All the samples have 
showed the ability to differentiate in vitro into three lineages; adipocytes, osteoblasts and 
chondrocytes as shown in (Figure 3.6). At high and low calcium concentrations, MSCs 
showed the ability to differentiate into lipid droplets (Figure 3.6 A), which represent the 
early stages of adipogenesis. These lipid vacuoles when stained with oil red dye give a 
red to orange colour. In addition, when MSCs were grown in osteogenic differentiation 
media for three weeks, they were able to differentiate into osteoblasts and developed 
calcium crystals, which turned to black when stained with Von Kossa stain. The observed 
purple colour resulted from the binding of ALP stain to other minerals present in the bone 
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such as iron (Figure 3.6 B). They were also able to differentiate into chondroblasts by 
growing as pellet in vitro and formed proteoglycan when grown in chondrogenic 
differentiation media for three weeks as demonstrated in (Figure 3.6 C). 
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Figure 3.6 Differentiation potential of MSCs into tri-lineages. 
Representative images showing the ability of MSCs to differentiate into tri-lineages; adipocytes, 
osteoblasts and chondrocytes. (A) MSCs grown in adipogenic differentiation media for 18 days 
developed into lipid vacuoles which upon staining with oil red dye gave a red to orange colour. (B) 
MSCs grown in osteogenic differentiation media for 21 days developed into osteoblasts which contained 
osteogenic minerals such calcium which upon staining with gave the dark blue and purple colour. (C) 
MSCs grown in chondrogenic differentiation media for 21 days developed to a pellet when stained with 
Alcian blue, shown as a bright blue colour indicating the formation of proteoglycan demonstrating the 
early stage of chondrogenesis. Scale bar 100 µm.  
3.3.2.4 DIFFERENTIATION OF MSCS INTO EPIDERMAL-LIKE CELLS 
In these experiments, the potential of MSCs to differentiate into epidermal-like cells in 2D 
cell culture was investigated. MSCs were grown in epidermal differentiation medium 
(EDM) for 17 days and both their morphology and ability to express epidermal 
differentiation markers at different time points was investigated. Morphologically, after 14 
and 17 days of growth in EDM, MSCs changed their shape and no longer became spindle-
shaped cells and lost their long body becoming rounded cells with reduction in their 
processes (Figure 3.7 A and B).compared to the control cells C and D respectively.  
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(A)14 Days (B) 17 Days 
  
(C) 14 Days Control  (D) 17 Days Control  
Figure 3.7 Morphology of MSCs in EDM at different time points. 
Representative images showing MSC ability to change their morphology with time when grown in EDM. 
(A) and (B) MSCs grown in EDM for 14 and 17 days respectively; they changed their shape from spindle 
shaped cell to rounded cells with reduced protrusions from their body. (C) and (D) MSCs grown in 
standard MSC media (NH media) for 14 and 17 days respectively kept their morphology as fibroblast 
like cells with an elongated cell body. EDM= Epidermal differentiation media, Scale bar= 100 µm.    
MSCs were shown to express epidermal markers. For example, after 10 days cytokeratin 
14 (K14) was investigated and there was no expression as shown in (Figure 3.8 A). 
However, after 14 days, some cells started to express K14 as shown in (Figure 3.8 B) 
indicating that MSCs started to differentiate into keratinocyte-like cells. Moreover, after 17 
days more MSCs started to express both cytokeratin 10 (K10) and loricrin as shown in 
(Figure 3.8 C and D) respectively. 
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Figure 3.8 Differentiation potential of MSCs into epidermal like cells (ELCs). 
Representative immunofluorescence images showing that MSCs have the ability to differentiate into 
epidermal like cells when grown in EDM. (A) MSCs grown in EDM for 10 days and failed to express K14. 
(B) MSCs grown in DMEM for 14 days expressed K14. MSCs in (A) and (B) are stained with Anti-
Cytokeratin 14 antibody giving green signal with Alexa fluor 488 goat anti-mouse IgG (H+L) secondary 
antibody. (C) MSCs grown in DMEM for 17 days expressed K10 when stained with Anti-Cytokeratin 10 
antibody (ab111447) gives green signal with Donkey Anti-Rabbit IgG H&L (Alexa Fluor® 488). (D) MSCs 
grown in DMEM for 17 days expressed the late differentiation marker (loricrin) when stained with Anti-
Loricrin antibody (ab85679) and gives green signal with Donkey Anti-Rabbit IgG H&L (Alexa Fluor® 488). 
Blue stain DAPI stain. Scale bar=50 µm.  
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3.3.2.5 PROTEOMIC CONTENT OF MSC-CM 
MSC-CM was analysed by ELISA kits as listed in (Table 2.3) to detect the protein content 
of growth factors, cytokines and chemokines that may influence migration, proliferation 
and differentiation of skin cells (keratinocytes and fibroblasts). As mentioned in Chapter 
2, MSC-CM was collected at different time points (24, 48 and 72) hours in different media; 
stem cell non-haematopoietic media (NHM), low calcium media (LC-Media) and standard 
high calcium media (HC-Media). To avoid the confusion in the nomenclature of media 
types, serum levels, calcium levels and types of MSC-CM collected at different time points 
are shown in (Table 3.2). 
Media 
Name 
Serum 
Calcium 
Level 
MSC 
Secretion 
Experimental Use 
Collection Time (hours) 
24 48 72 
NH Complete 1.8 mM NH-CM Comparison NH-CM24 NH-CM48 NH-CM72 
DMEM 10% FCS 1.8 mM HC-CM 
HaCat cells 
Primary 
Fibroblasts 
HC-CM24 HC-CM48 HC-CM72 
MCDB NIL 0.04 mM LC-CM 
Primary 
keratinocytes 
LC-CM24 LC-CM48 LC-CM72 
Table 3.2 Information about MSC secretions in different media. 
MSC secretions were collected in different types of media with varying levels of calcium and serum for 
different experiments. For example, NH media is the standard growth media of MSCs used to collect 
MSC-CM and was used as a control. DMEM was used to collect MSC-CM (high calcium HC-CM) for 
fibroblast and HaCat experiments. MCDB was used to collect MSC-CM (low calcium LC-CM) for primary 
keratinocyte experiments. 
LC-CM was collected for use in keratinocyte experiments and the standard calcium media 
was termed high calcium media (HC-CM) for fibroblast and HaCat experiments. MSCs 
secreted detectable levels of some growth factors, cytokines and chemokines at different 
concentrations in the three types of media (Figure 3.9 A, B and C) such as keratinocyte 
growth factor (KGF), hepatocyte growth factor (HGF), platelet derived growth factor-AB 
(PDGF-AB), stromal derived factor-1 alpha (SDF-1α) and macrophage stimulating 
protein-1 (MSP-1). 
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Figure 3.9 Growth factors present in MSC-CM. 
MSC secretions in media different types and their concentrations in (A) HC-CM (1.8 mM/L) serum free 
media. (B) LC-CM (0.04 mM/L). (D) Standard MSC growth media with HC-CM (1.8 mM/L). X-axis 
represents mean of concentrations of growth factors in pg/ml. Data presented as mean of the 
concentration for a given growth factor. Error bars= standard error of the mean (SEM), (N=3). 
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As shown in (Figure 3.9 A), HC-CM collected at different time points contained different 
concentrations of the six growth factors; HGF, KGF, PDGF-AB, TGF-β1, SDF-1α and 
MSP-1. HGF was the only growth factor that increased during time; i.e. the concentration 
was significantly increased after 48 hours and 72 hours (P<0.001) and (P<0.01) 
respectively, when compared to the concentration at 24 hours. There was no significant 
variation between the concentrations of other growth factors collected at the same time 
points (P>0.05). For example, there was no significant increase in concentrations of KGF, 
PDGF-AB, TGF-β1, SDF-1α and MSP-1 neither after 48 hours nor after 72 hours (P>0.05) 
when compared to their concentrations at 24 hours. 
In LC-CM, the concentrations of HGF had significantly reduced after 24 hours; e.g., it was 
reduced after 48 hours with continuous reduction after 72 hours (P<0.001) and (P<0.01) 
respectively when compared to its concentration at 24 hours. While other growth factors 
and cytokines showed similar concentrations during all collection times (24, 48 and 72 
hours) (P>0.05) (Figure 3.9 B). 
In case of NH media, the concentration of HGF remained the same during the different 
time points since there was no significant increase in the concentration after 72 hours 
(P>0.05) when compared to 24 hours. Again, other growth factors showed similar 
concentrations during the different time points; 24, 48 and 72 hours (P>0.05) (Figure 3.9 
C). 
The amounts of growth factors collected at the different time points, in the three types of 
media were then compared. For example, NH-CM72 contained higher concentrations of 
HGF when compared with HC-CM72 and LC-CM72 (P<0.0001) (Figure 3.10 A). At high 
calcium media (HC-Media) and serum free conditions, MSCs secreted higher 
concentrations of PDGF-AB when compared to LCL-serum free media. While other 
growth factors; KGF, TGF-β1, SDF-1α and MSP-1 were secreted equal amounts in the 
different types of media (P>0.999) (Figure 3.10 B, C, D, E and F). 
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Figure 3.10 Concentrations of growth factors and cytokines present in MSC-CM collected at 
different conditions. 
Concentrations of growth factors and cytokines secreted by MSCs at different calcium levels. (A) HGF 
concentration in NH media was higher than the concentration in LC-CM and HC-CM at the 72 hour 
collection time point (P<0.0001). (B) Concentrations of KGF collected in the three types of media were 
closer to each at 72 hours (P>0.999). (C) PDGR-AB was secreted in equal quantities at different calcium 
levels. (D) Concentrations of TGF-ß1 (E) Concentrations of SDF-1α. (F) Concentrations of MSP-1. Data 
represented as mean of the concentration of a given growth factor. Error bars= standard error of the 
mean (SEM), N=3.      
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3.4 DISCUSSION 
Mesenchymal stem cells (MSCs) represent a promising tool for use in regenerative 
medicine with potential therapeutic applications in many diseases including repairing 
injured tissues and healing chronic wounds. This is due to their differentiation potential 
and their secretory contents which harbour a variety of growth factors and cytokines (Mafi 
et al., 2011). Although they could be isolated from different sources such as adipose 
tissue, umbilical cord and Wharton’s jelly, bone marrow (BM) represents the most 
frequently used source (Secunda et al., 2015). The preference of BM over other sources 
is due to the high yield of cells, more homogeneity of the MSCs, and lack of differentiated 
or committed cells (Mareschi et al., 2012) as well as their higher proliferation rate 
(Secunda et al., 2015). In this Chapter, MSCs were isolated from the femoral head of 
human hip joints and characterised according to the criteria stipulated by The International 
Society for Cell Therapy (ISCT) (Dominici et al., 2006). The MSC spindle-like shape 
facilitates cell distribution and homing and makes the cell ready to initiate proliferation. 
The faster the cells become spindle shaped after adherence to the flask surface the more 
proliferative and duplicative the cells become (Secunda et al., 2015). MSCs also undergo 
self-renewal, which is a criterion of stem cells, and could be defined as the ability of cells 
to generate numerous clones from a single cell with the ability to retain their stemness 
characteristics. Therefore, isolated MSCs should be able to renew themselves and 
produce clones of cells similar in shape and characteristics to their parent cells (Roccaro 
et al., 2013). The ISCT stated that MSCs should have the ability to differentiate into to tri-
linages; adipocytes, chondrocytes and osteoblasts, which are mesodermal cell types 
(Dominici et al., 2006). The mesoderm is one of the three germ layers that is formed at 
early stages of embryonic development (Sadler, 2010). Mesodermal adipocytes are 
lineages of the lateral plate mesoderm and represent the majority of adipocytes in adult 
body (Sheng, 2015). They perform specific functions such as energy storage including 
development of the brown fat heat insulator assisting the skin to control the temperature 
of the human body, in addition to protecting and supporting some organs such as the 
kidneys (Cristancho and Lazar, 2011). Therefore, adipose tissues are very important for 
the human body. Hence, the mesodermal adipocytes and the majority of the human body 
adipose tissue could be originated from MSCs. Consequently, the differentiation potential 
of MSCs into adipocytes is an important feature which could be used for mesodermal 
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tissue morphogenesis and regeneration. On the other hand, the ability of MSCs to 
differentiate into skeletogenic lineages such as chondrocytes, and osteoblasts suggest 
that the biological characteristics of MSCs is similar to those of mesodermal precursors 
when they still part of the epiblast (Alev et al., 2013) which, in turn generates all the 
skeletal elements (except the cranial bones) (Sheng, 2015). Hence, MSCs act as 
functional pluripotent progenitors and share several common molecular and cellular 
similarities to embryonic stem cells (ESC) and could be involved in the application of bone 
and cartilage repair and regeneration (Klontzas et al., 2015; Goldberg et al., 2017). 
Collectively, both self-renewal and differentiation ability to mesodermal lineages are 
hallmarks of stem cells; therefore,  by possessing these features, MSCs are important for 
sustaining tissue regeneration, development, maintenance and serial transplantation 
ability of MSCs (Nombela-Arrieta et al., 2011). 
Besides the ability to adhere to plastic, a panel of phenotypic positive and negative 
phenotypic markers has been proposed by the ISCT in an attempt to reduce experimental 
variability and confirm the purity of and homogeneity of isolated MSCs. For example, 
antibodies against CD73, CD90 and CD105 represent the positive selection panel for 
MSCs while antibodies against the haematopoietic stem cell markers CD14, CD19, CD34, 
CD45 and HLA-DR represent the negative selection panel (Dominici et al., 2006; Jung et 
al., 2012). MSCs were able to express the panel of markers proposed by the ISCT. Over 
95 % of the isolated cells were positive for cluster differentiation (CD) antigens CD73, 
CD90 and CD105. CD73 is also called ecto-5’-nucleotidase and is a general marker for 
variant stem cells and is expressed by the cell membrane on many cell types e.g. dendritic 
cells (DCs), endothelial cells, epithelial cells, lymphocytes and macrophages. It is a 
multifunctional cell surface protein and performs many physiological roles such as 
organises epithelial ion and fluid transport, controls tissue barrier functions, enhances 
adaptive response of the cell to hypoxic conditions, preconditions the cell for the ischemic 
stresses, and attenuates an inflammatory response (Antonioli et al., 2013). CD73 is a 
coenzyme which catalyses the conversion of monophosphate (AMP) to adenosine, which 
in turn binds to one of four adenosine receptors (A1, A2A, A2B or A3) and initiates cell 
activation to perform one of the functions mentioned above (St. Hilaire et al., 2009) et al., 
2011). Although, the expression of this marker is not restricted to MSCs, the ability to 
express it is very important for facilitating cell adhesion, migration and proliferation (Wang 
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et al., 2008). CD90 is also referred to as Thy-1, because it was first antigen detected on 
mouse thymocytes by (Reif and Allen, 1964). It is a cell surface glycoprotein with 111 
amino acids expressed by variant stem cells in addition to activated endothelial cells, brain 
cells, fibroblasts, neurons and ovarian follicular cells (Kisselbach et al., 2009). It binds 
mainly to integrins β2, β3 and β5 and activates several cellular activities including 
adhesion, extravasation and migration of cells, activation of T-cells, regulation of axon 
growth and suppression of tumours (Wetzel et al., 2004). CD105 is also known as 
endoglin, is cell membrane glycoprotein and acts as TGF-β receptor with a high affinity to 
TGF-β1 TGF-β3 and a low affinity to TGF-β2 (Guerrero-Esteo et al., 2002). It is activated 
upon ligand binding and involved in many cellular functions such as the development of 
the cardiovascular system, differentiation of smooth muscle, morphology and migration of 
the cell, remodelling of the vascular system and neovascularisation and angiogenesis 
(Guerrero-Esteo et al., 2002). Although CD73, CD90 and CD105 are expressed on many 
other cell types separately, their expression in one cell type the MSC, will verify them as 
stem cell-like cells with stemness traits enabling them to perform  a wide range of functions 
and increased differentiation potential. 
On the other hand, 98% of the isolated MSCs were negative for the haematopoietic stem 
cell markers. For example, CD14, is a marker, expressed by macrophages, monocytes, 
neutrophils, dendritic cells and endothelial progenitor cells and is involved in their 
differentiation (Deans and Moseley, 2000). CD19, is a B-lymphocyte antigen, involved in 
their proliferation and differentiation (Tedder and Isaacs, 1989). CD34 is a haematopoietic 
progenitor cell antigen (Griffiths et al., 2005; Hass et al., 2011; Jin et al., 2013a), It is 
expressed on haematopoietic and vascular tissue (Nielsen and McNagny, 2008). It acts 
as adhesion molecule, supports T-cells to penetration into the lymph nodes (Suzawa et 
al., 2007) and plays a role in migration of eosinophils and precursors of dendritic cells 
(Blanchet et al., 2011). CD45 is a marker of all mature haematopoietic cells and involved 
in their activation with the exclusion of erythrocytes and plasma cells (Zuk et al., 2002; Jin 
et al., 2013a). It is also involved in the regulation of haematopoiesis and used to 
distinguish between haematopoietic stem cells (HSCs) and MSCs derived from the bone 
marrow (Saint-Paul et al., 2016). Finally, MSCs are negative for human leukocyte antigen 
(HLA-DR) which is typically found on immune cells such as antigen presenting cells i.e. 
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macrophages, B-cells and dendritic cells and evoke THelper cells to help B cells produce 
antibodies upon binding to foreign antigen (Hass et al., 2011; Jin et al., 2013a). 
The phenotypic positive and negative panels proposed ISCT are collectively strong 
evidence that MSCs derived from bone marrow are non-haematopoietic stem cells (Lin et 
al., 2012). However, there may be some variations in the percentages of the cells in 
expressing some markers such as HLA class II under cytokine stimulation (Lin et al., 2012; 
Mabuchi et al., 2013). Moreover, CD34 has shown to be a controversial marker since 
some studies reported that adipose tissue derived MSCs could express CD34 at the time 
of isolation but that it is lost later during in vitro expansion (Quirici et al., 2010; Bourin et 
al., 2013). Therefore positive or negative selection using CD34 may vary depending on 
the MSC source.      
Growth factors, cytokines and chemokines are involved in the main signalling pathways 
and play a pivotal role in signal transduction during the daily cellular activities including 
cell division, homeostasis, proliferation, migration, differentiation, survival, tissue repair 
and regeneration and apoptosis (Vlahopoulos et al., 2015). Some growth factors are 
multifunctional molecules and promote cellular activities in a variety of cells; however, 
others are monofunctional and are restricted to one cell type. The main receptors of 
growth factors are tyrosine kinases, small G-protein coupled receptors (GPCRs) and 
serine/threonine kinases (Alfaro et al., 2013; van de Kamp et al., 2013). 
These biomolecules (growth factors and cytokines) may work synergistically and form an 
intricate network, which controls and amplifies cellular responses upon stimulation 
conferring flexibility and stability of the cell. Dysregulation therefore, of the secretion of 
this panel of biomolecules by progressive disease will affect the biological function of the 
cell (Park et al., 2009). Therefore, the presence of this wide spectrum of growth factors 
and cytokines in MSC secretions boosts the application, contribution and utilisation of 
MSCs and their secretions in cellular therapies including tissue regeneration and 
regenerative medicine. In this study, the presence of some growth factors and cytokines 
were detected in MSC secretions that could promote wound healing. These included 
keratinocyte growth factor (KGF), hepatocyte growth factor (HGF), platelet derived growth 
factor-AB (PDGF-AB), stromal derived factor-1α (SDF-1α) and macrophage stimulating 
protein-1 (MSP-1). The secretions of this panel of biomolecules was shown to be 
conserved amongst three different samples of MSCs.     
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Previous studies have described using of serum free medium to collect MSC conditioned 
medium (MSC-CM) for cellular therapy applications to avoid xenogeneic interactions. For 
wound healing experiments, using primary cells, in particular, trials on primary 
keratinocytes have given more realistic results than those obtained from cell lines and 
hence giving a better understanding about cell behaviour at the injury site. The main 
formula of serum free media is DMEM which contains HC-Media ranging from 1.0 mM/L 
- 1.8 mM/L which is sufficient to enhance primary keratinocyte differentiation; thereby, 
affecting their migration and proliferation which could give inaccurate results about 
keratinocyte behaviour at the injury site. This therefore limits the value of in vitro studies 
of MSC-CM collected in HC-Media when the target cells are primary keratinocytes. 
Therefore, there is an urgent demand to find an alternative solution. In this study a new 
method was developed to isolate and grow MSCs in LCL (0.04 mM/L) cell culture medium 
and to develop the optimal conditions to collect MSC secretions for their effect on human 
skin cell (including primary cells) viability, differentiation and would healing. The ability of 
MSCs to grow in a low calcium environment has rarely been studied. Only two studies 
described the effect of different calcium levels on growth, proliferation and differentiation 
of MSCs. The first study conducted by (Yu Kan et al., 2009) described the effect of 
different combinations of calcium and inorganic phosphatase (Pi) (0, 0.45, 0.9, 1.8, 3.6 
and 7.2 mM/L) on bone marrow derived MSCs (BM-MSCs). They reported that the 
optimum concentration of calcium and Pi for MSC growth and osteogenic differentiation 
was1.8 mM/L and 0.09 mM/L, respectively. Any decrease or increase in these 
concentrations for five days inhibited the growth of BM-MSC. In addition, treating BM-
MSCs with lower or higher concentrations of calcium and Pi for 15 days retarded the ability 
of BM-MSCs to differentiate into osteogenic linages. Another team (Dry et al., 2013) tested 
the effect of different HC-Media (1.9, 3.4, 5.0 and 6.9 mM/L) on porcine synovium derived 
MSCs (S-MSCs) and reported that elevated calcium levels promoted S-MSCs proliferation 
A concentration of 5.0 mM/L calcium resulted in the greatest increase in growth after 5 
days when compared with higher and lower concentrations. Additionally, they found that 
S-MSCs were positive for expression of CD29, CD90 and CD105 and negative for CD14 
and CD45 and were able to tri-differentiate towards the adipogenic, osteogenic and 
chondrogenic lineages.  
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Comparing the two studies, there is a clear discrepancy between the findings because 
(Yu Kan et al., 2009) reported that any calcium concentration higher or lower than1.8 
mM/L would inhibit MSCs proliferation and differentiation. On the other hand, Dry and 
colleagues (Dry et al., 2013) showed that MSCs could proliferate and differentiate 
successfully with an optimised calcium concentration of 5.0 mM/L. Therefore, the ability 
of MSCs to grow in LCL remains controversial and more studies are required about this 
topic. 
The results presented in Chapter 3 were in agreement with (Yu Kan et al., 2009) in that 
MSC proliferation was arrested in reduced calcium conditions (0.04 mM/L); however, they 
were able to survive for three days, which is the period required to collect MSC-CM and 
remained in keeping with the criteria stipulated by the ISCT. Moreover, secretions of 
MSCs grown at LCL were similar to that of MSCs grown at high calcium conditions since 
they were able to secret different concentrations of the same growth factors and cytokines 
such as KGF, HGF, PDGF-AB, SDF-1α and MSP-1. 
In both conditions (high and low calcium), HGF was produced in the highest 
concentrations indicating that HGF might be a growth factor released predominantly by 
MSCs and involved in several biological processes such as proliferation, migration, 
angiogenesis and production of matrix metalloproteinase (Maxson et al., 2012). 
Separately or collectively, this panel of growth factors and cytokines may play a core 
functional role in tissue repair and regeneration by evoking diverse cellular functions 
including cell division, proliferation, migration, differentiation, survival and apoptosis.  
Inhibition of MSC proliferation noticed by (Yu Kan et al., 2009) and this present study 
could be attributed not only to the low calcium level but also due to the medium was serum 
free, since it is well reported that MSCs require complete medium for expansion and 
proliferation. On the other hand, MSCs showed the ability to differentiate into keratinocyte-
like cells and expressed K14, K10 and loricrin. This differentiation ability  has a potential 
application of MSCs in wound healing by fulfilling the need of the damaged tissue by 
compensating for the cells lost during tissue damage and participating in tissue 
regeneration by replenishing cells and other cellular components (Sasaki et al., 2008). 
However, more investigations are required to confirm the potential participation of MSCs 
in wound healing via transdifferentiation into skin-like cells.  More information about this 
issue will be discussed in Chapter 6 when MSCs were used to generate a 3D-SEM to test 
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their ability to form an epidermal like structure and to investigate their role in skin 
regeneration.       
In summary, regardless of the trophic environment, MSCs showed the ability to grow 
normally at LCL for three days keeping their identity, stemness characteristics and 
secretory molecules. These criteria collectively raising the valuable insight of MSC 
applications in various conditions and disorders and facilitate the future research on 
primary cells instead of cell lines underlying their pivotal role in cell therapy and 
regenerative medicine. The  study demonstrated a novel method to isolate and grow 
MSCs in low calcium medium and the optimal conditions to collect MSC secretions for the 
analysis of their effect on human skin cell (in particular, primary cells) viability, 
differentiation and wound healing in vitro. Previous studies have described culture 
medium in which to grow MSCs and collect growth factor rich supernatants but have not 
addressed issues of high calcium level contained in such media, which is sufficient to 
induce keratinocyte differentiation and restricts the potential beneficial effects of MSC 
secretions on wound healing in primary keratinocytes. Therefore, the protocol reported in 
this study addresses the issue of HC-Media in MSC-CM. Hence, in the next chapter 
(Chapter 4) the effect of high and low calcium levels in MSC- CM on the migration of skin 
cells will be addressed. 
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CHAPTER FOUR: EFFECT OF MSC-CM ON MIGRATION OF SKIN CELLS 
4.1  INTRODUCTION 
Migration is a generic term used in biology to describe any controlled and directed cell 
motility inside the body when cells change their place and position between tissues or 
other organs (Kramer et al., 2013).  Cell migration is a highly organised cellular response 
and a substantial process for live cells and a key role for not only normal embryonic 
development and regeneration but also, disease restriction such as cancer metastasis, 
wound healing and the immune response (Mak et al., 2016). Cell motility could be singular 
cell movement i.e., migration of embryonic cells and leukocytes through the extracellular 
matrix (ECM) (Fackler and Grosse, 2008), or multicellular movement or so called 
collective cellular streaming i.e., motility of epithelial sheets through the base membrane 
during wound healing (Gerharz et al., 2007; Kramer et al., 2013). Cell migration, in 
particular, collective cellular streaming is one of the main steps required for tissue 
regeneration and wound healing since epithelial cells migrate as cohesive sheets of cells 
(Friedl and Gilmour, 2009; Vitorino et al., 2011). Additionally, collective cell migration 
maintains intercellular connection, relative velocity and conserved position of cells during 
wound healing for several types of epithelial wounds e.g., cornea, skin, epithelia and 
endothelia of respiratory and digestive tissue (Fong et al., 2010; Vitorino et al., 2011). 
Therefore, studying the migratory behaviour of the cell is a very useful tool for many 
biomedical disciplines and related fields e.g., biology and bioengineering (Yoshida et al., 
2003; Justus et al., 2014). Migrating cells undergo some basic changes such as changing 
body shape via actomyosin-cytoskeleton (Keren et al., 2008), displaying directional 
polarity and possessing leading and lagging edges in the cell body (Ridley et al., 2003). 
In culture, cell motility can be detected and investigated using different migratory assays; 
for example, the trans-well migration assay (Boyden chamber assay) (Boyden, 1962), the 
scratch assay (wound closure assay) (Todaro et al., 1965), the microfluidic chamber assay 
(capillary chamber migration assays) (Zigmond, 1988; Zicha et al., 1991), the fence assay 
(ring assay) (Fischer et al., 1990), the micro-carrier beads assay (Rosen et al., 1990), the 
spheroid migration assay (Konduri et al., 2001) and the cell exclusion zone assay 
(Poujade et al., 2007). Additionally, there are specific assays to evaluate single cell 
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migration e.g., the leukocyte migration agarose technique assay (LMAT assay) (Carpenter 
et al., 1968), the colloidal particle assay (colloidal gold single cell migration assay) 
(Albrecht-Buehler, 1977) and the time-lapse/cell tracking assay (Jaqaman et al., 2008). 
The scratch assay is a popular, inexpensive technique to measure cell migration in 2D 
culture (Liang et al., 2007). In a scratch assay, a scratch is induced in a confluent cellular 
layer of any cell type grown on a plastic or glass surface, using a pipette tip. Cells migrate 
from the edges of the gap towards the scratch centre and cell migration microscopically 
monitored between time zero until the time of full closure or assay termination at a specific 
time point (Liang et al., 2007; Kramer et al., 2013). Wound healing is evaluated by 
measuring the scratch areas at different time points between time zero and full treatment 
time (Todaro et al., 1965; Justus et al., 2014). To mimic in vivo cell migration, cells are 
grown on a plastic surface pre-coated with different substrates i.e., collagen type I or type 
IV, fibronectin or matrigel (basal membrane extract “BME”) (Friedl et al., 2004; Kramer et 
al., 2013; Justus et al., 2014). Migration of various cell types have been analysed using a 
2D scratch assay e.g., keratinocytes (Chigurupati et al., 2007), a human keratinocyte cell 
line (HaCat) and fibroblasts (Walter et al., 2010), endothelial cells (Zhang et al., 2011c), 
epithelial and mesenchymal cancer cells (Inoue et al., 2007) and normal epithelial cells 
(Doehn et al., 2009). Aside from low cost, ease and simplicity of data analysis, 2D scratch 
assay mimics, to some extent, migration of endothelial cells (ECs) into the wounded area 
upon induction of an in vivo wound in the endothelium of blood vessels. It is also suitable 
for studying the regulation of cell migration upon interaction with the extracellular matrix 
and cell-to-cell interaction (Liang et al., 2007; Kramer et al., 2013). Additionally, it is 
compatible with live cell imaging thereby enabling evaluation and analysis of intracellular 
signalling events and activities such as detecting subcellular localisation by visualisation 
of green fluorescent protein (GFP)-tagged proteins or detection of energy transfer during 
protein–protein interactions (Liang et al., 2007). Moreover, it can be combined with other 
techniques e.g., gene transfection and microinjection, to analyse the impact of gene 
expression on cell migration (Abbi et al., 2002). One of the drawbacks of the scratch assay 
is that it takes a long time to perform in comparison to other methods, it also consumes 
relatively large number of cells and large volumes of test substances for one assay, since 
it is performed in a tissue culture plate. Therefore, it is not a choice when the availability 
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of the cells is limited and the testing compound is expensive. Despite these technical 
drawbacks, the 2D scratch assay remains the most applicable assay for monitoring cell 
migration (Liang et al., 2007). Collectively, migration of skin cells is a critical and the most 
important repair mechanism in the healing process (Qing, 2017). Therefore, studying the 
effect of MSC-CM on the migration of skin cells and monitoring cell behaviour through 
these events are very important and critical for a better understanding of the cellular 
mechanisms during the skin healing process. 
4.2  SPECIFIC AIMS OF CHAPTER FOUR 
1. To study the effect of MSC-CM on the migration of skin cells (keratinocytes 
and fibroblasts). 
2. To study the effect MSC-CM on the migration of primary keratinocytes at hypoxic 
conditions. 
3. To study the effect of MSC-CM on the migration of primary keratinocytes while blocking 
SDF-1α. 
4. To compare the effect of high calcium conditioned media (HC-CM) and low calcium 
conditioned media (LC-CM) on the migration of primary keratinocytes. 
5. To determine the best time for collecting MSC secretions in order to enhance the 
wound healing process.
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4.3  RESULTS 
4.3.1 SKIN CELLS 
All human skin cells used in this study; HaCat cell line, human primary keratinocytes, 
human primary dermal fibroblasts (Figure 4.1 A, B, C and D) respectively, were provided 
by the Dermatology Department and Tissue Solutions Ltd / Glasgow, UK. 
   
(A) HaCat Cell Line      (B) Primary Keratinocytes (C) Dermal Fibroblasts 
 
DAPI K14 Antibody Merge 
   
(D) Primary Keratinocytes Expressing (K14)  
Figure 4.1 Human skin cells used in the study. 
This figure shows human skin cells used during the study. (A) Monolayer of HaCat cell line (50% 
confluence). (B) Confluent monolayer of primary keratinocytes. (C) Confluent monolayer of dermal 
fibroblasts. (D) Primary keratinocytes stained with Anti-Cytokeratin 14 antibody [LL002] (ab7800) at 
(1:200) diluted in (10% foetal bovine serum (FBS) in PBS) and Goat Anti-Mouse IgG H&L (Alexa Fluor® 
488) preadsorbed (ab150117) at (1:200) diluted in (10% FBS in PBS). Scale bar= 50 µm. 
All cells, including the HaCat cell line and primary keratinocytes were obtained as frozen 
cells from the Dermatology Department, Newcastle University, other samples were 
obtained from Alcyomics Ltd. as shown in (Table 4.1). 
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 Cell Code Provider Passage Age (Year) Collection Date Experimental Use 
1 HaCat DER 1 N/A 25.03.14 SA+MTS 
2 S859FK DER 1 41 26.06.14 SA+MTS 
3 S912FK DER 1 50 27.10.14 SA+MTS 
4 S916FK DER 2 22 03.11.14 SA+MTS+3D Model 
5 S920FK DER 2 54 10.11.14 SA+MTS+3D Model 
6 S955FK DER 2 61 16.02.15 SA+MTS 
7 S962FK DER 2 58 23.03.15 SA+MTS 
8 S936FK DER 3 53 05.01.15 3D Model 
9 AL-O4 Alcyomics 0 NONE 21.12.15 3D Model+SA+Gene Expression 
10 S946FK DER 2 79 27.01.15 3D Model+SA+Gene Expression 
11 S937FK DER 2 24 15.01.15 3D Model+SA+Gene Expression 
12 AL-O3 Alcyomics   1 NONE 15.01.16 3D Model+SA+Gene Expression 
13 K935FK DER   2 NONE 06.01.15 SA Block  SDF-1α 
14 S936FK DER    2 53 05.01.15 SA Block  SDF-1α 
15 S1212FK Alcyomics   2 NONE NONE BrdU labelling SA 
16 S1214FK Alcyomics   2 NONE NONE BrdU labelling SA 
17 S1216FK Alcyomics   2 NONE NONE BrdU labelling SA 
Table 4.1 Human epidermal keratinocytes and HaCat cell line obtained as frozen cells. 
Information about skin cells which were collected as frozen cells including sample code, provider, 
passage, age and gender of donors, collection date and experimental use. DER= Dermatology 
Department, S#FK=Sample # Foreskin Keratinocyte, SA= Scratch Assay, MTS= (3-(4,5-dimethylthiazol-
2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium. 
Human dermal fibroblasts listed in (Table 4.2) were also obtained as frozen cells from the 
Dermatology Department, Newcastle University. 
 Cell Code Provider Passage Age (Year) Collection Date Experimental Use 
1 S920FF DER 1 54 10.11.14 SA+MTS 
2 S916FF DER 3 22 03.11.14 SA+3D Model 
3 S945FF DER 5 33 22.01.15 SA+MTS 
4 S990FF DER 5 67 26.5.15 SA+MTS 
5 S1053FF DER 2 34 29.10.15 SA+3D Model 
6 S1054FF DER  2 27 28.10.15 SA+3D Model 
7 S1055FF DER 2 47 28.10.15 SA+3D Model 
8 S1056FF DER 2 43 29.10.15 SA+3D Model 
Table 4.2 Human dermal fibroblasts obtained as frozen cells. 
Information about skin dermal fibroblasts which were collected as frozen cells including sample code, 
provider, passage, age and gender of donors, collection date and experimental use. DER= 
Dermatology Department, S#FF=Sample # Foreskin Fibroblast, SA= Scratch Assay, MTS= (3-(4,5-
dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium. 
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While other samples, which listed in (Table 4.3) below were received as either plastic 
surgery skin sample or skin biopsies provided by Tissue Solutions Ltd. Glasgow / UK, 
Dermatology Department or Alcyomics Ltd. These samples were processed in Academic 
Haematology for the isolation of human skin cells; primary keratinocytes and primary 
dermal fibroblasts. 
 
Sample 
Code 
Provider 
Age 
(Year) 
Region 
Surgery 
Date 
Experimental Use 
1 PSS1 Alcyomics  56 
Abdominal 
07.04.15 Wound healing/miRNA Profiling 
2 PSS2 Alcyomics  26 
Abdominal 
09.04.15 Wound healing/miRNA Profiling 
3 AL-10 Alcyomics  58 
Abdominal 
25.02.16 SA Block SDF-1α + 3D Model  
4 AL-11 Alcyomics  33 
Breast 
25.02.16 SA Block SDF-1α + 3D Model  
5 DO62 Tissue Solutions 40  
Abdominal 
23.06.16 SA Block SDF-1α + 3D Model  
6 DO63 Tissue Solutions 33 
Abdominal 
23.06.16 SA Block SDF-1α + 3D Model  
7 D064 Tissue Solutions 46 
Abdominal 
23.06.16 SA Block SDF-1α + 3D Model  
8 ALCO-733 Alcyomics  30 
Abdominal 
02.08.16 SA Block SDF-1α + 3D Model  
9 ALCO-734 Alcyomics 31 
Abdominal 
02.08.16 SA Block SDF-1α + 3D Model  
1
0 
S1135F DER 83 
Abdominal 
23.08.16 SA Block SDF-1α + 3D Model  
1
1 
S1136F DER 45 
Abdominal 
23.08.16 SA Block SDF-1α + 3D Model  
1
2 
S1156F DER 51 
Abdominal 
07.12.16 3D-SEM / miRNA Profiling 
1
3 
S1157F DER 51 
Abdominal 
07.12.16 3D-SEM / miRNA Profiling 
1
4 
S1158F DER 17 
Abdominal 
07.12.16 3D-SEM / miRNA Profiling 
Table 4.3 Skin samples and biopsies used to isolate human primary skin cells. 
Information about skin samples which were collected as skin biopsies or plastic surgery skin (PSS) 
including sample code, provider, passage, age and gender of donors, collection date and experimental 
use. DER= Dermatology Department, S#F= S#Foreskin, SA= Scratch Assay. 
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4.3.2 EFFECT OF MSC-CM ON MIGRATION OF SKIN CELLS 
The 2D scratch assay was used to detect the effect of MSC-CM on migration of primary 
skin cells (primary keratinocytes and primary fibroblasts), whereas the HaCat cell line was 
used to optimise the assay. Since, the calcium level is a critical factor for differentiation of 
primary keratinocytes, two types of MSC-CM; high calcium conditioned media (HC-CM) 
and low calcium conditioned media (LC-CM) were tested on the migration of primary 
keratinocytes. Additionally, LC-CM was also tested on migration of primary keratinocytes 
at, hypoxia and after blocking SDF-1α. Primary fibroblasts were treated with HC-CM only. 
4.3.2.1 OPTIMISATION OF 2D SCRATCH ASSAY USING HACAT CELL LINE 
HaCat cells were seeded at a density of 1×105 cells per well in 24 well plates and 
incubated at standard culture conditions (SCC in humidified incubator, 37°C and 5 % CO2) 
for 24 hours to allow cell adhesion. A scratch was then made in the monolayer using a 
sterile yellow tip. The dislodged cells were discarded and the wells were washed with 
PBS, followed by adding MSC-CM (HC-CM24, HC-CM48 and HC-CM72) to the 
corresponding wells. Celle treated with DMEM supplemented with 10% foetal calf serum 
(DMEM-FCS) were used as a control (HC-CTRL). Results showed that MSC-CM (HC-
CM) collected at different time points enhanced the migration of HaCat cells leading to 
close of the scratch area with increased effect during time. After 28 hours of treatment the 
gap was closed when compared to both controls (Figure 4.2). 
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Figure 4.2 Scratch assay of HaCat cell line. 
Representative images of migration of HaCat cells during scratch closure assay. A monolayer of HaCat 
cells were scratched and treated with MSC-CM for 28 hours. (A) HC-CM24. (B) HC-CM48. (C) HC-
CM72. (D) HC-CTRL (DMEM-FCS) as a control. HaCat cells treated with all types of HC-CM (A, B and 
C) migrated from the wound edged towards the scratch centre with time and closed the scratch area 
completely at 28 hours. HaCat cells in the control (D) failed to close the scratch area at 28 hours. HaCat 
cells used at passage 6, Scale bar=50 µm. 
Two way ANOVA showed that all MSC-CM (HC-CM24, HC-CM48 and HCCM72) 
accelerated the migration of HaCat cells and enhanced cell migration after 8 hours of 
treatment compared to HC-CTRL (P<0.01, P<0.001). The effect of the three MSC-CM 
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increased with time to completely close the scratch area after 28 hours of treatment 
whereas the cells treated with control failed to close the whole scratch area leaving a gap 
after the same treatment period (28 hours) (P<0.001. P<0.01 and P<0.001) respectively 
(Figure 4.3). 
 
Figure 4.3 Kinetics of scratch closure of HaCat cells. 
Statistical analysis revealed that the three MSC-CM (HC-CM24: Blue columns, HC-CM48: Red columns 
and HC-CM72: Green columns) significantly reduced the scratch areas with times compared to the 
control (HC-CTRL) (Purple columns). Significant variations between HC-CM and HC-CTRL started at 8 
hours (P<0.01) and increased at other time points (at 16 and 28 hours P<0.0001). Columns = mean of 
scratch areas (N=3 technical replicates), Error bars= standard error of the mean (SEM). (**=P<0.01), 
(****=P<0.0001).  
4.3.2.2 EFFECT OF HIGH CALCIUM-CM (HC-CM) ON MIGRATION OF PRIMARY KERATINOCYTES 
When the effect of HC-CM was tested on the migration of primary keratinocyte, HC-CM 
failed to promote the migration of primary keratinocyte towards the wound centre (Figure 
4.4). After 8 hours of treatment with HC-CM, cells became more flattened, enlarged and 
contacted via cell-to-cell narrow junctions. In addition, after 72 hours cells formed a tissue 
like structure compared to the control, which still showed cells as a confluent monolayer 
in low calcium conditions. These signs are indicators for keratinocyte differentiation. HC-
CM was collected in DMEM based formula containing high calcium levels (ranging from 
1.2 to 1.8 mM/L) which was sufficient to enhance differentiation of primary keratinocytes. 
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To overcome this obstacle, MSC secretions were collected in low calcium conditions (LC-
CM) then scratch assay repeated. 
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Figure 4.4 The effect of HC-CM on migration of primary keratinocytes. 
Representative images of the scratch assay of primary keratinocytes treated with HC-CM for 72 hours. 
(A) HC-CM24. (B) HC-CM48. (C) HC-CM72. (D) Keratinocytes treated with LC-CTRL (MCDB). 
Migration of keratinocytes treated with HC-CM was arrested and the cells failed to close the scratch 
gap after 72 hours. Cells used at passage 3, Scale bar=50 µm. 
Two way ANOVA showed that there was no obvious migration of the cells treated with the 
different types of MSC-CM without any progress in wound closure (P=0.77, P=0.85 and 
P= 0.86) respectively compared to the control cells grown in low calcium conditions across 
the whole treatment period (Figure 4.5). These results demonstrated that it is necessary 
to optimise the culture media formula when testing the effect of MSC-CM on migration of 
different cell types. 
 
Figure 4.5 Kinetics of scratch closure of primary keratinocytes treated with HC-CM. 
Statistical analysis revealed that HC-CM24 (Blue columns), HC-CM48 (Red columns) and HC-CM72 
(Green columns) failed to reduce the scratch area with time compared to the control (Purple columns). 
Data presented as mean of scratch areas (N=4), Error bars= standard error of the mean (SEM). 
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4.3.2.3 EFFECT OF LOW CALCIUM-CM (LC-CM) ON MIGRATION OF PRIMARY KERATINOCYTES 
The effect of MSC-CM collected at low calcium levels (LC-CM) on the migration of primary 
keratinocyte was tested. LC-CM collected at different time points enhanced the migration 
of primary keratinocytes and accelerated wound closure compared to the control 
(LC=CTRL) and closed the scratch area completely at 72 hours using LC-CM24 and 
partially at 72 hours using LC-CM48 and LC-CM72 (Figure 4.6). 
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Figure 4.6 Effect of LC-CM on migration of primary keratinocytes using scratch assay. 
Representative images of migration of primary keratinocytes during the scratch closure assay. 
Monolayers of primary keratinocytes (N=4) were scratched and treated with MSC-CM (LC-CM) for 72 
hours. (A) LC-CM24. (B) LC-CM48. (C) LC-CM72. (D) LC-CTRL (MCDB) and used as a control. Primary 
keratinocytes treated with all types of HC-CM (A, B and C) started migration at 24 hours from the wound 
edge towards the scratch centre. LC-CM24 revealed the best effect and closed the gap within 72 hours 
compared to the control (D). Cells used at passage 3, Scale bar=50 µm. 
Significant enhancement in scratch closure was observed for all LC-CM at 16 hours of 
treatment (P<0.01) compared to the control with increasing effects over time (P<0.0001) 
at 72 hours (Figure 4.7). 
 
 Figure 4.7 Kinetics of migration of primary keratinocytes treated with LC-CM. 
Statistical analysis revealed that LC-CM24 (Blue columns), LC-CM48 (Red columns) and LC-CM72 
(Green columns) significantly reduced the scratch areas with time compared to the control (LC-CTRL) 
(Purple columns). Significant variations between LC-CM and LC-CTRL started at 16 hours (P<0.01). 
The reduction in scratch area was reduced within time with maximum reduction at 72 hours (P<0.0001). 
Data presented as mean of scratch areas (N=4), Error bars= standard error of the mean (SEM). 
(**=P<0.01), (****=P<0.0001). 
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LC-CM and HC-CM were compared at different time points in pairs (LC-CM24 vs HC-
CM24, LC-CM48 vs HC-CM48 and LC-CM72 vs HC-CM72). Results revealed that LC-
CM were the most effective in enhancing cell migration than their counterparts (HC-CM24, 
HC-CM48 and HC-CM72). The effect of LC-CM24 could be observed after 16 hours of 
treatment with significant effects (P<0.05) which increased over time until full closure of 
the scratched areas after 72 hours (P<0.0001) (Figure 4.8 A, B and C).  
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Figure 4.8 Comparison between the effect of LC-CM and HC-CM on migration of primary 
keratinocytes. 
(A) Statistical comparison between (LC-CM24 and HC-CM24) showed that LC-CM24 had a stronger effect 
on wound closure than HC-CM24. (B) Statistical comparison between (LC-CM48 and HC-CM48) showed 
that LC-CM48 had a stronger effect on wound closure than HC-CM48. (C) Statistical comparison between 
(LC-CM72 and HC-CM72) showed that LC-CM72 had a stronger effect on wound closure than HC-CM72. 
Data presented as mean of scratch areas (N=4), Error bars= standard error of the mean (SEM). (*=P<0.05), 
(**=P<0.01), (****=P<0.0001). 
4.3.2.4 EFFECT OF LC-CM ON MIGRATION OF PRIMARY KERATINOCYTES IN HYPOXIC 
CONDITIONS 
Since the environment of chronic wounds is usually hypoxic (Bosco et al., 2008; Sen, 
2009), the effect of MSC-CM on the migration of primary keratinocytes was performed 
under hypoxic conditions to examine whether MSC secretions were able to enhance 
migration of epidermal cells at low levels of oxygen. All LC-CM enhanced primary 
keratinocyte migration at 24 hours and proceeded to promote migration until 72 hours, 
although, complete closure was only observed in LC-CM24 treated cells (Figure 4.9). 
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Figure 4.9 Migration of primary keratinocytes treated with LC-CM in hypoxic conditions. 
Representative images of scratched monolayers of primary keratinocytes treated with LC-CM for 72 
hours in hypoxic conditions (37°C, 5%CO2, ≈1% O2). (A) LC-CM24. (B) LC-CM48. (C) LC-CM72. (D) 
LC-CTRL (control). All LC-CM enhanced cell migration compared to the control and only LC-CM24 
caused full closure at the end of the assay. Cells used at passage (3). Scale bar= 50µm. 
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LC-CM24 showed a significant effect on cell migration at 24 hours (P<0.05) which 
increased with time (P<0.001) till 72 hours compared to the control. Both LC-CM48 and 
LC-CM72 had no significant effect on cell migration during the entire treatment time 
(P>0.05) compared to the control. At the end of the assay (72 hours) LC-CM24 showed a 
significant effect compared to LC-CM48 and LC-CM72 (P<0.01) (Figure 4.10). 
 
Figure 4.10 Kinetics of the effect of LC-CM on migration of primary keratinocytes in hypoxic 
conditions. 
Effect of MSC-CM (LC-CM24: Blue columns, LC-CM48: Red columns and LC-CM72: Green columns) 
Only LC-CM24 reduced scratch area with time and the effect started at 24 hours (P<0.01) which increased 
with time (P<0.001) compared to the LC-CTRL (Purple columns). Scratch areas treated with both LC-
CM48 and LC-CM72 showed no progress in wound closure by the end of the assay (P>0.05) compared 
to the LC-CTRL. Cells used at passage 3, Data presented as the mean of scratch areas (N=4), Error 
bars= standard error of the mean (SEM). (*=P<0.05), (**=P<0.01), (****=P<0.0001).  
4.3.2.5 EFFECT OF MSC-CM ON MIGRATION OF PRIMARY KERATINOCYTES DURING BLOCKING 
SDF-1Α RECEPTOR (CXCR4)  
SDF-1α is a well-known chemokine that enhances cell mobility during many physiological 
processes (Cherla and Ganju, 2001; Arenzana-Seisdedos, 2015). The effect of MSC-CM 
on migration of primary keratinocytes was examined during SDF-1α blocking. A 
concentration of 0.02 µg/ml of SDF-1α antibody (MAB310-500) was added to the cell 
monolayer 30 minutes prior to the initiation of the scratch assay to block SDF-1α receptor 
(CXCR4). Cells were then scratched and treated with the following substances; LC-CM24, 
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LC-CM72, SDF-1α recombinant human protein (rSDF-1α) and a mixture of rSDF-1α with 
MSC-CM (rSDF-1α-CM) (1:1 v/v) and LC-CTRL (MCDB media). Concurrently, the same 
experiment was set up without blocking SDF-1α i.e. without addition of antibody (MAB310-
500 to the cell monolayer to compare results of blocking (BC) and non-blocking conditions 
(NBC). 
Under NBC, results revealed that LC-CM24 closed the scratched area after 16 hours 
(Figure 4.11 A). LC-CM72 accelerated the migration of primary keratinocytes closing the 
scratch area completely by 48 hours (Figure 4.11 B) while rSDF-1α-CM closed the gap at 
72 hours compared to the control (Figure 4.11 C). Cells treated with rSDF-1α alone 
migrated at 24 hours with increasing migration with time compared to the control, however, 
cells failed to close the scratch area completely at 72 hours (Figure 4.11 D). 
 0 Hours 16 Hours 48 Hours 72 Hours 
(A) 
    
LC
-C
M
24 
     
(B) 
    
LC
-C
M
72 
     
(C) 
    
M
IX
 (rS
D
F
-1α
-C
M
) 
     
 
 
 
Chapter 4                                                                                  Effect of MSC-CM on Migration of Skin Cells 
 
158 
 
(D) 
    
rS
D
F
-1α
 
     
(E) 
    
LC
-C
T
R
L 
Figure 4.11 Migration of primary keratinocytes treated with LC-CM during SDF-1α non-blocking 
conditions. 
Representative images of primary keratinocytes treated with different substances during wound healing 
assay to set SDF-1α blocking experiment. (A) LC-CM24 closed the scratch area completely at 16 
hours. (B) LC-CM72 closed the scratch area completely at 48 hours. (C) rSDF-1α-CM closed the scratch 
area completely at 48 hours. (D) rSDF-1α started migration at 26 hours; however, failed to close the 
scratch area completely at 72 hours. (E) LC-CTRL showed no observed migration. Cells used at 
passage 3. Error bar=50 µm.   
Two way ANOVA demonstrated that all tested substances showed significant effect on 
wound closure at 72 hours (P<0.0001). However, LC-CM24 was the most effective since 
it caused an effect at 16 hours (P<0.0001), followed by rSDF-1α (P<0.01), rSDF-1α-CM 
(p<0.05) and then LC-CM72 (P<0.001) at 20 hours compared to the control (Figure 4.12). 
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Figure 4.12 Kinetics of the effect of LC-CM on migration of primary keratinocytes during non-
blocking of SDF-1α. 
Scratched keratinocytes treated with different substances; LC-CM24: blue columns started the effect at 
16 hours (P<0.0001). LC-CM72: red columns started the effect at 20 hours (P<0.001). rSDF-1α: purple 
columns started the effect at 16 hours (P<0.01) A mixture of rSDF-1α-CM: orange columns started the 
effect at 16 hours (P<0.05) compared to the LC-CTRL: green columns. Cells used at passage 3, Data 
presented as mean of scratch areas (N=4), Error bars= standard error of the mean (SEM), (*=P<0.05), 
(**=P<0.01), (***=P<0.0001), (****=P<0.0001). 
 
Under blocking conditions (BC), LC-CM and rSDF-1α-CM accelerated migration of 
primary keratinocyte and closed the scratch gap at 48 hours compared to controls. While 
rSDF-1α failed to enhance cell migration with time and cell mobility was arrested leaving 
a scratch gap during the whole treatment time compared to the control (Figure 4.13). 
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Figure 4.13 Migration of primary keratinocytes treated with LC-CM during SDF-1α blocking. 
Representative images of primary keratinocytes treated with SDF-1α antibody to block CXCR4 then 
scratched and treated with different substances. (A) LC-CM24 closed the scratch area completely at 48 
hours. (B) LC-CM72 closed the scratch area completely at 48 hours. (C) rSDF-1α-CM closed the scratch 
area completely at 48 hours. (D) rSDF-1α failed to close the scratch area completely at 72 hours. (E) 
LC-CTRL showed no observed migration. Cells used at passage 3, Scale bar=50 µm. 
Chapter 4                                                                                  Effect of MSC-CM on Migration of Skin Cells 
 
161 
 
Two way ANOVA showed that LC-CM24 caused an effect after 16 hours of treatment 
compared to the control (P<0.5) with increased effect with time until complete closure at 
48 hours (P<0.0001). Again LC-CM72 started the effect at 20 hours (P<0.5) with complete 
closure at 48 hours (P<0.0001) compared to the control. The rSDF-1α-CM combination 
caused an effect after 24 hours of treatment (P<0.5) with complete closure at 48 hours 
(P<0.0001) in comparison to the control. Interestingly, rSDF-1α failed to enhance 
migration of primary keratinocytes during the entire treatment time and cells failed to 
migrate and close the scratch gap at the end of treatment (P>0.05) as explained in (Figure 
4.14). 
 
Figure 4.14 Kinetics of the effect of LC-CM on migration of primary keratinocytes during blocking 
SDF-1α. 
Scratched keratinocytes treated with SDF-1α antibody to block CXCR4 then treated with different 
substances; LC-CM24: blue columns, LC-CM72: red columns, rSDF-1α: purple columns, A mixture of 
rSDF-1α-CM: orange columns and LC-CTRL: green columns. Cells used at passage 3, Data presented 
as mean of scratch areas (N=4), Error bars= standard error of the mean (SEM). (*=P<0.05), (**=P<0.01), 
(***=P<0.0001), (****=P<0.0001). 
The effect of each tested substance was compared under blocking and non-blocking 
conditions (BC and NBC). No significant variations were observed between the effects of 
LC-CM24, LC-CM72 and rSDF-1α-CM under BC and NBC (P>0.05) at the end of the 
assay (72 hours) (Figure 4.15 A, B and C) respectively. The effect of rSDF-1α was 
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significantly stronger under NBC than under BC (P<0.05) at 16 hours and (P<0.0001) 72 
hours (Figure 4.15 D). 
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Figure 4.15 Kinetics the effects of different substances on migration of primary keratinocytes 
during blocking and non-blocking of SDF-1α. 
A statistical comparison revealed that LC-CM24 (A), LC-CM72 (B) and rSDF1α-CM (C) equally reduced 
the scratch area under both BC (Black columns) and NBC (Gray columns) with time (P>0.05). (D) rSDF-
1α reduced the scratch area under NBC only (P<0.05) at 16 hours and (P<0.0001) at 72 hours and failed 
to reduce scratch area under BC. Cells used at passage 3, Data presented as mean of scratch areas 
(N=4), Error bars= standard error of the mean (SEM). (*=P<0.05), (**=P<0.01), (***=P<0.0001), 
(****=P<0.0001). 
4.3.2.6 EFFECT OF MSC-CM ON MIGRATION OF PRIMARY FIBROBLASTS 
MSC-CM (HC-CM24, HC-CM48 and HC-CM72) accelerated migration of primary 
fibroblasts with time. As explained in (Figure 4.16), all HC-CM enhanced migration of the 
fibroblasts by 16 hours and closed the scratch area completely at the end of the 
experiment (72 hours) compared to the control cells treated with HC-CTRL (DMEM-FCS 
media). 
 
 
 
 
 
 
 
 
 
Chapter 4                                                                                  Effect of MSC-CM on Migration of Skin Cells 
 
164 
 
  0 Hours 16 Hours 32 Hours 66 Hours 
(A) 
    
H
C
-C
M
24 
     
(B) 
    
H
C
-C
M
48 
     
(C) 
    
H
C
-C
M
72 
     
(D) 
    
H
C
-C
T
R
L 
Figure 4.16 Migration of primary dermal fibroblasts after treatment with HC-CM. 
Representative images of fibroblast migration during scratch closure after treatment with HC-CM for 
66 hours. (A) HC-CM24 caused cell migration at 16 hours and the scratch area completely closed at 
66 hours. (B) HC-CM48 caused cell migration at 16 hours and the scratch area completely closed at 
32 hours. (C) HC-CM72 caused cell migration at 16 hours and the scratch area completely closed at 
72 hours. (D) HC-CTRL caused cell migration at 32 and 66 hours without complete closure. Cells 
used at passages 4 and 5. Scale bar=50 µm. 
Two way NOVA showed that HC-CM24 enhanced migration by 32 hours (P<0.05) with 
increasing effect with time until complete closure of the scratch gap at 48 hours (P<0.01). 
HC-CM48 enhanced migration earlier than other HC-CM and significantly enhanced cell 
migration at 16 hours (P<0.01) with increasing effect until full closure of the gap after 32 
hours (P<0.001). HC-CM72 enhanced migration at 24 hours (P<0.05) with increasing 
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effect with time until complete closure at 48 hours (P<0.001) compared to the control 
(Figure 4.17).    
 
Figure 4.17 Kinetics of the effect of HC-CM on migration of primary fibroblasts. 
Scratched fibroblasts treated with HC-CM24: blue column, HC-CM48: red columns HC-CM72: green 
column and DMEM as a control (HC-CTRL): purple columns. Cells used at passage 4 and 5, Data 
presented as mean of scratch areas (N=4), Error bars= standard error of the mean (SEM), (*=P<0.05), 
(***=P<0.001). 
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4.4 DISCUSSION 
Migration, of keratinocytes and fibroblasts are important mechanisms for cutaneous 
wound healing. It is well known that MSCs and their secretions could be used as 
therapeutic options in the healing process. Some studies have previously shown that 
MSC-CM possess positive effect on migration of keratinocyte cell line (HaCat) during 
wound closure (Walter et al., 2010). The same results were obtained in the current study 
during the optimisation of the scratch assay. The use of cell lines in research has 
disadvantages since immortalised cells are highly proliferative with differences in their 
morphology and genetics compared to primary tissue. In contrast, primary cells maintain 
original phenotypic markers and functions as well as possess normal morphology (Alge 
et al., 2006; Pan et al., 2009). Scientists are therefore cautious when interpreting results 
obtained from experiments carried out on cell lines (Alston-Roberts et al., 2010; Lorsch et 
al., 2014). The use of primary epidermal keratinocytes are a more realistic approach to 
study the healing process and are more representative for use in skin wound healing 
studies than the use of cell lines. The highly proliferative of HaCat cell line could 
significantly affect the results of assays that depend on the proliferation rate such as the 
migration assay and proliferation assays. In addition, to date, there is no satisfactory 
study, which has investigated the effect of MSC-CM on primary keratinocytes. All previous 
studies have collected MSC secretions in serum free media (DMEM-based formula) to 
avoid any interference due to serum constituents. The use of MSC secretions collected in 
serum free DMEM is still unsatisfactory and inapplicable for primary keratinocyte wound 
healing studies due to the high calcium levels (1.8 mM/L) present in this type of media. It 
is well established that calcium is a key regulator for keratinocyte differentiation both in 
vitro and in vivo. It is involved in many internal and external signalling pathways that 
enhance successive differentiation in the epidermal keratinocyte to form the different 
layers of the epidermis including the permeable barrier of the stratum corneum (Bikle et 
al., 1996; Bikle et al., 2012). On the other hand, keratinocytes can grow rapidly as 
monolayers and proliferate without differentiation in low calcium concentrations (0.05 – 
0.1 mM/L), whereas calcium concentration higher than 0.1 mM enhances keratinocyte 
differentiation (Hennings et al., 1980). Therefore, DMEM contains calcium levels which 
enhance cell differentiation and thereby arrest their migration and proliferation. Arrested 
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migration of primary keratinocytes treated with HC-CM could be therefore interpreted by 
the effect of high calcium levels in the media. The high calcium concentrations could 
interfere with the effect of growth factors present in MSC-CM, due to its high permeability 
through the cell membrane and its involvement in the vast majority of intrinsic and extrinsic 
signalling pathways. This explanation due to the high calcium permeability through cell 
membrane could be supported by the results of (Bikle et al., 2012). They reported that 
keratinocytes responded to calcium acutely due to the presence of the GTP-binding 
protein receptor, a group of seven transmembrane proteins which spread on cell 
membrane of different tissues including keratinocytes (Bikle et al., 1996; Oda et al., 1998; 
Tu et al., 2001). Therefore, high calcium levels direct the primary cells to enter a 
differentiation state, where the cells start to change their morphological characteristics 
and became flattened, engage via cell-to-cell tight channels and form tissue-like structures 
which in turn immobilise the cells and inhibit their migration.        
The ability of MSC to grow successfully in low calcium-serum free media for three days 
opened the possibility to collect their secretions in low calcium conditions for further 
applications in wound healing studies using primary keratinocytes. In this research, the 
scratch assay was used to show that primary keratinocyte treated with LC-CM migrated 
to promote void closure more rapidly than primary keratinocytes grown in keratinocyte 
growth medium. In addition, a comparison was made between LC-CM and HC-CM for 
their effect on cell migration. Under the same conditions in the absence of serum, LC-CM 
enhanced primary cells to migrate and completely fill the scratch area compared to HC-
CM. This novel method using low calcium media (LC-Media) to collect MSC secretions 
may provide a useful protocol for collecting growth factors and cytokines that affect 
cutaneous wound healing. Variations in responses of primary keratinocytes to both HC-
CM and LC-CM during the healing process using a 2D scratch assay could be due to the 
high calcium concentrations (1.8 mM/L) contained in HC-CM which is sufficient to enhance 
differentiation of primary keratinocytes. Segrelles and colleagues stated that 
differentiation of primary keratinocytes could be induced by elevating the calcium level to 
(1.2 mM/L) which after 24 hours cause the keratinocytes to become more flattened and 
make contact with each other thereby arresting their migration. Hence, LC-CM and HC-
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CM differed in their effect on cell migration depending on the calcium level (Segrelles et 
al., 2011)  
The response of primary keratinocytes to close wounds under low calcium levels could 
also include alterations in gene expression involved in cell matrix interaction (Walter et al., 
2010). Results obtained in the current study showed that MSC secretions (MSC-CM) 
collected in serum free and low calcium conditions significantly promoted primary 
keratinocyte migration to close the scratched area under normal oxygen levels compared 
to the control. This is therefore a strong evidence in support of the use of MSCs as a 
therapeutic strategy for cutaneous wound healing. 
Oxygen levels play a vital role during the healing process and are essential for oxidation, 
phosphorylation, signalling pathways and enzymatic reactions (Yan et al., 2017). Oxygen 
is also a key regulator and pivotal requirement for several physiological events during the 
repair process such as angiogenesis, re-epithelisation, collagen deposition, fibroplasia 
and even infection resistance (Castilla et al., 2012). During cell migration under hypoxic 
conditions, positive effect was observed with LC-CM24 whereas neither LC-CM48 nor LC-
MC72 showed a positive effect during the entire treatment time. It has been reported that 
hypoxic conditions promote keratinocyte migration during wound closure (Benizri et al., 
2008). However, hypoxic conditions enhance the production of hypoxia inducible factor 
(HIF) which arrests cell proliferation at G1-phase of cell cycle (Cho et al., 2008; Straseski 
et al., 2009). Therefore, the positive effect of hypoxia on cell migration could be simply 
illustrated by the fact that tissue deprivation of oxygen stop many cellular actions such as 
proliferation and differentiation (Benizri et al., 2008; Yan et al., 2017). On the other hand, 
hypoxic conditions suppress keratinocyte proliferation via miR-210 and impair wound 
closure (Biswas et al., 2010). Failure of LC-CM48 and LC-CM72 to enhance cell migration 
could be simply interpreted by the fact that hypoxia enhanced cell migration to some 
extent in the control cells; subsequently, the effect of LC-CM48 and LC-CM72 was non-
significant (Darby et al., 2014). In another words, the closure rate of the migrating cells by 
the effect of LC-CM48 and LC-CM72 equalled to the closure rate of the migrating cells by 
the effect of hypoxia. While the significant positive effect of LC-CM24 could be attributed 
to the fact that the biomolecules present in this media contained secretions collected 
earlier than LCCM48 and LCCM72 when MSCs were still active and before prolonged 
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stress conditions, such as low calcium and serum free conditions at 48 and 72 hours 
prevailed. It has been well documented that deprivation of tissue from adequate oxygen 
will hinder the healing outcomes (Castilla et al., 2012). In addition, only tissue under mild 
or moderate hypoxia could survive while those experiencing severe or chronic hypoxia 
are unable to survive (Sen, 2009). Yan and colleagues (Yan et al., 2017) showed that 
hypoxia enhances motility and migration of keratinocytes but not proliferation and 
differentiation within 24 hours but did not explain the overall outcome of the healing 
process after prolonged hypoxic conditions i.e. 72 hours. Modarressi and others reported 
that mild hypoxia enhances the healing process while the chronic hypoxia delay it. They 
reported that hypoxia is initiated due to the disruption of vascular perfusion by injury and 
induces growth factors that promote the healing process such as vascular endothelial 
growth factor (VEGF) (Modarressi et al., 2010). Therefore, within the first 24 hours of the 
healing process, hypoxia plays a key role in the healing process. However, in chronic 
wounds, hypoxia reduces the synthesis of collagen and impairs differentiation and 
function of the myofibroblasts (Darby et al., 2014). Migrating keratinocytes present in the 
wound site therefore represent hypoxia-induced migrating cells when the hypoxic 
condition is still mild or moderate enable the cells to adapt and produce HIF and promote 
their migration. In another words, in a hypoxic microenvironment cell migration within the 
first 24 hours or early phases could be mainly attributed to moderate levels of hypoxia 
when the level of hypoxia still moderate. Later during a prolonged healing process, the 
hypoxic conditions become more detrimental to the cells and stop all cellular activities 
including cell motility rather than inducing migration inducer. Hence, the continuous 
consistent positive effect of LC-CM24 on keratinocyte migration in hypoxic conditions after 
24 hours of treatment could be mainly attributed to the active biomolecules of LC-CM24. 
Additionally, when cells continue migrate after 24 hours, these cells had survived the 
hypoxic conditions and retained their physiological activity.    
When SDF-1α was blocked, LC-CM24, LC-CM72 and rSDF-1α-CM retained their ability 
to enhance cell migration and resulted in full scratch closure at 72 hours while rSDF-1α 
treated cells failed to migrate within the time and a gap still remained at the end of the 
assay at 72 hours. These data suggest that LC-CM enhance cell migration with and 
without the action of SDF-1α. This could be clarified by the hypothesis that LC-CM contain 
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a wide spectrum of growth factors and cytokines in addition to SDF-1α. These 
biomolecules work separately of collectively to enhance cell migration during the healing 
process (Tamama and Kerpedjieva, 2012). 
Fibroblast migration is a key requirement for formation of granulation tissue and further 
dermal wound healing. Since fibroblasts grow in high calcium levels, HC-CM was used to 
enhance their migration. Schreier and colleagues reported that participation of fibroblasts 
in wound repair could be attributed to the action of growth factors such as PDGF and TGF-
β that attract fibroblasts and accumulate them at the wound edges within the first 24 hours 
post wounding. They produce the first set of matrix proteins which fill the gap with 
granulation tissue (Schreier et al., 1993). Therefore, in the case of a deficiency in growth 
factors at the injury site, MSC secretions would play an important role in attracting 
fibroblasts towards the wound. 
The effect of different MSC-CMs (LC-CM24, LC-48 and LC-CM72) on cell migration were 
compared under different conditions such as normoxia, hypoxia and SDF-1α blocking. 
Notably, LC-CM24, LC-CM48 and LC-CM72 promoted keratinocyte migration with time 
under normal oxygen levels (≈ 20% O2) and the effects were all initiated at 16 hours 
(P<0.01) and resulted in almost full closure. Under hypoxic conditions (≈1% O2), only LC-
CM24 showed positive effect starting at 24 hours (P<0.05) and resulted in full closure at 
the termination of the experiment, whereas LC-CM48 and LC-CM72 failed to enhance cell 
migration and resulted in non-closed closure at the end of the assay. Under BC, LC-CM24 
initiated the effect at 16 hours (P<0.05) while LC-CM72 initiated the effect after 20 hours. 
Overall, LC-CM24 always initiated cell migration earlier than LC-CM48 and LC-CM72. 
Therefore, CM24 appeared the most effective and consistent type of conditioned media 
to enhance migration of different cell types under different conditions. Collectively, 
migration of skin cells (keratinocyte and fibroblast) were enhanced by the action of MSC-
CM. As explained in Chapter 3, a number of growth factors and cytokines were secreted 
in MSC-CM under serum free conditions containing both low and high calcium levels. 
Many factors collected from the MSC cultures are known to enhance the healing process. 
In particular, KGF promotes wound closure (Barrientos et al., 2008a; Chen et al., 2008) 
by being a transporter for alveolar epithelial fluid (Wang et al., 2012c) and by being 
involved in tissue remodelling (Maxson et al., 2012). Also, HGF which is referred to as 
Chapter 4                                                                                  Effect of MSC-CM on Migration of Skin Cells 
 
171 
 
plasminogen-related growth factor-1 (PRGF-1) and scatter factor (SF) as a powerful 
mitogen for hepatocytes and a stimulator for epithelial cell dissociation (Werner and 
Grose, 2003). Additionally, it enhances keratinocytes to migrate, proliferate and produce 
matrix metalloproteinases; as well as, stimulating new blood vessel formation. It has 
therefore been suggested to play a role in cutaneous wound repair (van de Kamp et al., 
2013). Moreover, it has widely been suggested that PDGF is the major player in treating 
non healing wound and wound disorders especially human ulcers (Werner and Grose, 
2003). This view has been attributed to the main roles played by this growth factor. 
According to Maxson and colleagues, PDGF was first chemotactic growth factor described 
to be involved in the migration of fibroblasts, monocytes, and neutrophils into the skin 
wound. In addition, it stimulates these cells to produce the extracellular matrix and induces 
the myofibroblast phenotype in these cells. Additionally, it enhances fibroblasts to 
proliferate and contract collagen matrices. Finally, it promotes proliferation (Maxson et al., 
2012). As per Werner and Grose, SDF-1α is suggested to play a role in regulating skin 
homeostasis and tissue remodelling (Werner and Grose, 2003). It also promotes wound 
closure (Barrientos et al., 2008a; Chen et al., 2008) by inducing cell migration especially 
MSC migration (Patel et al., 2013). Like HGF, MSP also known by other names such as 
scatter factor-2 (SF-2) and hepatocyte growth factor like protein (HGFL) since it is derived 
from liver serum. It regulates the proliferation and differentiation of different cells including 
keratinocytes and macrophages (Werner and Grose, 2003). Finally, secretions of MSCs 
collected at low calcium conditions (LC-CM) enhanced migration of primary keratinocyte 
while HC-CM failed to enhance cell migration. The results showed that LC-CM is better 
for wound healing studies than HC-CM since the later activates cell differentiation, which 
in turn arrests cell proliferation and migration. Consequently, HC-CM gives false negative 
results when the target cells are primary keratinocytes. Results here showed that the use 
of LC-CM overcomes the false negative problem caused by using inappropriate HC-CM 
and generates results which are a true reflection of the in vivo healing process. However, 
more investigations are required to verify whether cell migration is the only the mechanism 
enhanced by MSC-CM during the healing process or whether other cellular responses 
can be evoked as well by MSC-CM such as cell proliferation and differentiation. 
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In summary, a new method was developed for skin wound healing studies based on MSC 
secretions collected under low calcium conditions (LC-CM) which was more suitable for 
studying skin wound healing using a 2D scratch assay under serum free conditions. 
Findings from this study indicate that biomolecules collected during early MSC expansion 
could be more effective than those collected at later time points. Moreover, a number of 
growth factors and cytokines secreted by MSCs were shown to participate in the wound 
healing process. These findings provide a new way to develop in vitro studies in order to 
analyse the effect of MSC secretions on the migration of primary keratinocyte skin wound 
healing studies. In the next chapter (Chapter 5), the effect of MSC-CM on the proliferation 
of skin cells during the scratch assay will studied.
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CHAPTER FIVE: EFFECT OF MSC-CM ON PROLIFERATION OF SKIN CELLS 
5.1  INTRODUCTION 
Cell proliferation is another key step in wound healing which is defined as a duplication of 
cell number balancing the number of dividing cells and the number of lost cells by death 
or differentiation (Reinke and Sorg, 2012). In intact skin, keratinocytes of the basal layer 
represent the infrastructure of epidermis since they proliferate and migrate towards the 
skin surface crossing the spinous, granular and stratum corneum (Pastar et al., 2014). 
During the healing process, keratinocytes migrate to cover the wounded site, proliferate, 
move upwards and differentiate to form spinous, granular and stratum corneum epidermal 
layers (Werner and Grose, 2003; Morasso and Tomic-Canic, 2005). They therefore 
reconstitute full thickness skin and retain tissue integrity (Santoro and Gaudino, 2005). 
Cell proliferation can be measured by one of four main methods; DNA synthesis cell 
proliferation assays (Bick and Davidson, 1974; Gratzner, 1982), metabolic cell 
proliferation assays (colorimetric methods) (Mosmann, 1983; Berridge et al., 2005; Quent 
et al., 2010), detection of proliferation markers (Mokry and Nemecek, 1995) and 
measurement of adenosine triphosphate (ATP) (Lundin et al., 1986; Stanley, 1986; 
Crouch et al., 1993). Determination of metabolic activity for a population of cells is one of 
the most popular methods to measure cell viability. MTS (3-(4,5-dimethylthiazol-2-yl)-5-
(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium is one of the most common 
substances used in this method  which, upon reduction by metabolically active cells, 
produce a coloured compound called formazan, which subsequently changes the media 
colour depending on the density of active cells (Mosmann, 1983; Berridge et al., 2005). 
Compared to other substances, MTS requires no additional steps or additives such as 
DMSO or isopropanol, and is completely reduced by metabolically active cells and for 
these reasons it was chosen to detect cell viability in this study. Mitomycin C MMC is an 
anti-proliferative substance, which cross-links to DNA and inhibits cell proliferation via 
many mechanisms. MMC reacts with cytosine and guanine when one phosphate group 
separates them (5'—C—phosphate—G—3') (CpG) site in a DNA sequence. It exerts its 
mode of action in a concentration dependant manner resulting in varying effects between 
proliferation inhibition and arrest of the cell cycle at S and G2/M phase to cell death via 
induction of apoptosis (Tomasz, 1995; Kang et al., 2001; Kersey and Vivian, 2008) and is 
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used in cancer chemotherapy (Tomasz, 1995). Collectively, proliferation of skin cells 
during wound healing is a critical and important repair mechanism in the healing process 
(Qing, 2017). Therefore, studying the effect of MSC-CM on proliferation of skin cells and 
monitoring cell behaviour through these events is very important and critical to the 
understanding of the cellular mechanisms occurring during the healing process.  
5.2  SPECIFIC AIMS OF CHAPTER FIVE 
1. To assess the effect of stock and diluted MSC-CM on proliferation of skin cells 
(keratinocytes and fibroblasts). 
2. To compare the effect of high calcium conditioned media (HC-CM) and low calcium 
conditioned media (LC-CM) on proliferation of primary keratinocytes. 
3. To determine the effect of MSC-CM on the migration of primary keratinocytes during 
inhibition of proliferation. 
4. To determine whether migration or proliferation is the first initiation event in the MSC-
CM on the healing process. 
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5.3 RESULTS 
5.3.1 EFFECT OF MSC-CM ON PROLIFERATION OF SKIN CELLS 
MTS proliferation assay was used to detect the effect of MSC-CM on proliferation of skin 
cells (primary keratinocytes and primary fibroblasts). The HaCat cell line was used to 
optimise the assay. Both HC-CM and LC-CM were tested for their effect on proliferation 
of primary keratinocytes. Primary fibroblasts were treated with HC-CM only. 
 OPTIMISATION OF MTS PROLIFERATION ASSAY USING THE HACAT CELL LINE 
HaCat cells were seeded at a density of 0.01×106 cells per well in 96 well plates and 
incubated under standard culture conditions (SCC) (humidified incubator, 37°C and 5 % 
CO2) for 4 hours to allow cell adhesion. The culture media was then discarded and the 
cells were washed twice in PBS followed by addition of MSC-CM (HC-CM24, HC-CM48 
and HC-CM72) to the corresponding wells. DMEM supplemented with 10% foetal calf 
serum (DMEM-FCS) was used as a control (HC-CTRL). Cell viability was estimated after 
different time points (0, 24, 48 72 and 96 hours) by treating cells with 20 µl MTS salt for 3 
hours followed by reading the absorbance of the developed colour at 492 nm using a 
micro-plate reader. Results showed that HaCat cells could proliferate normally in MSC-
CM collected at different time points when compared to the control. 
Statistically, viability of HaCat cells treated with MSC-CM significantly increased during 
time. For example, after 24 hours cell viability increased in comparison to cell viability at 
time zero (P<0.0001) for the three MSC-CM and there was no significant differences in 
comparison to the control tested at the same time points. Again at the end of the 
experiment (72) hours, viability of the cells treated with MSC-CM was higher than the cell 
viability at 24 hours (P<0.05, P<0.001 and P<0.05) for CM24, CM48 and CM72 
respectively indicating that the cells were continuing to proliferate during this time. On the 
other hand, there was no significant variation between cell viability of cells treated with 
MSC-CM and the control at the end of the treatment time (72 hours) (P>0.05) as shown 
in (Figure 5.1).        
Chapter 5                                                                              Effect of MSC-CM on Proliferation of Skin Cells 
177 
 
 
Figure 5.1 Statistical analysis of the effect of MSC-CM on proliferation of HaCat cells using MTS 
assay.  
Different line colours represent cell viability of HaCat cell line treated with the different types of MSC-CM 
in addition to the control at different time points (0, 24, 48 and 72 hours). The blue line represents the mean 
of optical density of viable HaCat cells treated with HC-CM24. The red line represents the mean of optical 
density of viable HaCat cells treated with HC-CM48. The green line represents the mean of optical density 
of viable HaCat cells treated with HC-CM72. The purple line represents the mean of optical density of 
viable HaCat cell control treated with DMEM-FCS (HC-CTRL). Data presented as mean of optical density 
(N=4 technical replicates). Error bars= Standard error of the mean (SEM), (*=P<0.05). Cell viability was 
measured at 450 nm.  
 EFFECT OF MSC-CM ON PROLIFERATION OF PRIMARY KERATINOCYTES 
Primary keratinocytes were treated with high calcium conditioned media (HC-CM) and 
incubated for 96 hours. As demonstrated in (Figure 5.2) all HC-CM (HC-CM24, HC-CM48 
and HC-CM72) arrested the proliferation of primary keratinocytes. There was no 
significant variation in cell viability at time zero compared with cell viability at 96 hours 
(P>0.5). Interestingly, the viability of control cells, which were treated with DMEM-FCS 
was arrested as well due to the high calcium level (1.8 mM/L) present in the DMEM media. 
For example, there was no significant variation in cell viability at 48 hours compared with 
the cell viability at time zero (P>0.05). However, after 72 hours and 96 hours, cell viability 
of the control slightly increased in comparison to the viability at time zero (P<0.05). 
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Figure 5.2 Statistical analysis of the effect of high calcium-conditioned media (HC-CM) on 
proliferation of primary keratinocytes using MTS assay. 
Different line colours represent cell viability of primary keratinocytes treated with the different types of 
HC-CM in addition to the control (HC-CTRL) at different time points (0, 24, 48, 72 and 96 hours). The 
blue line represents the mean of the optical density of viable primary keratinocytes treated with HC-
CM24. The red line represents the mean of the optical density of viable primary keratinocytes treated 
with HC-CM48. The green line represents the mean of the optical density of viable primary keratinocytes 
treated with HC-CM72. The purple line represents the mean of the optical density of viable primary 
keratinocytes control treated with high calcium media (DMEM-FCS) (HC-CTRL). Data presented as 
mean of optical density (N=4). Error bars= Standard error of the mean (SEM). Cell viability was 
measured at 450 nm.  
On the other hand, the same experiment repeated using low calcium conditioned media 
(LC-CM) showed that all LC-CM (LC-CM24, LC-CM48 and LC-CM72) had a negative 
effect on proliferation of primary keratinocytes (Figure 5.3). For example, after 48 hours 
there was no significant increase in cell viability compared to the viability at time zero 
(P>0.05). However, after 72 hours cells treated with MSC-CM started to proliferate 
significantly (P<0.0001, P<0.01 and P<0.05) for (LC-CM24, LC-CM48 and LC-CM72) 
respectively compared to the viability at time zero. Cells also retained their ability to 
proliferate until the end of the assay (96 hours) when cell viability significantly increased 
compared to cell viability at 48 hours (P<0.0001). The control cells (low calcium 
concentration treated= 0.04 mM/L) significantly proliferated (P<0.0001) during the entire 
treatment time (96 hours) compared to cell viability at 48 hours. 
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Figure 5.3 Statistical analysis of the effect of low calcium-conditioned media (LC-CM) on 
proliferation of primary keratinocytes using MTS assay. 
Different line colours represent cell viability of primary keratinocytes treated with the different types of 
LC-CM in addition to the control (LC-CTRL) at different time points (0, 24, 48, 72 and 96 hours). The 
blue line represents the optical density of viable primary keratinocytes treated with LC-CM24. The red 
line represents the optical density of viable primary keratinocytes treated with LC-CM48. The green line 
represents the optical density of viable primary keratinocytes treated with LC-CM72. The purple line 
represents the optical density of viable primary keratinocytes control (LC-CTRL). Data presented as 
mean of optical density of viable cells (N=4). Error bars= standard error of the mean (SEM). Cell viability 
was measured at 450 nm.  
LC-CM and HC-CM were compared at different paired time points (LC-CM24 vs HC-
CM24, LC-CM48 vs HC-CM48 and LC-CM72 vs HC-CM72). Results showed that LC-CM 
was more effective at inducing cell proliferation. As shown in (Figure 5.4 A), after 72 hours, 
cells treated with LC-CM24 proliferated to a greater extent than those treated with HC-
CM24 (P<0.05) with increased significant viability at 96 hours (P<0.001). The increase in 
cell proliferation between cells treated with LC-CM48 and HC-CM48 was also observed 
at 96 hours (P<0.01) (Figure 5.4 B). The same was observed for LC-CM72 versus HC-
CM72 with no significant difference in cell viability at 72 hours (P>0.5) until 96 hours 
(P<0.01) (Figure 5.4 C). 
These data collectively suggest that primary keratinocytes proliferate normally during 
treatment with LC-CM. In contrast, cell proliferation was arrested with HC-CM compared 
to the controls. 
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Figure 5.4 Comparison between the effect of LC-CM and HC-CM on proliferation of primary 
keratinocytes using MTS assay. 
Cell viability of primary keratinocytes treated with LC-CM and HC-CM at different time points (0, 24, 48, 
72 and 96 hours). (A) The blue line is the optical density of viable primary keratinocytes treated with 
HC-CM24, while the red line is the optical density of viable primary keratinocytes treated with LC-CM24. 
(B) The blue line is the optical density of viable primary keratinocytes treated with HC-CM48 and the 
red line is the optical density of viable primary keratinocytes treated with LC-CM48. (C) The blue line is 
the optical density of viable primary keratinocytes treated with HC-CM72 and the red line is the optical 
density of viable primary keratinocytes treated with LC-CM72. Data presented as mean of optical 
density of viable cells (N=4), Error bar= standard error of the mean (SEM), (*=P<0.05), (***=P<0.001), 
Cell viability was measured at 450 nm.  
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Both HC-CM and LC-CM arrested proliferation of keratinocytes until 48 hours. The 
negative effect of HC-CM continued until the termination of the assay at 96 hours. 
However, LC-CM enhanced cell proliferation post 48 hours and the positive effect 
increased until the end of the assay. The reason for the lack of proliferation with HC-CM 
could be attributed to the high calcium level, which enhances cell differentiation rather 
than cell proliferation. More investigations were required to decipher the main role of MSC-
CM on the behaviour of the primary keratinocytes at the injury site. One of these 
investigations is the detection of proliferation markers during cell migration in the presence 
and absence of MMC. 
 EFFECT OF MSC-CM (MSC-CM) ON PROLIFERATION OF PRIMARY FIBROBLASTS 
Primary fibroblasts were treated with HC-CM because they were grown in DMEM 
containing calcium at a high concentration (1.8 Mm/L). Results in (Figure 5.5) showed that 
primary fibroblasts proliferated in MSC-CM. HC-CM24, HC-CM48 and HC-CM72 and 
demonstrated a positive effect on fibroblast proliferation at 24 hours (P<0.05) which 
increased at 48 and 72 hours (P<0.01) compared to time zero. The viability of the control 
cells significantly increased with time (24, 48 and 72 hours (P<0.0001) in comparison to 
the viability at time zero. Comparing the MSC-CM to the control showed that there was 
no significant variation (P>0.05) at 48 hours and the proliferation of the control was 
significantly higher than MSC-CM-treated cells at 72 hours (P<0.01).    
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Figure 5.5 Statistical analysis of the effect of MSC-CM (HC-CM) on proliferation of primary 
fibroblasts using MTS assay. 
Different line colours represent cell viability of primary fibroblasts treated with HC-CM in addition to the 
control (HC-CTRL) at different time points (0, 24, 48 and 72 hours). The blue line represents the optical 
density of viable primary fibroblasts treated with HC-CM24. The red line represents the optical density 
of viable primary fibroblasts treated with HC-CM48. The green line represents the optical density of 
viable primary fibroblasts treated with HC-CM72. The purple line represents the optical density of viable 
primary fibroblast control treated with high calcium media (HC-CTRL). Fibroblasts treated with HC-
CM24, HC-CM48 and HC-CM72 significantly proliferated at 72 hours (P<0.001, P<0.01 and P<0.001) 
respectively. Proliferation of control cells was significantly higher than proliferation of MSC-CM treated 
cells (P<0.01) at 72 hours. Data presented as mean of the optical density of viable cells (N=4), Error 
bars= standard error of the mean (SEM), (*=P<0.05), (**=P=0.01), (***=P=0.001), (****P=0.0001), Cell 
viability was measured at 450 nm. 
5.3.2 DETERMINING MIGRATING AND PROLIFERATING CELLS DURING WOUND CLOSURE 
The scratch assay was used to assess if MSC-CM could enhance cell migration rather 
than proliferation during wound closure. Proliferating cells were detected in the scratch 
area post wound closure. Proliferating cells were detected by using the specific 
proliferation marker 5-bromo-2'-deoxyuridine (BrdU). Original nucleosides of the DNA of 
proliferating cells are replaced by these synthetic nucleoside analogues. BrdU is a 
synthetic nucleoside analogue to thymidine and used to detect proliferating cells (Lehner 
et al., 2011). During the S-phase of the cell cycle of replicating cells, BrdU is translocated 
into the newly synthesised DNA  and replaces thymidine during DNA replication (Konishi 
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et al., 2011). Interestingly, BrdU passes to the daughter cells upon replication (Kee et al., 
2002) and can be detected two years post incorporation (Eriksson et al., 1998). Upon 
staining with specific anti-BrdU antibodies, BrdU positive cells can be easily detected 
indicating that these cells are actively replicating their DNA and proliferating normally 
(Konishi et al., 2011).    
 OPTIMISATION: USING HELA CELL LINE AND PRIMARY KERATINOCYTES 
HeLa cells were used as a positive control to optimise the proliferation assay. Briefly, 
0.005×106 cells / well were seeded in DMEM-FCS in an 8-well glass chamber and 
incubated under SCC (37°C in a humidified incubator supplemented with 5% CO2) for 4 
hours to allow cell attachment. Two conditions were used to investigate proliferation. The 
first one was HeLa cells grown in their normal growth media (DMEM supplemented with 
10% FCS, 5% penicillin-streptomycin and 200 mM L-glutamine). The second condition 
was HeLa cells treated with 30 µg/ml mitomycin C (MMC) for three hours to inhibit their 
proliferation. Cells were then incubated with 3 µg/ml of synthetic BrdU nucleoside 
overnight under SCC to allow sufficient time for replacing BrdU with thymidine in the 
replicating cells. Following day, cells were stained with anti-BrdU antibody and then a 
secondary antibody (Donkey Anti-Rabbit IgG H&L (Alexa Fluor® 488) following a standard 
immunofluorescence (IF) staining protocol (See Methods Chapter 2, Section 2.3.9) using 
anti-BrdU antibody to investigate BrdU incorporation. Bioimaging analysis (Figure 5.6 A) 
showed that cells treated with MMC had no increase in cell number after 24 hours with no 
staining with the anti-BrdU antibodies. In contrast, untreated cells (Figure 5.6 B) 
demonstrated an increased cell count after 24 hours with positive staining for BrdU 
antibodies. Continuous DNA replication led to continuous BrdU-thymidine replacement, 
which resulted in an increased number of BrdU positive cells after 24 hours suggesting 
that MMC inhibited the proliferation of HeLa cells. 
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Figure 5.6 Proliferating HeLa cells express the proliferation marker (BrdU). 
Representative immunofluorescence image revealing proliferating and non-proliferating HeLa cells. (A) 
HeLa cells treated with 20 µg/ml MMC for 3 hours at SCC. (B) HeLa cells grown in standard culture 
media for 3 hours at SCC. HeLa cells in (A) and (B) are labelled with BrdU overnight at SCC then stained 
with anti-BrdU antibody (ab152095) at (1:60) in (1% bovine serum albumin (BSA). Green signal in (B) 
revealed binding of anti-BrdU antibody with BrdU of replicating cells and when stained with Donkey Anti-
Rabbit IgG H&L (Alexa Fluor® 488) (ab150073) at (1:250) in (1% bovine serum albumin) gave green 
signal (FITC). MMC treated HeLa cells (A) revealed negative staining for anti-BrdU antibody. Blue= 
DAPI stain (1:1000) in (1% BSA). Scale bar= 100 µm. 
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Upon successful optimisation of the protocol with HeLa cells, the same conditions were 
used to detect proliferation in primary keratinocytes. Since the doubling time of primary 
keratinocytes is longer than that of HeLa cells, keratinocytes were seeded at a density of 
0.03×106 cells/well in an 8-well glass chamber and incubated overnight at SCC to allow 
cell adhesion. On the next day, cell proliferation was inhibited by treating the cells with 20 
µg/ml MMC for 3 hours at SCC. Cells were then treated with 3 µg/ml BrdU. The cells were 
then stained with anti-BrdU antibody and secondary antibody using the standard IF 
staining protocol. Figure 5.7 A and Figure 5.7 B show cells treated with MMC and normal 
untreated keratinocytes respectively. When stained with DAPI after 24 hours of treatment 
with MMC, cells were less dense after staining with anti-BrdU antibody and secondary 
antibody and showed fewer positive signals compared to normal cells.  
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Figure 5.7 Proliferating primary keratinocytes express the proliferation marker (BrdU).  
Representative immunofluorescence image revealing proliferating and non-proliferating primary 
keratinocytes. (A) Primary keratinocytes treated with 20 µg/ml MMC for 3 hours at SCC. (B) Primary 
keratinocytes grown in keratinocyte growth media (KGM) for 3 hours at SCC. Primary keratinocytes in 
(A) and (B) are labelled with BrdU overnight at SCC then stained with anti-BrdU antibody (ab152095) at 
(1:60) in (1% bovine serum albumin (BSA). Green signal in (B) revealed binding of anti-BrdU antibody 
with BrdU of replicating cells and when stained with Donkey Anti-Rabbit IgG H&L (Alexa Fluor® 488) 
(ab150073) at (1:250) in (1% bovine serum albumin) gave a green signal (FITC). MMC treated HeLa cells 
(A) Showed negative staining for anti-BrdU antibody. Blue= DAPI stain (1:1000) in (1% BSA). Scale bar= 
100 µm. 
 DETECTION OF MIGRATING AND PROLIFERATING CELLS DURING WOUND CLOSURE AT 
NORMAL CONDITIONS (NON INHIBITED PROLIFERATION “NIP”) 
Proliferating cells were detected in the scratch area at different time points (24, 48 and 72 
hours) during wound closure after treatment with MSC-CM. Briefly; primary keratinocytes 
(N=3; S1212K, S1214K and S1216K) were seeded at a density of 0.04×106 cells/well in 
an 8-well glass chamber for 24 hours at SCC to allow cell adhesion. On the next day, a 
scratch was made in the confluent monolayer and cells were treated with MSC-CM for 
different time points (24, 48 and 72 hours). 24 hours before the staining, cells were treated 
with 3 µg/ml BrdU followed by standard IF staining with BrdU antibody and secondary 
Donkey Anti-Rabbit IgG H&L (Alexa Fluor® 488) (ab150073). Results are shown in 
(Figure 5.8), (Figure 5.9) and (Figure 5.10) for samples S1212K, S1214K and S1216K 
respectively. Part A of each figure represents cell migration after 24 hours showing cells 
which have moved from the edges of the scratch towards the centre compared to the 
control at time zero. The number of proliferating cells (BrdU positive cells) were less than 
non-proliferating cells (BrdU negative cells) or migrating cells. Part B of each figure 
represents cell migration after 48 hours showing an increase in the cell density in the 
scratch area in comparison to time zero and 24 hours. Migrating cells (BrdU negative 
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cells) were proportionally higher than proliferating cells (BrdU +ve cells). In part C of each 
figure, cell densities of migrating cells (BrdU negative cells) at 72 hours in the scratch area 
were higher than the cell densities of BrdU +ve cells (proliferating cells) at 0, 24 and 48 
hours. These data suggest that MSC-CM mainly enhance cell migration rather than cell 
proliferation in the scratch area during the wound healing process. 
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Figure 5.8 Migrating and proliferating cells during wound closure in sample S1212K. 
Representative immunofluorescence images revealing proliferating and migrating primary 
keratinocytes during wound closure assay for different time points (A) 24 hours, (B) 48 hours and (C) 
72 hours. Confluent monolayer of primary keratinocytes labelled with BrdU overnight at SCC then 
scratched and treated with MSC-CM. Green signal represent Proliferating cells (BrdU positive cells) 
stained with anti-BrdU antibody (ab152095) at (1:60) in (1% bovine serum albumin (BSA). Green 
signal revealed binding of anti-BrdU antibody with BrdU of replicating cells and when stained with 
Donkey Anti-Rabbit IgG H&L (Alexa Fluor® 488) (ab150073) at (1:250) in (1% bovine serum albumin) 
gave green signal (FITC). BrdU negative cells represent migrating cells which mainly stained with 
DAPI. Time zero control cells are DAPI stained. Blue= DAPI stain (1:1000) in (1% BSA). Scale 
bar=100 µm. 
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Figure 5.9 Migrating and proliferating cells during wound closure in sample S1214K. 
Representative immunofluorescence images revealing proliferating and migrating primary keratinocytes 
during wound closure assay for different time points (A) 24 hours, (B) 48 hours and (C) 72 hours. 
Confluent monolayer of primary keratinocytes labelled with BrdU overnight at SCC then scratched and 
treated with MSC-CM. Green signal represent Proliferating cells (BrdU positive cells) stained with anti-
BrdU antibody (ab152095) at (1:60) in (1% bovine serum albumin (BSA). Green signal revealed binding 
of anti-BrdU antibody with BrdU of replicating cells and when stained with Donkey Anti-Rabbit IgG H&L 
(Alexa Fluor® 488) (ab150073) at (1:250) in (1% bovine serum albumin) gave green signal (FITC). BrdU 
negative cells represent migrating cells which mainly stained with DAPI. Time zero control cells are 
DAPI stained. Blue= DAPI stain (1:1000) in (1% BSA). Scale bar=100 µm. 
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Figure 5.10 Migrating and proliferating cells during wound closure in sample S1216K. 
Representative immunofluorescence images revealing proliferating and migrating primary keratinocytes 
during wound closure assay for different time points (A) 24 hours, (B) 48 hours and (C) 72 hours. 
Confluent monolayer of primary keratinocytes labelled with BrdU overnight at SCC then scratched and 
treated with MSC-CM. Green signal represent Proliferating cells (BrdU positive cells) stained with anti-
BrdU antibody (ab152095) at (1:60) in (1% bovine serum albumin (BSA). Green signal revealed binding 
of anti-BrdU antibody with BrdU of replicating cells and when stained with Donkey Anti-Rabbit IgG H&L 
(Alexa Fluor® 488) (ab150073) at (1:250) in (1% bovine serum albumin) gave green signal (FITC). BrdU 
negative cells represent migrating cells which mainly stained with DAPI. Time zero control cells are DAPI 
stained. Blue= DAPI stain (1:1000) in (1% BSA). Scale bar=100 µm. 
For statistical analysis, numbers and ratios of cells in the scratch area were calculated at 
different time points (24, 48 and 72 hours) and presented in (Table 5.1 A and B).    
(A) 
Time 
Migrating Cells Proliferating Cells 
S1212K S1214K S1216K Total S1212K S1214K S1216K Total 
24 Hours 80 80 96 256 21 18 23 62 
48 Hours 216 212 244 672 27 21 49 97 
72 Hours 272 266 248 786 60 28 68 156 
(B) 
Time 
Migrating Cells Proliferating Cells 
S1212K S1214K S1216K Average S1212K S1214K S1216K Average 
24 Hours 79 82 81 80.66 21 18 19 19.33 
48 Hours 89 91 83 87.66 11 9 17 12.33 
72 Hours 82 90 78 83.33 18 10 22 16.66 
Table 5.1 Numbers and percentages of migrating and proliferating cells in the scratch area during 
wound healing. 
Counts and ratios of migrating and proliferating keratinocytes (N=3) during wound closure at different 
time points (24, 48 and 72 hours). (A) Numbers presented as cell number seen in a field of 10X 
magnification. (B) Percentages of cells in the scratch area at different time points.   
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Two way ANOVA showed that there was a significant increase in cell number of migrating 
cells at the different time points during wound closure. The number of migrating cells in 
the scratch area after 72 hours (262±7) was significantly higher than cell number at 48 
hours (1912±40) (P<0.05) which in turn was significantly higher than cell number after 24 
hours (85±5) (P<0.01). The cell number at 72 (P<0.001) was significantly higher than the 
cell number at 24 hours (Table 5.1 A) and (Figure 5.11 A). In another words, at every time 
point (24, 58 and 72 hours) more than 80±2.28% of the cells in the scratch area were 
migrating cells while the proliferating cells represented 20±2.28% only (Table 5.1 B) 
(Figure 5.11 B). The results also show that there was no significant increase in numbers 
of proliferating cells after 48 hours of treatment compared to 24 hours (P>0.05) with a 
slight increase in number of proliferating cells after 72 hours compared to 48 hours 
(P<0.05) (Figure 5.11 B). Again, when migrating and proliferating cells were compared at 
each time point, migrating cells were always significantly higher than proliferating cells. 
For instance, after 24, 48 and 72 hours the numbers of migrating cells were higher than 
numbers of proliferating cells (P<0.0001). These data suggest that MSC-CM enhanced 
primary keratinocyte migration during wound closure until the wound was healed overtime. 
Keratinocyte proliferation was arrested between time zero and 48 hours of treatment with 
MSC-CM and when migrating cells reached an optimum number in the scratch area (after 
48 hours) some of the early migrating cells appeared to stop their migration and switch to 
proliferation and / or differentiation. 
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(A) 
 
(B) 
 
Figure 5.11 Numbers and ratios of migrating and proliferating cells during wound closure. 
Numbers and ratios of migrating and proliferating cells in the scratched area at different time points (24, 
48 and 72 hours). (A) Numbers of cells seen in a field of 10X magnification and revealed that numbers of 
migrating cells were larger than numbers than proliferating cells at the different time points. (B) 
Percentages of migrating and proliferating cells in the field of 10X magnification and presented as 
percentage ± standard error (SE) and showed that percentage of migrating cells were higher than numbers 
of proliferating cells. Bars and error bar= mean and standard error of mean (SEM), (*=P<0.05), 
(**=P<0.01), (***=P<0.001) and (****=P<0.0001). 
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 EFFECT OF MSC-CM ON MIGRATION OF PRIMARY KERATINOCYTES TREATED WITH 
MITOMYCIN C (MMC) 
Since the ratio of proliferating keratinocytes during the healing process were non-
significant compared to migrating cells within the first 48 hours, more experiments were 
undertaken to confirm whether wound closure was mainly attributed to migration, 
proliferation, or both. Therefore, the scratch assay using primary keratinocytes was 
repeated again in the presence of the proliferation inhibitor Mitomycin C (MMC). In the 
scratch assay, 20 µg / ml of MMC was added to the cells 3 hours before scratching the 
monolayer and prior to treatment with MSC-CM (LC-CM). 
As shown in (Figure 4.10) LC-CM enhanced migration of the cells towards the scratch 
centre after 24 hours of treatment compared to the control. However, at the end of the 
treatment time (72 hours), cells treated with LC-CM failed to close the scratch area 
completely. Interestingly, after 40 hours of treatment, there were some changes observed 
in the migrating cells. For instance, the cells started to change their morphology, became 
more flattened and stacked up against each other resulting in a tissue-like structure and 
no single cells could be observed. In addition, migration was restricted resulting in partial 
and incomplete closure. These features were signs of keratinocyte differentiation 
suggesting that after 40 hours, when cells stopped migrating and did not proliferate 
anymore because of the action of MMC, they switched from migration to differentiation 
leading to the formation of an epidermal-like layer instead of a single cell monolayer. 
Subsequently, cells pulled outwards from the wound from centre resulting in non-complete 
or partial wound closure.
Chapter 5                                                                                                                                               Effect of MSC-CM on Proliferation of Skin Cells 
196 
 
   0 Hour 16 Hours 24 Hours 40 Hours 72 Hours Representative 
images of the 
scratch assay using 
primary 
keratinocytes 
treated with 20 
µg/ml MMC for 3 
hours then treated 
with (A) LC-CM24, 
(B) LC-CM48, (C) 
LC-CM72, (D) 
control (LC-CTRL) 
for 72 hours. LC-
CM enhanced 
migration of 
keratinocytes after 
16 hours compared 
to the control. At 40 
hours cells stopped 
migrating, changed 
their morphology 
and gained 
differentiation 
characteristics with 
partial closure at 72 
hours. Scale bar=50 
µm. 
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Figure 5.12 Migration of primary keratinocytes treated with MMC using a 2D scratch assay. 
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Two way ANOVA (Figure 5.13) showed that both LC-CM24 and LC-CM72 caused 
enhanced cell migration after 16 hours of treatment (P<0.01) while LC-CM48 enhanced 
migration at 48 hours (P<0.0001) compared to the control. Migration was arrested 
between 24 and 40 hours, since cells treated with MSC-CM stopped migrating and the 
wound size at 48 hours was the same in size as the gap at 24 hours (P>0.05). However, 
the three LC-CM caused enhanced cell migration again at 48 hours until the end of the 
assay (72 hours) (P<0.0001) compared to the control. 
 
Figure 5.13 Statistical analysis of the effect of LC-CM on migration of primary keratinocytes 
treated with MMC. 
MSC-CM (LC-CM) significantly enhanced migration of keratinocytes inhibited to proliferate (IP) by MMC 
compared to the control. LC-CM24 and LC-CM72 enhanced migration after 16 hours (P<0.01) while LC-
CM48 started the effect after 48 hours (P<0.01). Migration of cells treated with the three CM was arrested 
between 24 and 48 hours (P>0.0001). However, the cells retained their ability to migrate again after 40 
hours resulting in reduction of the scratch area after 72 hours compared to the control (P<0.0001). Bar 
and error bars= Mean and standard error of mean (SEM). (*=P<0.05), (**=P<0.01), (***=P<0.001) and 
(****=P<0.0001). 
These data suggest that primary keratinocytes can migrate, proliferate and differentiate 
during the healing process. The order of these activities may vary depending on demand 
at the injury site. 
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 DETECTION OF MIGRATING AND PROLIFERATING CELLS DURING WOUND CLOSURE OF 
MMC-TREATED KERATINOCYTES (INHIBITED PROLIFERATION “IP”) 
The same samples (S112K, S1214K and S1216K) (N=3) were treated with 20 µg/ml MMC 
for 3 hours at SCC followed by incubation with 3 µg/ml BrdU overnight. The following day, 
cells were scratched and treated with MSC-CM and stained with anti-BrdU antibody and 
secondary antibody at different time points (24, 48 and 72 hours). As shown in (Figure 
5.14), (Figure 5.15), and (Figure 5.16) part A of each figure showed no BrdU positive cells 
were observed in the scratch area at 24 hours. Meanwhile, there was mobility of non-
proliferating cells (BrdU negative cells) which represented migrating cells (DAPI stained). 
Parts B and C represent wound closure at 48 and 72 hours respectively and showed that 
more proliferating cells were observed in the scratch area compared to 24 hours. These 
data suggest that when cells were treated with MMC they lost their ability to proliferate, 
hence they either migrated or differentiated. Since the biological demand requires cell 
migration to fill the wound gap, cells migrated rather than differentiated until the end of the 
assay. 
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Figure 5.14 Migrating and proliferating MMC-treated cells during wound closure using sample 
S1212K.  
Representative immunofluorescence images revealing proliferating and migrating primary keratinocytes 
during the wound closure assay for different time points (A) 24 hours, (B) 48 hours and (C) 72 hours. 
Confluent monolayer of primary keratinocytes treated with 20 µg/ml MMC for 3 hours at SCC then labelled 
with BrdU overnight at SCC then scratched and treated with MSC-CM. Green signal represent 
proliferating cells (BrdU positive cells) stained with anti-BrdU antibody (ab152095) at (1:60) in (1% bovine 
serum albumin (BSA). Green signal revealed binding of anti-BrdU antibody with BrdU of replicating cells 
and when stained with Donkey Anti-Rabbit IgG H&L (Alexa Fluor® 488) (ab150073) at (1:250) in (1% 
bovine serum albumin) gave a green signal (FITC). BrdU negative cells represent migrating cells which 
mainly stained with DAPI. Time zero control cells are DAPI stained. Blue= DAPI stain (1:1000) in (1% 
BSA). Magnifier 10X, Scale bar= 100 µm. 
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Figure 5.15 Migrating and proliferating MMC-treated cells during wound closure using sample 
S1214K. 
Representative immunofluorescence images revealing proliferating and migrating primary keratinocytes 
during the wound closure assay for different time points (A) 24 hours, (B) 48 hours and (C) 72 hours. 
Confluent monolayer of primary keratinocytes treated with 20 µg/ml MMC for 3 hours at SCC then labelled 
with BrdU overnight at SCC then scratched and treated with MSC-CM. Green signal represent 
proliferating cells (BrdU positive cells) stained with anti-BrdU antibody (ab152095) at (1:60) in (1% bovine 
serum albumin (BSA). Green signal revealed binding of anti-BrdU antibody with BrdU of replicating cells 
and when stained with Donkey Anti-Rabbit IgG H&L (Alexa Fluor® 488) (ab150073) at (1:250) in (1% 
bovine serum albumin) gave a green signal (FITC). BrdU negative cells represent migrating cells which 
mainly stained with DAPI. Time zero control cells are DAPI stained. Blue= DAPI stain (1:1000) in (1% 
BSA). Magnifier 10X, Scale bar= 100 µm. 
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Figure 5.16 Migrating and proliferating MMC-treated cells of inhibited proliferation during wound 
closure using sample S1216K. 
Representative immunofluorescence images revealing proliferating and migrating primary 
keratinocytes during the wound closure assay for different time points (A) 24 hours, (B) 48 hours and 
(C) 72 hours. Confluent monolayer of primary keratinocytes treated with 20 µg/ml MMC for 3 hours at 
SCC then labelled with BrdU overnight at SCC then scratched and treated with MSC-CM. Green signal 
represent proliferating cells (BrdU positive cells) stained with anti-BrdU antibody (ab152095) at (1:60) 
in (1% bovine serum albumin (BSA). Green signal revealed binding of anti-BrdU antibody with BrdU of 
replicating cells and when stained with Donkey Anti-Rabbit IgG H&L (Alexa Fluor® 488) (ab150073) at 
(1:250) in (1% bovine serum albumin) gave a green signal (FITC). BrdU negative cells represent 
migrating cells which mainly stained with DAPI. Time zero control cells are DAPI stained. Blue= DAPI 
stain (1:1000) in (1% BSA). Magnifier 10X, Scale bar= 100 µm. 
For statistical analysis, counts and percentages of cells in the scratch area were 
calculated at different time points (24, 48 and 72 hours) and presented in (Table 5.2 A and 
B). 
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 (A) 
Time 
Migrating Cells Proliferating Cells 
S1212K S1214K S1216K Total S1212K S1214K S1216K Total 
24 Hours 72 97 122 291 4 9 3 16 
48 Hours 254 131 114 499 25 12 15 52 
72 Hours 278 119 240 637 25 16 17 58 
(B) 
Time 
Migrating Cells Proliferating Cells 
S1212K S1214K S1216K Average S1212K S1214K S1216K Average 
24 Hours 95 92 97 94.66 5 8 3 5.33 
48 Hours 91 92 88 90.33 9 8 12 9.66 
72 Hours 92 88 93 91 8 12 7 9 
Table 5.2 Numbers and ratios of migrating and proliferating MMC-treated cells in the scratch area 
during wound healing. 
Counts and ratios of migrating and proliferating keratinocytes treated with MMC to inhibit their 
proliferation during wound closure at different time points (24, 48 and 72 hours). (A) Numbers presented 
as cell number seen in a field of 10X magnification. (B) Percentages of cells in the scratch area at 
different time points.   
Two way ANOVA showed that there was a significant increase in the number of migrating 
cells with time. As explained in (Table 5.2 A) and (Figure 5.17 A), the cell count after 72 
hours (212±47) was significantly higher than the cell count at 24 hours (97±14) (P<0.05) 
and (P<0.01). However, there was no significant difference in cell count between 48 hours 
(166±44) and 24 hours (P>0.05). The numbers of migrating cells at 24, 48 and 72 hours 
were significantly increased compared to the numbers of proliferating cells (5±2, 17±4 and 
19±3) at the same time points (P<0.05, P<0.01 and P<0.0001) respectively. In other 
words, the percentage of migrating cells (95±1%, 90±1% and 91±2%) was significantly 
higher than the percentage of proliferating cells (5±1%, 10±2% and 9±2%) (P<0.0001) at 
the three time points (24, 48 and 72 hours) respectively as illustrated in (Table 5.2 B) and 
(Figure 5.17 B). On the other hand, there was no significant increase in the percentage of 
proliferating cells at 24, 48 and 72 hours (P>0.05). 
Chapter 5                                                                              Effect of MSC-CM on Proliferation of Skin Cells 
206 
 
(A) 
 
(B) 
 
 
Figure 5.17 Numbers and ratios of migrating and proliferating keratinocytes treated with MMC 
inhibited proliferation (IP) during wound closure. 
Numbers and ratios of migrating and proliferating cells (MMC treated keratinocytes) in the scratched 
area at different time points (24, 48 and 72 hours). (A) Numbers of cells seen in a field of 10X 
magnification and revealed that numbers of migrating cells were larger than numbers of proliferating 
cells at the different time points. (B) Percentages of migrating and proliferating cells in the field of 10X 
magnifier presented as percentage ± standard error (SE) and revealed that percentage of migrating 
cells were higher than that of proliferating cells. Bars and error bar= mean and standard error of mean 
(SEM), (*=P<0.05), (**=P<0.01), (***=P<0.001) and (****=P<0.0001).   
Migration of MMC treated and untreated keratinocytes (inhibition of proliferation (IP) and 
non-inhibition of proliferation (NIP)) were statistically compared using two-way ANOVA. 
There was no significant differences (P>0.05) between the numbers of migrating cells in 
the scratch area in both conditions (IP and NIP) at the different time points (24, 48 and 72 
hours) (Figure 5.18 A). In addition, there was no significant variations (P>0.05) between 
the percentage of migrating cells in both conditions (IP and NIP) at 48 and 72 hours. 
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However, at 24 hours the ratio of migrating IP cells in the scratch area was significantly 
higher than the ratio of migrating NIP cells (P<0.01) (Figure 5.18 B). Interestingly, the 
percentage of IP cells was higher than that of NIP cells at 24 hours (P<0.01). However, 
there was no significant variation between proliferating IP and NIP cells at time 48 and 72 
hours (P>0.05). These data suggest that MSC-CM mainly enhanced migration of primary 
keratinocytes during wound healing rather than proliferation and differentiation.  
 (A) 
 
 
 (B) 
 
 
Figure 5.18 Statistical comparison between numbers of migrating keratinocytes treated with MMC 
(inhibition of proliferation (IP) and untreated keratinocytes (non-inhibition of proliferation (NIP) 
during wound closure. 
Migrating keratinocytes in both conditions (IP and NIP) showed consistent ability to migrate during wound 
closure. (A) Cell numbers at the two conditions were similar with no significant variation (P>0.05) at the 
different time points (24, 48 and 72 hours). (B) Percentages of migrating IP cells was significantly higher 
(P<0.01) than the percentage of NIP cells at 24 hours. Bar and error bars= mean and standard error of 
mean (SEM), (**=P<0.01). 
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The statistical comparison of proliferating cells in IP cells and NIP cells revealed that 
numbers of proliferating NIP cells and IP cells were similar at 24 and 48 hours (P>0.05) 
while the number of NIP cells was greater  than IP cells at 72 hours (P<0.01) as shown in 
(Figure 5.19 A). On the other hand, percentages of proliferating NIP cells were significantly 
higher than that of proliferating IP cells only at 24 hours (P<0.01) while they were similar 
at 48 and 72 hours (P>0.05) (Figure 5.19 B). 
 (A) 
 
 
 (B) 
 
 
Figure 5.19 Comparison between proliferating cells with inhibited (IP) and non-inhibited 
proliferation (NIP) during wound closure. 
Primary keratinocytes in both conditions (IP and NIP) showed only a slight ability to proliferate during 
wound closure. (A) Cell numbers at the two conditions were similar with only significantly higher 
numbers of NIP cells (P<0.01) at 72 hours. (B) Percentages of proliferating cells at the two conditions 
were similar with only significantly higher numbers of NIP cells (P<0.01) at 24 hours. Bar and error 
bars= mean and standard error of mean (SEM), (**=P<0.01). 
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5.4 DISCUSSION 
During normal conditions and homeostasis, proliferation and differentiation of 
keratinocytes are equally balanced. In contrast, during skin disease and pathological 
conditions such as epidermal wounds these two cellular activities will be imbalanced and 
dysregulated. Cross talk of growth factors and cytokines derived from MSCs can affect 
these events (Taniguchi et al., 2014). Therefore, the effect of MSC-CM was tested on 
proliferation of keratinocytes and fibroblasts. Keratinocyte proliferation was tested at 
different conditions including intact primary cells at normal conditions and scratched 
keratinocytes with and without MMC (proliferation inhibitor) to determine whether MSC-
CM enhanced migration or proliferation or both during the healing process. Beyond 
covering the wound with the epidermal layer by migrating keratinocytes, the early 
migrating cells start to proliferate and act as a supply for cells to enclose the wound area. 
Results of HaCat cells treated with MSC-CM showed that they retained their ability to grow 
and proliferate normally without significant variation compared to the control. As 
mentioned before, studies from cell lines are inaccurate due to the highly proliferative 
ability of the cells, which may interfere with the actual effect that could be caused by MSC-
CM, subsequently, giving rise to false positive results. 
Treating primary keratinocytes with HC-CM showed no significant changes in cell 
proliferation between time zero and 96 hours indicating that MSC-CM arrested cell 
proliferation. However, results using LC-CM showed that cell proliferation was arrested 
between time zero and 48 hours and that there was significant increase in cells viability 
after 96 hours indicating that MSC-CM enhanced cell proliferation. These results suggest 
that the high calcium level present in HC-CM enhances cell differentiation rather than 
proliferation. Proliferation and differentiation are remarkably inverse relationships since 
precursor cells retain their dividing ability until acquisition of full differentiation, whereas 
terminally differentiated cells trigger the cell to exit cell division and thereby, arrest cell 
proliferation (Ruijtenberg and van den Heuvel, 2016). Therefore, during normal conditions 
(where there is no damage), upon stimulation by the external stimulators cells respond 
and evoke one main cellular activity. In the case of monolayer culture, cells are directed 
to either proliferate or differentiate. Upon treatment with MSC-CM (HC-CM), the high 
calcium level promoted cell differentiation rather than proliferation in contrast to LC-CM, 
which enhanced cell proliferation at 48 hours, which in turn blocked differentiation. 
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Consequently, using of LC-CM was preferred for the wound healing studies. However, 
HC-CM could be used when fibroblast were tested since primary fibroblasts retained their 
proliferative ability when treated with HC-CM and showed significant increase in cell 
viability within time. 
The increase in viability of primary keratinocytes treated with LC-CM was not significantly 
different compared to the serum free control within 48 hours, suggesting that migration of 
these cells, instead of proliferation, was the major mechanism for accelerated wound 
closure, irrespective of LC-CM. In contrast, HC-CM arrested both proliferation and 
migration of primary keratinocytes during the entire treatment period (72 hours) and 
resulted in non-closed scratches compared with the control. This could be attributed to 
the early differentiation of these cells which was enhanced at 24 hours by the high calcium 
level (Segrelles et al., 2011). Since primary keratinocyte retained their ability to proliferate 
in LC-CM, more investigations were carried out to identify which cellular response could 
be the first to enhance wound closure; migration or proliferation. The 2D scratch assay 
was repeated again to detect migrating and proliferating cells in the scratch area in the 
presence of MMC to inhibit proliferation. In the absence of MMC, cells at the wound area 
were increased during time resulting in wound closure. Upon analysis of BrdU positive 
proliferating cells, less than 20±2.28% of the cells in the scratch area were positive 
indicating that the rest of cells (80±2.28%) were migrating cells. To explore the hypothesis 
that MSC-CM enhanced both migration and proliferation in the early stages of the healing 
process, the ability of cells to migrate in response to MSC-CM in the presence of MMC 
was further tested. Results were in agreement of Wickert and colleagues and revealed 
that inhibition of proliferation did not have a negative effect on wound repair (Wickert et 
al., 2016). On the other hand, cells treated with MMC retained their ability to migrate under 
the effect of LC-CM, moving towards the scratch centre and significantly reducing the gap 
with time. The presence of 20±2.28% proliferating cells in the scratch area could be 
interpreted by the fact that keratinocytes at the wound edges are highly proliferative rather 
than being migrating or differentiating (Usui et al., 2008b; Wickert et al., 2016). In another 
words, the proliferating cells at the wound edges could not be attributed to the action of 
MSC-CM. Usui and colleagues have suggested that although keratinocyte proliferation is 
needed to fill the wound gap, the absence of the appropriate signalling molecules that 
downregulate proliferation and upregulate migration would delay the healing process 
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(Usui et al., 2008b). The activity of MSC-CM appear to perform two functions; the first one 
is preventing the proliferation of the cells and the second is enhancing them to migrate. 
The consistency of migrating cells during the entire healing process (80±2.28%) at 24, 48 
and 72 hours indicating that MSC-CM enhanced primary keratinocyte migratory behaviour 
during the healing process resulting in a so-called collective cell migration, an important 
step for re-epithelialisation. Treatment with MSC-CM therefore overcomes discontinuous 
migration leading to successful repair (Ng et al., 2012).    
In the MMC treated cell scratch assay, termination of cell migration at 40 hours was 
observed and the primary cells started to change their morphology, became flatten cells, 
contacted neighbouring cells, and started to form tissue-like structures indicating their 
differentiation. This could be interpreted by the fact that upon termination of migration, 
cells started to either proliferate or differentiate. Since their proliferation was inhibited by 
MMC in this experiment, the only activity they can respond to is cell differentiation. Another 
explanation of termination of migration and starting differentiation is the fact that upon 
filling the gap, cells started to contact each other and became under physical stress due 
to the formation of cell adhesion structures. These structures in turn activate membrane 
kinases, leading to increasing membranous permeability for calcium, thereby, enhancing 
differentiation and terminating migration (Jacinto et al., 2001).   
The activity of MSC-CM on wound healing could be caused by HGF which enhances 
keratinocytes to migrate, proliferate and produce matrix metalloproteinase (van de Kamp 
et al., 2013) and MSP-1 which regulates proliferation and differentiation of different cells 
including keratinocytes (Werner and Grose, 2003). As discussed above, several factors 
secreted by MSCs create an optimal environment for the healing process including 
controlling cell migration, cell division, survival and / or proliferation and differentiation. 
Therefore, the role of MSC-CM in the wound healing process suggests increasing 
stimulating cell mobility, proliferation and differentiation. 
Comparing the ratio of proliferating cells in the scratch area after 72 hours in both MMC 
treated and MMC-untreated assays showed that there was no variation between cell 
counts suggesting that during damage, the primary cell behaviour is enhancing cell 
migration rather than cell proliferation. MSC secretions could significantly affect this on/off 
switching of cellular activities. 
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Collective data from this study suggest a combination of cell responses during the healing 
process. Healing of cutaneous wounds represent a paradigm for the spatiotemporal 
interactions of growth factors and cytokines to regulate cell mobility and cell division and 
proliferation (Werner and Grose, 2003). It is well documented that keratinocytes at the 
wound borders are highly proliferative (Werner and Grose, 2003; Usui et al., 2008b; 
Wickert et al., 2016). Since proliferation and motility are mutually exclusive (De Donatis et 
al., 2008), the challenge will be to terminate cell proliferation and enhance cell migration 
in order to promote the healing process (Werner and Grose, 2003). This mechanism could 
be achieved by growth factors such as KGF, HGF (Florin et al., 2004; Schnickmann et al., 
2009) and PDGF (De Donatis et al., 2008). A possible interpretation of how these growth 
factors coordinate two cellular activities concurrently is demonstrated by Donatis and 
colleagues who reported that cell migration could be evoked by low concentrations of 
platelet derived growth factor (PDGF) and terminated with high concentrations and vice 
versa for cell proliferation. In another words, low concentrations of PDGF evokes 
signalling pathways related to cytoskeletal cascades required for cell mobility while high 
concentrations of PDGF trigger signalling pathways related to mitogenesis induction (De 
Donatis et al., 2008). Alternatively, cell growth factor requirements for migration may be 
lower than that required for proliferation. This explanation could be one interpretation of 
the scratch assays, when keratinocyte migration was always evoked at early stages of the 
healing process (after 8 hours of inducing the scratch). In contrast, cell proliferation was 
evoked after 72 hours of the scratch when cell migration terminated and the concentration 
of growth factors had increased with time. 
In summary, secretions of mesenchymal stem cells (MSC-CM) collected at low calcium 
conditions (LC-CM) exerted a positive effect on primary keratinocyte proliferation while 
HC-CM failed to enhance cell proliferation. These data suggest four main findings. First, 
there was an inverse relationship between migrating and proliferating cells after 24 hours; 
when proliferating cells were inhibited, their migration increased. Second, migrating cells 
were observed in greater numbers than proliferating cells in the scratch area regardless 
of whether their proliferation was inhibited or not. Third, migrating cells at both conditions 
(IP and NIP) were similar after 24 hours. Fourth, the ratio of proliferating cells of both IP 
and NIP were relatively the same after 24 hours. Collectively, these data suggest that 
MSC-CM enhanced cell migration during wound healing rather than proliferation and 
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differentiation. When the cells filled the scratch area, they appeared to switch their 
biological function from migration to proliferation and/or differentiation. However, results 
obtained from 2D culture are still inadequate and more investigations using 3D model are 
required to verify the vital role of MSC-CM on cell migration and proliferation during the 
healing process using a realistic wound healing 3D skin model involving whole tissue 
layers or tissue-like structures. In the next chapter (Chapter 6), a 3D skin model equivalent 
is developed for use in wound healing studies.    
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CHAPTER 6 DEVELOPING A PROTOTYPE 3D 
SKIN EQUIVALENT MODEL (3D-SEM) AND ROBUST 
PROTOCOL FOR WOUND HEALING STUDIES 
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CHAPTER SIX: ADAPTING A PROTOTYPE 3D SKIN EQUIVALENT MODEL (3D-SEM) FOR 
WOUND HEALING STUDIES 
6.1 INTRODUCTION 
The standard screening procedure in drug discovery involves assessing the compound of 
interest through three main serial assessment steps; (1) testing in vitro in 2D cell culture, 
(2) testing in vivo in animal models and (3) clinical trials (DiMasi and Grabowski, 2007; 
Breslin and O’Driscoll, 2013). About 90% of the compounds and drugs tested following 
this procedure lacked clinical efficacy and showed unaccepted toxicity during clinical 
development indicating failure of the compound of interest (Hopkins, 2008; Breslin and 
O’Driscoll, 2013). Many of these failures may be attributed to the misleading results 
obtained from 2D cell culture assays, which represent an unnatural microenvironment with 
inappropriate cellular response to drugs (Edmondson et al., 2014). To overcome the 
limitations such as high cost of clinical development and ineffective toxicity during in vivo 
trials, there is an urgent need to establish a new screening step before the in vivo 
screening phase in animal models. The 3D in vitro screening represents the most realistic 
step and mimics the cellular behaviour of cells living in the in vivo niche thereby, providing 
more predictable data and more accurate results (Breslin and O’Driscoll, 2013; 
Edmondson et al., 2014). 
All cutaneous models constructed for wound healing studies demand a standard method 
for wound induction. The main protocols for wound creation include needle puncture (Xu 
and Chisholm, 2014), laser exposure (Xu and Chisholm, 2014; Marquardt et al., 2015), 
electric cauterisation, ultrasound irradiation, punch biopsy (Marquardt et al., 2015) and 
the suction blister method, used only for wound induction in vivo and not applicable for 3D 
models (Ferraq et al., 2012) . The first and second methods require extra professional 
manipulation; and frequently result in a wound of inconsistent depth, size and shape 
making the comparison between the test and the control inaccurate (Ferraq et al., 2012; 
Marquardt et al., 2015). To date, there is an urgent need to adapt and establish more 
robust 3D-SEM suitable for the application of wound healing that mimics the conditions of 
a cutaneous wound in vivo (Marquardt et al., 2015). Invention of the Alvetex®Scaffold has 
provided new means through which to establish a 3D-SEM for wound healing studies. The 
Alvetex®Scaffold is a highly porous cross-linked polystyrene membrane (200 μm in 
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thickness) with approximate pore sizes 36-40 microns, allowing cells and specifically 
fibroblasts to grow in a microenvironment similar to in vivo conditions while enabling them 
to retain their morphological and physiological characteristics and achieve cellular 
responses and communication to neighboring cells, similar to that of the in vivo 
environment (ReproCell Europe Ltd,) (former name: Reinnervate). Furthermore, the 
Alvetex®Scaffold has extended the application to different research areas. For example, 
Hill and colleagues developed a reliable robust 3D model for melanoma invasion studies 
using the Alvetex®Scaffold that does not contain collagen and relies on the production of 
the extra cellular matrix by dermal fibroblasts and is therefore most like human skin (Hill 
et al., 2015). The Alvetex®Scaffold could be used not only for constructing a 3D skin 
model, but also for characterising other cell types and their behaviour in 3D cell culture 
rather than 2D culture. For example, in this study the Alvetex®Scaffold was used for 
testing the ability of MSCs to penetrate the Alvetex®Scaffold and testing their 
differentiation potential into skin or epidermal-like structures in vitro. Although, the ability 
of MSCs to differentiate into multi-lineages has been well studied and documented using 
scaffolds, the differentiation potential of these cells into skin or epidermal like cells remains 
largely undefined. A few papers have reported the ability of MSCs to differentiate into K14-
expressing cells in 2D culture (Sasaki et al., 2008). Ma and colleagues developed an 
organotypic co-culture of MSCs and fibroblasts enriched with collagen type I to test the 
ability of MSC to form an epidermal-like structure (Ma et al., 2009). The disadvantages of 
this method however, are that it is constructed from animal materials and the generated 
model is very contractible, despite the use of a metal ring to prevent the contraction 
making the procedure more complicated. In this model, MSCs showed the ability to 
express keratin 10 and filaggrin but failed to express involucrin. In addition, haematoxylin-
eosin (H-E) staining showed MSC’s failed to form an epidermal like structure with clear 
stratification similar to that of real skin. Given the limitations of current 3D skin equivalents, 
which mainly contain animal materials and the lack of a consistent protocol for wound 
healing studies using fully humanised 3D skin models, the aims of the present chapter 
described below, were to further investigate the use 3D-SEM for wound healing studies.   
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6.2 SPECIFIC AIMS OF CHAPTER SIX 
1. To reproduce a 3D skin equivalent model (3D-SEM) developed by Hill et al (Hill et al., 
2015). 
2. To validate the constructed 3D-SEM histopathologically by haematoxylin-eosin (H-E) 
staining and by the detection of dermal and epidermal differentiation markers using 
immunofluorescence (IF) and compare with normal skin. 
3. To adapt the above in vitro 3D-SEM for wound healing studies.  
4. To develop a donor-matched 3D-SEM protocol to induce either a superficial or a full 
thickness wound in the 3D-SEM with consistent depth, size and shape and fully 
characterised by IF. 
5. To test the effect of MSC-CM on wound healing in the developed 3D-SEM.  
6. To evaluate the differentiation potential of MSCs into epidermal-like cells in 3D culture 
using the Alvetex®Scaffold.
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6.3 RESULTS 
6.3.1 VALIDATION OF THE REPRODUCED 3D SKIN EQUIVALENT MODEL 
All models generated in this study (N=3) were prepared as an organotypic culture 
composed of dermal and epidermal layers. The dermal layer was built from seeding 
fibroblasts which was then encased with the epidermal layer by seeding primary 
keratinocytes to form a multi-layered skin-like structure as  
Haematoxylin-eosin (H-E) staining (Figure 6.1) revealed two distinct layers of dermis and 
epidermis separated by an obvious undulating junction with some collagen filaments were 
evident in the dermal layer. Additionally, the epidermal layer showed apparent 
stratification indicating full differentiation of keratinocytes into different epidermal 
sublayers, i.e. spinosum, granulosum, lucidum and corneum. 
 
Figure 6.1 Haematoxylin-Eosin (H-E) image of constructed 3D skin equivalent model (3D-SEM). 
Representative H and E image of a full thickness 3D-SEM depicting distinct dermal and epidermal 
layers separated by a distinct basal membrane. Red arrows= basal keratinocytes, Green 
arrows=dermal fibroblast, Blue arrows= collagen filaments, Scale bar: 50 µm. 
The immunofluorescent expression of cutaneous differentiation markers (loricrin, K10 and 
K14) was optimised (Figure 6.2 A, B and C) in paraffin embedded human primary skin 
prior to confirmation of their expression in the 3D human skin equivalent. 
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Figure 6.2 Epidermal differentiation markers expressed by human skin. 
Representative Immunofluorescence images of normal human skin (Paraffin embedded) depicting the 
expression of loricrin, K10 and K14 in the epidermis. (A) Loricrin expressed in the stratum corneum layer 
of epidermis (Red=Rhodamine stain). (B) K10 expressed in the spinous and granular layer of epidermis 
(Red=Rhodamine stain). (C) Keratin 14 expressed in the basal layer of epidermis (Green=FITC stain). 
Blue=DAPI stain (depicting cell nuclei). Scale bar=200 µm.  
Results clearly revealed the differentiation of keratinocytes within different epidermal 
layers as evidenced by the expression of K10, an early differentiation marker expressed 
by keratinocytes in the spinous and granular layers, as well as the expression of involucrin 
and loricirn, late differentiation markers expressed in the stratum corneum layer.  
To verify the reconstructed 3D-SEM, the formation of the basal layer was assessed by 
evaluating the expression of K14, while the immunofluorescent expression of collagen III 
was assessed in the dermal layer. Results revealed a thick layer of cells expressing K14 
indicating the formation of a basal layer (Figure 6.3 D). Consistent with basal keratinocytes 
entering a differentiation phase, results also revealed the expression of the early 
differentiation marker K10 (Figure 6.3 C). In addition, the expression of the late 
differentiation markers involucrin (Figure 6.3 B) and loricrin (Figure 6.3 A) were also 
observed, confirming the formation of an epidermal layer in the 3D-SEM closely 
resembling that of human skin. Finally, fibroblasts of the dermal layer expressed collagen 
type III (Figure 6.3 E) in addition to collagen IV (Figure 6.3 F) confirming the formation of 
a dermal layer and basement membrane respectively in the 3D-SEM closely resembling 
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human skin. These data thus confirmed the successful formation of 3D-SEM that mimics 
the cutaneous in vivo environment. 
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Figure 6.3 Epidermal Differentiation and Dermal markers expressed by a reconstructed 3D skin 
equivalent model (3D-SEM). 
Representative Immunofluorescence images of a 3D-SEM revealing the expression of epidermal 
differentation markers. (A) Loricrin, (B) Involucrin, (C) Keratin 10, (D) Keratin 14, (D) Dermal markers 
collagen III (F) Collagen IV. Green=FITC stain, Red= Rhodamine stain, Blue=DAPI stained-cell nuclei. 
Scale Bar=100 µm. 
Multiple immunofluorescence staining of reconstructed 3D-SEM also (Figure 6.4) 
revealed full stratification of the epidermal layer as evidenced by K14 expression just over 
the dermal layer followed by a layer of positive staining for K10 in the superficial layer.  
  
(A)  DAPI (B)  FITC 
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(C)  Rhodamine (D)  MERGE 
Figure 6.4 Multiple immunofluorescence staining of 3D skin equivalent model (3D-SEM). 
Representative sequential immunofluorescence images of a 3D-SEM revealing epidermal differentiation 
markers. (A) Cell nuclei in the epidermal and dermal compartments stained with DAPI (blue). (B) FITC 
green fluorescent expression of involucrin in the stratum lucidum layer of the epidermis and keratin 14 
expression in the basal layers. (C) Red Rhodamine fluorescent staining of K10 in the spinosum, 
granulosum layer of the epidermis and (D) A merged image of involucrin, keratin 14 (green), K10 (red) 
expression. In addition to DAPI (blue). Scale Bar: 200 µm. The exposure time was raised to obtain 
stronger signal. 
6.3.2 DEVELOPING A PROTOTYPE 3D SKIN EQUIVALENT MODEL (3D-SEM) FOR WOUND 
HEALING STUDIES 
To establish a reproducible means of wounding the established 3D-SEM described above, 
an additional step of seeding the fully stratified equivalent onto additional fibroblast 
monolayer was explored. A full thickness wound penetrating both the epidermis and the 
dermis was first created by means of a 3 mm punch biopsy before the wounded full 
thickness skin equivalent was then placed over a previously established fibroblast layer 
in 6-well plates and culture continued in the presence or absence of MSC-CM for1,2 or 4 
weeks.  At each time point (1,2 or 4 weeks), wounded 3D-SEM on a fibroblast layer in 
MSC-CM were then fixed and stained with haematoxylin-eosin (H-E) staining in order to 
visualise dermal and epidermal migration as a measure of wound healing. As 
demonstrated in (Figure 6.5 A), epidermal layers at the punch margins of models treated 
with MSC-CM migrated towards the punch centre after 1 week, forming an epidermal 
tongue covering the punch area. In contrast, there was no evidence for cell movement at 
the epidermal edges of wounded 3D skin equivalents exposed to control media (Figure 
6.5 B). After 2 weeks, epidermal tongues of models treated with MSC-CM continued to 
migrate towards the punch centre (Figure 6.5 C) while the epidermal layers of control 
models just started to form an epidermal tongue from one side (figure 6.5 D). Interestingly, 
MSC-CM enhanced cell migration at all wound edges to move towards the centre, in 
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contrast to the wound margins of the control models, which showed inconsistent 
movement, although some control models showed migration from only one side, which 
resulted in delayed healing. Notably, after 4 weeks of culture with MSC-CM, punch areas 
were completely encased with the epidermal layer and fully stratified epidermal layers, 
(Figure 6.5 E). Meanwhile, epidermal layers of control models moved very slowly over 
time and failed to cover the whole wound area with a gap still remaining at assay 
termination (Figure 6.5 F). 
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Figure 6.5 MSC-CM enhances wound healing in 3D skin equivalents model (3D-SEM).  
Representative Photomicrographs of haematoxylin-eosin (H-E) staining revealing that 3D-SEM seeded 
onto fibroblast mono layers post induction of a 3 mm punch biopsy and cultured for 1 week (A & B), 2 
weeks (C & D) or 4 weeks (E & F) in the presence of MSC-CM (A, C and E) or control (CTRL) media 
(B, D and F).  (A) depicts the formation of an epidermal tongue at the two margins of the punch wound 
after 1 week in the presence of MSC-CM, not observed in wounded  3D-SEM’s in CTRL media, while in 
(C), MSC-CM-increased epidermal migration is observed over the induced wound, with complete 
recovery and the presence of a fully stratified epidermis by week 4. Red brackets represent the wound 
gap. Black brackets indicate epidermal tongue/migration. Scale bar = 200 µm. 
To best clarify the spatial-temporal events in the healing process in 3D-SEM, a 3D scheme 
was created (Figure 6.6), aligning the 3 dimensional measurements that may be used to 
evaluate the healing process i.e. the length of epidermal tongue (LET), the thickness of 
epidermal tongue (TET) epithelialisation (ER) and healing rates (HR). 
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(B)  (E) 
 
 
 
(C)  (F) 
Figure 6.6 Schematic figure of the healing process in in vitro 3D skin equivalent model (3D-SEM). 
Schematic representing 3D migration of cellular epidermal sheets over wounded (punched) 3D-SEM 
over time. (A) New induced punch. (B) Initiation of cell migration. (C) Continuous cell migration with 
initiation of proliferation of cells that stopped their migration. (D) Complete epithelialisation of the punch 
area with migrating cells and increased proliferation. (E) Complete proliferation with initiation of 
differentiation resulting in an epidermis of partial thickness. (F) Recovery of full thickness epidermis with 
full differentiation. Blue Balls= Migrating Cells, Turquoise Balls= Proliferating Cells, Yellow Balls= 
Differentiating Cells. 
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To clarify mathematical calculations of the wound size to further evaluate the progress in 
the healing process, explanatory images are illustrated in (Figure 6.7) depicting the 
dimension of the wound and the newly growing epidermal sheet. 
(A) 
 
 
(B) 
 
  
  
(C) (D) 
Figure 6.7 Schematic figure indicating the adopted process to quantify the healing progress and 
epithelialisation rate. 
This figure explains the healing progress in an induced circular punch in 3D-SEM. (A) A 2D 
haematoxylin-eosin (H-E) image of a side view of a fully recovered epidermal sheet which covered the 
punch area. Scale bar=200 µm. (B) A 3D geometric figure explaining that the fully recovered epidermal 
sheet is actually cylindrical in shape which is recovered after 4 weeks of treatment with MSC-CM. (C) A 
2D H-E image of a side view explaining that the newly formed epidermal sheet (the epidermal tongue) 
is a triangular shape which is formed after 1 week of treatment with MSC-CM. Scale bar=100 µm. (D)  
A 3D geometric figure explaining that the newly formed epidermal sheet (epidermal tongue) is actually 
a round triangular prism in shape. 
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As illustrated in (Figure 6.6) and (Figure 6.7 A), the wound healing process is presented 
by moving cells over a circular surface area. Hence, a formula of the circle area (Equation 
6.1) was applied to measure the area of induced wound at day 0 for further comparison 
of reduction in wound area over time.  
 𝑨 = 𝝅𝒓𝟐 µm2 . . . . . Equation 6.1 
When: 
A= Area of Circular Punch. 
π =3.14  
r= radius of the punch area. 
In addition, the circumference of the punch wound was calculated by applying the 
following equation (Equation 6.2): 
   𝑪𝒊𝒓𝒄𝒖𝒎𝒇𝒆𝒓𝒆𝒏𝒄𝒆 (𝑪) = 𝝅 ×  𝐃𝐢𝐚𝐦𝐞𝐭𝐞𝐫 (𝐃) mm . . . . . Equation 6.2 
 
Depending on the general formula of the circle area (Equation 6.1), a formula was then 
derived to evaluate the progress in the healing process (Epithelialisation) over time by 
calculating the healed area (HA). The HA could easily be calculated by measuring the 
length of the newly formed epidermis or so-called length of epidermal tongue (LET) to 
replace the radius in the main formula of circle area in (Equation 6.1). Therefore, the new 
derived formula to calculate the healed area (HA) so-called epithelialisation is presented 
as (Equation 6.3): 
   𝑬𝒑𝒊𝒕𝒉𝒆𝒍𝒊𝒂𝒍𝒊𝒛𝒂𝒕𝒊𝒐𝒏 = 𝑯𝑨 = 𝝅 (𝑳𝑬𝑻)𝟐 mm2 . . . . . Equation 6.3 
When: 
HA= Healed Area. 
π =3.14  
LET= Length of Epidermal Tongue. 
To evaluate the epithelialisation rate (ER), which represents an increase in the healed 
area at a given time point the following equation (Equation 6.4) was used.   
 𝑬𝑹 =
𝑯𝑨𝑻𝟐 − 𝑯𝑨𝑻𝟏
𝑻𝟐 − 𝑻𝟏
 mm2 / Week  . . . . . Equation 6.4 
When: 
ER= Epithelialisation Rate 
HAT2= Healed Area at time point 2. 
HAT1= Healed Area at time point 1. 
 
Chapter 6                                                                                                                3D Skin Equivalent Model 
229 
 
On the other hand, the general formula of cylinder volume (Equation 6.5) was used to 
measure the void volume of the punch for further comparing the reduction in wound size 
(volume). 
 𝑪𝒚𝒍𝒊𝒏𝒅𝒆𝒓 𝑽𝒐𝒍𝒖𝒎𝒆 = π r2 h mm3 . . . . . Equation 6.5 
 
The healing rate (HR) was thus evaluated by measuring the thickness of the newly formed 
epidermis, calculated by measuring the length, width and the height of the newly formed 
epidermis.  
Results demonstrated that the development of the new epidermis was irregular in shape; 
i.e. while initially a triangular shape at week one and two (Figure 6.7 B and C) this became 
more cylinder like once the formation of a full thickness epidermis (Figure 6.7 A) was 
complete. Therefore, the most appropriate formula to calculate the different thicknesses 
of the newly regenerated epidermis at weeks 1 and 2 was (Equation 6.6). 
 𝑽𝒐𝒍𝒖𝒎𝒆 𝒐𝒇 𝑻𝒓𝒊𝒈𝒐𝒏𝒂𝒍 𝑷𝒓𝒊𝒔𝒎 =
𝟏
𝟐
 ×  𝒃 × 𝒉 ×  𝒘 mm3 . . . . . Equation 6.6 
When: 
b= base, h= height, w= width. 
To calculate the volume of a newly formed epidermal tongue with triangular prism like 
shape, equation (Equation 6.6) was further adapted. Since the newly formed epidermis 
regenerates a round area, the circumference (C) was used instead of the width (W). Using 
of (W) in the standard formula of triangular prism volume will give the volume of a straight 
prism as explained in (Figure 6.8 C) while, using (C) instead, as explained in (Figure 6.8 
A and B), enabled the calculation of the newly formed epidermal tongue in wounded skin 
equivalents at week one and two using (Equation 6.7). 
 𝑬𝑻𝑽 =
𝟏
𝟐
 ×  𝑻 × 𝑳𝑬𝑻 ×  𝑪 mm3 . . . . . Equation 6.7 
ETV= Epidermal Tongue Volume or Size (Triangular prism shape). 
T= Thickness of newly formed epidermis close to the wound edge. 
LET= Length of Epidermal Tongue (the newly formed epidermis). 
C= Circumference of the punch. 
Theoretically, a round triangular prism could be cut at any point and spacing the ends of 
each other as explained in (Figure 6.8 B) to produce a standard triangular prism as 
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demonstrated in (Figure 6.8 C), hence, the newly developed formula is an accurate means 
of measuring the volume of a round triangular prism. 
(A) 
 
 
   
(B) 
 
 
   
(C) 
 
 
   
Figure 6.8 Explanatory geometric figure of the newly formed epidermal sheet. 
Schematic image depicting the relationship between the shape of newly generated epidermal layer and 
a triangular prism during cutaneous wound healing of 3D-SEM. (A) Triangular prism with dimensions 
and the standard formula for calculating its volume. (B) Geometric figure resembles the newly formed 
epidermis according to the hypothesis that the regenerated epidermal tongue is a round triangular prism 
in shape. (C) An opened round triangular prism will give a straight triangular prism, hence the 
circumference of round triangular prism equals the width of straight triangular prism      
In contrast the (Equation 6.8) derived from the general formula of cylinder volume was 
used to measure the wound size after 4 weeks (cylindrical shape). 
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    𝑬𝑻𝑽 = π r2 T mm3 . . . . . Equation 6.8 
ETV= Epidermal Tongue Volume or Size (Cylindrical shape). 
r= Radius of punch area. 
T= Thickness of newly formed epidermis.  
and allowing, the calculation of the HR by (Equation 6.9). 
 𝑯𝑹 =
𝑬𝑻𝑺𝑻𝟐 − 𝑬𝑻𝑺𝑻𝑻𝟏
𝑻𝟐 − 𝑻𝟏
 mm2 / Week  . . . . . Equation 6.9 
When: 
HR= Healing Rate 
ETVT2= Epidermal Tongue Volume at time point 2. 
ETVT1= Epidermal Tongue Volume at time point 1. 
Finally, the fold change (FC) in epithelialisation rate (ER) and healing rate (HR) for MSC-
CM treated models and control models was calculated at different time points using 
(Equation 6.10).  
 𝑭𝑪 =
𝑹𝑨𝑻𝑬𝟐
𝑹𝑨𝑻𝑬𝟏
 − 𝟏  . . . . . Equation 6.10 
 
Migration of epidermal cells was evaluated by measuring the area of a newly regenerated 
epidermal sheet at different time points during the healing process. Two way ANOVA in 
(Figure 6.9 A) revealed that the newly formed epidermal layer of MSC-CM treated models 
covered a wound area significantly larger than the area covered by epidermal layers of 
control models at different time points (P<0.05 after1 week, P<0.01 after 2 weeks and 4 
weeks). Moreover, the epithelialisation rate (ER) was measured to evaluate the 
consistency in the healing process (Figure 6.9 B). Although there was a significant 
increase in the area of the newly formed epidermal sheet, the variation between the ER 
was non-significant between the different time points of models treated with MSC-CM 
(P>0.05) indicating the consistency of the formation of the new epidermis. In another 
words, the velocity of cell migration was consistent during the healing process suggesting 
that MSC-CM exerted a constant effect on cell migration during the entire healing process 
without any fluctuation. 
The proliferation behaviour of epidermal cells was estimated by measuring the thickness 
of the newly generated epidermal sheet over different times of the healing process. As 
demonstrated in (Figure 6.9 C), two way ANOVA revealed that the thickness of the newly 
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formed epidermal layers was significantly increased over time in the presence of MSC-
CM when compared to wounded equivalents cultured in control media (P<0.001 for 1 
week and P<0.0001 for 2 and 4 weeks). Comparing models treated with MSC-CM at 
different time points, results demonstrated that the epidermal layer of models after four 
weeks was significantly thicker than the epidermal layer after two weeks (P<0.001). 
However, there was no significant variation between the thickness of the epidermis at 
week 1 or 2 (P>0.05). Furthermore, there was no significant increase in epidermal 
thickness of control models treated with media A (P>0.05) at any time point. On the other 
hand, the HR was consistent without collapsing during the entire healing process in the 
presence of MSC-CM. As demonstrated in (Figure 6.9), there was no significant difference 
between after 1 week or 2 weeks (P>0.05). However, the HR after 4 weeks was 
significantly higher than the HR at weeks 1 and 2 (P<0.001). Concurrently, control models 
showed no significant increase in the HR after completion of the healing process, with no 
significant difference at week, 1, 2 or 4 (P>0.05). 
 (A) 
 
  
(B) 
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Figure 6.9 MSC-CM promotes epithelialisation and wound healing rates in 3D skin equivalent 
models (3D-SEM).   
A graphical representation (A) Mean of epithelialisation (mm2) in models treated with MSC-CM (Black 
boxes) and control (CTRL) models (Gray boxes) at 1, 2 or 4 weeks. (B) Mean of epithelialisation rate 
(mm2/week) in models treated with MSC-CM (Black boxes) and control (CTRL) models (Gray boxes) at 
1, 2 or 4 weeks. (C) Mean of epidermal thickness (mm3) in models treated with MSC-CM (Black boxes) 
and control (CTRL) models (Gray boxes) at 1, 2 or 4 weeks. (D) Mean of healing rate (mm3/week) in 
models treated with MSC-CM (Black boxes) and control (CTRL) models (Gray boxes) at 1, 2 or 4 weeks. 
In all graphs, N=3, Data presented as mean and the standard error of the mean (SEM), (* P<0.05), 
(**P=0.01), (***=P=0.001), (****P=0.0001).  
Evaluation of the structure and morphology of the epidermal layer at the wound site of 3D-
SEM revealed that culture in MSC-CM resulted in full recovery of fully stratified epidermal 
layers. As demonstrated in (Figure 6.10), the recovered epidermal sheet that encased the 
wound area after 4 weeks of treatment with MSC-CM was composed of the main 
components of an intact epidermis. Interestingly, a very distinct basement membrane 
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could be observed between the dermal and the basal layers of epidermis. The newly 
formed basal layer was also fully reconstituted as an intact layer, containing basal 
keratinocytes able to promote the recovery of other epidermal layers. Additionally, full 
stratification was observed after 4 weeks, with the observation of three to four distinct and 
intact stratum layers indicative of competent wound healing. Notably, the dermis and 
epidermis were also consistently attached to each other providing a firm skin structure. 
 
Figure 6.10 MSC-CM promotes re-epithelialisation in a punched 3D skin equivalent model (3D-
SEM). 
Representative photomicrograph of an H and E stained 3D skin equivalent previously subjected to a 
wound punch and cultured subsequently for 4 weeks in the presence of MSC-CM and depicting an 
epidermal layer containing all counterparts of an intact epidermis, a fully stratified corneum and showing 
the recovery of an intact basal layer containing basal keratinocytes. Additionally, a basement membrane 
could be observed between the dermal and epidermal layers. Scale bar = 200 µm. 
Beyond evaluation of the structure and morphology of the recovered epidermis, the effect 
of MSC-CM on the expression of key epidermal and dermal biomarker expression on the 
wounded 3D skin models was also evaluated. Specifically, the expression K14, K10, 
involucrin, loricrin, collagen IV, and collagen III were evaluated. 
As demonstrated in (Figure 6.11), culture of wounded 3D skin models in MSC-CM resulted 
in the induction of K14 after one week, indicating the presence and migration of basal 
keratinocyte from intact neighbouring margins surrounding the punch site. Beyond two 
weeks, the epidermal stretches retained expression of K14 suggesting continuous 
migration of basal keratinocytes from outside the wound. After four weeks, K14 positive 
cells were detected over the entire punched area indicating that the basal cells were 
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continuously moving during the healing process and forming a basal layer critical to the 
generation of upward epidermal layers. 
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Figure 6.11 MSC-CM promotes expression of K14 by the epidermal layer at different times during 
the healing process. 
Representative immunofluorescence images of K14 expression in wounded 3D skin equivalent cultured 
in MSC-CM for 1, 2 or 4 weeks. Green fluorescence represents. Blue stain= cell nuclei stained with 
DAPI. Scale Bar: 200 µm. 
Additionally, the newly formed epidermal tongue expressed K10 following one week of 
culture in MSC-CM which was continually expressed until formation of a full epidermal 
sheet at week 4 (Figure 6.12) and confirming the differentiation of basal keratinocytes into 
spinous and granular layers. 
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Figure 6.12 MSC-CM promotes expression of K10 by the epidermal layer at different time points 
during the healing process. 
Representative immunofluorescence images of K10 expression in wounded 3D skin equivalents 
cultured in MSC-CM for 1, 2 or 4 weeks. Red Rhodamine fluorescence represents keratinocytes stained 
with Anti-Cytokeratin 10 antibody Blue= Cell nuclei stained with DAPI. Scale Bar=200 µm. 
Analysis of involucrin expression (Figure 6.13) revealed expression in the newly 
generated epidermal sheet following culture in MSC-CM for one week, which was 
continually expressed until the wound site and was completely covered suggestive of the 
epidermal layer differentiating into the stratum lucidum layer. 
    Involucrin 
W
e
e
k
 1
 
D
A
P
I 
 
  In
v
o
lu
c
rin
 A
n
tib
o
d
y
 (F
IT
C
)  
  
Chapter 6                                                                                                                3D Skin Equivalent Model 
240 
 
M
E
R
G
E
 
 
   
W
e
e
k
 2
 
D
A
P
I 
 
  In
v
o
lu
c
rin
 A
n
tib
o
d
y
 (F
IT
C
)  
  
M
E
R
G
E
 
 
   
W
e
e
k
 4
 
D
A
P
I 
 
  
Chapter 6                                                                                                                3D Skin Equivalent Model 
241 
 
In
v
o
lu
c
rin
 A
n
tib
o
d
y
 (F
IT
C
)  
  
M
E
R
G
E
 
 
Figure 6.13 MSC-CM mediated expression of involucrin by the epidermal layer at different time 
points during the healing process. 
Representative immunofluorescence images of involucrin expression in wounded 3D skin equivalents 
cultured in MSC-CM for different time points (1, 2 or 4 weeks). Green FITC fluorescence represents 
keratinocytes stained with anti-involucrin antibody. Blue= cell nuclei stained with DAPI. Scale Bar: 200 
µm. 
Furthermore, the re-epithelialised layer also expressed the differentiation marker, loricrin 
from the early stages of the healing process as illustrated in (Figure 6.14), further 
emphasising the ability of MSC-CM to promote terminal epidermal differentiation. 
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Figure 6.14 MSC-CM promotes Expression of loricrin by the epidermal layer at different time 
points during the wound healing process. 
Representative immunofluorescence images of loricrin expression in wounded 3D skin equivalents 
cultured in MSC-CM for (1, 2 or 4 weeks). Red Rhodamine fluorescence represents keratinocytes 
stained with loricrin Blue= cell nuclei stained with DAPI. Scale Bar=200 µm. 
In addition, MSC-CM also promoted the expression of collagen IV at the recovered wound 
site (Figure 6.15 A). Expression of this marker beneath the re-epithelialised sheet and 
over the dermal layer indicates that the recovered wound site was able to form dermal-
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epidermal junction or the basement membrane. Additionally, the dermal layer beneath the 
damaged epidermis retained its ability to express collagen III fibres during the entire 
healing process (Figure 6.15 B). 
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Figure 6.15 MSC-CM promotes expression of collagen IV (column A) and collagen III (column B) 
by the dermal layer during the healing process. 
Representative immunofluorescence images of collagen III and collagen IV expression in wounded 3D 
skin equivalents cultured in MSC-CM at 4 weeks. (A) Green fluorescence represents collagen IV 
expression in the dermal layer.  (B) Green FITC stain represents keratinocytes stained collagen III. 
Blue= cell nuclei stained with DAPI. Scale Bar=200 µm. 
6.3.3 MSCS DIFFERENTIATE INTO 3D EPIDERMAL-LIKE STRUCTURES WHEN INCORPORATED 
OVER DERMAL FIBROBLAST LAYERS USING THE ALVETEX® SCAFFOLD  
The potential for MSC’s to differentiate into epidermal-like cells in 3D cell culture was 
evaluated by construction of a MSC derived epidermal like structure (MSC-ELS). MSCs 
were tested for their ability to form a full thickness epidermal layer using the same protocol 
for constructing the 3D skin model with some differences i.e., after obtaining the first 
fibroblast layer, MSCs were seeded over this fibroblast layer instead of primary 
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keratinocytes and maintained in epidermal differentiation media (EDM) for three weeks. 
While some models were harvested after 14 days, others were evaluated after 21 days. 
Evaluation of MSC differentiation into an epidermal like structure (ELS) was detected by 
two techniques; haematoxylin-eosin (H-E) staining (Figure 6.16) and immunofluorescence 
staining (Figure 6.17). 
As demonstrated in (Figure 6.16), MSCs formed epidermal like layers similar to that of 
real skin following 3 weeks treatment with EDM, forming distinct layers stacked over each 
other, similar to stratified epidermis and indicating that MSCs were able to differentiate 
into different epidermal layers. On the other hand, the dermal layers were able to grow 
and retain their ability to produce collage fibres when covered with MSCs. Notably, the 
two layers (dermis and epidermis) were separated by an obvious junction which could 
serve as a basal zone between the two layers suggesting that both MSC and fibroblast 
co-culture could successfully produce a skin like structure. 
 
Figure 6.16 MSCs differentiate into epidermal like structure when incorporated onto dermal 
fibroblast layer on Alvetex® scaffold. 
Representative photomicrograph of an H and E revealing that MSCs are able to differentiate into 
epidermal-like cells and form stratified epidermal like structures when seeded over a fibroblast layer in a 
3D culture forming together a skin-like structure similar to real skin. The fibroblast in the dermal layer 
(green arrows) showed the ability to form collagen fibres (blue arrows). The dermal and epidermal layers 
are separated by a junction labelled with yellow arrows which could be a basal membrane. 
Additionally the immunofluorescent expression of epidermal differentiation markers was 
analysed. As shown in figure (Figure 6.17) MSCs seeded over dermal fibroblasts 
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expressed almost the full panel of epidermal differentiation markers, including K14 in the 
basal layer (Figure 6.17 D), and K10, suggesting their ability to differentiate into spinoum 
and granum keratinocytes (Figure 6.17 C). MSCs also expressed involucrin (Figure 6.17 
B) and loricrin (Figure 6.17 A). In addition, the dermal fibroblasts covered with MSCs 
retained their expression of collagen III (Figure 6.17 E) indicating the formation of collagen 
fibers. Furthermore, collagen IV expression was observed in the middle junction between 
the two layers (Figure 6.17F). Collectively the expression of this panel of biomarkers by 
MSC-fibroblast co-cultures suggested that MSCs could participate in skin regeneration 
and could perhaps thus be used as a cellular therapy for chronic wounds to compensate 
for the damaged epidermal cells in the wound site. 
 DAPI Antibody Stain Merge 
(A) 
   
L
o
ric
rin
 
    
(B) 
   
In
v
o
lu
c
rin
 
    
(C) 
   
K
e
ra
tin
 1
0
 
    
 
 
Chapter 6                                                                                                                3D Skin Equivalent Model 
247 
 
(D) 
   
K
e
ra
tin
 1
4
 
    
(E) 
   
C
o
lla
g
e
n
 III 
    
(F) 
   
C
o
lla
g
e
n
 IV
 
Figure 6.17 MSCs express full panel of epidermal differentiation markers and dermal markers when 
fed with epidermal differentiation media. 
Immunofluorescence images of MSC-3D model revealing the expression of epidermal differentiation 
markers. (A) Loricrin (Rhodamine red), (B) Involucrin (FITC green), (C) Keratin 10 (Rhodamine red), (D) 
Keratin 14 (FITC green) and dermal markers (E) Collagen III (FITC green) and (F) Collagen IV (FITC 
green). Blue= cell nuclei stained with DAPI. Scale Bar=100 µm. 
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6.4 DISCUSSION 
Not all events of the healing process are able to be evaluated in 2D culture. Instead, 3D 
models are required to investigate important events such as collective cell migration, 
epidermal layer formation, dermal substrate formation, re-epithelialisation and collagen 
production. In addition, to date there are no consistent protocols for screening the efficacy 
of wound healing drugs, and hence leaving an urgent demand to develop 3D skin models 
for wound healing studies and drug testing, including those suitable for evaluating the 
potential efficacy of  MSC secretions on wound healing. The present study sought to 
develop a new model and robust protocol for wound healing studies to test MSC-CM as a 
candidate wound healing agent. 
6.4.1 CREATING AND CHARACTERISING THE 3D-SEM FOR WOUND HEALING  
The model developed in this study has been shown to be a reproducible tool for wound 
healing studies for many reasons. First, it is an autologous model as all cellular 
components are derived from the same donor. Secondly, it provides an easy means of 
inducing a consistent wound, in terms of size and depth without using complicated 
methods such as a laser, electricity or radiation. Thirdly, it allows for the migration of the 
epidermal layer at the wound edge over other cellular components (the second dermal 
layer) thereby mimicking cell migration in an in vivo wound. Furthermore, this adapted skin 
equivalent and novel model of wound healing also provides a healing index consistent 
with cutaneous wound repair, including collective cell migration, epidermal thickness and 
full stratification, constructed on a second fibroblast layer, promoting collagen production 
and increased longevity This model therefore is able to remain in culture for more than 
one month, which would allow investigation of cellular responses that require monitoring 
and which cannot be achieved via a 2D scratch assay.  
Results also revealed that the seeding of a wounded 3D skin equivalent onto a second 
matched donor fibroblast monolayer served as an effective and stable bed, promoting the 
overall stability of the 3D equivalent and providing an optimal means through which to 
evaluate the wound healing process in 3D culture. Use of this system may therefore open 
up new trends for the possibility of constructing allogenic or autologous models for 
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immunological studies during the healing process. Collectively, this system thus closely 
mimics in vivo wounding and wound healing. 
Compared to other studies, results obtained from experiments performed on this adapted 
3D-SEM revealed that the epidermal cells exhibited collective migration similar to that of 
in vivo wound healing, as reported by Chavez and colleagues, who demonstrated the 
migration of K14 positive keratinocytes as a sheet from the intact edges around the wound 
towards the wound centre (Chavez et al., 2012).  
Results obtained here are consistent with previous studies and in the context of 
proliferation during wound healing, results from the present study also revealed the 
generation of an epidermal sheet (epidermal tongue) which grew as a triangle like shape 
with the thicker part close to the wound edge and the thinner element close to the wound 
centre (Evans et al., 2013). Far from random regeneration, this represents a highly 
organised process comprising overlapping events of more than one cellular activity 
leading to ideal healing. Here it could be suggested that cells are firstly evoked to migrate 
to encase the wound area rather than proliferate at the early stages of the healing, with a 
later switch to a proliferative response. Upon termination of proliferation, results revealed 
that keratinocytes started to differentiate to retain a full thickness epidermis.  
These findings are also supported by results derived from wound healing in 2D cultures 
(Chapter 5 Section 5.3.2.4) where keratinocyte proliferation was inhibited by MMC, and 
detection of the BrdU proliferation marker in migrated keratinocytes. The presence of 20% 
of proliferating cells in the scratch area of wounded keratinocytes in 2D and the presence 
of continuous migration during inhibition of proliferation indicated that the majority of 
keratinocytes undergo migration rather than proliferation or differentiation. It could 
therefore perhaps be suggested that migrating cells from the wound sides towards the 
wound centre move from the unwounded intact edges and not from the extending 
epidermal tongue. Later, migrating cells in the wound healing response may act as a bed 
to be further covered with proliferative cells generated from the intact wound edges. In 
another words, during the healing process, the first cellular layer that encases the wound 
area comprises migrating keratinocytes, while in other upper layers keratinocytes are 
proliferative; these findings are consistent with previous studies demonstrating that the 
healthy tissue surrounding the wound acts as a generator and supplier of migrating 
keratinocytes towards the punch centre while proliferative keratinocytes are supplied by 
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the intact wound margins (Safferling et al., 2013). Another interpretation is that in addition 
to proliferative keratinocytes, cells coming from the intact wound margins, the migrating 
cells, stop migrating due to lack of space and switch their response from a migratory to a 
proliferative response. Hence, this newly formed epidermal layer acts as a basal 
keratinocyte layer that serves to supply the developing/differentiating upwards layers of 
epidermis. This suggestion could also explain the observed doubling in thickness of the 
newly generated epidermal tongue at the wound borders in comparison to the thickness 
of intact epidermis and supported by the fact that the upper epidermal layers close to the 
wound edges are supplied with keratinocytes from two sources i.e. from the intact wound 
margin and the to the newly formed epidermal sheet (Garlick, 2007). The thickness of the 
newly formed epidermal layer at the wound borders observed in the developed 3D model 
were in agreement with Odland and Ross, who reported that upon injury, epidermal 
keratinocytes are activated to participate in the healing process and enter a hypertrophic 
state when cells enlarge, resulting in an increase in tissue size (Odland and Ross, 1968). 
Observations from epithelialisation and epidermal thickness at different time points during 
the healing of the 3D skin model suggest that cell migration is the first response to be 
triggered during the healing process.  
The healing rate (HR) of wounded 3D skin equivalents was evaluated by measuring the 
full epidermal thickness over time, calculated by combining the thickness of newly formed 
epidermis plus with the area covered by it or in another words, migration and proliferation 
rates collectively. Collectively, migration and proliferation of skin cells during wound 
healing are termed as regeneration (resulting in the formation of a tongue-like extension), 
which is a critical and the most important repair mechanism in the healing process (Qing, 
2017). Since the early 1970s, many studies have investigated the mechanisms 
responsible for the regeneration of the new epidermis in the injury site. Three migration 
patterns have been reported through which the new epidermal layers are generated. The 
first pattern is a leapfrog mechanism in which, keratinocytes close to the wound edges 
crawl over each other implying that cells of the suprabasal layer move down into the basal 
layer and suggesting that migration of cells in the basal layer is slower than the migration 
of cells in the upper layers (Krawczyk, 1971; Paladini et al., 1996; Danjo and Gipson, 
2002; Safferling et al., 2013). The second model is a continuous track-tread (cell sliding) 
through which cells of every layer migrate along their original extension without 
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overlapping and implying that cells of the suprabasal layer keep migrating over the basal 
layer retaining their position (Danjo and Gipson, 2002; Tanner et al., 2009; Safferling et 
al., 2013). However, this model suggests that that velocity of basal cells is 3 times higher 
than the velocity of the upper layers (Tanner et al., 2009). The last mechanism proposed 
by Usui and colleagues (Usui et al., 2005), suggests that only a few basal keratinocytes 
at the leading edges will migrate, while other post-wounding changes (proliferation and 
cascading movement of the cells of the suprabasal layer) will cover the wound bed and 
represent the primary players in recreation of the new epidermis. Formation of a triangular-
like sheet could only be attributed to the track-tread mechanism by which basal cells 
migrate faster than suprabasal cells. However, IF studies in the present study revealed 
that cells from different layers are present in the newly extending tongue. Furthermore, 
observations from the present study and other studies suggest that both models (leapfrog 
and track-tread) could be involved in the wound healing process depending on 
circumstances such as epidermal thickness and the health and activity of cells close to 
the wound area. Although, it has been reported by (Tanner et al., 2009) that cells at the 
wound edges are highly proliferative and act as a positive feedback to the wounding. Other 
studies have reported that in contrast to other terminally differentiated cells in the 
suprabasal layer, basal keratinocytes are the only cells with proliferative ability (Morasso 
and Tomic-Canic, 2005). 
Immunofluorescence studies in the present Chapter showed that at week one, expression 
of K14 was not restricted to the basal layer, but rather expression was evident in the entire 
epidermal part at the wound margins, consistent with studies by Usui et al (Usui et al., 
2008b). This striking difference in K14 expression at the wound edge in comparison to 
intact skin has also been reported in other studies demonstrating that keratinocytes at the 
wound edges enter so-called keratinocyte activation (Wawersik et al., 2001). During this 
stage, keratinocytes switch their response from terminal differentiation to participate in the 
healing process, undergoing morphological changes and genetic modifications. 
Additionally, they undergo alterations in keratin expression including the downregulation 
of differentiation markers (Tomic-Canic et al., 1998). Interestingly, in the present study 
K14 was strictly expressed by the basal layer after 2 and 4 weeks. On the other hand, the 
newly formed epidermal sheet expressed the majority of the differentiation markers, from 
week 1 to full wound closure. These findings further suggest that cells in the regenerated 
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epidermis retain differential cellular responses such as migration, proliferation and 
differentiation.  
Collectively, observations from the present 3D model for wound healing suggest that 
combined migration of both basal and suprabasal cells follow either a leapfrog or track-
tread pattern. Concurrently, basal keratinocytes of terminated migration could switch their 
response to proliferate into upper layer cells giving rise to suprabasal cells instead of 
proliferation of the suprabasal cells themselves as suggested by (Usui et al., 2005). 
Hence, the thickness of epidermal tongue at the thick side could be attributed not only to 
the highly proliferative rate of cells present in the wound margins but also to the newly 
generated cells from newly formed basal layer. Collectively, these post-wounding events 
may duplicate the cell count during the injury leading to increased thickness of the 
epidermal layer at the area close to the wound borders. 
The shape of newly formed epidermis (thinner in the wound centre than wound edges) in 
3D-SEM and presence of 80% migrating cells in the scratch area from the 2D scratch 
assay, are supported by published findings. For instance, Bellayr and colleagues 
attributed the priority of keratinocyte migration over cell proliferation at early stages of the 
healing process is probably mediated by the numerous amounts of chemoattractant 
growth factors in the niche of the wounded area (and in the current study of MSC-CM) 
overcoming the amount of proliferation-inducing factors, as evidenced by the rapid 
migratory response of keratinocytes within a few hours (between 6 and 24 hours) (Bellayr 
et al., 2010). However, the proliferation phase represents another pivotal phase 
responsible for actual wound closure. Upon termination of migration, in the case of skin 
wounds, endothelial non-inflammatory cells such as keratinocytes and fibroblasts start to 
proliferate to develop new tissues (Santoro and Gaudino, 2005; Usui et al., 2008b; Bellayr 
et al., 2010). Additionally, fibroblasts are activated and start to differentiate into 
myofibroblasts which participate in reducing the wound size by contracting and secreting 
extracellular matrix (ECM) proteins giving rise to healing of the connective tissue (Li and 
Wang, 2011; Li et al., 2011a).  
Expression of collagen III in the dermal layer beneath the injured epidermis of wounded 
3D skin equivalents treated with MSC-CM indicated the ability of the dermal layer to 
survive following injury. Availability of the intact dermal layer is another critical factor that 
aids the healing process via collagen production and the formation of the dermal-
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epidermal zone (basal membrane). Collagen deposition is an important step in formation 
of granulation tissue during the remodelling phase of the healing process (Mora and 
Pessin, 2002). Additionally, the dermal fibroblasts in the wounded 3D equivalents in the 
presence of MSC-CM demonstrated consistent production of collagen III, a consistency 
that is important for successful remodelling (Zhou et al., 2013). Moreover, continuous 
production of collagen is critical to compensate for lost collagen by the activity of 
collagenases and metalloproteinases, which aid in the removal of the excess collagen 
(Greenhalgh, 1998; Ruszczak, 2003). Additionally, intact dermal fibroblasts in association 
with the recovered epidermal keratinocytes contribute in the formation of a basement 
membrane (Varkey et al., 2014). On the other hand, success of the punched model to 
express collagen IV, which is an essential collagenous glycoprotein produced by the 
basement membrane (Pöschl et al., 2004) is another indicator for dermal-epidermal cross 
talk during the healing process since the production of this protein requires keratinocyte-
fibroblast interaction (Marionnet et al., 2006). Survival of dermal fibroblasts, their ability to 
produce collagen and collagen regulating enzymes, participation in formation of basement 
membrane and tissue remodelling could be mainly attributed to the activity of some growth 
factors secreted by MSCs such as PDGF and TGF-ß1 (Lynch et al., 1987; Heldin and 
Westermark, 1999; Ruszczak, 2003). 
6.4.2 INVESTIGATING THE ROLE OF MSC-CM ON WOUND HEALING USING THE DEVELOPED 
3D-SEM 
To determine the potential benefits of MSC-CM on cutaneous wound healing using 
wounded 3D skin equivalents, the punched models were seeded on a secondary 
fibroblast layer and treated with MSC-CM while the control models were cultured in media 
A. This healing pattern enhanced by MSC-CM compared to medium control, could be 
attributed to the role of growth factors present in MSC-CM such as KGF, HGF. PDGF-AB, 
TGF-1ß, SDF-1α and MSP-1, since these growth factors are well known to enhance cell 
migration with noted effects of HGF and SDF-1α on the promotion of both migration and 
proliferation (Alfaro et al., 2008). Availability of this proteomic panel in MSC-CM is 
sufficient to enhance cutaneous healing with full thickness recovery. These biomolecules 
work separately or synergistically to heal the damaged tissue. For example, KGF 
promotes keratinocyte migration and proliferation (Pastar et al., 2014), improving the 
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healing rate, the quality of epithelialisation, the density of blood vessels (Marti et al., 2008) 
as well as playing a role in tissue remodelling (Maxson et al., 2012). PDGF stimulates 
DNA synthesis, attracting fibroblasts to wound sites, controlling collagen production by 
enhancing fibroblast to produce collagenase, collagen and glycosaminoglycan (Lynch et 
al., 1987). PDGF is also the first chemotactic growth factor to participate in the migration 
of fibroblasts, monocytes, and neutrophils into the skin wound, subsequently stimulating 
the production of  extracellular matrix and the induction of a myofibroblast phenotype 
(Heldin and Westermark, 1999). Additionally, PDGF participates in the inflammatory 
phase, and tissue remodelling (Barrientos et al., 2008b) and promotes keratinocyte 
proliferation (Safari et al., 2014). HGF also referred to as plasminogen-related growth 
factor-1 (PRGF-1) and scatter factor (SF), has been derived from its action as a powerful 
mitogen for hepatocytes and as a stimulator for epithelial cell dissociation (Werner and 
Grose, 2003). It also inhibits fibrosis and promotes re-epithelialisation (Chen et al., 2012) 
as well as enhancing keratinocytes to migrate, proliferate and produce matrix 
metalloproteinase and stimulate new blood vessel formation. It has therefore been 
suggested to play a role in cutaneous wound repair (van de Kamp et al., 2013). Like HGF, 
MSP is also known as scatter factor-2 (SF-2) or hepatocyte growth factor like protein 
(HGFL). The main actions of this molecule are acceleration of cell migration and 
proliferation with regulation of proliferation and differentiation of keratinocytes and 
macrophages. TGF-β1 regulates the inflammatory phase (Barrientos et al., 2008b) by 
activating macrophages, and suppressing T-lymphocytes (Wang et al., 2012c). TGF-β3 
stimulates remodelling (Maxson et al., 2012). Activins which are members of TGF-β family 
act as enhancers for granulation tissue formation and the induction of extracellular matrix 
deposition (Werner and Grose, 2003). Zhang and colleagues reported that activin B 
supports wound repair and regeneration of hair follicles (Zhang et al., 2013); promoting 
wound closure  (Barrientos et al., 2008a; Chen et al., 2008).  It has been reported that 
SDF-1 plays a role in regulating skin homeostasis and tissue remodelling (Werner and 
Grose, 2003). It also promotes wound closure by inducing cell migration including MSCs 
migration (Patel et al., 2013). Many of which play an integral role in inflammation, 
proliferation, migration, differentiation, collagen regulation, angiogenesis and the 
remodelling phases of the healing process (Cowin et al., 2001)Werner and Grose, 2003). 
Collectively, these bioactive molecules as components of MSC secretion guide and judge 
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the healing process in acute and chronic wounds by coordinating numerous cellular 
responses of different cell types resulting in the re-establishment of the damaged barrier 
(Barrientos et al., 2008b). In the present study MSC-CM treated models recovered full 
epithelialisation within two weeks, while control models took four weeks to recover full 
epithelialisation. On the other hand, epidermal thickness was significantly increased at 
week 4 indicating termination of migration when the entire punched area was completely 
encased with cells and the cellular response was switched from migration to proliferation. 
Hence, it could be suggested that MSC-CM enhances cellular responses including 
migration, proliferation and differentiation during the healing process and suggests that 
MSC secretions create an optimal environment for the wound healing process, 
underpinning their potential as a therapeutic strategy for chronic wounds. Under specific 
environments (stem cell niche), MSCs show ability to proliferate and differentiate into more 
specialised cell types to compensate and replace the damaged tissue and ameliorate the 
injury site (Sun et al., 2007). Again, in the present study, MSCs showed the ability to 
differentiate into epidermal like cells in 2D culture; however, use of the derived 3D model 
was more convenient means through which to test the true ability of MSCs to form an 
epidermal like structure. MSCs in the 3D model in this study, were exposed to an air-liquid 
interface, they developed a fully stratified epidermis similar to the architecture of real skin 
and better than in 2D culture. These observations are supported by a hypothesis reported 
by (Tokuda et al., 2000; Gangatirkar et al., 2007; Ma et al., 2009) that exposure of the 
culture surface to air will enhance the differentiation and stratification of keratinocytes due 
to the high oxygen level. 
Structurally, MSCs formed a multilayered epidermal like structure in which MSCs 
possessed epidermal phenotypic traits. Additionally, they expressed the basal 
keratinocyte marker (K14) and other epidermal differentiation biomarkers such as K10, 
loricrin and involucrin. These data suggest that MSCs differentiate into the epidermal 
sublayers and that such differentiation is integral to skin regeneration raising the possibility 
that MSCs may compensate for lost cells in damaged tissue during the healing process. 
The ability of MSCs to produce fully differentiated and stratified epidermis is promising for 
wound healing therapies since differentiation and stratification are integral properties of 
intact skin when forming a cornified cell barrier that provides rigidity and water resistance 
(Segre, 2006).  
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In summary, the protocol developed in this thesis represents a novel, robust and 
reproducible means of studying wound healing that closely mimics wound healing in vivo. 
Critically, the second fibroblast layer based on seeding dermal fibroblast cells on an inert 
polystyrene membrane (Alvetex®scaffold) resulted in a dermal layer which served as a 
stable bed for the previously punched model to lie upon, allowing keratinocytes at the 
wound edges to migrate over the cellular components. Further modification however, such 
as the construction of a second dermal layer incorporating immune cells would be required 
to study the impact and contribution of the immune response to cutaneous healing. 
Importantly, the present study reveals that MSCs participate in wound healing in two ways; 
secretory-mediated repair via secretion of growth factors such as HGF, KGF, PDGF-AB, 
TGFß1, SDF-1α and MSP-1 and via cell-mediated repair. Specifically in this context MSCs 
might differentiate into basal keratinocytes and act as a reservoir for other epidermal 
multilayers, while their differentiation into any epidermal cell types might compensate for 
the required cell type resulting in full epidermal differentiation. The ability of MSC’s to 
function in this capacity during wound healing suggests their potential as a cellular therapy 
to promote cutaneous wound healing due to their secretions and differentiation potential. 
However, more research is required to confirm this issue.   
Due to the success of the constructed 3D-SEM to visualise the cellular response and 
behaviour during the healing process at the cellular level, more investigations were carried 
out to characterise and validate the model at the molecular level as will be discussed in 
Chapter 7.
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CHAPTER SEVEN: THE MOLECULAR BIOLOGY OF WOUND HEALING 
7.1 INTRODUCTION 
Alongside the cellular mechanisms of wound healing, understanding the molecular events 
is also crucial in order to fully decipher the processes of chronic wound healing. Examples 
of these mechanisms include the molecular biology of growth factors and cytokines and 
their receptors (Qing, 2017), in addition to other molecules such as microRNAs (Banerjee 
and Sen, 2013). 
MicroRNAs represent an essential player in cell fate, and have been identified as useful 
biomarkers to identify tissue differentiation and organism development (Alvarez (Alvarez-
Garcia and Miska, 2005). Additionally, evaluation of microRNA expression is an important 
technique for understanding complex gene regulation during system-wide investigations, 
such as the interaction between microRNA expression, microRNA profiling and 
downstream protein regulation (Rosenfeld et al., 2008). Moreover, microRNAs are 
advantageous to study over proteins as they are better conserved and preserved, with 
greater measurable sensitivity in a variety of specimen types such as urine, serum, plasma 
and even formalin-fixed tissue (Boeri et al., 2011). Therefore, profiling of these small RNAs 
is an important molecular approach to study and understand the biogenesis, repair and 
progress in healing processes and diagnosis of many disorders at the molecular level 
(Rosenfeld et al., 2008; Pritchard et al., 2012). Importantly, microRNA expression profiling 
of the 3D skin model has not previously been performed, and investigation into the 
microRNA profile differences between the 3D skin model and real skin is lacking. Hence, 
developing a 3D-skin explant model ( 3D-SEM) retaining the same molecular signature of 
real human skin will open a new trend to use this model as an alternative tool for wound 
healing studies rather than animal models or in vivo clinical trials on patients. Therefore, 
in this study microRNA profiling was carried out on the 3D skin model and was compared 
to real skin at different time points during wound healing. 
Advances in biotechnology and the development of new techniques has enabled 
scientists to investigate new mechanisms and strategies for studying and treating 
disorders including skin diseases. One of the most advanced technologies in this field is 
nCounter technology from Nanostring Technologies. The nCounter microRNA expression 
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assay is a novel technique that utilises molecular barcodes (nCounter Reporter Probes) 
to detect microRNAs in total RNA, during different biological levels of expression. The 
technique does not require reverse transcription or amplification, and thus provides an 
ultra-sensitive, reproducible and highly-multiplexed method. Utilising the assay, a large 
number of data points can be obtained after two principal steps; sample preparation and 
hybridisation. In the case of standard DNA and RNA analysis, the probe of 
oligonucleotide-based biosensors captures the sequences based on a 100bp region. 
However, since microRNAs are short sequences (19-24nucleotides), they need an extra 
step which involves a bridge sequence specifically binding to the target microRNA, to 
elongate the microRNA sequence and make it possible to be captured by the probe (Jolly 
et al., 2016). Therefore, the initial preparation step involves multiplex annealing of the 
molecular tags to their target microRNAs, followed by the ligation reaction through which 
a complex (Tag-miRNA) is formed with high specificity and sensitivity at a specifically 
controlled temperature. A subsequent enzymatic purification removes unbound tags and 
the remaining barcode-bound microRNAs can be detected from total RNA in the sample 
(www.nanostring.com) as explained in (Figure.7.1).   
 
Figure.7.1 Ligation of specific tags to target microRNAs.  
The Figure, adapted from (www.nanostring.com), explains the ligation process. The nCounter 
microRNA Expression Assay contains specific tags that recognise their target microRNA and anneal to 
these sequences, followed by a ligation step that forms a bridge through precise, stepwise control at 
specific annealing and ligation temperatures. 
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In the hybridisation process, a probe pair is introduced in order to achieve the molecular 
barcoding. It contains two sequences; the capture sequence (Capture Probe), which has 
a biotin molecule on its 3’ end and the reporter sequence (Reporter Probe), which has a 
signal comprised of four colours in six positions on its 5’ end (www.nanostring.com) 
(Figure 7.2 A). 
(A) 
 
(B) 
 
(C) 
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(D) 
  
Figure 7.2 Hybridisation of specific tags to the target microRNAs.  
The Figure, adapted from (www.nanostring.com). (A) Explains the hybridisation step. Hybridisation of 
target microRNAs is accomplished via specific binding of probe pairs (Capture probe and Reporter 
Probe), to form a target-probe complex containing a molecular barcode for digital detection. (B) Binding 
of the probe to cartridge surface. (C) Immobilisation of the reporters. (D) Image capturing. 
During an overnight hybridisation step, incubation with a large excess of probe pairs 
ensures that every target will bind to a probe pair. The complexity of the coloured barcodes 
enables a large number of target microRNAs in the same sample for resolution and 
identification during data collection. After the hybridisation, unbound probes are removed 
by magnetic-bead purification through two steps; the first is binding of the target-probe 
complex on magnetic beads that are complementary to a sequence within the capture 
probe, followed by a washing step to remove unbound reporter probes and non-targeted 
molecular sequences. In the second step, the target-probe complex and capture probes 
are eluted from the beads, followed by a further hybridisation to magnetic beads 
complementary to sequences on the reporter probe. Another washing step is then applied 
in order to remove the excess capture probes. The final step involves eluting the purified 
target-probe complex from the beads and binding the hybridised probes to the NanoString 
cartridge surface which is coated with streptavidin to enable binding of the biotin present 
in the target-probe complex (Figure 7.2 B). Then, the reporter is immobilised and aligned 
for image collecting and barcode counting (Figure 7.2 C). Collected data is then analysed 
and processed by the nCounter digital analyser in order to translate the varying coloured 
barcodes into digital target counts for every individual microRNA (Figure 7.2 D). 
Potential molecules that may be targeted by microRNAs during wound healing are growth 
factors and their receptors on keratinocytes. Growth factors are a group of proteins 
secreted by many cell types and serve as multifunctional molecules that promote cellular 
activities in a variety of cells; however, others are monofunctional and restricted to elicit a 
response in only one cell type. Hence, growth factors act as signalling molecules to initiate 
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signalling cascades and evoke cell responses via binding to transmembrane receptors to 
promote and regulate a variety of cell activities including cell proliferation, division, 
migration, differentiation, angiogenesis, morphogenesis and apoptosis (Alfaro et al., 2013; 
Barrientos et al., 2008b; Chen et al., 2008; Maxson et al., 2012; Wang et al., 2012; Werner 
and Grose, 2003; van de Kamp et al., 2013). Since the main role of MSCs in promoting 
wound healing could be attributed to their secretion of growth factors, including those 
previously detected in MSC-CM such as HGF, KGF, PDGF-AB, TGF-β1, SDF-1α and 
MSP-1, it is also important to investigate the expression of receptors of these growth 
factors (c-MET, FGFR-2, PDGF-A, TGF-βR1, CXCR4 and MST-R1 “RON”). Therefore in 
addition to studying microRNA profiles, growth factor receptors were detected in primary 
keratinocytes at normal and damaged conditions of wound healing using RT-qPCR. 
Furthermore, the potential roles of microRNA on these receptors were analysed using 
various online prediction algorithm software.  
Therefore, microRNA profiling was used to characterise the developed 3D SEM, in order 
to further understand the microRNA expression profiles of the model and to validate the 
model at the molecular level for future applications in wound healing studies. In addition, 
microRNA expression profiles were investigated at different time points during the wound 
healing process, in order to assign microRNA expression signatures. This data may be 
used to further investigate functional roles of the individual microRNAs and their impact 
during the wound healing process, which is an important field for developing future 
molecular therapies to treat non-healing wounds. 
7.2  SPECIFIC AIMS OF CHAPTER SEVEN 
1. To characterise the developed 3D skin model (3D-SEM) in comparison to 
human skin at the molecular level using microRNA expression profiling. 
2. To detect differentially expressed microRNAs in the 3D-SEM during the wound 
healing process after treatment with MSC-CM. 
3. To detect growth factor receptors in primary keratinocytes at different time points 
during wound healing. 
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7.3  RESULTS 
Three samples of normal human skin (S1156K, S1157K and S1158K) were used to study 
the expression of microRNAs in cutaneous wound healing. Each sample was divided into 
2 pieces. The first piece of skin was initially used directly for microRNA isolation, and later 
used as a reference and control. A second piece of skin was used for constructing an 
autologous 3D skin model for microRNA isolation after different time points of wound 
healing. Therefore, comparisons were made between microRNAs isolated from a 3D 
autologous skin model as well as microRNAs originating from the original autologous skin.  
7.3.1 CHARACTERISATION OF THE 3D SKIN MODEL -MICRORNA EXPRESSION PROFILES 
In addition to the previous characterisation of the 3D skin model (morphological, structural 
and epidermal differentiation markers, as mentioned in (Chapter 6), the models were also 
characterised at the molecular level by investigating their microRNA expression profiles 
using Nanostring technology which does not need any further amplification and enables 
the detection of up to 799 microRNAs per sample using bar code imaging. MicroRNA 
expression in intact 3D-SEM models were compared to expression of microRNAs isolated 
from the reference real skin in order to a) validate the 3D model as a replica of real skin 
and also to b) identify microRNAs that show similar expression profiles in the 3D model 
and real skin, which could be further evaluated to study wound healing. Results showed 
that the 3D skin model microRNA expression profiles significantly correlated with the 
original real skin at the molecular level; S1156K R=0.64, p<0.001, S1157K R=0.5, 
p<0.001 and S1158K R=0.69, p<0.001 (Figure 7.3 A, B and C). 
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(A) 
 
(B) 
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(C) 
 
Figure 7.3 Correlation between microRNA expression in real skin and the derived 3D skin models. 
Correlation plots represent similarities in the expression of microRNAs between real skin and their derived 
3D skin equivalent model (3D-SEM). (A) The correlation between microRNA expressed by the skin sample 
(S1156K) (y-axis) and its derived 3D-SEM (x-axis) revealed significant correlation between the skin and 
the 3D-SEM (R=0.64, P=0.001 “Spearman”). (B) The correlation between microRNAs expressed by skin 
sample (S1157K) (y-axis) and its derived 3D-SEM (x-axis) revealed significant correlation between the 
skin and the 3D-SEM (R=0.5, P=0.001 “Spearman”). (C) The correlation between microRNAs expressed 
by the skin sample (S1158K) (y-axis) and its derived 3D-SEM (x-axis) revealed significant correlation 
between the skin and the 3D-SEM (R=0.69, P=0.001 “Spearman”). Counts of microRNA expression in 
this figure were generated by the nCounter platform and are represented as log2 of original values. 
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Despite a general correlation between the real skin and their derived 3D models, there 
was a significant difference in expression of 31 microRNAs out of the 787 tested 
microRNAs between the 3D models (N=3) and their original skin (N=3); P<0.05, as 
explained in (Figure 7.4 A and B). 
   
(A) 
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(B) 
 
Figure 7.4 Differential microRNA expression between real skin and their derived 3D skin 
equivalent models (3D-SEM). 
This figure shows that the microRNAs expressed by real skin (N=3) and their derived 3D-SEM (N=3). 
(A) Volcano plot representing a statistical analysis (fold change”x-axis” versus - log10 of P value “y-
axis”) of the whole panel of microRNAs assessed in 3D-SEM compared to their original skin sources. 
The analysis revealed that 31 microRNAs (pale blue colour) were significantly differentially expressed 
by the 3D models compared to the skin sample. A larger -log10 value represents a smaller P-value e.g. 
miR-518b has (-log 10 (4.5) ~ (P=0.00003)) which means it has the most significant variation in 
expression between the two groups. (B) Heat map plot representing the 31 significantly differentially 
expressed microRNAs between the 3D models compared to heir corresponding real skin. Colour Key; 
Red = Higher microRNA count, i.e. gradual change from orange to red means gradual increase in 
microRNA count. Blue = Lower microRNA count i.e. gradual change from light blue to dark blue means 
gradual decrease in microRNA count. 
Details of the 31 differentially expressed microRNAs and more information about 
differences in their expression and their roles in skin morphogenesis and regeneration are 
listed in (Table 7.1). Fold change showed that some of these microRNAs (1-17) showed 
significantly higher expression in 3D-SEM than in real skin, while the opposite expression 
pattern was shown for other microRNAs (18-31), which demonstrated significantly lower 
expression in 3D-SEM compared to real skin.   
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   MicroRNAs 
Expression 
 (↑) or (↓) 
Fold 
Change 
P value Role in Skin References 
1 has-let-7e-5p ↑ 3.05 0.001 
Keratinocyte 
differentiation 
Hildebrand et 
al. 2011 
2 has-let-7f-5p ↑ 8.26 0.012 
Keratinocyte 
differentiation 
Hildebrand et 
al. 2011 
3 miR-125a-5p ↑ 8.90 0.013 
Terminal keratinocyte 
differentiation 
Hildebrand et 
al. 2011 
4 miR-125b-5p ↑ 4.47 0.032 
Skin development 
and morphogenesis 
and epidermal 
differentiation 
Yi et al., 2008 
5 miR-199a-5p ↑ 3.76 0.034 
Skin development 
and morphogenesis 
Zhang et al., 
2011 
6 miR-30a-3p ↑ 3.69 0.044 
Sclerosis and 
rheumatoid arthritis 
in dermal fibroblast  
Alsaleh et al., 
2014 
7 miR-30c-5p ↑ 4.09 0.001 
Regulates 
coagulation 
Marchand et 
al., 2012 
8 miR-31-5p ↑ 3.89 0.012 
Enhances 
proliferation and 
migration of 
keratinocytes 
Li et al., 2015 
9 miR-3195 ↑ 
5.10 0.017 Dermal papilla cell 
related molecule 
Cha et al., 
2014 
10 miR-331-3p ↑ 
4.23 0.036 Normal melanocyte 
related molecule 
Villaruz et al., 
2015 and Sha 
et al., 2016 
11 miR-34a-5p ↑ 7.36 0.006 
Scarless wound 
healing 
Zhao et al., 
2015 
12 miR-34c-5p ↑ 
5.43 0.031 Scarless wound 
healing 
Zhao et al., 
2015 
13 miR-365a-3p+miR-365b-3p ↑ 5.27 0.001 No Data Found  
14 miR-5196-3p+miR-6732-3p ↑ 2.85 0.049 No Data Found  
15 miR-574-3p ↑ 5.29 0.007 
Enhances 
keratinocyte 
differentiation and 
reduces cell 
proliferation 
Chikh et al., 
2011 
16 miR-590-5p ↑ 2.80 0.042 Atopic dermatitis 
Rozalski, 
Rudnicka, 
Samochocki, 
2011 
17 miR-99b-5p ↑ 10.23 0.0006 
Promotes wound 
healing 
Jin et al., 2013 
18 miR-1299 ↓ -4.36 0.016 
Melasma 
pigmentation 
Kim et al., 
2017 
19 miR-140-5p ↓ -2.03 0.006 
Terminal keratinocyte 
differentiation 
Hildebrand et 
al. 2011 
20 miR-148a-3p ↓ -3.016 0.004 
Terminal keratinocyte 
differentiation 
Hildebrand et 
al. 2011 
21 miR-1910-3p ↓ -8.18 0.031 No Data Found  
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22 miR-203a-3p ↓ -2.85 0.040 
Enhances migration 
and proliferation of 
keratinocytes. 
Re-epithelialisation 
and haemostasis. 
Viticchiè et al., 
2012 
Supports 
proliferation of basal 
keratinocytes. 
Maintains the 
stratification 
potential of epithelial 
cells. 
Banerjee, 
Chan and Sen, 
2011 
23 miR-370-5p ↓ -8.99 0.021 
Therapeutic target 
for Psoriasis 
Anandaram 
and Anand, 
2017 
24 miR-423-5p ↓ -2.55 0.031 
Involved in many skin 
diseases 
Lawrence and 
Ceccoli, 2017 
25 miR-506-3p ↓ -7.64 0.009 
Melanoma related 
molecule 
Carpi et al., 
2016 
26 miR-507 ↓ -5.86 0.002 
Melanoma related 
molecule 
Wei et al., 
2016 
27 miR-518b ↓ -12.41 0.00002 
Epithelial lineage 
differentiation 
Kushwaha et 
al., 2014 
28 miR-548d-5p ↓ -2.70 0.045 No Data Found  
29 miR-612 ↓ -4.24 0.007 
Migration and 
proliferation of RPE1 
(Normal human 
epithelial cell l ine) 
Bhajun et al., 
2015 
30 miR-615-5p ↓ -5.86 0.0004 No Data Found  
31 miR-629-5p ↓ -4.81 0.045 No Data Found  
Table 7.1 Further details of differentially expressed microRNAs by real skin and their derived 3D 
skin model equivalents (3D-SEM). 
The table illustrates the 31 microRNAs that were differentially expressed between 3D models in 
comparison to their original source of real skin, including direction of expression fold change, fold 
change value, P-value and their roles in skin morphogenesis and regeneration according to recent 
literature. Expression of 17 microRNAs (1-17) in 3D-SEM were significantly higher than their 
counterparts in real skin. While expression of 14 microRNAs (18-31) were significantly lower than their 
counterparts in the real skin. (↑)= higher expression and (↓) = lower expression in 3D-SEM than real 
skin. 
7.3.2 DIFFERENTIALLY EXPRESSED MICRORNAS BY THE 3D SKIN MODEL DURING WOUND 
HEALING 
To investigate the alterations in microRNA expression profiles during skin wound healing, 
the modified 3D model, validated and confirmed in Chapter 6, to mimic in vivo wound 
healing, was used monitor repair of the wound during real-time at different time points. 
For example, 2 and 4 hours (Madhyastha et al., 2012; Li et al., 2015b), 24 hours (Jin et 
al., 2013b; Li et al., 2014; Bhattacharya et al., 2015; Li et al., 2015b), 72 hours (Viticchie 
et al., 2012) and 1 week (Wang et al., 2012b; Bhattacharya et al., 2015; Li et al., 2015b). 
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These time points were selected to study microRNAs that were expected to participate in 
all phases of the healing process (haemostasis, inflammation, epithelialisation, 
contraction and remodelling) at different time points.   
Data analysis revealed specific signatures using nCounter Human v3 microRNA 
Expression Assay Kit (GXA-MIR3-12) which allow detection of up to 799 microRNAs per 
sample.  Briefly, a wound was induced to the 3D-SEM via 3 mm punch biopsy and models 
then treated with MSC-CM and harvested after different time points i.e. 2, 4, 24, 72 hours 
and 1 week for microRNA analysis. All Nanostring data was passed through quality 
control, normalisation and analysed according to statistical analysis of microRNA profiling 
(Chapter 2, Section 2.4.2) to detect microRNAs that were differentially expressed and 
modulated at the different time points during wound healing in comparison to the intact 
3D models.   
After 2 hours of initiating the healing process, microRNA expression analysis showed that 
14 microRNAs were significantly differentially expressed in the wounded models 
compared to the intact models, as detailed in the (Figure 7.5 A and B) volcano plot and 
heat map. 
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(B) 
 
Figure 7.5 Differentially expressed microRNAs between intact 3D skin equivalent model (3D-SEM) 
and wounded 3D-SEM after 2 hours of initiating the healing process. 
This figure demonstrates the microRNAs expressed by intact 3D-SEM (N=3) and wounded 3D-SEM 
(N=3) after two hours of initiating the healing process. (A) Volcano plot representing a statistical analysis 
(fold change ”x-axis” versus - log10 of P value “y-axis”) of the whole panel of microRNAs expressed in 
the wounded 3D-SEM compared to intact 3D-SEM. The analysis revealed that 14 microRNAs (pale blue 
colour) were significantly differentially expressed by the wounded 3D-SEM compared to intact 3D-SEM. 
A larger -log10 value represents a smaller P value e.g. miR-1180-3p has (-log 10 (3.9) ~ (P=0.00013)) 
which means it has the most significant variation in expression between the two groups. (B) Heat map 
plot representing the 14 significantly differentially expressed microRNAs between the wounded 3D-SEM 
compared to intact 3D-SEM. Colour Key; Red = Higher microRNA count, i.e. gradual change from 
orange to red means gradual increase in microRNA count. Blue = Lower microRNA count i.e. gradual 
change from light blue to dark blue means gradual decrease in microRNA count. 
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Fold changes in microRNA expression and corresponding p values showed that 12 out of 
the 14 differentially expressed microRNAs (1-12) were significantly downregulated in the 
punched wound models within 2 hours post initiation of the wound healing process, in 
comparison to intact models. In contrast, only two microRNAs (13 and 14) were 
significantly upregulated, as explained in (Table 7.2).  
 MicroRNAs Regulation (↑↓) Fold Change P value 
1 hsa-miR-1180-3p ↓ -2.18 0.00012 
2 hsa-miR-1204 ↓ -1.29 0.00354 
3 hsa-miR-1234-3p ↓ -3.79 0.01898 
4 hsa-miR-1307-3p ↓ -2.66 0.04180 
5 hsa-miR-203a-5p ↓ -3.41 0.03332 
6 hsa-miR-362-3p ↓ -1.48 0.02965 
7 hsa-miR-505-3p ↓ -2.72 0.03563 
8 hsa-miR-5196-3p+hsa-miR-6732-3p ↓ -1.35 0.01173 
9 hsa-miR-526a+hsa-miR-518c-5p+hsa-miR-518d-5p ↓ -3.36 0.01483 
10 hsa-miR-141-3p ↓ -1.14 0.03250 
11 hsa-miR-296-5p ↓ -11.53 0.04771 
12 hsa-miR-323b-3p ↓ -1.76 0.04948 
13 hsa-miR-149-5p ↑ 1.55 0.01887 
14 hsa-miR-2117 ↑ 3.08 0.01368 
Table 7.2 Further details of differentially expressed microRNAs between intact 3D-SEM and wounded 
3D-SEM after 2 hours of initiating the healing process. 
Data presented in this table represents the 14 microRNAs that were significantly differentially expressed by 
the wounded 3D-SEM after two hours of the healing progress. 12 microRNAs (numbered 1-12) were 
significantly downregulated, while only 2 (numbered 13 & 14) were significantly upregulated in the wounded 
3D-SEM compared to intact 3D-SEM. (↑)= Upregulation and (↓)= downregulation in wounded 3D-SEM 
compared to intact 3D-SEM.  
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At 4 hours into the healing progress, 30 microRNAs were significantly differentially 
expressed between the punched models in comparison to intact models as demonstrated 
in (Figure 7.6). 
(A) 
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(B) 
 
Figure 7.6 Differentially expressed microRNAs between intact 3D-SEM and wounded 3D-SEM after 
4 hours of initiating the healing process. 
This figure demonstrates the microRNAs expressed by intact 3D-SEM (N=3) and wounded 3D-SEM (N=3) 
after 4 hours of initiating the healing process. (A) Volcano plot representing a statistical analysis (fold 
change” x-axis” versus - log10 of P value “y-axis”) of the whole panel of microRNAs expressed in the 
wounded 3D-SEM compared to intact 3D-SEM. The analysis revealed that 30 microRNAs (pale blue 
colour) were significantly differentially expressed by the wounded 3D-SEM compared to intact 3D-SEM. 
A larger (-log10 value) represents a smaller P value e.g. miR-1973 has -log 10 (2.8) ~ (P=0.0015) which 
means it has the most significant variation in expression between the two groups. (B) Heat map plot 
representing the 30 significantly differentially expressed microRNAs between the wounded 3D-SEM 
compared to intact 3D-SEM. Colour Key; Red = Higher microRNA count, i.e. gradual change from orange 
to red means gradual increase in microRNA count. Blue = Lower microRNA count i.e. gradual change 
from light blue to dark blue means gradual decrease in microRNA count. 
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Fold change analysis and p values of microRNAs revealed that 19 microRNAs (1-19) were 
significantly downregulated after 4 hours of the wound healing process in comparison to 
intact models, while 11 microRNAs (20-30) were significantly upregulated as explained in 
(Table 7.3). 
 MicroRNAs Regulation (↑↓) Fold Change P value 
1 hsa-miR-302e ↓ -1.79 0.01495 
2 hsa-miR-33a-5p ↓ -1.81 0.02960 
3 hsa-miR-505-3p ↓ -2.74 0.01250 
4 hsa-miR-526a+hsa-miR-518c-5p+hsa-miR-518d-5p ↓ -2.58 0.04936 
5 hsa-let-7e-5p ↓ -1.31 0.01926 
6 hsa-let-7g-5p ↓ -1.26 0.02725 
7 hsa-miR-106a-5p+hsa-miR-17-5p ↓ -1.44 0.03815 
8 hsa-miR-148a-3p ↓ -1.50 0.02345 
9 hsa-miR-151a-5p ↓ -1.21 0.00898 
10 hsa-miR-15a-5p ↓ -1.08 0.00530 
11 hsa-miR-181a-5p ↓ -1.15 0.03656 
12 hsa-miR-192-5p ↓ -1.57 0.03511 
13 hsa-miR-222-3p ↓ -1.14 0.01279 
14 hsa-miR-29c-3p ↓ -1.21 0.04902 
15 hsa-miR-100-5p ↓ -1.25 0.03442 
16 hsa-miR-1268a ↓ -1.80 0.02666 
17 hsa-miR-1206 ↓ -2.34 0.01087 
18 hsa-miR-597-5p ↓ -1.88 0.01813 
19 hsa-miR-196a-5p ↓ -1.20 0.02328 
20 hsa-miR-10a-5p ↑ 1.54 0.00413 
21 hsa-miR-1236-3p ↑ 1.45 0.03221 
22 hsa-miR-1973 ↑ 1.32 0.00155 
23 hsa-miR-520d-5p+hsa-miR-527+hsa-miR-518a-5p ↑ 1.95 0.04683 
24 hsa-miR-139-3p ↑ 1.29 0.03377 
25 hsa-miR-2117 ↑ 3.45 0.03556 
26 hsa-miR-320e ↑ 2.78 0.01458 
27 hsa-miR-4485-3p ↑ 2.05 0.03220 
28 hsa-miR-4532 ↑ 2.18 0.03918 
29 hsa-miR-584-5p ↑ 3.03 0.03442 
30 hsa-miR-1281 ↑ 2.47 0.01574 
Table 7.3 Further details of differentially expressed microRNAs between intact 3D-SEM and 
wounded 3D-SEM after 4 hours of initiating the healing process. 
Data presented in this table represents the 30 microRNAs that were significantly differentially expressed 
by the wounded 3D-SEM at 4 hours of the wound healing progress. 19 microRNAs (numbered 1-19) 
were significantly downregulated and 11 (numbered 20-30) were significantly upregulated in the 
wounded 3D-SEM compared to intact 3D-SEM. (↑) = upregulation and (↓) = downregulation in wounded 
3D-SEM compared to intact 3D-SEM. 
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Moreover, after 24 hours of the wound healing progress, 23 microRNAs were differentially 
expressed by the punched wound models in comparison to the intact models as illustrated 
in (Figure 7.7).   
(A) 
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Figure 7.7 Differentially expressed microRNAs between intact 3D-SEM and wounded 3D-SEM after 
24 hours of initiating the healing process. 
This figure demonstrates the microRNAs that were significantly differentially expressed by intact 3D-
SEM (N=3) and wounded 3D-SEM (N=3) after 24 hours of initiating the healing process. (A) Volcano 
plot representing a statistical analysis (fold change ”x-axis” versus - log10 of P value “y-axis”) of the 
whole panel of microRNAs expressed in wounded 3D-SEM compared to intact 3D-SEM. The analysis 
revealed that 23 microRNAs (pale blue colour) were significantly differentially expressed by the wounded 
3D-SEM compared to intact 3D-SEM. A larger (-log10 value) = represents a smaller P value e.g. miR-
488-3p has (-log 10 (2.8) ~ (P=0.0015)) which means it has the most significant variation in expression 
between the two groups. (B) Heat map plot representing the 23 significantly differentially expressed 
microRNAs between the wounded 3D-SEM compared to intact 3D-SEM. Colour Key; Red = Higher 
microRNA count, i.e. gradual change from orange to red means gradual increase in microRNA count. 
Blue = Lower microRNA count i.e. gradual change from light blue to dark blue means gradual decrease 
in microRNA count.  
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As demonstrated in (Table 7.4), statistical analysis, as reflected by fold change and p 
values, illustrated that 10 (1-10) microRNAs were significantly downregulated, while 13 
microRNAs (11-23) were significantly upregulated in the 3D models in comparison to the 
intact models. 
 MicroRNAs Regulation (↑↓) Fold Change P value 
1 hsa-miR-1204 ↓ -1.26 0.00434 
2 hsa-miR-1297 ↓ -1.26 0.00434 
3 hsa-miR-30e-3p ↓ -1.48 0.03988 
4 hsa-miR-33a-5p ↓ -1.85 0.02231 
5 hsa-miR-362-3p ↓ -1.64 0.03107 
6 hsa-miR-362-5p ↓ -1.46 0.04347 
7 hsa-miR-526a+hsa-miR-518c-5p+hsa-miR-518d-5p ↓ -2.99 0.00874 
8 hsa-miR-4455 ↓ -2.66 0.01720 
9 hsa-miR-664a-3p ↓ -1.41 0.02317 
10 hsa-miR-488-3p ↓ -2.84 0.00159 
11 hsa-miR-137 ↑ 2.04 0.00838 
12 hsa-miR-214-3p ↑ 1.45 0.02587 
13 hsa-miR-431-5p ↑ 3.01 0.01635 
14 hsa-miR-1285-5p ↑ 1.39 0.02295 
15 hsa-miR-26a-5p ↑ 1.51 0.00942 
16 hsa-miR-30b-5p ↑ 1.46 0.03357 
17 hsa-miR-542-3p ↑ 4.07 0.04798 
18 hsa-miR-1272 ↑ 3.72 0.01223 
19 hsa-miR-323a-3p ↑ 1.71 0.00548 
20 hsa-miR-345-5p ↑ 1.72 0.04188 
21 hsa-miR-382-5p ↑ 2.14 0.04509 
22 hsa-miR-495-5p ↑ 3.32 0.01759 
23 hsa-miR-99b-5p ↑ 1.20 0.01180 
Table 7.4 Further details of differentially expressed microRNAs between intact 3D-SEM and 
wounded 3D-SEM after 24 hours of initiating the healing process.  
Data presented in this table represents the 23 microRNAs that were significantly differentially expressed 
by the wounded 3D-SEM at 24 hours of the healing process. Ten microRNAs (numbered 1-10) were 
significantly downregulated and 13 (numbered 11-23) were significantly upregulated in the wounded 3D-
SEM compared to intact 3D-SEM. (↑)= upregulation and (↓)= downregulation in wounded 3D-SEM 
compared to intact 3D-SEM. 
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After 72 hours of wound healing, punched models differentially and significantly expressed 
15 microRNAs in comparison to the intact models, as shown in (Figure 7.8). 
(A) 
 
Chapter 7                                                                                               Molecular Biology of Wound Healing 
 
281 
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Figure 7.8 Differentially expressed microRNAs between intact 3D-SEM and wounded 3D-SEM 
after 72 hours of initiating the healing process.  
This figure demonstrates the microRNAs expressed by intact 3D-SEM (N=3) and wounded 3D-SEM 
(N=3) after 72 hours of initiating the healing process. (A) Volcano plot representing a statistical analysis 
(fold change ”x-axis” versus - log10 of P value “y-axis”) of the whole panel of microRNAs expressed in 
wounded 3D-SEM compared to intact 3D-SEM. The analysis revealed that 15 microRNAs (pale blue 
colour) were significantly differentially expressed by the wounded 3D-SEM compared to intact 3D-SEM. 
A larger -log10 value represents a smaller P value i.e. miR-320e has -log 10 (2.398) ~ (P=0.004) which 
means it has the most significant variation in expression between the two groups. (B) Heat map plot 
representing the 15 significantly differentially expressed microRNAs between the wounded 3D-SEM 
compared to intact 3D-SEM. Colour Key; Red = Higher microRNA count, i.e. gradual change from 
orange to red means gradual increase in microRNA count. Blue = Lower microRNA count i.e. gradual 
change from light blue to dark blue means gradual decrease in microRNA count.  
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Among the fifteen significantly differentially expressed microRNAs, fold change and p 
values revealed that 11 were significantly downregulated and only 4 microRNAs were 
upregulated in wounded models compared to intact models after 72 hours following 
initiation of the healing process, as explained in (Table 7.5).   
 MicroRNAs Regulation (↑↓) Fold Change P value 
1 hsa-let-7g-5p ↓ -1.24 0.02628 
2 hsa-miR-1287-5p 
↓ 
-1.6 0.00858 
3 hsa-miR-1307-3p 
↓ 
-2.16 0.03529 
4 hsa-miR-200a-3p 
↓ 
-1.7 0.03244 
5 hsa-miR-29c-3p 
↓ 
-1.33 0.00771 
6 hsa-miR-660-5p 
↓ 
-1.64 0.00789 
7 hsa-miR-888-5p 
↓ 
-2.17 0.01922 
8 hsa-miR-34a-5p 
↓ 
-1.19 0.02963 
9 hsa-miR-421 
↓ 
-2.03 0.01881 
10 hsa-miR-196a-5p 
↓ 
-1.58 0.04921 
11 hsa-miR-488-3p 
↓ 
-2.07 0.04183 
12 hsa-miR-382-5p 
↑ 
1.77 0.03141 
13 hsa-miR-320e 
↑ 
1.96 0.00425 
14 hsa-miR-4284 
↑ 
8.42 0.02297 
15 hsa-miR-601 
↑ 
2.05 0.03693 
Table 7.5 Further details of differentially expressed microRNAs between intact 3D-SEM and 
wounded 3D-SEM after 72 hours of initiating the healing process.  
Data presented in this table represents the 15 microRNAs that were significantly differentially expressed 
by the wounded 3D-SEM at 72 hours of the wound healing progress. 11 microRNAs (numbered 1-11) 
were significantly downregulated and only 4 microRNAs (numbered 12-15) were significantly upregulated 
in the wounded 3D-SEM compared to intact 3D-SEM. (↑)= upregulation and (↓)= downregulation in 
wounded 3D-SEM compared to intact 3D-SEM.  
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The healing process continued to demonstrate differential expression of microRNAs after 
1 week in comparison to the intact models, as shown in (Figure 7.9).    
(A) 
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(B) 
 
Figure 7.9 Differentially expressed microRNAs between intact 3D-SEM and wounded 3D-SEM after 
1 week of initiating the healing process.  
This figure demonstrates the microRNAs that were significantly differentially expressed by intact 3D-
SEM (N=3) and wounded 3D-SEM (N=3) after 1 week of initiating the healing process. (A) Volcano plot 
representing a statistical analysis (fold change ”x-axis” versus - log10 of P value “y-axis”) of the whole 
panel of microRNAs expressed in wounded 3D-SEM compared to intact 3D-SEM. The analysis revealed 
that 22 microRNAs (pale blue colour) were significantly differentially expressed by the wounded 3D-
SEM compared to intact 3D-SEM. A larger -log10 value represents a smaller P value e.g. miR-320e has 
-log 10 (2.8) ~ (P=0.0015) which means it has the most significant variation in expression between the 
two groups. (B) Heat map plot representing the 22 significantly differentially expressed microRNAs 
between the wounded 3D-SEM compared to intact 3D-SEM. Colour Key; Red = Higher microRNA count, 
i.e. gradual change from orange to red means gradual increase in microRNA count. Blue = Lower 
microRNA count i.e. gradual change from light blue to dark blue means gradual decrease in microRNA 
count. 
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As illustrated in (Table 7.6), analysis showed that 10 of the differentially expressed 
microRNAs were significantly downregulated, while 12 microRNAs were significantly 
upregulated after 1 week’s progress of the healing process in comparison to the intact 
models, as demonstrated by fold change and p values. 
 MicroRNAs Regulation (↑↓) Fold Change P value 
1 hsa-miR-1204 ↓ -1.29 0.00354 
2 hsa-miR-1297 ↓ -1.29 0.00354 
3 hsa-miR-200a-3p ↓ -1.78 0.00369 
4 hsa-miR-302c-3p ↓ -3.98 0.03556 
5 hsa-miR-302e ↓ -1.86 0.00157 
6 hsa-miR-33a-5p ↓ -1.83 0.02897 
7 hsa-miR-505-3p ↓ -2.21 0.01792 
8 hsa-miR-29c-3p ↓ -1.26 0.02724 
9 hsa-miR-612 ↓ -1.81 0.02687 
10 hsa-miR-1285-5p ↓ -1.84 0.01143 
11 hsa-miR-22-3p ↑ 1.07 0.02472 
12 hsa-miR-376a-3p ↑ 1.35 0.01519 
13 hsa-miR-629-5p ↑ 1.34 0.01443 
14 hsa-miR-107 ↑ 1.21 0.03740 
15 hsa-miR-193a-3p ↑ 1.77 0.03962 
16 hsa-miR-1973 ↑ 1.94 0.02455 
17 hsa-miR-210-3p ↑ 1.95 0.01541 
18 hsa-miR-2117 ↑ 1.83 0.00343 
19 hsa-miR-324-5p ↑ 1.32 0.01938 
20 hsa-miR-337-3p ↑ 2.00 0.00668 
21 hsa-miR-4284 ↑ 3.77 0.04145 
22 hsa-miR-99b-5p ↑ 1.25 0.03328 
Table 7.6 Further details of differentially expressed microRNAs between intact 3D-SEM and 
wounded 3D-SEM after 1 week of initiating the healing process.  
Data presented in this table represents the 30 microRNAs that were significantly differentially expressed 
by the wounded 3D-SEM at 1 week of the wound healing progress. Ten microRNAs (numbered 1-10) 
were significantly downregulated and 12 molecules (numbered 11-22) were significantly upregulated in 
the wounded 3D-SEM compared to intact 3D-SEM. (↑)= upregulation and (↓)= downregulation in 
wounded 3D-SEM compared to intact 3D-SEM.  
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Interestingly, twenty microRNAs were differentially expressed at more than one time point 
analysed during the healing process (overlapping microRNAs), suggesting that these 
microRNAs may play a role in different phases of the healing process. Twelve of these 
microRNAs were always downregulated, while seven were always upregulated in 
wounded 3D-SEM compared to intact 3D-SEM (Table 7.7). Only miR-1285-5p 
demonstrated fluctuation in expression over time. This microRNA was upregulated at 24 
hours and downregulated after 1 week of the healing process. More information about 
these microRNAs is listed in (Table 7.7) and (Figure 7.10). 
 MicroRNAs 
Regulation at Time points 
2 Hours 4 Hours 24 Hours 72 Hours 1 Week 
1 miR-1204 -1.29 ↓   -1.26 ↓   -1.29 ↓ 
2 miR-1307-3p -2.66 ↓     2.16 ↓   
3 miR-362-3p -1.48 ↓   1.64 ↓     
4 miR-505-3p -2.72 ↓ -2.74 ↓      -2.72 ↓ 
5 miR-526a+miR-518c-5p+miR-518d-5p -3.36 ↓ -2.58 ↓ -2.99 ↓     
6 miR-2117 3.08 ↑ 3.45 ↑     1.83 ↑ 
7 miR-302e   -1.79 ↓     -1.86 ↓ 
8 miR-33a-5p   -1.81 ↓ -1.85 ↓   -1.83 ↓ 
9 miR-let-7g-5p   -1.26 ↓   -1.24 ↓   
10 miR-29c-3p   -1.21 ↓   -1.33 ↓ 1.26 ↓ 
11 miR-196a-5p   -1.2 ↓   -1.58 ↓   
12 miR-1973   1.32 ↑     1.94 ↑ 
13 miR-320e   2.78 ↑   1.96 ↑   
14 miR-1297     -1.26 ↓   -1.29 ↓ 
15 miR-488-3p     -2.84 ↓ -2.07 ↓   
16 miR-1285-5p     1.39 ↑   -1.84 ↓ 
17 miR-382-5p     2.14 ↑ 1.77 ↑   
18 miR-99b-5p     1.20 ↑   1.25 ↑ 
19 miR-200a-3p       -1.70 ↓ -1.78 ↓ 
20 miR-4284       -8.42 ↑ -3.77 ↑ 
Table 7.7 Common differentially expressed microRNAs at different time points during the wound 
healing process. 
There were 20 microRNAs that were commonly differentially expressed by wounded 3D-SEM compared 
to intact 3D-SEM at a minimum of two different time points during the wound healing process. Some were 
upregulated while others were down regulated, all with a significant fold change in expression.  
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Figure 7.10 Fold change of overlapping microRNAs at different time points during the healing 
process. 
The figure illustrates overlapping microRNAs that were significantly up or downregulated in wounded 
3D-SEM compared to intact 3D-SEM at different time points during the healing process. Positive fold 
change (from 0 to 10) = upregulation. Negative fold change (from 0 to -5) = downregulation of microRNA 
expression in wounded 3D-SEM compared to intact 3D-SEM.   
Ingenuity target explore from (targetexplorer.ingenuity.com) microT-CDS, TarBase v.8 
and MirPath v.3 from DIANA tools (diana.imis.athena-innovation.gr) were used to 
investigate potential genes that might be targeted by the differentially expressed 
microRNAs. Only genes relating to signalling pathways that affect cellular responses 
during skin morphogenesis and wound healing were reported (Table 7.8). Some 
microRNAs such as miR-1307-3p, miR-302e, miR-33a-5p, miR-let-7g-5p, miR-196a-5p, 
miR-382-5p and miR-4284 were shown to influence more than one gene, and the gene 
targets may in turn participate in multiple cellular responses and signalling pathways. 
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 MicroRNAs 
Regulation 
↑↓ 
Target Gene(s) Target Detector / Explorer (Software) 
1 miR-1204 ↓ TP53 (p53) Ingenuity Target Explorer  
2 miR-1307-3p ↓ EHMT1, NDRG2, FLII MicroT-CDS / DIANA 
3 miR-362-3p ↓ TRIM11 TarBase v.8 / DIANA 
4 miR-505-3p ↓ TNC MirPath v.3 / DIANA 
5 
miR-526a+miR-518c-5p+miR-
518d-5p 
↓ APC Ingenuity Target Explorer  
6 miR-2117 ↑ VAV3 TarBase v.8 / DIANA 
7 miR-302e ↓ TGFBR2, ENDRB MicroT-CDS / DIANA 
8 miR-33a-5p ↓ EDN1, MYC (c-MYC) TarBase v.8 / DIANA 
9 
miR-let-7g-5p ↓ 
MYC (c-MYC), 
HMGA2 
TarBase v.8 / DIANA 
10 miR-29c-3p ↓ MPP TarBase v.8 / DIANA 
11 
miR-196a-5p ↓ 
HOMEBOX Genes, 
KRT5, COL1A1 
Ingenuity Target Explorer  
12 miR-1973 ↑ CRABP1 MicroT-CDS / DIANA 
13 miR-320e ↑ JUN MicroT-CDS / DIANA 
14 miR-1297 ↓ KLF5 TarBase v.8 / DIANA 
15 miR-488-3p ↓ CRHR2 TarBase v.8 / DIANA 
16 miR-1285-5p ↑ - ↓ HIPK 1 TarBase v.8 / DIANA 
17 miR-382-5p 
↑ 
CALPAIIN, TAGLN, 
VIM 
Ingenuity Target Explorer  
18 miR-99b-5p ↑ HOXA1 TarBase v.8 / DIANA 
19 miR-200a-3p ↓ BAP1 TarBase v.8 / DIANA 
20 miR-4284 ↑ RUFY2, KMT2D TarBase v.8 / DIANA 
Table 7.8 Target genes of overlapping microRNAs during the healing process. 
This table illustrates 20 microRNAs that consistently demonstrated differential expression during wound 
healing compared to intact skin models, and their predicted target genes. Predicted target genes were 
determined using online target explorer software such as Ingenuity target explore and DIANA tools (MicroT-
CDS, TarBase v.8 and MirPath v.3). Some of the overlapping microRNAs were shown to target more than 
one gene. (↑)= Upregulated and (↓) = downregulated microRNAs expressed by wounded 3D-SEM 
compared to intact 3D-SEM. (↑ - ↓) = upregulated microRNA at specific time point and then downregulated 
at another time point, such as miR-1285-5p. 
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Conversely, there were 26 microRNAs that were upregulated at only one time point of the 
wound healing process, as explained in (Table 7.9).    
 MicroRNAs 
Time points 
2 Hours 4 Hours 24 Hours 72 Hours 1 Week 
1 hsa-miR-149-5p 1.55 ↑         
2 hsa-miR-10a-5p   1.54 ↑       
3 hsa-miR-1236-3p   1.45 ↑       
4 hsa-miR-520d-5p+hsa-miR-527+hsa-miR-518a-5p   1.95 ↑       
5 hsa-miR-139-3p   1.29 ↑       
6 hsa-miR-4485-3p   2.05 ↑       
7 hsa-miR-4532   2.18 ↑       
8 hsa-miR-584-5p   3.03 ↑       
9 hsa-miR-1281   2.47 ↑       
10 hsa-miR-214-3p     1.45 ↑     
11 hsa-miR-431-5p     3.01 ↑     
12 hsa-miR-26a-5p     1.51 ↑     
13 hsa-miR-30b-5p     1.46 ↑     
14 hsa-miR-542-3p     4.07 ↑     
15 hsa-miR-1272     3.72 ↑     
16 hsa-miR-323a-3p     1.71 ↑     
17 hsa-miR-345-5p     1.72 ↑     
18 hsa-miR-495-5p     3.32 ↑     
19 hsa-miR-601       2.05 ↑   
20 hsa-miR-376a-3p         1.35 ↑ 
21 hsa-miR-629-5p         1.34 ↑ 
22 hsa-miR-107         1.21 ↑ 
23 hsa-miR-193a-3p         1.77 ↑ 
24 hsa-miR-210-3p         1.95 ↑ 
25 hsa-miR-324-5p         1.32 ↑ 
26 hsa-miR-337-3p         2.00 ↑ 
Table 7.9 MicroRNAs upregulated in wounded 3D-SEM compared to intact 3D-SEM at only one time 
point during the entire healing process. 
This table includes 26 microRNAs which were significantly upregulated at only one time point during the 
wound healing process and their corresponding fold change values. One microRNA was upregulated at 2 
hours only, 8 microRNA were upregulated at 4 hours only, 9 microRNAs were upregulated at 24 hours 
only, one microRNA was upregulated at 72 hours only and 7 microRNAs were upregulated at 1 week only. 
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7.3.3 DETECTION OF GROWTH FACTOR RECEPTORS USING GENE EXPRESSION 
Since six growth factors were detected in MSC-CM (HGF, KGF, PDGF-AB, TGF-β1, SDF-
1α and MSP-1), receptors of these growth factors (c-MET, FGFR-2, PDGF-A, TGF-βR1, 
CXCR4 and MST-R1 “RON”) respectively were investigated in primary keratinocytes 
under different conditions during wound (scratch) closure. Primary keratinocytes were 
incubated at different conditions i.e., non-scratched cells (NSC), scratched non-treated 
(SNT) and scratched treated with MSC-CM (ST-CM), then RT-qPCR was used to quantify 
gene expression in the cells. Target genes were quantified via relative quantification with 
the housekeeping gene (GAPDH). Although, under all conditions primary keratinocytes 
(N=4) expressed essential growth factor receptors, as explained in (Figure 7.11), there 
was no significant difference in expression of the growth factor receptors under any of the 
culture conditions assessed (P>0.05). These receptors which are tyrosine kinases are 
spread across the cell surface and could be activated immediately upon binding to their 
corresponding growth factors. Therefore the growth factors present in MSC-CM, work 
collectively to initiate several cell responses during the healing process. 
(A) 
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Figure 7.11 Receptors expressed by primary keratinocytes. 
Primary keratinocytes at different conditions (normal non-scratched cells (NSC), scratched non-treated 
(SNT) and scratched treated with MSC-CM (ST-CM)) expressed the receptors of important growth 
factors and cytokines that participate in successful wound healing. (A) HGF receptor (c-MET). (B) KGF 
receptor (FGFR2). (C) PDGF-AB receptor (PDGFRA). (D) TGF-β1 receptor (TGFBR1). (E) SDF-1α 
receptor (CXCR4). (F) MSP-1 receptor (MST-1R or RON). Relative expression represents the 
expression of the target gene compared to the housekeeping gene (GAPDH). Comparative expression 
represents the expression of the target gene compared to the control cells (Non-scratched cells “NSC”). 
Data in this figure is presented as Log 2 of original values of normalised gene expression. Bars and 
error bars represent mean and standard error of the mean (SEM) (N=4).     
To further understand the molecular mechanisms of wound healing, the relationship 
between microRNAs that were significantly differentially expressed at various time points 
and cellular receptors was investigated using TarBase v.8 software. As illustrated in 
(Table 7.10), some receptors were predicted to be regulated by one microRNA molecule 
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such as c-MET and FGFR2), while other receptors were shown to be targeted by more 
than on microRNA molecule such as PDGFRA, TGRBR1 and MST1R. Concerning 
CXCR4, information from TarBase v.8 software demonstrated that hsa-miR-106a-5p is 
the only molecule that regulates CXCR4. Data from this study revealed that hsa-miR-
106a-5p+hsa-miR-17-5p which are different microRNAs, but with very similar base 
sequences (AAAAGUGCUUACAGUGCAGGUAG and 
CAAAGUGCUUACAGUGCAGGUAG) (www.mirbase.org), cannot be distinguished 
between by the NanoString platform due to the similarity of their sequences. Interestingly, 
the seed sequence of both of these microRNAs is the same. Therefore, despite target 
prediction software indicating that only miR-106a-5p may target CXCR4, it is possible that 
miR-17-5p may also regulate this gene. 
Receptors MicroRNAs Expression Time 
c-MET miR-34a-5p 72 hours 
FGFR2 miR-34a-5p 72 hours 
PDGFRA 
miR-15a-5p 4 hours 
miR-29c-3p 4 hours, 72 hours & 1 week 
miR-34a-5p 72 hours 
TGFBR1 
hsa-let-7g-5p 4 hours & 72 hours 
hsa-let-7e-5p 4 hours 
miR-196a-5p 4 hours & 72 hours 
miR-148a-3p 4 hours 
miR-30e-3p 24 hours 
miR-33a-5p 4 hours, 24 hours & 1 Week 
miR-362-3p 2 hours & 24 hours 
MST1R 
miR-34a-5p 72 hours 
miR-210-3p 1 Week 
CXCR4 hsa-miR-106a-5p+hsa-miR-17-5p 4 hours 
Table 7.10 MicroRNAs that are predicted to target cell surface receptors. 
This table demonstrates receptors of growth factors and cytokines that could be regulated by microRNAs 
at different time points during the healing process, as predicted by TarBase v.8 software. Some of these 
receptors may be regulated by more than one microRNA such as PDGFRA, TGFBR1 and MST1R, while 
others, such c-MET and CXCR4, were only predicted to be targeted by one microRNA of the N=799 
studied by the NanoString codeset. Expression time indicates the time point at which the microRNA was 
shown to be significantly differentially expressed. 
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7.4  DISCUSSION 
In order to identify candidate microRNAs that might play a role in the wound healing and 
therefore, participate in the regeneration of damaged skin, an extended study was 
performed using a fully humanised 3D skin model. This study profiled microRNA 
expression of N=799 mature microRNAs in the 3D skin model (3D-SEM) compared to 
intact real skin, at varying time points of wound healing. This is a novel study and 
demonstrates for the first time the microRNA expression profiles of 3D-SEM compared to 
intact human skin, and is also the first study to assess the microRNA expression profiles 
of a 3D-SEM during the wound healing process. To better understand the potential roles 
of these microRNAs, their predicted effects on target genes were investigated using 
different in silico algorithms via online software packages. Previous studies investigated 
microRNA signatures in in vivo studies for different skin disorders and compared the 
results between normal and abnormal skin biopsies. For example, Mansuri and 
colleagues investigated skin microRNA profiling from non-segmental vitiligo patients using 
microarray customised kits for microRNA detection by RT PCR which investigate limited 
numbers of microRNAs (Mansuri et al., 2014; Mansuri et al., 2016). Other study 
investigated microRNAs profiling related to keratinocytes differentiation using stem loop 
primer-based real-time PCR methods which detect up to 380 microRNAs (Hildebrand et 
al., 2012). Another study investigated microRNAs profiling in skin of wounded mouse and 
the study was restricted to investigate the role of miR-200 family member on wound 
healing (Aunin et al., 2017). The only study investigated whole microRNA panel was 
carried out in surgical wounds of 5 healthy volunteers using TaqMan microRNA low-
density array which allow to detect 754 microRNAs (Li et al., 2015c). Hence, there is no 
previous studies used a constructed 3D-SEM for full profiling and comparing to real skin. 
Therefore, this study investigated for the first time the whole microRNA signature (799 
microRNAs) in 3D model compared to real skin using NanoString technology, the most 
developed technology in the field of molecular investigations. Also, this study detected for 
the first time the whole panel of microRNA profiling at different time points during the 
healing process. Although, there were 31 microRNAs differentially expressed between the 
3D-SEM and real skin (17 microRNAs were upregulated and 14 microRNAs were 
downregulated in 3D-SEM compared to real skin), the entire panel was similar. 
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Interestingly, the constructed 3D-SEM were able to express the same microRNA panel of 
real skin (799 microRNAs) indicating the ability of the constructed 3D-SEM to retain the 
molecular signature of real skin. Consequently confirming the validity of these models to 
be used as an experimental tool for future wound healing studies and testing drugs that 
might potentiate the healing process. Although, the massive compatibility between the 
models and real skin, microRNA profiling during wound healing was compared between 
wounded models and intact models not to real skin to avoid the variations in the 31 
microRNAs differentially expressed between the models and real skin.   
In context to comparing wounded 3D-SEM to intact models data showed that some 
microRNAs (26 microRNAs) were significantly differentially expressed at only one time 
point studied, while others (20 microRNAs) were differentially expressed at more than one 
of the time points under investigation (overlapping microRNAs). There was fluctuation in 
expression of these overlapping microRNAs, as although some microRNAs were 
downregulated at early stages, they then regulated back to the same level expression as 
intact models and then became downregulated in the 3D-SEM at later time points.  
miR-1204 is shown to be downregulated at 2 hour, 24 hours and 1 week by 3D-SEM 
compared to the intact model, indicating its potential importance in the healing process. 
Among the predicted target genes of miR-1204 is tumour protein 53 (TP53), which plays 
an important role in arresting cell cycle at the G1/S phase (Rother et al., 2007). Hence, 
downregulation of this microRNA may prevent suppression of TP53 and subsequently, 
cell cycle progression will activated resulting in continuous cell proliferation and/or 
migration. Additionally, Peng and colleagues reported that miR-1204 inhibits tumour 
growth and migration in nasopharyngeal carcinoma (Peng et al., 2015). Hence, this 
microRNA may play a similar role in cutaneous wounds, by down-regulated expression 
resulting in increased cell growth and migration of skin cells. Therefore, its down regulation 
may be considered as advantageous in the 3D-SEM during the wound healing process.  
Another microRNA, miR-1307-3p was downregulated at 2 and 72 hours of the wound 
healing process in the 3D-SEM compared to intact 3D-SEM. One of the potential target 
genes of this microRNA is euchromatic histone-lysine N-methyltransferase 1 (EHMT1), a 
gene encoding Metallothionein 1 h, which suppress migration and invasiveness of 
prostate cancerous cells (Han et al., 2013). Additionally, miR-1307-3p targets proto-
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oncogene protein (N-Myc) downstream regulated gene 2 (NDRG2), a gene which reduces 
cell viability and proliferation of epithelial cells involved in age-related cataracts in human 
(Zhang et al., 2011c). Moreover, miR-1307-3p also targets protein flightless-1 homolog 
(FLII) gene, which produces cytoskeletal protein flightless I protein that inhibits fibroblast 
proliferation and reduces its function, resulting in impaired healing process (Ruzehaji et 
al., 2012). It has been reported that attenuating FLII with neutralising antibodies improve 
the healing process in mice (Ruzehaji et al., 2012) and in porcine (Turner et al., 2017). 
Based on this information, upregulation of miR-1307-3p would be advantages during 
wound healing, as the effect would be to downregulate genes (EHMT1, NDRG2 and FLII) 
that are detrimental to the wound healing process. Hence, it is surprising that this 
microRNA is downregulated during time points of the healing process. The role of miR-
1307-3p during wound healing warrants further investigation. It may also represent a 
potential target molecule to artificially upregulate, in order to improve wound healing and 
therefore be used as a potential molecular therapy for wound treatment. 
miR-362-3p was downregulated at 2 and 24 hours in the 3D-SEM. This molecule is 
predicted to target tripartite motif-containing protein 11 (TRIM11), a gene that promotes 
proliferation and migration of glial tumour cells (Di et al., 2013). Additionally, miR-362-3p 
inhibits growth, proliferation and migration of breast cancer cells (MCF7 cells) (Kang et 
al., 2016). Therefore, miR-362-3p may possess similar functions in relation to wound 
healing, by suppressing skin cell proliferation and migration. Thus, downregulation of this 
microRNA at early stages of the healing process (2 hours and 24 hours) may be beneficial 
for the wound healing process. However, more studies are required to investigate the 
regulatory effect of miR-362-3p on TRIM11. 
Another microRNA shown to be downregulated at more than one time point was miR-505-
3p (downregulated at 2, 4 hours and at 1 week). This microRNA targets TNC gene which 
produces tenascin C (TN-C), a protein responsible for regulating cell migration and 
proliferation, particularly during developmental differentiation and wound healing 
(Erickson, 1993). Hence, if TN-C is upregulated, the effect may be enhanced migration, 
proliferation and differentiation of skin cells (mainly keratinocytes), consequently, 
enhanceing the healing process. It is therefore advantageous to wound healing that miR-
505-3p is downregulated, resulting in increased TN-C expression. It would be interesting 
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to assess TN-C expression at the various time points of healing in the 3D-SEM, in order 
to assess whether expression is directly correlated with miiR-505-3p. 
miR-526a+miR-518c-5p+miR-518d-5p was downregulated at 2, 4 and 72 hours.  One of 
the target genes for this group of microRNA is adenomatous olyposis coli (APC) gene, 
which is involved in many cellular responses such as cell division, attachment and 
movement (Lesko et al., 2015). Therefore, downregulation of this group of microRNAs 
between 2 and 24 hours during the healing process could result in upregulated, allowing 
this gene to play pivotal role in cell migration and proliferation. Interestingly, after 72 hours 
this molecule was regulated to the same level as the intact model, suggesting that the role 
of this microRNA molecule is mainly related to enhance cell migration during the early 
stages of healing.  
miR-302e was also found to be downregulated at 4 hours and 1 week. One of the target 
genes of miR-302e is TGFRB2, which regulates the transforming growth factor beta-
receptor (TGFRB) subfamily. This family are a group of transmembrane proteins that form 
a heterodimeric complex with another receptor, and binds TGF-beta to further regulate 
the transcription of genes related to cell proliferation (Yao et al., 2002). Schultze-Mosgau 
and others reported that TGFRB2 is up regulated during the healing process (Schultze-
Mosgau et al., 2003). Hence, downregulation of miR-302e gives rise for the production of 
TGFRB2 to evoke numerous responses and signalling pathways regulated by the different 
members of TGF-ß family. Another target of miR-302e is EDNRB, which encodes 
endothelin receptor type B, a receptor involved in the Edn/EdnrB signalling pathway to 
promote proliferation and differentiation of epidermal melanocyte stem cell and hair 
regeneration in association with Wnt signalling pathway (Takeo et al., 2016). However, 
the constructed models are free of melanocytes, miR-302e may target Edn/EdnrB 
cascade during in vivo injuries and participate in the healing process. On the other hand, 
downregulation of this microRNA could be attributed to the hypothesis that the role of this 
microRNA is mainly related and restricted to affect only melanocytes and since the 
constructed models are free of melanocytes, there was no participation was expected to 
be achieved by miR-302e resulted in its downregulation. 
Expression of miR-33a-5p was downregulated at 4, 24 hours and 1 week in the wounded 
3D-SEM. One of the target genes of this microRNA is MYC (c-MYC) which plays a pivotal 
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role in proliferation of epidermal stem cells, migration and differentiation of keratinocytes, 
and hair follicle regeneration via activation of the Wnt/β-catenin signalling pathway (Shi et 
al., 2015). This data suggests a significant role for miR-33a-5p in wound repair, by which 
its lower expression at specific time points during the wound healing process may allow 
for MYC expression to promote mechanisms of wound healing. Interestingly, MYC is also 
targeted by miR-let-7g-5p (which was expressed at 4 and 72 hours), suggesting a 
synergistic role between miR-33a-5p and miR-let-7g-5p during the healing process. An 
additional target of miR-let-7g-5p is HMGA2, which encodes high-mobility group AT-hook 
2. Kou and colleagues reported that HMGA2 facilitates migration and invasion of renal cell 
carcinoma cells by modulating the TGF-β/Smad2 signalling cascade (Kou et al., 2018). 
Therefore, it could be suggested that a similar role (enhancing keratinocyte migration) 
could be achieved by miR-let-7g-5p via targeting HMGA2 for further activation of TGF-
β/Smad2 during the healing process. 
miR-29c-3p expression was downregulated at 4, 72 hours and 1 week in the 3D-SEM. It 
has been predicted that miR-29c-3p regulates matrix metalloproteinases (MMP) (Zhang 
et al., 2017). These enzymes are necessary for repairing both acute and chronic wounds, 
by playing a vital role, with their inhibitory activity, in regulation of extracellular matrix 
deposition and degradation, which is an essential step for wound re-epithelialisation and 
tissue remodelling (Caley et al., 2015). Additionally, miR-29c-3p has been reported to 
regulate secreted protein acidic and rich in cysteine (SPARC) which also called basement-
membrane protein 40 (BM-40) (Zhang et al., 2017) and shown to be beneficial to tumor 
invasion within bone by controlling many responses and events including  cell-
matrix interactions, and collagen binding angiogenesis, proliferation and migration 
(Guweidhi et al., 2005). Hence, miR-29c-3p could be suggested to play a regulatory effect, 
by controlling collagen production and deposition, migration and proliferation during the 
healing process. However, more investigations are needed to ensure the regulatory 
manner of miR-29c-3p SPARC modulation.   
Expression of miR-196a-5p was downregulated at 4 and 72 hours and this microRNA has 
been shown to influence Homeobox gene family including (HOXA7, HOXB8 HOXC8 and 
HOXD8). This gene family plays vital roles in morphogenesis of all multicellular organisms 
(Gehring, 1993). Subsequently, downregulation of miR-196a-5p between 24 and 72 hours 
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might be beneficial to enhance expression of one or all genes of the homeobox family, 
allowing these genes to participate in skin morphogenesis during the healing process. 
Additionally, keratin 5 gene (KRT5) is predicted as another target of miR-196a-5p. Keratin 
5 enhances filament and cytoskeletal formation in the stratified epithelium of the skin 
(Atkinson et al., 2011). These filaments are anchored to the desmosomes of basal cells 
and connect neighbouring basal cells to each other, and also to the basal lamina 
(Bouameur et al., 2014). In addition, KRT5 modulates cell architecture, supporting the 
cells and increasing their hardness during mechanical and non-mechanical stresses 
(Coulombe and Omary, 2002; Atkinson et al., 2011; Bouameur et al., 2014). At the 
intermediate filament surface, keratin 5 has a non-helical tail, causing it to undergo 
extensive bundling with increased elasticity, thereby providing the epidermis with 
mechanical resilience (Coulombe and Omary, 2002). Furthermore, miR-196a-5p affects 
S100 calcium binding protein A9 (S100A9), which encodes S100A9 and is localised in the 
cytoplasm and/or nucleus of variety of cell types. This protein binds to calcium ions (Ca+2) 
and regulates the amount of unbound calcium ions, thereby playing an axial role in calcium 
signalling pathways and cellular responses including cell cycle and cell differentiation. 
Taken together, this may suggest its role in keratinocyte differentiation during the healing 
process (Schnetkamp, 2016). Moreover, miR-196a-5p influences COL1A1 gene that 
encodes collagen type I alpha 1 chain, which is gives support and strength to many tissue 
types, including skin. Hence, the role of miR-196a-5p may be critical in skin development 
and regeneration and it’s functional role in the 3D-SEM warrants further investigation. 
miR-1297 expression was downregulated at 24 hours and 1 week in the 3D-SEM. It is 
predicted to controls Kruppel-like factor 5 (KLF5). This protein is a member of a 
transcription factor family that regulates numerous cellular responses including 
proliferation, differentiation and development. Additionally, it is expressed in proliferating 
epithelial cells (Li et al., 2015d). Therefore, downregulation of miR-1297 after 24 hours of 
healing progress could be an indicator that cells have started to switch their response from 
migration to proliferation. 
miR-488-3p expression was downregulated at 24 and 72 hours in the 3D-SEM. This 
microRNA has been predicted to modulate corticotropin releasing hormone receptor 2 
(CRHR2) protein. This molecule has been shown to play a crucial role in promoting 
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proliferation, migration, and viability of epithelial cells and to initiate restoration of the 
epithelial barrier (Hoffman et al., 2016). Thus, the results of this study suggest that 
downregulation of miR-488-3p between 24 and 72 hours may modulate CRHR2, 
subsequently enhancing cell proliferation. 
Expression of miR-200a-3p was downregulated at 72 hours and 1 week. One of the 
predicted target genes regulated by miR-200a-3p is BAP1, a gene responsible for 
production of BRCA1 associated protein-1. This protein is a major player in promoting 
proliferation and migration of basal breast cells during tumour growth and metastasis (Qin 
et al., 2015). Therefore, downregulation of miR-200a-3p during the healing process may 
function to upregulate BAP1 production for further enhancing proliferation and migration 
of skin cells. 
While the majority of microRNAs that were differentially expressed were shown to be 
down-regulated in the 3D-SEM during wound healing compared to the control, there were 
some microRNAs that were upregulated at different time points during the healing 
process. For example, miR-2117 was upregulated at 2, 4 hours and 1 week. This 
microRNA has is predicted to modulate VAV3 gene, which plays a critical role in the 
healing process by promoting macrophage migration and phagocytosis activity of 
apoptotic neutrophils, via regulation of beta (2)-integrins. VAV3 deficient macrophages, 
but no other cells, demonstrate impaired wound healing in mice (Sindrilaru et al., 2009). 
The 3D model used in this study lacks the presence of macrophage and other immune 
cells. Therefore, upregulation of miR-2117 could be of similar function to enhance skin 
cell migration. 
miR-1973 expression was upregulated at 4 hours and 1 week in the 3D-SEM. It is 
predicted to target CRABP1 gene, which encodes cellular retinoic acid-binding protein 1. 
The latter is reported to slow proliferation of embryonic stem cells and neural stem cells 
in mice (Lin et al., 2017). Therefore, upregulation of miR-1973 after 4 hours of initiating 
the healing process could suppress CRABP1, resulting in promoted cell proliferation. 
Expression of miR-320e was upregulated 4 and 72 hours. One of the predicted genes 
regulated by miR-320e is JUN, a gene encoding c-jun protein. Giles and colleagues 
reported that inhibition of c-jun by a peptide inhibitor promotes wound healing via 
promoting proliferation of keratinocytes, but not fibroblasts. In addition, supressing 
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expression of c-jun using peptide inhibitors resulted in an increased rate of re-
epithelialisation and reduced apoptosis in mouse suffering from full skin burns (Giles et 
al., 2008). Therefore, upregulation of miR-320e after 4 hours of initiation of the healing 
process may have the effect of inhibiting c-jun expression and therefore, supporting 
improved and faster healing. 
miR-382-5p expression was upregulated at 24 and 72 hours. It is predicted to influence 
calcium-dependent, non-lysosomal cysteine proteases (CALPAIN) gene. Nassar and 
colleagues reported that CALPAIN is a principal player in granulation tissue formation and 
TGF-β induced differentiation; however, it reduces collagen production and wound fibrosis 
resulting in scar formation (Nassar et al., 2012). Therefore, normal levels of miR-382-5p 
during early time points of the healing process (within 24 hours) may allow CALPAIN to 
participate in the healing process through granulation tissue formation and differentiation. 
Later, (after 24 hours) miR-382-5p was upregulated which have the effect of suppressing 
CALPAIN and thus, reducing scar formation. Another target gene for miR-382-5p is 
TAGLN, a gene responsible for transgelin production. The latter is a protein reported to 
affect cell mobility and proliferation and its suppression results in impaired growth and 
migration (Zhou et al., 2013). Therefore, upregulation of miR-382-5p may be 
advantageous by upregulating TAGLN; subsequently, promoting the production of 
transgelin leading to activated cell proliferation and migration. Another predicted target of 
miR-382-5p is VIM gene, which is responsible for production of vimentin, plays an 
important role in the healing process by enhancing fibroblast proliferation and keratinocyte 
differentiation (Cheng et al., 2016). Upregulation of miR-382-5p between 24 and 72 hours 
may be explained by the fact that the priority of the cell response during this time is cell 
migration, rather than proliferation and differentiation. Therefore, after 72 hours regulation 
of miR-382-5p expression back down to levels similar to those seen in intact models may 
potentially give rise to upregulation of VIM, resulting in increased vimentin levels which 
functions to direct keratinocytes to switch their response to proliferation and/or 
differentiation instead of migration.  
miR-99b-5p expression was upregulated at 24 hours and 1 week. It has been shown to 
regulate HOXA1 (Li et al., 2015f), a gene responsible for production of homeobox protein 
Hox-A1. This protein along with other homebox proteins, is responsible for accelerating 
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wound healing via promoting cell migration and angiogenesis (Kachgal et al., 2012). In 
another word, miR-99b-5p regulate HOXA1 to further promote the healing process. 
miR-4284 was upregulated at 72 hours and 1 week. It is predicted to target RUFY2, a 
gene that produces the two RUN and FYVE domains of the RUFY family. Members of this 
family have been shown to enhance cell migration in gastric cancer cells (Wang et al., 
2015). Downregulation of miR-4284 could suppress the production of RUFY2 protein; 
subsequently delaying cell migration. Interestingly, levels of miR-4284 were upregulated 
at 72 hours of wound healing until the last time point measured (1 week). This data 
suggests that miR-4284 demonstrates normal levels during early wound healing (2-72 
hours), similar to those seen in the intact model, resulting in normal levels of RUFY2 to 
enhance cell migration during this period. On the other hand, miR-4284 also predicted to 
downregulate histone-lysine N-methyltransferase 2D (KMT2D). Deficiency of this protein 
reduces proliferation of cancer cells in many colon and breast cancer cell lines (Guo et 
al., 2013a; Kim et al., 2014). These findings suggest that upregulation of miR-4284 after 
72 hours might downregulate KMT2D, to suppress cell proliferation and retain cell 
migration. It would be of great interest to further study the role of miR-4284 in relation to 
cell migration and proliferation during wound healing. 
Expression of miR-1285-5p was upregulated within the early stages (24 hours) of the 
healing process compared to intact 3D models, but downregulated at later time points (1 
week). It has been shown that miR-1285-5p influences proliferation and migration of lung 
carcinoma cells (Zhou et al., 2017). Hence, it could be suggested that miR-1285-5p may 
be upregulated within the first 24 hours to enhance cell mobility and propagation, and then 
downregulated after 1 week to terminate cell migration and proliferation in order to switch 
the cell response to differentiation. However, this hypothesis required further investigation. 
Additionally, miR-1285-5p downregulates homeodomain-interacting protein kinase 1 
(HIPK1). Downregulation of this protein has been shown to reduce cell migration, 
proliferation and tumorigenic potential of A549 cell line (Lee et al., 2012). Therefore, down 
regulation of miR-1285-5p after 1 week may upregulate HIPK, resulting in enhancing cell 
migration and proliferation and switching the cell response to differentiation. Hence, these 
data suggest that miR-1285-5p play a bi-functional role in wound healing, by controlling 
cell migration and proliferation at different time points. It would be of great interest to 
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investigate markers of cell migration and proliferation in relation to miR-1285-5p 
expression in the 3D-SEM.  
This study also focussed on microRNAs that were upregulated at only one time point 
during the healing process. Here in, representative microRNAs (the highly upregulated 
microRNAs) at different time points were selected for further investigation of their 
predicted target genes. For example, miR-149-5p which is upregulated after 2 hours of 
the healing process, is reported by Jin and co-workers to control many cellular activities. 
Its downregulation has been shown to suppress migration and proliferation of renal 
carcinoma cells, in addition to promoting cell apoptosis (Jin et al., 2016). Hence, 
upregulation of this molecule may be beneficial to the healing process, because it might 
have the same effect on skin cells i.e. promoting their migration and proliferation. 
Another microRNA that was upregulated at 4 hours is miR-584-5p. This molecule was 
shown to target rho-associated, coiled-coil-containing protein kinase 1 (ROCK-1), a 
protein that suppresses migration and proliferation of human renal carcinoma cells (Ueno 
et al., 2011). Therefore, upregulation of miR-584-5p may have the effect of reducing 
ROCK-1 expression, therby resulting in increased migration and proliferation of skin cells. 
However, ROCK-1 has also been shown to regulate other processes such as activating 
VEGF-driven retinal neovascularisation and sprouting angiogenesis (Jens et al., 2009). 
Therefore, upregulation of this molecule at 4 hours may downregulate ROCK-1 and 
support migration and proliferation of skin cells, and enhances neovascularisation and 
angiogenesis leading wound repair. 
Another microRNA molecule that was upregulated after 24 hours is miR-542-3p. This 
microRNA targets bone morphogenesis protein-7 (BMP-7) signalling. BMP-7 has been 
shown to play a pivotal role in suppression of excessive scar formation (Guo et al., 2017). 
Therefore, upregulation of miR-542-3p might downregulate BMP-7 and increase collagen 
production and resulting in scar formation. Yuan and colleagues reported that miR-542-
3p inhibits proliferation and migration of colorectal cancer cells via targeting ubiquitin 
thioesterase also known as otubain-1 (OTUB1). Additionally, miR-542-3p inhibits 
epithelial-mesenchymal transition (EMT) during hepatocellular carcinoma, suppress cell 
motility and reduce cancer metastasis by targeting Ubiquitin-protein ligase E3C (UBE3C) 
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(Tao et al., 2017). These data suggest that this microRNA is determinant of healing 
progress and its inhibition is supporting wound repair. 
After 72 hours, miR-601 was upregulated, which has been shown to modulate epithelial–
mesenchymal transition (EMT) progression and activate (PI3K)/AKT signalling (Cao et al., 
2017). Both EMT and the (PI3K)/AKT cascade are well documented to play a role in 
physiologic tissue repair and participate in the healing process by accelerating cutaneous 
wound healing (Chen et al., 2014; Stone et al., 2016). Therefore, upregulation of this 
microRNA is advantageous to the healing process, by activating these signalling 
cascades. 
Expession of miR-337-3p was upregulated after 1 week in the 3D-SEM. This molecule is 
reported to target HOXB7 (Zhang et al., 2014) a well-documented molecule that enhances 
growth, proliferation and migration of hepatocellular carcinoma by promoting stemness 
and epithelial-mesenchymal transition. Therefore, a similar activity of this microRNA may 
be achieved in chronic wounds i.e. by High level of miR-337-3p downregulates HOXB7 to 
terminate cell migration, proliferation and switch the cellular response to differentiation. 
Hence, upregulation of this microRNA is advantageous to the healing process. 
Despite the investigation of predicted microRNA targets using in silico algorithms 
performed in this study, the function of these microRNAs in wound healing remains 
hypothetical. Additional investigations are required to confirm the direct targets of these 
microRNAs in the 3D-SEM and wound healing setting. In addition, functional studies may 
further elucidate the modulatory effect of these microRNAs and their targets, for better 
understanding of the molecular mechanism of wound healing. 
 
The ability of keratinocytes to express receptors of target growth factors and cytokines at 
different time points during the healing process is another important factor in promoting 
tissue repair and wound healing. Expression of these receptors on the cell surface will 
activate soluble biomolecules (growth factors and cytokines) upon binding, to further 
activate relevant signalling cascades and evoke cellular response. Maintained expression 
of theses receptors during the different conditions and time points of the 3D-SEM wound 
healing model suggest their importance during the repair process. The role of microRNAs 
during the wound healing process may also be demonstrated by their ability to target key 
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grown factor and cytokine receptors, as demonstrated in (Table 7.10). Indeed, TGFBR1 
has been predicted to be targeted by microRNAs that were differentially downregulated at 
several different time points (4 hours, 24 hours, 72 hours and 1 week), and PDGFRA is 
predicted to be targeted by 3 microRNAs that were differentially downregulated at 3 
different time points (4 hours, 24 hours and 1 week) suggesting that these microRNAs are 
downregulated to give rise for upregulation the genes responsible for production of 
TGFBR1 and PDGFRA to participate in the healing process. MST1R was predicted to be 
targeted by two microRNAs tat demonstrated differential expression in the 3D-SEM, while 
other receptors such as c-MET, FFGFR2 and CXCR4 were predicted to be modulated by 
only one target microRNA.  
In summary, we have shown that the wound healing model developed in this study is a 
good tool for a wide range of molecular investigations such as; gene expression, 
microRNA profiling, DNA analysis and proteomic studies. In addition to its advantages 
described in Chapter 6, using this model is preferable to using the 2D scratch assay at 
the molecular level analysis. For instance, in 2D culture, microRNAs are isolated from only 
one cell type such as keratinocytes, which is different from microRNA profiling of real skin, 
which contain keratinocyte and fibroblast. This drawback may be overcome by using the 
3D model, which is comprised of both epidermal and dermal layers. Furthermore, in this 
Chapter we have shown that the 3D-SEM generally mimics microRNA profiling of real 
skin, with the exception of a signature of differentially expressed microRNAs, which have 
been discussed. Consequently, data obtained from this study could be used as a 
reference library for microRNA profiling studies during the wound healing process for 
future investigations in this field. MicroRNAs could also be used as molecular markers for 
characterising and validating 3D skin models constructed in vitro for further evaluating 
these 3D skin equivalents for their suitability for pre-clinical applications. Additionally, 
microRNAs are differentially expressed during the different phases of the healing process. 
Some of these molecules are upregulated while others are down regulated suggesting 
their essential participation in regulating the repair process. One of the mechanisms by 
which microRNAs may be involved in the repair mechanism is by targeting different genes 
with a role in wound repair. It would be of essential importance for further understanding 
of the wound healing process to further investigate these predicted target genes. 
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MicroRNAs may also be used as signals to evoke signalling pathways and trigger cellular 
responses during wound healing cascades. The most important genes regulated by these 
microRNAs are those related to cell migration, proliferation, differentiation, re-
epithelialisation, cell cycle and receptors of growth factors. Giving these features, 
manipulation and control of microRNA expression during the healing process has the 
potential to be applied as a molecular therapy for non-healing wounds, and this would be 
an essential area of future investigation.
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CHAPTER EIGHT: GENERAL DISCUSSION AND CONCLUDING REMARKS 
8.1 INTRODUCTION 
Cellular therapies for cutaneous wound healing have been given a large amount of 
research attention in order to try to address the problems associated with chronic wounds. 
Among the approaches has included applying keratinocytes to the wounded skin (Kopp 
et al., 2004), using engineered skin equivalents for burns (Hocking, 2012) and specific 
extra cellular matrix (ECM) proteins to damaged skin (Maxson et al., 2012). However, 
these approaches fail to successfully treat non-healing wounds due to complications such 
alteration of immune responses to avoid any further fibrotic reactions and incomplete 
integration of the implanted cells into normal uninjured skin (Metcalfe and Ferguson, 
2007). Recently mesenchymal stem cells (MSCs) and their secretions have gained an 
attention as a potential cellular therapy for treating non healing wounds (Hocking, 2012; 
Tamama and Kerpedjieva, 2012). However, the cellular and molecular mechanisms of 
how MSCs and their secretions could be utilised for treating chronic wounds is still not 
fully understood and some issues need to be addressed before using MSCs as a 
treatment for wounds. This research was therefore conducted to investigate the main 
cellular and molecular mechanisms that could be involved in the healing process under 
the effect of MSC secretions. 
8.2  GENERAL DISCUSSION 
Wound healing is a complicated process consisting of overlapping phases and events. 
Cellular therapy is a promising strategy for treating chronic wounds. Migration, 
proliferation and differentiation of epidermal keratinocytes represent the most important 
steps in a successful healing process. Success of the healing process mainly depends on 
the time of initiation and termination of these overlapping phases. A substantial criteria for 
successful repair is recovery of an intact epidermal layer (Velnar et al., 2009). Therefore, 
migration of epidermal cells is the first rate-determining step in the healing process (Yan 
et al., 2017). Hence, the first aim of this study was investigating the effect of MSC-CM on 
migration of skin cells. To this aim, a new method was developed to enable the study of 
MSC-CM on primary keratinocytes, instead of using cell lines, by collecting MSC-CM in 
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low calcium level medium (LC-CM) and avoiding the interference caused by high calcium 
levels. Consequently, more realistic results were obtained using the developed protocol. 
To the best of our knowledge, this study has showed for the first time, the ability of MSCs 
to grow in low calcium level and serum free media conditions retaining their ability to 
secrete biologically active substances. 
Migration and proliferation collectively comprise re-epithelialisation, which is the important 
key step in the healing process, restoring barrier function and initiating the healing process 
(Lau et al., 2009). Therefore, the second aim of the study was to test the effect of MSC-
CM on proliferation of skin cells during wound closure using the developed method by 
collecting MSC secretions in low calcium level containing media (LC-CM). The study 
showed that LC-CM enhanced cell proliferation by 48 hours after the initiation of the 
healing process. Observations from this study confirmed that the cellular responses, at 
the injury site were initiated in a step-wise manner. For example, cell migration is the most 
important response during the early stages of the healing process in order to successfully 
cover the wound. Covering the wounds with a newly formed cellular sheet protects from 
microbial contamination. Hence, it could be suggested that the treatment of non-healing 
wounds should be gradual i.e. in the early stages, growth factors that enhance cell 
migration could be given first until positive results are observed. Proliferation inducing 
factors could be given later followed by introducing differentiation inducing factors to finally 
obtain the best healing results (Wickert et al., 2016). This study confirmed that cellular 
responses enhanced by LC-CM were ordered, depending on the cellular demand at the 
injury site i.e. LC-CM enhances cell migration during the first hours of injury (0 - 48 hours) 
when the cells then switch their response from migration to proliferation and differentiation. 
On the other hand, cells which were inhibited to proliferate due to mitomycin C (MMC) 
retained their ability to migrate under low calcium (LC-CM) conditions. LC-CM also 
enhanced cell migration at different conditions such as normoxia, hypoxia and after 
blocking SDF-1α. An interesting observation from this study was that MSC secretions 
collected at early times during their expansion (LC-CM24) demonstrated  a stronger effect 
on cell migration compared to those collected at later time points (LC-CM48 and LC-
CM72). In addition, there were no differences in the concentrations of growth factors 
present in either LC-CM 24, LC-CM 48 or LC-CM 72. This is a novel finding and since 
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previous studies collected MSCs secretions after 72 hours (Walter et al., 2010) could be 
useful for future research in terms of reducing the collection time, sparing media and other 
cell culture consumables. The stratum basal layer of the epidermis contains the epidermal 
stem cells, which proliferate and act as a source of cells that differentiate into upper 
epidermal layers (Bikle et al., 2012). Upon injury, all the epidermal layers will be lost 
including the basal layer and epidermal stem cell precursor. The potential of MSCs to 
differentiate into epidermal like structures is a possible strategy which could be applied as 
a cellular therapeutic for chronic wounds, since they could be injected into the injury site 
in order to differentiate into epidermal layers and promote wound healing. This study also 
showed for the first time that MSCs were able to differentiate into epidermal like structures 
retaining the ability to express epidermal differentiation markers when seeded over human 
dermal fibroblast layers free of animal collagen. These results suggest cross-talk between 
MSCs and dermal fibroblasts in order to recover the damaged epidermis via differentiation 
into the different epidermal layers. Other studies have tested the ability of MSCs to 
differentiate into epidermal cells when seeded over dermal layers enriched with bovine 
collagen type I (Ma et al., 2009) which may interfere with the interpretation of results for 
use in human studies.   
Growth factors such as PDGF-AB, TGF-ß1, HGF, KGF, SDF-1α and MSP-1 are secreted 
by MSC in in vitro culture and are reported to enhance cell migration and proliferation 
during wound repair. One of the critical parameters that impact the healing progress is the 
ability of skin cells, mainly keratinocytes, to express receptors that bind to the growth 
factors and cytokines and initiate signalling pathways to further evoke an appropriate 
cellular response. Failure of skin cells to express surface receptors hinder the healing 
process and introducing new therapeutics based on growth factors would be of no value 
unless the cells at and around the injury site expressed these receptors. A possible 
strategy therefore, could be to activate the cells surrounding the damaged tissue to 
express membrane receptors for the growth factor of interest. For example, PDGF 
interacts with its receptor on the cell surface of the target cell, induces and regulates 
several cellular pathological and physiological responses involved in tissue repair and 
wound healing (De Donatis et al., 2008). Therefore, enhancing cells to express PDGFRA 
could be useful for ensuring the binding of the growth factor to the target cells and 
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enhancing tissue repair. A part from the 2D culture, in this study a 3D skin equivalent 
model for wound healing was developed and confirmed for its suitability at the cellular and 
molecular for use as a replica for skin for wound healing studies. Additionally, a robust 
reproducible protocol for wound healing studies was also developed with consistent and 
reproducible results. The developed 3D model was used, for the first time in this study, to 
investigate microRNA profiling compared to intact models at different time points during 
the healing process. Another strategy which could be considered for treating chronic 
wounds is using growth factors with high binding affinity to skin cells. For instance, the 
binding affinity could be determined by the parameters that enable the target cells to 
express receptors on the cell surface. MicroRNAs are molecules that can regulate 
receptor expression and these molecules may be up- or down-regulated to enhance the 
cells to express relevant receptors. Additionally, some receptors are predicted to be 
targeted by more than one microRNA and these are expressed on the cell surface at 
higher levels compare to receptors targeted by one only microRNA. Furthermore, 
expression of microRNAs at different time points during the wound healing process that 
target the same receptor may ensure controlled expression of their target receptor. An 
example of these receptors are TGFBR1 and PDGFRA, which are predicted to be  
targeted by more than 3 microRNAs that were differentially expressed at different time 
points of 3D-SEM wound healing. Therefore, treatment with growth factors TGF-1ß and 
PDGF may give rise to a better response than using other growth factors, such as HGF 
and KGF, which bind to c-MET and FGFR2 receptors respectively and are predicted to 
be regulated by microRNAs molecule that are only differentially expressed at one time 
point during wound healing (72 hours). 
MicroRNAs have the potential to be used for treating non-healing wounds, by upregulating 
beneficial microRNAs and inhibiting detrimental microRNAs to the wound healing process. 
Inhibiting detrimental microRNAs at early stages of the healing process could be an 
effective therapeutic approach by arresting cell migration and proliferation. Our results 
showed that miR-542-3p retained its normal levels within the first 24 hours and was then 
down regulated after 24 hours in the 3D-SEM wound healing model. Therefore, it’s 
possible that this molecule was interacting with other microRNAs or target genes that 
enhance cell migration during the first 24 hours. A similar observation was made for miR-
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584-5p, miR-601 and miR-337-3p. Hence, early inhibition of these molecules may allow 
for increased wound repair and support the healing process. 
8.3 CONCLUSION 
Mesenchymal stem cells (MSCs) and their secretions are promising therapeutics for 
chronic wounds. Availability, ease of isolation and expansion in vitro make MSCs an 
excellent candidate for treating wounds compared to other stem cells including embryonic 
stem cells (ESCs). Two main strategies could be applied for the use of MSCs in the 
treatment of chronic wounds. The first is cell mediated repair, when MSCs differentiate 
into epidermal like cells and the second, secretory mediated repair by the use of the 
biomolecules secreted by MSC in vitro. MSCs, therefore, are an improvement on 
therapies which involve implanting keratinocytes into the injury site, when keratinocytes 
can only differentiate but have no secretory role. At the molecular level, up or down 
regulation of certain genes should be carried out in an ordered manner, since cellular 
responses during the healing process are ordered events and switching on cell responses 
at particular times would lead to improved healing. Since the healing process is composed 
of overlapping phases and events, the function of microRNAs involved in the healing 
cascades may also be overlapping. Hence, microRNAs have the potential to control the 
healing process in a highly organised manner. For example, some microRNAs enhance 
cell migration mainly during the early stages (2-24 hours) of wound healing, while other 
microRNAs start to enhance cell proliferation (between 24 and 48 hours). However, some 
microRNAs that promote cell migration remain up regulated and retain cell migration until 
full coverage of the injury site. Other microRNAs that are related to differentiation are up 
regulated after 72 hours, when migration and proliferation are no longer required; 
therefore, these molecules start to switch the cellular responses to differentiation instead 
of mobility and propagation. In addition, some microRNAs play a major role in the healing 
process while others play a secondary role. MicroRNAs which play a major role are those 
involved at early stages (2-4 hours), to enhance the required response such as migration-
inducing microRNAs which are upregulated first, followed by microRNAs required for 
proliferation which are upregulated later (24-72 hours). Finally, differentiation related 
microRNAs are up regulated during the final stages of wound healing, after 1 week. 
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Secondary microRNAs are those regulated at time points when there is more demand for 
specific cellular responses. For example, if the migration related major microRNAs are 
initiated but do not sufficiently enhance migration, secondary microRNAs are upregulated 
to aid the major microRNAs to induce an improved response.       
8.4 LIMITATIONS OF USING MSCS IN WOUND TREATMENT 
MSCs can be considered as a promising tool for treating non-healing wounds; however, 
some aspects relating to MSC biology need to be studied intensively before using them 
for clinical application. One of these problems is finding a source of MSCs which does not 
involve an invasive procedure i.e. isolation of MSCs from peripheral blood instead of bone 
marrow. Other questions include the following: what is the ideal number and timing for 
MSC administration / implantation? How long can MSCs survive in the injury site after 
implantation? Are multiple implantations required for successful healing? When do the 
implanted MSCs start to secrete their effective soluble molecules after implantation? And 
finally, are MSC secretions controllable? Answers to these questions are important and 
essential for the therapeutic use of MSCs and for a safer and more effective treatment for 
non-healing wounds. 
8.5  FUTURE WORK 
Extracellular vesicles of MSCs, in particular, MSC-exosomes, may also play a significant 
role in the healing process; therefore, investigating the involvement of these molecules on 
wound healing in both 2D and 3D culture, may enable further strategies or micro therapy, 
to be developed for the treatment of chronic wounds  
At the molecular level, there have been no previous studies or evidence that MSC-CM 
modulate (up or down regulate) the expression of specific microRNAs during the healing 
process.  More investigations are therefore required to confirm the exact effect of MSC 
secretions (triggers or inhibitors) of microRNAs in both 2D and 3D culture. 
More research into the involvement of microRNAs in signalling pathways, including 
functional studies, is required to investigate the interaction between microRNAs and 
supposed target genes or receptors to confirm the regulation type (up or down) and to 
clarify the role of these molecules in the healing process at the molecular level. 
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The modified 3D skin equivalent model, developed in this study, could be further 
developed to include immune cells for studying the immunological and inflammatory 
responses during the healing process. Finally, specific targeted genes could be further 
investigated for use as a genetic therapy for chronic wounds.
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